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Molecular imaging has revolutionized the practice of medicine and patient healthcare. The use of 
targeted imaging tools have enabled the non-invasive and selective interrogation of biological 
processes triggering pathology. This approach includes a variety of complementary techniques such 
as PET, MRI, and optical imaging. In particular, fluorescent probes allow for the synergistic evaluation 
of the drug, the target, and treatment response in real-time and excellent spatiotemporal resolution. 
Generally, three main components should be considered for the design of a fluorescent probe: (i) a 
recognition element (ligand or pharmacophore) that tolerates further chemical functionalization while 
preserving its affinity and selectivity towards the protein-target, (ii) an appropriate reporter unit 
(fluorophore), and (iii) a linker that combines these two functionalities. Each of these constituents 
poses unique challenges for the successful design of a molecular probe as their selection will strongly 
depend on the imaging technique the probe will be applied to (Chapter 1.).  
The presented thesis displays a case in which the design, synthesis, and pharmacological 
characterization of highly specific imaging probes led to the labeling of two relevant drug targets. In 
both projects, a modular synthesis strategy enabled the assembly of ligand and fluorophore units 
tailored for specific optical imaging applications.  
The first part of this thesis described the development of fluorescent ligands to trace the cannabinoid 
type 2 receptor (CB2R) (Chapter 2.). This receptor is known to be strongly up-regulated in pathological 
conditions correlated with the onset of inflammation and, thus, represents an important protein-target 
for both therapeutic and diagnostic purposes. Exploiting a preclinical CB2R agonist drug as 
recognition element, investigations on suitable linker length, composition, and placement were 
conducted. Of particular interest was to avoid detrimental interactions of the linker-reporter construct 
with the CB2R, while providing a linker trajectory that reaches the extracellular space, i.e., outside the 
receptor binding pocket. This strategy resulted in the generation of a robust platform where binding 
affinity and selectivity were largely independent of fluorophore attachment. 
The second part of this thesis aimed at the synthesis of imaging ligands containing multiple targeting 
moieties, i.e., multivalent for applications in the early detection of pancreatic cancer (PDAC) (Chapter 
3.). Here, probe design was based on the fourfold derivatization of the cyclen scaffold to develop a 
“clickable” platform encompassing three terminal maleimides and one alkyne. This cyclen-based 
platform enabled the one-pot assembly of PDAC-targeted agents which were labeled with two different 
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cyanine fluorophores. These fluorescent compounds displayed high specificity for the detection of 





Molekulare Bildgebung hat die klinische Praxis der Patientenversorgung grundlegend verändert. Der 
Einsatz zielgerichteter Reportermoleküle hat es ermöglicht, biologische Prozesse als Auslöser von 
Krankheiten nichtinvasiv und selektiv zu untersuchen. Diese Methodologie vereint eine Reihe 
komplementärer Verfahren einschließlich PET, MRI und optischer Bildgebung. Insbesondere 
Fluoreszente Sonden ermöglichen die synergistische Bewertung von Medikamenten, Targets, und 
Therapieansprache in Echtzeit mit ausgezeichneter räumlicher und zeitlicher Auflösung. Im 
Allgemeinen müssen drei grundlegende Komponenten für das Design einer fluoreszenten Sonde 
berücksichtigt werden: (i) ein Erkennungselement (Ligand oder Pharmakophor), welches chemische 
Funktionalisierungen unter Erhaltung seiner Affinität und Selektivität zum Protein-Target toleriert, 
(ii) eine geeignete Reportereinheit (Fluorophor), und (iii) ein Linker, welcher beide Funktionalitäten 
verbindet. Jedes dieser Bestandteile stellt spezifische Anforderungen an das erfolgreiche Design einer 
molekularen Sonde und hängt stark vom Bilgebungsverfahren ab, für das die Sonde eingesetzt werden 
soll (Kapitel 1). 
Die vorliegende Arbeit behandelt das Design, die Synthese und die pharmakologische 
Charakterisierung hochspezifischer bildgebender Sonden, welche weiterführend zur Untersuchung 
von zwei pharmakologisch relevanten Targets eingesetzt wurden. In beiden Projekten ermöglichte 
eine modulare Synthesestrategie die Verknüpfung spezifischer Liganden mit Reportereinheiten, 
welche jeweils auf spezielle Anwendungen optischer Bildgebung zugeschnitten sind.  
Der erste Teil dieser Arbeit beschreibt die Entwicklung fluoreszenter Sonden für die Untersuchung 
des Cannabinoid Typ 2 Rezeptors (CB2R) (Kapitel 2). Die starke Hochregulierung dieses Rezeptors 
wird mit pathologischen Zuständen assoziiert, die hauptsächlich von Entzündungsprozessen 
ausgelöst werden. CB2R stellt daher ein wichtiges Protein-Target für sowohl therapeutische als auch 
diagnostische Ansätze dar. Ausgehend von einem präklinischen CB2R Agonisten als 
Erkennungselement wurden geeignete strukturelle Verknüpfungspunkte für einen Linker sowie der 
Einfluss von Linkeraufbau und –Länge untersucht. Von besonderer Bedeutung war es dabei, eine 
Linkertrajektorie zu finden, die aus der Bindungstasche des Proteins in die umgebende Matrix reicht 
und gleichzeitig abträgliche Interaktionen zwischen Linker-Reporter Konstrukt und Rezeptor zu 
vermeiden. Diese Strategie resultierte in einer robusten synthetischen Plattform, bei der 
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Bindungsaffinität und –Selektivität überwiegend unbeeinflusst von der Art des angebrachten 
Farbstoffs sind.  
Der zweite Teil der Arbeit befasst sich mit der Synthese fluoreszenter Sonden zur Früherkennung von 
Bauchspeicheldrüsenkrebs (PDAC), die multivalent mit Targeting-Einheiten versehen sind (Kapitel 
3). Das Sondendesign basiert auf einem vierfach derivatisiertem Cyclengerüst zur Entwicklung einer 
„klickbaren“ Plattform, die aus drei terminalen Maleimid-Funktionalitäten und einem Alkin besteht. 
Diese cyclenbasierte Plattform ermöglichte die Eintopfsynthese von PDAC zielgerichteten Sonden, 
welche jeweils mit zwei verschiedenen Cyaninfarbstoffen markiert wurden. Die Sonden wiesen hohe 
Selektivitäten für die Detektion von PDAC in zellbasierten Assays im Vergleich zu ihren nicht-





2-AG 2-Arachidonoylglycerol 2,5-DHAP 2,5-Dihydroxyacetophenone 
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Acc. Acceptor AEA N-Arachidonoylethanolamide 
ACN Acetonitrile AlogP Atomic logP  
aq.  Aqueous  Bn Benzyl  
Boc tert-Butoxycarbonyl BOP-Cl Bis(2-oxo-3-oxazolidinyl)phosphinic 
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CB1R Cannabinoid type 1 receptor CB2R Cannabinoid type 2 receptor 
Cbz Carboxybenzyl CDI 1,1'-Carbonyldiimidazole 
cHex Cyclohexane CHO Chinese Hamster Ovary 
cRGD Cyclic RGD CuAAC Copper assisted azide-alkyne 
cycloaddition 
Cy Cyanine fluorophore Cyclam 1,4,8,11-Tetraazacyclotetradecane 
Cyclen 1,4,7,10-Tetraazacyclododecane Cys Cysteine 
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DMAP N,N-Dimethylaminopyridine DMF Dimethylformamide 
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phine) 
ee Enantiomeric excess EC50 Half maximal effective concentration 
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eCB Endocannabinoid ECL Extracellular loop 
EDTA Ethylenediaminetetraacetic acid eff. Efficacy 
EGFR Endothelial growth factor receptor equiv.  Equivalents 
ESI Electrospray ionization Et Ethyl 
et al.  Et alli (“and others”) FAAH Fatty acid amide hydrolase 
FACS Fluorescence-activated cell sorting FDA Food and Drug Administration 
FDG Fluorodeoxyglucose Fmoc Fluorenylmethoxycarbonyl 
GPCR  G protein-coupled receptor GRK GPCR kinases 







HMDS Hexamethyldisilazane HPLC High-pressure liquid chromatography 
HSTU N,N,N',N'-Tetramethyl-O-(N-succin-
imidyl)-uronium hexafluorophosphate 
HTRF Homogeneous time-resolved 
fluorescence 
Hz Hertz (s-1) IC50 Half maximal inhibitory concentration  
ID Identification ICG Indocyanine green 
ICL Intracellular loop ICP-MS Inductively coupled plasma mass 
spectrometry 
iPr Isopropyl J Coupling constant 
Kd Equilibrium dissociation constant (M) Ki Inhibitory constant (M) 
Kob Observed rate of association (min-1) Koff Dissociation constant (min-1) 
Kon Association rate constant (M-1min-1) KRAS Kirsten rat sarcoma gene 
LC-MS Liquid chromatography–mass 
spectrometry 
LDA Lithiumdiisopropyl amide 
LE Ligand efficiency m Mouse 
m Multiplet M  Molar (mol/L) 
MALDI Matrix-assisted laser desorption/ 
ionization 
MAPK Mitogen-activated protein kinase 
m-CPBA meta-Chloroperoxybenzoic acid Me Methyl 
Memb. Membrane MFI Mean fluorescence intensity 
MPLC Medium-pressure liquid chromatography MRI Magnetic resonance imaging 






NBS N-Bromosuccinimide NCS Isothiocyanate 
n.d. Not determined nHep n-Heptane 
NHS N-Hydroxysuccinimide NIR Near-infrared 
nm Nanometer (10-9 m) nM Nanomolar (10-9 M) 
NMR Nuclear magnetic resonance NOTA 2,2',2''-(1,4,7-Triazonane-1,4,7-triyl)tri-
acetic acid 
OI Optical imaging  OP Optimization 
P Partition coefficient  p53 Tumor protein p53 gene 
pAfBPP Photoaffinity-based protein profiling PALM Photoactivated localization microscopy 
PAMPA Parallel artificial membrane permeability 
assay 
PanIN Pancreatic intraneoplasia 
PBS Phosphate buffered saline Pd/C Palladium on charcoal 
PDAC Pancreatic ductal adenocarcinoma PDB Protein data bank 
PEG Polyethylene glycol PET Positron emission tomography 
PFP Perfluorophenol PI Photoacoustic imaging 
ppm Parts per million PSA Polar surface area 




qRT-PCR Real-time quantitative reverse trans-
cription polymerase chain reaction 
quant. Quantitative 
rcf Relative centrifugal force Rf Retention factor 
rpm Rotations per minute r.t. Room temperature 
RT Residence time (min) s Singlet 
SAR Structure activity relationship SERS Surface-enhanced Raman spectroscopy 
SFC Supercritical fluid chromatography SiR Silicon-Rhodamine fluorophore 
SNAP Type of self-labeling protein tag sol. Solution 
SPAAC Strain-promoted azide-alkyne 
cycloaddition 
SPECT Single-photon emission computed 
tomography 
SPIO Superparamagnetic iron oxide SST2R Somatostatin type 2 receptor 
STED Stimulated emission depletion STORM Stochastic optical reconstruction 
microscopy 
t  Triplet T  Temperature 
T1 Longitudinal relaxation T2 Transverse relaxation 
T3P Propanephosphonic acid anhydride Tacn 1,4,7-Triazonane 
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TATE Octreotate, cyclic peptide targeting 
SST2R 
TBAF tetra-N-Butylammonium fluoride 




TFA Trifluoroacetic acid 
THC Δ9-Tetrahydrocannabinol THF Tetrahydrofuran 
TOF Time-of-flight TR-FRET Time-resolved fluorescence resonance 
energy transfer 
Ts Tosyl UV Ultraviolet 
v Volume VEGFR2 Vascular endothelial growth factor 
receptor 2 
vs.  Versus w Weight 






1. Motivation and Background 
 
1.1. Molecular Imaging  
In 1665, Robert Hooke described in the essay “Micrographia” his observations using a microscope, 
including compartment-like structures in cork samples – which he termed cells.[1] The foundations of 
modern light microscopy were established 200 years later by Ernst Abbe with the demonstration that 
the resolution of a focusing light microscope is limited by diffraction.[2] In the same decade, Rudolf 
Virchow founded the field of cellular pathology by correlating the understanding of diseases with 
cellular abnormalities.[3] The emergence of the synthetic fluorescent dye industry[4] – in particular, the 
synthesis and commercialization of fluorescein by Adolf von Bayer in 1871[5] – aided Paul Ehrlich in 
developing his innovative cellular staining techniques,[6] which lastly evolved into the magic bullet 
concept.[7] However, it was only after the discovery of the X-ray by Wilhelm Conrad Röntgen in 1895 
that the first medical image was generated.[8] The image featured Ms. Röntgen hand wearing her 
wedding ring on the fourth finger. Over the following 125 years, the understanding of the cell, 
microscopy techniques, and anatomical imaging have vastly improved upon. Nowadays, image 
acquisition is performed at highly sophisticated instruments in a time-dependent manner with 
resolutions evolving up the nanometer range. 
With the ultimate goal of “seeing for believing”, scientists are motivated to decipher the underlying 
cellular and molecular mechanisms of action driving both health and disease. Methods to directly see 
into cells or see into the body have become essential tools for the study, diagnosis, and monitoring of 
pathologies. Seeing is, however, not always possible in biology as size, sensitivity, resolution, and 
additional concerns hamper an accurate investigation. Much research efforts have been directed 
toward understanding the function of specific genes and proteins, from subcellular compartments to 
humans, in a high-resolution, non-invasive, time, and costly manner. In the past two decades, the 
molecular imaging field has grown exponentially as it allows for the visualization, characterization, and 
tracing of biologic pathways at the cellular and molecular level.[9] Traditionally, medical imaging has 
been exploited for diagnostic purposes, enabling the identification and localization of diseased tissues. 
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In contrast to solely anatomy-based imaging techniques, molecular imaging has the potential to 
provide functional characterization of the molecular processes involved in pathology. 
Technological advances in imaging modalities i.e. laser, camera, and processing tools have largely 
impacted health care. The principles of molecular imaging can be now tailored to diverse imaging 
modalities, including positron emission tomography (PET)[10] and single-photon emission computed 
tomography (SPECT),[11] magnetic resonance imaging (MRI),[12] ultrasound,[13] photoacoustic imaging 
(PI),[14] optical imaging (OI),[15] and Raman spectroscopy.[16] These technologies differ in spatial and 
temporal resolution, depth penetration, energy expended for image generation (ionizing or non-
ionizing), availability of imaging probes, and the respective detection threshold of probes.[16b, 17] As 
each technology encounters particular limitations and challenges, choosing the appropriate readout 
strongly depends on the scientific question and specific research aims. At present, molecular imaging 
applications in medicine range from target validation[18] and target engagement studies[19] at drug 
development and pre-clinical stages to precision prevention[20] and early diagnosis of diseases[15b, 21] up 
to intraoperative imaging.[22] 
Besides the unprecedented development of imaging technology, targeted imaging ligands have played 
a central role in highlighting subcellular components that would be otherwise invisible under 
anatomical imaging analysis. The discovery and exploitation of imaging agents have evolved from 
more traditional pharmacological approaches – where advantage was taken from individual natural 
products and drugs for probe generation – to the current higher throughput methodologies, including 
phage display, DNA-encoded library screening, and fragment-based approaches.[23] These tools can 
be applied to tackle the biological and chemical space more systematically as they allow, e.g., to study 
molecular pathways, to thoroughly validate new pharmacological targets, and to transition therapeutics 
into the human situation. Yet, one major concern in the field is the use of poorly characterized imaging 
agents which may confound the interpretation of data and misleading biological conclusions about 
target relevance. Recent publications from both academia and pharmaceutical industry underscore the 
need for robust and reliable probes that are both chemically and pharmacologically fully 
characterized.[24] Therefore, the evaluation of several parameters, including stability, water solubility, 
cell permeability, on- and off-target effects, potency, and selectivity is of paramount importance. 
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Figure 1.1. Molecular imaging probe platforms developed in this thesis. A) CB2R-selective fluorescent ligand 
template and B) multivalent fluorescent agent targeting pancreatic cancer.  
The presented thesis illustrates a case in which the design, synthesis, and characterization of highly 
specific imaging probes led to the labeling of two relevant drug targets: the cannabinoid subtype 2 
receptor (CB2R) (Figure 1.1.A) and plectin-1 (Figure 1.1.B). Altogether, the fluorescently labeled 
platforms shown in Figure 1.1. derived from highly versatile precursors which were carefully designed 
and optimized to suit an array of biologically and pharmacologically relevant investigations. The two 
following sections give a brief introduction of commonly used molecular imaging modalities as well 
as highlight the key aspects of probe design and how imaging tools help to circumvent the intrinsic 




1.2. Molecular Imaging Modalities – Overview and Applications 
X-ray medical imaging has rapidly progressed, becoming the foundation of numerous modern 
diagnostic imaging procedures, including mammography, tomography, and angiography.[8] By the 
1950s, the administration of contrast agents containing barium or iodine allowed the identification 
and treatment of several cancers and pathologies in the gastrointestinal tract and brain. With the 
emergence of radioactivity, nuclear medicine promptly joined the arsenal of imaging modalities. The 
two most prominent tests in nuclear medicine today are single-photon emission computed 
tomography (SPECT) and positron emission tomography (PET) scanning. While SPECT utilizes 
gamma rays derived from radionuclides, such as 99mTC, 123I, and 111In, from which 3D images are 
reconstructed by computer analysis,[25] PET is based on the detection of high-energy photon pairs 
produced during annihilation collision between a positron and an electron as source for readout.[26] 
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Most PET is based on positron-emitting isotopes of 18F, 64Cu, and 68Ga which have typically short 
half-lives. Thus, incorporation of such isotopes into PET imaging tracers must occur in a cyclotron 
near the PET facility for immediate application. Both SPECT and PET techniques share similar 
strengths and drawbacks as they display unlimited depth penetration and high sensitivity, having the 
ability to provide detailed metabolic information, but are restricted by low spatial resolution, lack of 
anatomical information and high costs.  
Ultrasound was first used clinically in the 1970s.[27] Conversely to X-ray and nuclear medicine which 
require ionizing radiation, ultrasound is based solely on sound waves.[28] In particular, tomographic 
images are generated by the reflection of sound waves as they pass through tissues. This technique 
offers high spatial resolution and provides excellent anatomical features for coregistration with 
molecular information. Despite plenty of targeted imaging agents that have been designed for 
ultrasound applications, these molecules have often large sizes (>250 nm), which may hamper tissue 
penetration.[29] Therefore, ultrasound is commonly used for noninvasive imaging of the abdomen and 
pelvis, including imaging the fetus during pregnancy. 
Magnetic resonance imaging (MRI) and optical imaging (OI) also evolved during the 1970s.[30] Both 
modalities have the advantage of not requiring ionizing radiation and have considerably impacted the 
(bio)medical imaging field. The ability of MRI to provide soft tissue discrimination allowed clinicians 
to obtain earlier diagnoses. MRI images are generated from differences in longitudinal (T1) and 
transverse (T2) relaxation times of a specific active nucleus, such as 
1H and 19F, in different tissues 
when specific radiofrequency pulse sequences are applied.[31] By exploring proton density, perfusion, 
diffusion, and biochemical contrasts, MRI has the advantages of high spatial resolution and good 
depth penetration, offering anatomic, physiologic, and metabolic information. The primary limitation 
of MRI is its low sensitivity, which is partially overcome by longer acquisition times and the use of 
imaging agents for contrast enhancement. Especially, targeted paramagnetic, e.g., gadolinium(III) 
complexes and superparamagnetic, e.g., iron oxide nanoparticles (SPIO) contrast agents increase 
signal contrast in the tissue of interest by disturbing the local magnetic field, either T1 or T2.
[32] In 
particular, these agents are indirectly detected by their effect on bulk water molecules and the 
magnitude of this effect is strongly influenced by their chemical properties.[33] Taking advantage of 
these tunable properties, state-of-art MRI contrast agents are being explored as activatable tools, 
whose signal is modulated upon physiological changes, e.g., pH, enzymatic activity, and temperature. 
In the clinics, the vast majority of MRI contrast agents are composed by small, hydrophilic 
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gadolinium(III)-based complexes.[34] The chelating cage has the important role of reducing the 
inherent toxicity of gadolinium(III) ions and enhancing its excretion of the human body. These tools 
are primary indicated for imaging lesions of the central nervous system, with secondary applications 
bearing liver and angiographic imaging. 
Optical imaging (OI) is one of the most successful imaging modalities for preclinical studies, as it 
allows for real-time monitoring of molecular events in a highly sensitive, throughput, and inexpensive 
fashion. Recent clinical applications of OI comprise image-guided surgery[35] and ophthalmic, 
cardiovascular, and cancer imaging.[36] Particularly for in vivo applications, this modality covers a range 
of techniques which can be divided into bioluminescence and fluorescence imaging. Whilst 
bioluminescence imaging depends on luciferase expression, an enzyme available in nature and 
responsible for the glowing of some insects, jellyfish, and bacteria, fluorescence imaging detects light 
emitted from fluorescent reporters, including organic dyes,[37] quantum dots,[38] and lanthanides.[39] A 
major advantage of fluorescence imaging is the possibility of multichannel imaging experiments by 
simultaneously applying multiple fluorophores containing different photophysical properties.[36] 
Fluorescence emissions in the visible region (400–650 nm) usually have limited utility for in vivo 
imaging settings due to attenuation and scattering of light as well as interference caused by 
autofluorescence from endogenous substances, including cytochromes and hemoglobin. These 
drawbacks are minimized in the near-infrared (NIR) window (650–900 nm) which enables deeper 
penetration depths – up to 10 cm.[40] In addition, many new technologies and techniques have been 
developed that allow for combinations of deeper and faster, imaging at a higher resolution. For 
example, two-photon fluorescence microscopy allows for imaging thick samples, e.g., tissues both in 
vitro and in vivo by applying pulsed NIR excitation light.[41] The excitation occurs when fluorescent 
molecules absorb two photons simultaneously, thereby producing higher energy (700-1000 nm). This 
effect increases penetration depth, while limiting bleaching and phototoxicity. Alternatively, the 
nonlinear properties of fluorescent molecules, e.g., switching behaviors and on/off states enable to 
surpass the light diffraction limit.[42] The so-called super-resolution or nanoscopy techniques have 
demonstrated to resolve images in a 10–100 nm resolution range. Current super resolution methods 
fundamentally differ in the excitation mode of fluorophores and in the detection of emitted photons. 
Most common approaches for biological imaging are photoactivated localization microscopy 
(PALM),[43] stochastic optical reconstruction microscopy (STORM),[44] and stimulated emission 
depletion (STED).[45]  
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During the 1990s, photoacoustic imaging (PI) emerged as a new non-invasive imaging methodology.[46] 
This technique typically uses short-pulsed electromagnetic radiation as probing energy, while detecting 
ultrasound generated by photon absorption and thermoelastic expansion. The photoacoustic effect 
can be either generated by endogenous, e.g., cytochromes and hemoglobin, or exogenous absorbers, 
e.g., porphyrin-based derivatives. Because ultrasound undergoes considerably less scattering and 
attenuation in tissue compared with light, PI provides high spatial resolution and deep tissue 
penetration. Modern photoacoustic devices enable real-time visualization of physiological, 
morphological, vascular, and molecular details of diseased tissues.[47] Such measurements, however, 
still lack sensitivity in detection and image acquisition. 
Raman scattering of light by molecules was first observed by Raman and Krishnan in 1928,[48] however, 
it was only in the late 1990s that this technology has been applied to characterize biological systems.[49] 
Raman spectroscopy explores monochromatic light, from the NIR up to the ultraviolet (UV) range, 
to generate the Raman scattering effect, i.e., inelastic scattering of photons,[49] which is dependent on 
the vibrational modes associated with chemical bonds within the analyzed sample. During such 
experiments, each compound displays unique energy levels which it translates to a specific spectrum 
or Raman fingerprint.[50] For example, the Raman spectrum of a cell or tissue can provide detailed 
information on their chemical composition in a non-invasive manner.[51] As spontaneous Raman 
events are of low-probability, being detected only in a small fraction of the scattered light (circa 1 in 
107),[52] Raman spectroscopy lacks the required sensitivity for clinical applications.[53] To enhance 
sensitivity and penetration depth, variations of the Raman spectroscopy technique have been 
developed over the years, allowing for imaging studies to be conducted in vivo.[54] In particular, surface-
enhanced Raman spectroscopy (SERS) explores metal nanoparticles, usually gold or silver, in 
combination with fluorophores, such as cyanine (Cy) dyes, to increase Raman scattering. This 
approach enables image acquisition with superior sensitivity over label-free analysis with the possibility 
of multiplexing, i.e., detecting multiple analytes, thereby improving diagnostic specificity.  
Currently, various imaging modalities can be used to access specific molecular targets – certainly, 
depending on the application, some techniques are better suited than others. Nevertheless, no single 
modality is perfect and sufficient to provide all the necessary information on the structure and function 
of a subject. For example, PET displays high sensitivity but poor spatial resolution, MRI has good 
resolution yet low sensitivity and OI offers real-time images with remarkably high sensitivity and 
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resolution but has limited penetration depth.[16b, 17] The general characteristics of the imaging modalities 
here described are summarized in Table 1.1. and Figure 1.2. 







































































(< 100 µm) 












Very high in 
vitro (10 – 100 
nm); 










PI NIR light 
Photosensitizers: 



























[a] Ability to detect the probe relative to the background; [b] Measure of the accuracy and detail of graphic displayed 
in the images; [c] This includes the cost of equipment and cost per study; [d] Sensitivity limits not determined. 
Figure 1.2. Comparison of the resolution and penetration depth of the discussed imaging modalities. 
Usually, resolution decreases as depth increases, rendering modalities such as PET and MRI suitable for imaging 
whole organs in vivo whereas modalities with higher resolution such as OI are best suited for ex vivo and in vitro 
imaging at the sub-cellular level. 
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Amongst all these methodologies, the design of appropriate imaging probes is key to distinguish 
particular biological mechanisms of action and to reflect this information in the format of images. 
Therefore, it is presumable that important breakthroughs in the molecular imaging field will be largely 





1.3. Molecular Imaging Probes 
Besides the preferred imaging read-out, molecular imaging relies on the appropriate target or 
biomarker selection and the generation of reliable targeted imaging ligands. With the advance of 
genomics and proteomics as well as the increased knowledge on disease etiology, however, target 
identification has become an extremely faster process than probe development.[55] As a consequence, 
the pathophysiological rote of several pharmacological relevant targets remain uncharted due to the 
lack of appropriate chemical tools. Because of the central role of contrast agents in molecular imaging 
investigations, the design and validation of these molecules is one of the major research interests 
within the field.[17a, 56]  
By definition, imaging probes are thoroughly chemically characterized small molecules of well-defined 
biological affinity and selectivity which are used to visualize and investigate complex biological 
systems.[24a] The underlying differences between molecular imaging tools and conventional drugs 
reside in their distinctive application purposes, design strategy, and characterization.[57] For example, 
drugs are intended to treat abnormalities, and thus, may act on multiple targets in a 
polypharmacological approach to produce the desired clinical benefits. Whereas imaging ligands must 
be extremely selective to deliver accurate diagnostic information and address specific questions related 
to functional aspects of the target in the context of the disease – e.g., determining downstream 
signaling cascades related to specific phenotypes and investigating the mode-of-action of a 
pharmacophore. In particular, such tools enable the synergistic evaluation of the drug, the target, and 
the biological response, providing means for scientists and clinicians to identify and elucidate the 
molecular mechanisms triggering disease. In addition to their clinical applications which include 
disease diagnoses, assessment of treatment response, and surgery-guided options, imaging agents are 
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now an important component of drug development.[18, 23a, 24c] During early drug discovery research, 
labeled derivatives are used to determine expression levels of the target and its function, providing 
information related to biodistribution, pharmacokinetics, target engagement, toxicity, and dose 
selection of drug candidates.[58] 
A molecular imaging probe is generally constituted of three main components: (i) a reporter or 
contrast enhancing unit, (ii) a recognition element (ligand or pharmacophore) that tolerates further 
chemical functionalization while preserving its affinity and selectivity towards the target, and (iii) a 
linker that separates these two functionalities (Figure 1.3.).[59] Each of these constituents represents 
unique challenges for the design of a successful probe. The reporter unit produces the signal for 
imaging purposes and its nature will depend on the application of the probe in a respective imaging 
modality. Signal agents span from radionuclides for PET and SPECT to magnetic complexes for MRI 
up to fluorophores for OI, PI, and Raman-based SERS (see Table 1.1., Section 1.2.). The recognition 
element directs the probe to the site of interest and interacts with the target of a particular biological 
process. Any targeting ligand, such as drugs, natural products, endogenous molecules, peptides, 
proteins, antibodies and its fragments, can be exploited as recognition element. By connecting the 
reporter with the recognition element, the linker minimizes the interaction between these two 
moieties,[60] thereby, avoiding detrimental effects of the often bulky and charged signal agent with the 
target. Importantly, the linker composition has a significant impact on the pharmacology and 
biodistribution of the probe.[61] Thus, the length, flexibility, hydrophilicity, and charges are key features 
to be considered during linker selection. Another crucial aspect is the linker attachment point at the 
ligand as choosing the “wrong” position may lead to complete loss in affinity and/or selectivity.[62]  
In general, the composition of molecular imaging probes can be categorized into three major 
approaches: the linear, the multivalent, and the multimodal (Figures 1.3. to 1.5.).[57] The linear design 
is probably the most common approach and involves the coupling of the ligand with the reporter unit 
through a linker (Figure 1.3.A). One example of this labeled ligand class was developed for targeting 
the somatostatin type 2 receptor (SST2R) which is known to be overexpressed in a variety of cancers.
[63] 
The cyclic peptide octreotate (TATE, 1.1, Figure 1.3.B) was selected as recognition element for 
labeling at the N-terminus with a Sulfo-Cy5 dye (1.2, Figure 1.3.C). In a cell-based assay using cancer 
cells expressing the SST2R, compound 1.2 displayed an IC50 of 106 nM which corresponds to a fivefold 




this case study demonstrates how the introduction of a signal agent can influence the overall binding 
properties of the ligand conjugate.  
Figure 1.3. The linear probe design strategy combines the recognition element of choice with the reporter 
unit through a linker. A) Schematic representation of this design strategy, B) structure of the recognition element 
TATE chosen for probe development (1.1),[64] and C) SST2R-targeted fluorescent probe 1.2.[64] Modified after K. 
CHEN et al.[57]  
The combination of multiple ligands via covalent linkage to a template generates multivalency (Figure 
1.4.A). Many studies have described the benefits of compound multimerization to enhance target 
avidity and in vivo retention times at the site of interest.[65] For this design strategy, a delivery vehicle, 
such as a nanocapsule, can also function as a linker.[66] For example, multiple units of the TATE 
peptide (1.1, Figure 1.3.B) were employed for assembling the SST2R-targeted liposomal PET tracer 
1.3 (Figure 1.4.B).[67] The TATE peptides were conjugated via thiol-maleimide Michael- addition type 
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Figure 1.4. The Multivalent probe design combines multiple recognition elements and the reporter unit via 
covalent linkage to a template. A) Schematic representation of this design strategy, B) multivalent somatostatin 
type 2 receptor-targeted PET tracer 1.3,[67] and C) monovalent SST2R-targeted control 1.4.[67] Modified after K. CHEN 
et al.[57]  
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reaction to a PEG-ylated liposomal drug carrier with an encapsulated 64Cu positron emitter. PET 
images applying multivalent derivative 1.3 demonstrated very good in vivo uptake at the tumor region 
in comparison to surrounding healthy tissues. Moreover, this uptake was twofold higher than the 
monovalent TATE-tracer 1.4 (Figure 1.4.C) which was used as control for these PET experiments.[67] 
Figure 1.5. The dual-imaging design combines the recognition element with several reporters to enable 
complementary imaging read-outs. A) Schematic representation of this design strategy and B) dual-OI and PET 
probe 1.5 targeting the SST2R.[68] Modified after K. CHEN et al.[57] 
Alternatively, the ligand can be conjugated to several reporter units for dual-imaging applications 
(Figure 1.5.A).[65b, 69] Using this concept, the advantages of two imaging modalities are combined, whilst 
at the same time reducing the disadvantages of both. However, the synthesis of such a compound is 
an extremely challenging task as it requires a ligand with two amenable positions for conjugating both 
linker-reporter unit constructs. Each signal agent introduces a large amount of steric bulk to the probe 
scaffold which can significantly alter the pharmacology and physicochemical properties compared to 
the unconjugated recognition element. The TATE peptide (1.1, Figure 1.3.B) served as starting point 
for the synthesis of a multimodal OI and PET agent containing a NIR-dye at the side chain of the 
lysine amino acid and a 64Cu-DOTA group at the N-terminus (1.5, Figure 1.5.B).[68] These 




The best design approach for probe development will depend on the specific target and imaging 
modality and to achieve optimal performance, each component of the construct must be thoroughly 
investigated.[57] As illustrated by the TATE-based ligands (Figures 1.3. to 1.5.), the conjugation of the 
linker and reporter unit affects the structure, physicochemical and pharmacological properties of the 
recognition element. Therefore, the imaging probe should be considered as a completely new 
pharmacological entity when compared to the parent ligand and be fully characterized before its use 
in further studies. Overall, imaging agents should display good solubility and stability in aqueous media 
in order to avoid unwanted aggregation, be readily available in pure form, and have known cell 
permeability.[70] High-quality probes are pharmacologically well characterized, exhibiting high potency 
and selectivity profiles. Moreover, such tools need to demonstrate target engagement and, in some 
cases, even modulate a relevant biochemical pathway in cells. These parameters require experimental 
characterization not only from cell-free assays but also from multiple cellular test settings and/or 
whole animal assessment. Evaluation of these properties provides a robust characterization of the 
imaging ligand and helps to determine their suitability for exploratory biology. In addition, to minimize 
off-target effects and avoid false conclusions, the use of precisely designed control derivatives with 




1.4. General Aim of this Thesis 
The present thesis aims at the development, characterization, and application of two distinct optical 
imaging probe platforms. For both projects, a modular synthesis concept was applied to enable 
recognition element and reporter unit selection tailored for a multitude of imaging investigations and 
test settings.  
The first part of this thesis describes the design, synthesis, and biological in vitro evaluation of 
fluorescent ligands to visualize the cannabinoid type 2 receptor (CB2R), a relevant pharmacological 
target correlated with the onset of inflammation (Chapter 2.). The focus was set on the generation of 
a CB2R-specific fluorescent probe template based on the linear design approach (Figure 1.3.A, Section 
1.3.) exploring two small-molecule recognition elements derived from a CB2R agonist drug discovery 
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program from Hofmann La-Roche. In particular, this labeled compound should display high affinity 
towards human and mouse CB2R while retaining selectivity over the cannabinoid type 1 receptor 
(CB1R) subtype. Assisted by molecular modeling studies performed at Hofmann La-Roche by DR. 
WOLFGANG GUBA, two different attachment sites were investigated at each pharmacophore for linker 
conjugation (Section 2.1.1.). For both attachment sites, the linker properties were investigated through 
modifications of its length and composition. Of special interest was to identify a robust linker exit 
vector pointing towards the extracellular space of the receptor. This design would allow the 
introduction of diverse fluorescent dyes useful in a broad range of biological applications. 
For the second project, the 1,4,7,10-tetraazacyclododecane (cyclen) scaffold was exploited for the 
design of a multivalent probe template (Figure 1.4., Section 1.3.) targeting plectin-1, a cytoskeleton 
protein known to be overexpressed in pancreatic cancer (Chapter 3.). A plectin-1 targeting peptide 
sequence (PTP, NH2-KTLLPTPC-COOH) was selected as recognition element and two cyanine dyes, 
Cy3 and Cy5.5 served as reporter units. A modular synthesis approach was envisioned applying 
subsequent click chemistry reactions, i.e., biocompatible reactions that are simple to perform, provide 
high conversion rates to the product, and are broad in scope.[71] While Michael type addition reaction 
of cysteines and reactive thiols was planned to introduce three PTP sequences, the cyanine dyes would 
be attached through amide coupling or Copper-mediated azide alkyne cycloaddition (CuAAC). To 
evaluate the influence of multiple ligands on pancreatic cancer imaging, monovalent control congeners 










2.1.1. G Protein-Coupled Receptors  
G protein-coupled receptors (GPCRs) are key mediators of a wide range of cell signaling processes.[72] 
Due to their therapeutic potential in disease modulation and their chemical tractability as membrane 
proteins, GPCRs constitute one of the most important druggable human receptor families.[73] It is 
currently estimated that 35% of the approved drugs target GPCRs,[74] and these drugs act in diverse 
therapeutic areas, including neurological, inflammatory, cardiovascular, respiratory, and 
gastrointestinal disorders.[75] Structure-based tools are largely explored for GPCR drug design and lead 
optimization.[76] Recent crystal structures have the ability to reveal the three-dimensional structure of 
GPCRs, location of bound ligands, and details regarding receptor-ligand interactions.  
Generally, GPCRs share a highly conserved structure, consisting of seven transmembrane helices (I 
to VII) linked by three intracellular loops (ICLs), and three extracellular loops (ECLs)[77] (Figure 2.1.). 
The GPCR superfamily is subdivided into classes based on amino acid sequence homology and 
common physiological ligands,[78] such as neurotransmitters, hormones, cytokines, metabolites, and 
odorants.[79] In particular, the human proteome encompasses five of these subfamilies: rhodopsin 
(class A), adhesion and secretin (class B), glutamate (class C), as well as frizzled and smoothened (class 
F).[80] Among these, the Rhodopsin family contains the largest number of receptors, including many 
well-characterized drug targets. An example of this receptor class is the family of cannabinoid 
receptors, which are the subject of this thesis chapter. 
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Figure 2.1. General structure of a GPCR. Views from within the membrane plane (left) and extracellular side (right) 
represent the typical seven-pass transmembrane GPCR architecture. The 3D structure shown is from the active state 
of the CB2R, a representative class A GPCR, co-crystalized in complex with the agonist AM12033 (PDB 6KPF).[81] 
Transmembrane domains are colored from the N-terminus (dark blue) to the C-terminus (dark red). ECLs – 
extracellular loops, ICLs – intracellular loops.  
The activity of a GPCR is defined by its conformational state, which ranges from inactive to multiple 
active states.[82] In the absence of bound ligands, GPCRs exhibit variable basal activities. Upon binding, 
each ligand displays a characteristic efficacy, i.e., the ability to activate or deactivate its target, which 
affects their pharmacological properties. According to the inherent efficacy, GPCR modulators are 
classified as full agonists, partial agonists, antagonists, and inverse agonists (Figure 2.2.).[83]  
Figure 2.2. Representative plots of signaling activity versus ligand concentration illustrating different 
GPCR efficacies. 
In brief, full agonist binding induces conformational changes to an active state of the receptor, 
maximizing signaling response. Likewise, partial agonists also promote receptor activation but elicit 
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submaximal stimulation, even at saturating concentrations. Antagonists prevent binding of other 
modulators without modifying the basal activity of the target. Conversely, inverse agonists shift the 
receptor conformational equilibrium toward inactive conformations, thereby decreasing the level of 
activity below that of the unbound receptor.[83] 
Agonist binding activates the receptor by inducing conformational changes that trigger signal 
transduction mediated by G proteins, GPCR kinases (GRKs), and arrestins[84] (Figure 2.3.). Coupling 
of heterotrimeric G proteins to the receptor generates dissociation of the Gα subunit from the Gβγ 
subunits that regulate different downstream effector proteins, stimulating the production of second 
messengers such as cyclic AMP (cAMP), calcium, and phospholipases. Activation of the receptor may 
also promote phosphorylation by GRKs which is followed by coupling to arrestin. Signal transduction 
mediated by arrestins leads to receptor desensitization and activation of downstream cascades, 
including mitogen-activated protein kinases (MAPKs) and tyrosine kinases. In addition, arrestin 
activation stimulates endosomal receptor internalization and subsequent receptor degradation or 
recycling to the plasma membrane. The signaling modulation through G protein and arrestin pathways 
varies according to the ligand, and those that preferentially modulate one pathway over the others are 
referred to as biased ligands.[85] Importantly, differences in biased signaling critically affect the 
therapeutic properties of drugs acting on GPCRs, and offers new mechanisms for reducing side effects. 
Figure 2.3. Schematic diagram of GPCR signaling. Activated GPCRs induce signal transduction through 
independent signaling pathways via either G proteins (left) or GPCR kinases (GRKs) and arrestins (right). Modified 
after D. HILGER et al.[84]  
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Despite recent advances in the structural characterization of many GPCRs,[76] specific ligand-receptor 
interactions that drive the essential conformational changes and ultimately result in activation or 
inhibition of receptor-mediated signaling pathways remain uncharted. Understanding the 
pharmacology of an unmodified receptor in its native cellular environment and tracing of specific 
signaling cascades upon modulation is extremely important for the development of new and more 
efficient drugs. Here, molecular imaging provides diverse opportunities to evaluate the chemical 
environment and intermolecular interactions of GPCRs.[86] In particular, optical imaging (OI)-based 
techniques applying fluorescent probe modulators enable real-time visualization of protein trafficking 
and monitoring of many dynamic downstream pathways (see Sections 1.2s and 1.3.). Depending on 
their photophysical properties, fluorescent ligands can be applied to plenty of spectroscopic 
approaches, including confocal microscopy for high-resolution images, fluorescence activated cell 
sorting (FACS) for target engagement and selectivity studies, time-resolved fluorescence resonance 
energy transfer (TR-FRET) for equilibrium and kinetic binding investigations, and automated confocal 




2.1.2. Exploring the Cannabinoid Type 2 Receptor (CB2R) as a Drug Target 
The therapeutic and psychoactive properties of the plant Cannabis sativa have been known for centuries. 
However, research on cannabis chemistry and pharmacology advanced slowly. Over nearly a century, 
several unsuccessful attempts were made to isolate in pure form active marijuana constituents and to 
elucidate its structures.[88] The lack of success of former trials could retrospectively be explained by 
the numerous constituents of cannabis with closely related structures and physico-chemical properties, 
which hampered their separation.[89] In 1964, MECHOULAM and co-workers[90] were able to obtain and 
characterize Δ9-tetrahydrocannabinol (THC, 2.1), one of the most important active components of 
the plant (Figure 2.4.A). Since then, THC (2.1) has been the subject of many scientific investigations 
due to its intriguing biological properties.[91] In the early 1990s, the endogenous signaling system 
responsible for the in vivo effects of THC (2.1) was finally discovered.[92]  
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Figure 2.4. Structures of common plant-derived and endogenous cannabinoids. A) Δ9-Tetrahydrocannabinol 
(THC, 2.1), B) N-Arachidonoylethanolamide (AEA, 2.2), and C) 2-Arachidonoylglycerol (2-AG, 2.3). 
The endocannabinoid (eCB) system is a fundamental lipid signaling system present in all vertebrates 
and responsible for eliciting multiple physiological processes.[93] The endogenously synthesized 
cannabinoids, also named endocannabinoids, cannabinoid receptors, and the enzymes that metabolize 
endogenous ligands are the main constituents of this system. Among the range of endocannabinoids, 
the two most well-known lipid-signaling molecules are N-arachidonoylethanolamide (anandamide, 
AEA, 2.2, Figure 2.4.B) and 2-arachidonoylglycerol (2-AG, 2.3, Figure 2.4.C).[94] Unlike most 
neurotransmitters, such as acetylcholine, dopamine, and serotonin, AEA and 2-AG are not stored in 
vesicles but are rather synthesized when and where they are needed.[95] The biosynthesis of 2-AG (2.3) 
is mainly performed by diacylglycerol lipases and phospholipase C,[96] and degraded by 
monoacylglycerol lipase,[97] while AEA (2.2) is produced by N-acylphosphatidylethanolamine 
phospholipase D (NAPE-PLD),[98] and metabolized by fatty acid amide hydrolase (FAAH).[99] 
At present only two cannabinoid receptors – cannabinoid type 1 receptor (CB1R) and cannabinoid 
type 2 receptor (CB2R) – have been cloned, characterized, and confirmed as key members of the 
endocannabinoid system.[92, 100] Besides the modulation of various intracellular signal transduction 
cascades via G protein, GRK and arrestin signaling pathways, the eCB receptors are known to undergo 
ligand dependent biased modulation[101] and display interspecies differences.[102] Cannabinoid receptors 
share common features such as structure similarity and signaling mechanisms but largely differ in 
tissue distribution.[103] The CB1R is mainly expressed in the central nervous system – being one of the 
most abundant GPCR in the brain – and to a lesser extent in peripheral tissues.[104] Whereas the CB2R 
is found throughout the periphery and is primarily expressed in immune cells, having very low to 
undetectable expression levels in the central nervous system (CNS) under basal conditions.[105] 
Immediately after their discovery, these receptors have received considerable attention by both 
academic and industrial settings. The potential of CB1R receptors as target for diseases of the CNS 
and also peripheral disorders has been limited, however, by the psychoactive side effects derived from 
synthetic ligand antagonists – especially due to reports of severe depression and suicide.[106] Because 
of these unwanted responses, cannabinoid research has shifted the focus to CB2R pharmacology. The 
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strong upregulation of CB2R, both in the brain and periphery, occurs only under specific pathological 
conditions correlated with the pharmacological onset of inflammation.[107] Therefore, CB2R activation 
may provide pharmacological benefits to treat a multitude of inflammatory conditions without 
psychotropic effects derived from CB1R modulation. As most of these disorders are not only severely 
debilitating but also offer limited choices of available treatment. In particular, CB2R agonist-driven 
downstream signaling cascades promote reduction of inflammatory processes by altering microglia 
phenotype and stimulating the production of anti-inflammatory cytokines.[108] There is growing 
evidence that impairment of CB2R signaling in inflammatory conditions is correlated with several 
pathologies, especially organ and tissue injury.[109] Thus, many diseases including kidney, cardiovascular, 
gastrointestinal, lung, neurodegenerative, and psychiatric diseases, as well as pain and cancer are 
correlated with an impaired eCB system.[110]  
There are several distinct compound classes which have been reported to bind cannabinoid 
receptors.[111] Besides endocannabinoids 2.2 and 2.3 (Figure 2.4.B and 2.4.C), classical cannabinoids 
are based on the chemical structure of THC (2.1, Figure 2.4.A), possessing a characteristic tricyclic 
core, and synthetic cannabinoids encompass structurally diverse compounds, including 
aminoalkylindoles, diaryl pyrazoles, and bicyclic ligands.[111] Due to the sequence similarities between 
the cannabinoid receptors, a considerable number of cannabinoids are mixed ligands, i.e., not 
discriminate between particular receptor subtypes. Nevertheless, novel synthetic and classical 
cannabinoids designed to interact selectively with only one cannabinoid receptor have also been 
pursued. In particular, pyridines, pyrimidines, indols, quinolones, oxoquinolines, triazines, and other 
ligand series are selective modulators of the CB2R.
[103, 111a, 112] 
The only approved drugs targeting the eCB system to date are plant-derived and semi-synthetic, 
including medical cannabis as well as the isolated phytocannabinoids THC (2.1), cannabidiol (CBD, 
2.4), and their analogs or combinations (Figure 2.5.). Drugs containing dronabinol (2.1) and nabilone 
(2.5), synthetic THC analogs, are potent dual CB1R/CB2R agonists which are administered for the 
treatment of anorexia, cachexia, and chemotherapy-induced sickness.[113] In contrast, CBD (2.4) is a 
partial agonist of both CB1R and CB2R which is promiscuous to several other targets as well.
[114] Oral 
CBD (2.4) has been launched for treating two forms of epilepsy: Dravet and Lennox-Gastaut 
syndromes.[115] Moreover, combinations of THC (2.1) and CBD (2.4) are approved in various countries 
for spasticity and pain management with clinical trials being evaluated for additional implications, such 
as Alzheimer's disease.[116]  
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Figure 2.5. Chemical structure and in vitro binding affinity (Ki) or functional activity (EC50) of CB2R 
agonists which are launched or under active clinical development.[113-117] [a] The chemical structure of CNTX-
6016 was not disclosed to date, the structure activity relationship (SAR) series of this compound is described on the 
patent US10112934B2.[118] h – human, r – rat. 
The most advanced selective CB2R agonist under active clinical development are Lenabasum (JBT-
101, 2.6) and Olorinab (APD371, 2.7) (Figure 2.5.). While Lenabasum (2.6) is another 
phytocannabinoid which is currently in phase III trials for several disorders, including cystic fibrosis, 
systemic sclerosis, rheumatoid arthritis, and dermatomyositis.[117a-c] Olorinab (2.7) is a synthetic 
cannabinoid composed of a tricyclic 3−5−5-fused pyrazole 3-carboxamides template that reached 
phase II trials for abdominal pain in Crohn’s disease and irritable bowel syndrome.[117d, 117e] 
Numerous selective CB2R ligands were active in animal models of, e.g., chronic and inflammatory 
pain, (neuro)inflammatiory conditions, and liver and kidney fibrosis,[112, 119] yet only a few drug 
candidates are currently tested in clinical trials (Figure 2.5., compounds 2.8 to 2.11). These ligands vary 
from endocannabinoid-derived (CMX-020, 2.9) and classical cannabinoid structures (EPH-101, 2.10) 
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to more drug-like synthetic cannabinoids (CNTX-6016, 2.8 and NTRX-07, 2.11) and have been mostly 
explored for their analgesic and anti-inflammatory properties.[118, 120] Despite the promising 
experimental observations in preclinical settings, most ligands were discontinued in phase II trials due 
to poor therapeutic efficacy.[121] There are many potential factors which contribute to these failures, 
including (i) the lack of validation of CB2R as a therapeutic target for the patient cohort, (ii) the inability 
to translate preclinical in vitro and in vivo pharmacology into the clinic, which is probably related to 
differences across species, (iii) the lack of appropriate chemical and biological tools for dose selection 
in humans, and (iv) the absence of target engagement studies and information on the compound’s 
mechanisms of action.[122] Consequently, there is a tremendous need for the development of novel and 
well-characterized imaging probes to address CB2R questions regarding target validation, engagement, 
and signaling modulation as well as to enable further drug discovery efforts. Ideally, these tools should 
have a known pharmacological profile and be devoid of any interspecies difference between rodent 




2.1.3. Imaging Tools to Study the CB2R 
The high potential of CB2R as a prime drug target has promoted extensive efforts in drug discovery 
and clinical research. However, the underlying receptor-ligand interactions and molecular mechanisms 
driving its activation state are yet to be deciphered. The complexity of CB2R as a drug target is twofold. 
On the one hand, it belongs to the GPCR family and modulates the eCB lipid signaling system which 
are both biological entities characterized by promiscuous regulation of downstream signaling 
cascades.[123] On the other hand, its intriguing functional selectivity due to the bias against a variety of 
activation pathways.[101b] Together, these features make investigations of physiological responses to 
changes and pharmacological manipulations on the level of CB2R extremely challenging tasks. 
Therefore, experimental outcomes significantly vary according to the assay’s conditions, e.g., applied 
readout, cell type, receptor density, and ligand of choice.[124] As a consequence, tissue and cell-type 
specific receptor expression profiles remain poorly characterized. In particular, the expression of CB2R 
in non-immune brain cells and at which degree its upregulation occurs in pathology are under current 
debate.[101b, 108, 125]  
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Because any improvement of CB2R agonists as new therapeutics requires a thorough understanding 
of their molecular and cellular mechanisms of action,[126] many research efforts have been directed to 
the development of new strategies and biological and chemical tools to visualize CB2R. The use of 
recombinant expression systems to label CB2Rs with fluorescent and peptide reporters have enabled 
initial imaging studies and purification of this receptor.[127] Nevertheless, in more pharmacological 
relevant systems, such as native cells and tissues, CB2R is expressed at very low levels, even if the cells 
are known to be responsive to its activation.[62a, 128] Attempts on determining CB2R expression profiles 
have been made applying standard biochemical techniques, such as qRT-PCR[129] and 
immunohistochemistry[130] assays. The major drawbacks of these experiments rely on the poor 
correlation of mRNA levels with functional protein and the absence of sufficiently specific antibodies 
for both human (h) and rodent (r) CB2R which prevents studies at a cellular or sub-cellular level.
[131]  
As discussed in the previous sections, chemical probes targeting the CB2R can be applied to determine 
its pharmacology, distribution, expression levels, occupancy, and follow signaling cascades both in vitro 
and in vivo. At present, CB2R-selective PET tracers as well as covalent, fluorescent, biotinylated, and 
photochromic compounds have been reported.[62a, 132] This section highlights the advances in the 
development and applications of these tools. 
 
2.1.3.1. Positron Emission Tomography (PET) Tracer 
Positron emission tomography (PET) tracers were extensively used to study CB2R expression at tissue 
level.[133] This technique, however, lacks the cellular resolution required for many investigations, such 
as receptor occupancy and tracing internalization events.[134] Radioisotope introduction at the 
recognition element rarely implies significant structural changes, since a connective linker is not 
required (Figure 2.6.). Thus, the synthesis of radiotracers which are highly selective toward CB2R is 
considerably more straightforward than for other imaging modalities. 
One of the first CB2R-selective PET tracers developed was based on the thiazole A-836339 (2.12), a 
CB2R agonist form the Abbott pipeline (Figure 2.6.).
[135] The [11C]A-836339 analog (2.13), however, 
lacked CB2R specificity in vivo and displayed low stability.
[136] More recently the fluorinated derivative 
2.14 have been synthesized with promising results in rodents.[137] The first reports of a brain penetrant 
radiotracer to display selective CB2R binding explored the oxoquinoline core ([
11C]NE40, 2.15, Figure 
2.6.).[138] Besides promising results in rodents, discrepancies between preclinical and first in human 
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studies prevent [11C]-tracer 2.15 from further clinical applications.[139] In order to improve 
pharmacological parameters, such as affinity, plasma protein binding, lipophilicity, and half-life, this 
scaffold has undergone several optimization rounds. However, this probe series has still metabolic 
and pharmacokinetic issues, including nonspecific binding which limit their use for more relevant in 
vivo studies.  
Figure 2.6. Structures of CB2R-selective recognition element and PET tracers.[136-138, 140] These ligands are 
synthetic cannabinoids which are classified by their functional efficacy at the CB2R. Their literature reported binding 
affinities towards CB2R and CB1R of the respective nonradioactive analogs is given below each structure. PET 
reporters are highlighted in red. 
Indole derivatives, such as the agonist [11C]GW405833 (2.16) was also applied for biodistribution 
experiments both in rodent and rhesus monkey (Figure 2.6.).[140a, 140b] Due to its relatively low binding 
affinity, slow washout and nonspecific binding, investigations with this ligand are unlikely to advance. 
Recently oxadiazole and pyridine cores were also exploited for the synthesis of PET tracers targeting 
the CB2R (Figure 2.6.). The [
18F]MA3 (2.17) have demonstrated promising biodistribution in health 
mice and stronger brain uptake in comparison to previous tracers, but was unspecific.[140c, 140d] From 
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an extensive structure activity relationship (SAR) on the 2,5,6-substituted pyridine scaffold, a 5-
methoxyazetidine derivative was identified with best pharmacological profile.[141] Using a fluorinated 
derivative this analog ([18F]-2.18, Figure 2.6.), imaging experiments using postmortem human spinal 
cord tissues from a patient with amyotrophic lateral sclerosis and a healthy control showed significant 
compound uptake at diseased tissues.[140e] These promising results indicate that tracer 2.18 will possibly 
undergo further evaluation in neuroinflammation models. 
Up to now, the poor specificity due to highly lipophilic scaffolds, lack of CB2R selectivity against CB1R, 
low chemical stability, unfavorable metabolic fate, and low uptake of these radiotracers in preclinical 
applications have hampered the advance of such tracers into clinical settings and the precise 
characterization of CB2R expression in vivo. In addition, the higher costs, safety concerns, radioactive 
synthesis, storage, and waste management further limit the applicability of PET assays from 
investigations. Conversely, covalent, fluorescent, and biotinylated imaging ligands are sensitive tools 
that allow for real-time imaging in living cells with a high degree of spatiotemporal resolution,[87] while 
eliminating radioactive material demand. 
 
2.1.3.2. Covalent Probes 
The selective covalent binding to specific amino acids of GPCRs represents a valuable method for 
elucidating their structure and function, such as binding site mapping and stabilizing the receptor for 
X-ray crystal structure elucidation.[142] Covalent bond formation occurs through two main mechanisms 
of activation: (i) spontaneously reactive electrophilic moieties, e.g., reactive thiols, isothiocyanates 
(NCS), halomethylketones, and Michael acceptors or (ii) light activation of a photoaffinity group, e.g., 
azide, diazirine, and benzophenone. Usually ligands decorated with an electrophilic reactive handle are 
called covalent probes and react with nucleophilic amino acid side chains, such as serine, cysteine, 
threonine, while the ones containing a photoaffinity label are denominated photoactivatable probes 
and are not selective to amino acid types.[143]  
The MAKRIYANNIS GROUP at the Northeastern University have designed the majority of covalent 
probes so far described with the ultimate goal to define structural aspects of ligand recognition in 
hCB2R. Initially, this group generated a covalent mixed agonist series by introducing NCS groups at 
the THC scaffold.[144] Despite the lack of selectivity, analog AM841 (2.19, Figure 2.7.) has been used 
to map the CB2R binding site
[145] and to investigate the (patho)physiological role of CB2R in 
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inflammatory disorders in mouse models.[146] Based on the CB2R inverse agonist SR144528 (2.20), the 
CB2R-selective diarylpirazole AM1336 (2.21) was synthesized with a NCS-tag (Figure 2.7.) to enable 
complementary binding site mapping investigations.[147] The same group also explored the THC core 
to prepare the first photoactivatable probe with selective CB2R binding (AM967, 2.22, Figure 2.7.).
[148]  
Figure 2.7. Structures of recognition element and covalent tools to study the CB2R.[144, 147-149] These ligands 
are classified by type of covalent bond formation in covalent and photoactivatable probes and by compound class 
as classical and synthetic cannabinoids. Their functional efficacy at the CB2R and literature reported binding affinities 
towards CB2R and CB1R are given below each structure; due to plausible covalent binding this values refer to as 
“apparent Ki’s”. The covalent reactive moiety is highlighted in red. 
The major limitation of covalent tools is the lack of a signal agent, which would enable further imaging 
studies. To overcome detection issues, the VAN DER STELT GROUP at the University of Leiden designed 
a photoactivatable probe containing both a photoaffinity (diazirine) and a biorthogonal (terminal 
alkyne) ligation handle (LEI121, 2.23, Figure 2.7.).[149] Thereby, enabling covalently trapping of hCB2R 
upon irradiation, followed by in situ copper azide-alkyne cycloaddition (CuAAC) conjugation of the 
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reporter tag in a two-step procedure called photoaffinity-based protein profiling (pAfBPP). The CB2R 
inverse agonist 2.23 has been exploited for CB2R visualization in both overexpressing and primary 
cells using flow cytometry for target engagement evaluation of unlabeled CB2R ligands. This 
compound has great potential for monitoring of endogenous receptor expression and engagement in 
human cells. However, the applications of covalent tools are limited due to the irreversible binding, 
which is not appropriate for many in vitro assays, such as kinetic studies and can lead to unfavorable in 
vivo off-target interactions due to unspecific reactivity.  
 
2.1.3.3. Fluorescent Probes 
The need for CB2R-selective fluoroprobes with reversible binding modes and improved 
physicochemical properties has prompted the synthesis and evaluation of structurally diverse 
compounds. Initial efforts used in silico tools to design 7-nitrobenzofurazan (NBD)-labeled derivatives 
based on JWH015 (2.24), a highly potent CB2R agonist (Figure 2.8.).
[150] Introduction of the linker-
NBD construct, however, resulted in a significant loss in CB2R affinity (NBD-2.25). Modifications at 
the 3-position of the indole core for identifying less lipophilic linkers led to the discovery of the N-
alkyl isatin acylhydrazone compound series.[151] A fluorescent version of this scaffold containing a 
NBD moiety generated the NMP6 probe (2.26) which retained the good affinity and selectivity values 
from its parent compound (Figure 2.8.).[152] Confocal imaging and flow cytometry studies using ligand 
2.26 showed specific CB2R binding on primary CD4
+ T cells and B lymphocytes, which was blocked 
by preincubation with a CB2R agonist (GW842166X, for ligand structure see SI-1, Supplementary 
figure S-1, Section 5.2.1.). Motivated by these results, the N-alkyl isatin acylhydrazone scaffold was 
further explored for attachment of the more relevant far-red fluorophore BODIPY 630/650. 
However, these attempts led to complete loss in affinity.[153]  
Besides PET tracers, the oxoquinoline core also served as precursor for fluorescent ligands (see [11C]-
2.15 tracer, Figure 2.6.). A recent study evaluated different alkyl linker lengths at the N-1 position of 
the oxoquinoline scaffold for the attachment of green-emitting fluorophores, including NBD, 4-
dimethylaminophthalimide (4-DMAP) and fluorescein.[154] However, as for the scaffold of 2.26, only 
one labeled derivative demonstrated CB2R binding, the 4-DMAP-labeled 2.27 (Figure 2.8.). 
Compound 2.27 displayed 130 nM affinity for CB2R, being applied for flow cytometry imaging in both 
hCB2R over- and endogenously-expressing cells and for confocal microscopy in overexpressing cells. 
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Figure 2.8. Structures of recognition elements and CB2R-selective fluorescent probes.[150, 152, 154-155] These 
probes are classified as synthetic and classical cannabinoids. Their functional efficacy at the CB2R and literature 
reported binding affinities towards CB2R and CB1R are given below each structure. Fluorophore structures are 
highlighted in red. 
However, probe 2.27 suffered from unspecific binding in these experiments.[154] 
Fluorescent probes bearing classical phytocannabinoid-derived compounds as recognition elements 
are currently under evaluation. The VERNALL GROUP from the University of Otago reported a Cy5-
labeled CB2R inverse agonist (2.29, Figure 2.8.) which displayed 42 nM affinity toward the CB2R and 
131-fold selectivity over the CB1R.
[155b] Treatment of HEK-cells overexpressing hCB2R with Cy5-
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labeled 2.29 for wide-field fluorescence microscopy analysis showed good selectivity and low 
unspecific binding. However, additional attempts to replace the Cy5 dye with other fluorophores, such 
as TAMRA and BODIPY were inactive on the hCB2R, underscoring that dye selection and placement 
at the pharmacophore strongly influenced probe’s pharmacology. 
The most selective and well-validated derivatives up to date were developed by the CARREIRA GROUP 
from the ETH Zürich. Linker studies at the HU308 scaffold (2.28, Figure 2.8.), a potent CB2R agonist, 
led to double-functionalized CB2R-selective ligands decorated with an electrophile moiety and a 
polyethylene glycol (PEG) linker (template 2.30, Figure 2.8.).[156] Several reporter units were attached 
to the recognition element-linker template, including biotin, photoswitchable azobenzene and the 
NBD, DY480-XL, AttoThio12, and Alexa488 and 647 dyes.[155a] The agonist 2.30 labeled with 
AttoThio12 and DY480-XL fluorophores (Figure 2.8.) were the most active with Ki values of 4.7 nM 
and 21 nM, respectively. These compounds were applied for flow cytometry, confocal microscopy, 
and time-resolved fluorescence resonance energy transfer (TR-FRET) assay in both over- and 
endogenous expressing cells with good CB2R specificity. Likewise the biotinylated and 
photoswitchable analogs were highly potent, but evaluation of their in vitro performance has not been 
performed yet.  
The BAI GROUP from the Vanderbilt University developed the first successful NIR-probes targeting 
the CB2R by taking advantage of a different template: the biarylpyrazole mbc94 (2.31, Figure 2.9.).
[157] 
This compound is a derivative of the CB2R inverse agonist 2.20 (Figure 2.7.) and was successful in 
retaining high receptor subtype selectivity and CB2R affinity despite linker and fluorophore 
conjugation. In the following years, the same group reported several NIR-2.31 derivatives labeled with 
IRDye800CW,[158] NIR760[159], IR700DX[160] and zwitterionic ZW760[161] fluorophores (Figure 2.9.). In 
addition, the quinolone NIR760-Q (2.32)[162] and the pyrazolopyrimidine NIR760-XLP6(2.33)[163] both 
containing the NIR-dye NIR760 were also synthesized by the same research group (Figure 2.9.). These 
compounds were applied for CB2R imaging in tumor cells and also for in vivo imaging but displayed 
high nonspecific binding. Among these derivatives, pyrazolopyrimidine 2.33 had the best selectivity 
profiles in the tested cellular settings.[163] The therapeutic properties of the photosensitizer IR700DX-
2.31 were also explored for the treatment of CB2R-positive tumors both in vitro and in vivo.
[160, 164] 
Despite the promising results, no further studies exploiting these probes have been reported so far. 
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Figure 2.9. Structures of CB2R-selective NIR-probes.[158-163] These probes are based on synthetic cannabinoid 
scaffolds and have no described functional characterization. The literature reported equilibrium dissociation constant 
(Kd) towards CB2R and CB1R are given below each structure. NIR-fluorophore structures are highlighted in red. 
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2.1.3.4. Biotinylated Probes 
Indirect generation of fluorescence by bioaffinity probes has also been applied for tracing the CB2R. 
These compounds exploit the high affinity of biotin for avidin conjugates to obtain dye conjugation 
via a two-step labeling procedure.[165] A biotinylated version of the HU308 ligand 2.28 (2.34, Figure 
2.10.) was conjugated with streptavidin-Alexa488 for the visualization of CB2Rs in rat microglial cells 
using confocal microscopy.[166]  
Figure 2.10. Structure of CB2R-selective biotinylated probe 2.34.[166] The probe’s functional efficacy and 
literature reported binding affinities towards CB2R and CB1R are given below the structure. The biotin reporter is 
highlighted in red. 
 
2.1.3.5. Current Status and Major Limitations of the Reported Probes targeting the CB2R  
Despite the elegant investigations described in this section, no reversible high affinity fluorescently 
labeled ligand with favorable photophysical and pharmacological properties is currently available. 
Major obstacles encountered in the development of such a set of highly versatile agents is a lack of 
understanding of modular agonist probe design based on receptor-ligand interactions. The binding 
affinity of such “one-probe-one-dye” conjugates strongly depends on the nature of the attached 
fluorescent label, and consequently, they are likely unsuitable for multiple imaging applications. 
Furthermore, the highly lipophilic nature of classical cannabinoids derived CB2R ligands, which often 
serve as starting points for probe generation, when combined with highly lipophilic dyes, 
synergistically leads to high levels of nonspecific membrane binding and insufficient overall properties 
for reliable general imaging applications.[167]  
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A further hurdle in the CB2R research field is the poor functional characterization of many CB2R 
fluorescent ligands reported. Determination on how the fluorescent tool activates the receptor is of 
fundamental importance since a combination of agonist and inverse agonist derived probes allows for 
targeting active and inactive states of respective receptor populations and the analysis of trafficking 
aspects. Current CB2R fluorescently labeled compounds with reported function and in vitro 
applications are restricted to both irreversible (2.23, Figure 2.7.)[149] and reversible (Cy5-2.29, Figure 
2.8.)[155b] inverse agonists, addressing only the inactive state of the receptor. Conversely, approved 
drugs targeting the CB2R act as agonists. Therefore, the availability of reversible CB2R-agonist ligands 
with direct fluorophore attachment would allow exploration of the clinically more relevant activated 
state of CB2R and represent an important breakthrough and contribution to the existing CB2R probe 
toolset. The first CB2R fluorescent agonists with a reversible binding mode were recently reported 
exploiting the phytocannabinoid-derived HU308 (2.28) as recognition element (analog 2.30, Figure 
2.8.).[155a] However, as outlined above, ligand 2.28 displays a highly lipophilic structure, which may 
limit biological its applications.  
As discussed previously (see Section 1.3.), the generation of high-quality chemical probes involves 
broad and in-depth validation using complementary biochemical and cell-based techniques. Additional 
evaluation of several parameters, such as chemical stability, water solubility – in particular important 
to avoid compound aggregation – membrane permeability, potency and selectivity are essential for the 
targeted performance of such probes.[24b, 70] Moreover, extensive pharmacological characterization of 
these tools across species is crucial for the clinical development of drugs targeting the CB2R. Ideally, 
these labeled compounds should have applicability for rodent and human CB2Rs at the same time to 
allow for a clear and well validated translational path from preclinical pharmacological in vitro and 
animal data to the human situation. Currently, there are no accepted biomarkers monitoring CB2R 
functionality which display these characteristics to enable both the interrogation of signaling aspects 







2.1.4. Motivation for the Synthesis of a CB2R-Selective Fluorescent Ligand and Specific Aims  
The successful development of new drugs targeting the CB2R strongly relies on the determination of 
the downstream signaling events driving their agonistic effect.[19] However, the lack of specific and 
reliable molecular imaging tools to study CB2R pharmacology currently hampers the exploration of its 
therapeutic potential.[62a, 154, 168] The acquisition and validation of such a data set requires the synergistic 
combination of diverse microscopic and imaging modalities. As each technique has its intrinsic 
readout that correlates to specific fluorophores, the knowledge of CB2R signaling cascades associated 
with pathology will likely be built upon structurally and functionally diverse CB2R modulators. 
Therefore, molecular imaging probes that can be tunable for multiple applications and have defined 
functional activity – particularly agonists – are urgently needed.  
Figure 2.11. Components considered for the development of a CB2R-specific fluorescent probe: the 
appropriate recognition element, linker length and attachment site, and a suitable reporter unit, i.e., 
fluorophore. 
The aim of this project was to develop a robust CB2R-selective probe template where binding affinity 
and selectivity would be largely independent of the reporter unit attachment (Figure 2.11.). Following 
a linear design (see Figure 1.3.A, Section 1.3.), a modular synthesis strategy was adopted for fluorescent 
ligand assembling. Paramount for the generation of such a derivative is the selection and optimization 
of its structural components – recognition element (pharmacophore), linker, and fluorescent dye. The 
recognition element should tolerate further chemical functionalization while preserving its affinity, 
functional efficacy, and selectivity towards the target. Furthermore, the linker attachment point at the 
pharmacophore, length, and composition are crucial aspects for fine-tuning the overall 
physicochemical properties of the probe. To avoid detrimental interactions of bulky and charged 
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fluorophores with the receptor,[169] the linker would ideally allow for placing of the fluorescent label 
outside the receptor in the extracellular space, reaching outside the binding pocket of the receptor. 
These considerations were combined with an in silico structure-based docking approach to guide 
synthesis efforts.  
The novel fluorescent compounds should be applicable within a range of diverse imaging modalities 
while retaining the same recognition element. Therefore, a consistent interaction, i.e. activation 
cascades, binding dynamics, and expression profiles, with the CB2R was measured and validated across 





2.2.1. Recognition Element Selection and Fluorescent Probe Design 
In order to capitalize on agonist drug precursors with optimal affinity, lipophilicity, and drug-likeness, 
the 2,5,6-trisubstituted pyrazine RO6839251 (2.35)[170] and pyridine RO6852763 (2.36)[171] which are 
derived from a CB2R agonist drug discovery program
[141, 170-171] were selected as starting points for 
probe design (Figure 2.12.A, see Table 2.1. for full pharmacological profile). Conceptually this reduces 
the risk of unspecific lipophilic interactions arising from phytocannabinoid-like derived ligands.  
Physicochemical properties have direct influence on the efficacy, solubility, permeability, and 
metabolism of not only drug candidates, but also chemical probes.[172] For the identification of 
appropriate recognition elements for the development of a CB2R-selective probe, parameters such as 
atomic logP (AlogP)[173] and polar surface area (PSA)[174] were considered. The AlogP is an estimation 
of the lipophilicity of a compound (logP) which is based on the incremental contribution of each atom 
to the logP. In combination with PSA values, the AlogP can be used as a first predictor of cellular 
permeability – which then needs to be confirmed with experimental assays, such as the parallel artificial 
membrane permeability assay (PAMPA).[175]  
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Figure 2.12. Selected recognition element scaffolds and in silico studies used for probe design. A) Drug 
discovery derived agonists 2.35 and 2.36, used as starting points for the development of CB2R-selective fluorescent 
ligands; B) NBD-labeled 2.106 docked into the recently published co-crystal structure of active state CB2R in 
complex with agonist AM12033 (PDB 6KPF, for ligand structure see SI-2, Supplementary figure S-1, Section 
5.2.1.);[81] Polar and hydrophobic amino acid residues are highlighted with blue and light brown colors, respectively; 
In silico studies were conducted by DR. WOLFGANG GUBA at Hoffmann La-Roche. 
Table 2.1. In vitro pharmacology profiles of recognition elements 2.35 and 2.36.  



















hCB2R hCB1R  mCB2R  hCB2R  hCB1R  mCB2R  
1 2.35 
 







412.4 75 0.3 3.1 3.7 
2 2.36 
 







412.5 53 0.3 5.2 n.d. 
n.d. – not determined. [a] Functional potency (cAMP assay), percentage efficacy (%eff.) given in parenthesis; [b] 
Surface sum of all polar atoms in the molecule; [c] Ligand efficiency (LE), i.e., ratio between affinity and molecular 
size;[176] [d] Calculated partition coefficient values (AlogP) based on the contribution of each atom to the logP;[173] [e] 
Distribution coefficient values measured in a mixture of 1-octanol and water. Reference ligands data described in 
the Pharmacological Assessment, Section 5.2.10. Radioligand binding assays performed by ELISABETH ZIRWES and 
cAMP functional assays performed by ANJA OSTERWALD at Hoffmann La-Roche. 
The calculated physicochemical properties of the ligands 2.35 and 2.36 are superior to classical 
cannabinoids with regard to AlogP and PSA, i.e., standard agonist HU308 (2.28, Figure 2.8., Section 
2.1.3.) has an AlogP of 6.7 and a PSA of 27.4 Å2 whereas the utilized derivatives 2.35 and 2.36 have a 
favorable AlogP values of 3.1 and 5.2, and PSA of 75 and 53 Å2, respectively (Figure 2.12.A and Table 
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2.1.). Both molecules possess subnanomolar affinities for the human (h) CB2R and similar good 
binding affinity (Ki) for mouse (m) CB2R with Ki values of 2 nM.
[170-171] Pyrazine 2.35 and pyridine 
2.36 also exhibit good binding selectivity over hCB1R, which is very important for the visualization of 
CB2R in the central nervous system, where CB1R is highly expressed. 
Fluorescent analogs of 2.35 and 2.36 were designed with the support of molecular modeling studies 
conducted at Hoffmann La-Roche by DR. WOLFGANG GUBA using the X-ray structure of the active 
state of CB2R in complex with the agonist AM12033 (Figure 2.12.B; see Figure 2.1., Section 2.1.1. for 
the crystal structure, PDB 6KPF; for ligand structure see SI-2, Supplementary figure S-1, Section 
5.2.1.).[81] Parent agonists 2.35 and 2.36 possess three potential exit vectors that have been investigated 
for the elaboration of an extensive structure activity relationship (SAR) study – the positions 5 and 6 
of the heteroaryl group, and the geminal diethyl group (Figure 2.12.A),[170-171] thereby providing a basis 
for linker placement at different positions. Candidate molecules were docked into the CB2R binding 
cavity and prioritized on the likelihood of the linker trajectory to reach the extracellular space. This 
analysis suggested two different linker attachment sites preferentially: one at position 6 of the 
heteroaryl ring and the other at the geminal diethyl group (Figure 2.13.).  
Figure 2.13. Modular design of CB2R fluorescent probes and linker attachment strategies. Structure of 
recognition element-linker template designed with the guidance of molecular docking for conjugation with 
fluorophores, such as NBD and Alexa 488. The docking analysis suggested positions A) R2 and B) R3 of the pyrazine 
2.35 scaffold, or C) R3 of the pyridine 2.36 scaffold as preferred for linker attachment. 
Furthermore, in silico docking studies indicated that a linker length ranging from one to four 
polyethylene glycol (PEG) units would be sufficient to reach out to the extracellular space. For a 
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systematic investigation of the optimal linker, probes containing different linker lengths ranging from 
one to four ethylene glycol units were planned. PEG was chosen as an appropriate linker template to 
address issues of solubility and lipophilicity characteristics for CB2R-targeted ligands. However, 
considering the highly lipophilic nature of the CB2R binding cavity, a less polar alkyl linker was 
additionally selected in order to confirm the absence of detrimental effects by the pre-organized and 
highly hydrated PEG chain along the inner surface of the receptor.[177] For evaluation of binding 
affinity and physicochemical aspects, such as water solubility and chemical stability, the small, 
inexpensive, and non-charged 7-nitrobenzofurazan (NBD) dye would be initially conjugated to the 
probe template. The best ligand-linker systems identified in vitro would then be employed for the 
introduction of more relevant fluorophores for biological test settings, e.g., Alexa 488 (Figure 2.13.). 
 
 
2.2.2. Synthesis of the Recognition Element Scaffolds  
The synthesis of pyrazine carboxylic acid precursor (2.37) has been described by our collaboration 
partners[170] (Scheme 2.1.). This route commenced with the treatment of commercially available 5-
chloro-pyrazine 2.38 with 3,3-difluoroazetidine and a base to afford derivative 2.39 in a moderate 44% 
yield. Bromination of the 6-position of intermediate 2.39 using N-bromosuccinimide (NBS) and 
subsequent basic hydrolysis yielded the carboxylic acid 2.41 in a good 71% yield. Compound 2.41 was 
converted in a O-alkylation reaction with cyclopropyl-methanol under basic conditions to the desired 
pyrazine probe precursor 2.37 in 90%yield.  
Scheme 2.1. Synthesis of pyrazine carboxylic acid building block 2.37.  
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Picolinic acid 2.42 can be prepared in seven synthetic steps, according to literature procedures.[171] This 
approach started with the introduction of a nitrile group at the 2-position of pyridine 2.43 (Scheme 
2.2.). The cyclopropyl ring was subsequently installed to the 5-position of the pyridine scaffold using 
Suzuki conditions to afford intermediate 2.44 in low 11% yield, over these two synthetic steps. 
Treatment of compound 2.44 with m-chloroperoxybenzoic acid (m-CPBA) afforded N-oxide 2.45 
which underwent rearrangement upon trifluoroacetic anhydride treatment. Bromination at the 6-
position of the pyridine scaffold enabled a second Suzuki coupling to introduce the para-fluorophenyl 
substitution in moderate yield. The final hydrolysis of the nitrile group afforded the desired acid 
building block 2.42, leading to an overall 2% yield. 
Scheme 2.2. Synthesis of picolinic acid building block 2.42.[171] 
The carboxylic acid building blocks 2.37, 2.41, and 2.42 were exploited as pharmacophores for 




2.2.3. First Approach Towards CB2R-Selective Fluorescent Ligands: Probing the R2-Position 
of the Pyrazine Recognition Element as Linker Attachment Point 
The initial strategy towards fluorescently labeled analogs containing the 2,5,6-trisubstituted heteroaryl 
core as recognition element explored the 6-position of the pyrazine 2.35 scaffold for linker attachment 
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point (Figure 2.13.A, Section 2.2.1.). The concept behind the synthesis of this series was based on a 
modular approach with linker introduction and fluorophore conjugation as final steps (Scheme 2.3.). 
Such an approach would allow for a systematic evaluation of the linker length and composition as well 
as dye variation at the advanced probe template 2.60. This intermediate could be prepared from an 
amide coupling reaction of carboxylic acid 2.41 (Scheme 2.1., Section 2.2.2.) with amino ester 2.61.  
Scheme 2.3. Synthesis strategy for pyrazine probe series 2.47 to 2.53: Linker introduction at the 6-position 
of the pyrazine heteroaryl core. 
The preparation of amino ester 2.61 as a chloride salt has been already described by using a two-step 
synthetic route starting from diphenylmethylene protected glycine 2.62 (Scheme 2.4.).[178] However, 
attempts on performing the α,α-diethylation reaction of glycine 2.62 in one-pot to intermediate 2.64 
were unsuccessful, even with increased amounts of base potassium bis(trimethylsilyl)amide – from 2.2 
up to 6 equivalents. Full conversion to the desired compound was not observed at any attempted 
condition, instead, a mixture of starting material 2.62 with mono- (2.63) and diethylated (2.64) 
intermediates were obtained. The separation of these precursors also turned out to be challenging due 
to the nearly identical retention factors (Rf) values under a variety of solvent systems. This procedure 
led to extremely low amounts of isolated product (3% overall yield). 
 
48 
To improve the outcome of this reaction, the dialkylation step was divided into two separated 
reactions as shown in Scheme 2.4. (Synthetic route A). First, deprotonation of the α-carbon of glycine 
2.62 using 3 equivalents of cesium carbonate, followed by alkylation using iodoethane gave 
monoethylated compound 2.63 in good 59% yield. The second α-alkylation of the carbonyl group was 
performed using 1.5 equivalents of potassium bis(trimethylsilyl)amide and gave diethyl intermediate 
2.64 in very good 80% yield. However, after acidic deprotection of the diphenylmethylene protective 
group, amino ester 2.61 could be isolated in 6% yield.  
Scheme 2.4. Synthesis of amino ester intermediate 2.61 via the two investigated synthetic routes.  
To circumvent the issues related to the Synthetic route A, the approach for the α,α-dialkylation of 
amino esters reported by LIU and collaborators[179] was adapted for the preparation of building block 
2.61 (Scheme 2.4., Synthetic route B). Starting from aminobutyric acid 2.65, classical Fischer 
esterification conditions, followed by protection of the primary amine using benzaldehyde led to the 
formation of an amino ester intermediate. Subsequent α-alkylation of the carbonyl group using the 
same conditions as for diphenylmethylene 2.64 afforded diethyl ester 2.66. Benzylidene deprotection 
under acidic conditions afforded the chloride salt form of amino ester 2.61 in 64% yield, without the 
need for chromatographic purification. The use of diphenylmethylene or benzylidene protective 
groups was crucial for the α,α-dialkylation of the amino acid building blocks since it prevented 
untoward N-alkylations. 
The amide coupling of carboxylic acid 2.41 with amino ester 2.61 was carried out using 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium chloride (DMTMM) as coupling reagent to 
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afford probe template 2.60 in 61% yield (Scheme 2.5.). Subsequent screening of the linker length and 
composition was performed using PEG chains ranging from zero to five ethylene glycol units and an 
alkyl chain (Scheme 2.5.). Introduction of N-Boc protected linkers was achieved using potassium 
hydroxide in dimethyl sulfoxide. The consecutive deprotection of the Boc group under acidic 
conditions allowed for the final N-alkylation labeling step to yield NBD-pyrazine derivatives 2.47 to 
2.53. The synthesis of compound 2.47 bearing a methylene linker was accomplished with a slight 
modification of the main procedure, by introducing the NBD dye to the linker before conjugation to 
probe template 2.60.  
Scheme 2.5. Synthesis of pyrazine-based NBD-labeled probes 2.47 to 2.53. 
The low yields obtained for compounds 2.67 to 2.72 can be mainly attributed to the observed chemical 
instability of the formed aryl ether intermediates under these conditions. At the 6-position of the 
pyrazine core, PEG linkers underwent hydrolytic cleavage, particularly upon heating (40 °C), limiting 
the alternative synthetic approaches that could be applied. 
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The fluorescently labeled NBD-ligands and selected pyrazine-linker intermediates were submitted to 
in vitro evaluation of their binding affinity towards the CB2R and selectivity over the CB1R subtype 
(Table 2.2.).  






Ki hCB1R  
[nM] 








>10’000 >10’000 -- 559.6 3.2 n.d. 
2 2.68 
 
>10’000 >10’000 -- 603.7 3.1 3.5 
3 2.69 
 
>10’000 >10’000 -- 647.7 3.0 4.0 
4 2.70 
 
>10’000 >10’000 -- 691.8 2.8 3.9 
5 2.71 
 
>10’000 >10’000 -- 735.8 2.7 3.7 
6 2.72 
 
958 4’470 5 571.7 4.9 n.d. 
7 2.54 
 
>10’000 >10’000 -- 459.5 1.6 1.1 
8 2.55 
 
>10’000 >10’000 -- 503.5 1.5 0.7 
9 2.56 
 
>10’000 >10’000 -- 547.6 1.4 0.5 
10 2.57 
 
>10’000 >10’000 -- 591.7 n.d. n.d. 
11 2.58 
 
>10’000 >10’000 -- 635.7 1.1 -0.04 
12 2.59 
 
1’213 1’762 2 471.5 3.3 1.5 
13 2.47 
 
3’164 3’219 1 578.5 3.5 n.d. 
14 2.48 
 
>10’000 2’624 <0.3 622.6 3.4 3.0 
15 2.49 
 
>10’000 >10’000 -- 666.6 3.3 3.3 
16 2.50 
 
>10’000 >10’000 -- 710.7 n.d. n.d. 
17 2.51 
 
>10’000 >10’000 -- 754.7 3.0 3.1 
18 2.52 
 
>10’000 >10’000 -- 798.8 2.9 3.1 
19 2.53 
 
1’658 >10’000 >6 634.6 5.1 n.d. 
n.d. – not determined. [a] Calculated partition coefficient values (AlogP) based on the contribution of each atom to 
the logP;[173] [b] Distribution coefficient values measured in a mixture of 1-octanol and water. Reference ligands data 
described in the Pharmacological Assessment, Section 5.2.10. Radioligand binding assays performed by ELISABETH 
ZIRWES at Hoffmann La-Roche. 
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The radioligand binding assays were performed by ELISABETH ZIRWES at Hoffmann La-Roche using 
membrane preparations of Chinese Hamster Ovary (CHO) cells overexpressing either human CB2R 
or CB1R. None of the conjugated derivatives, however, exhibited the appropriate affinity for hCB2R. 
In addition, these molecules displayed insufficient stability in buffered aqueous media with linker 




2.2.4. Second Approach Towards CB2R-Selective Fluorescent Ligands: Probing the R3-
Position with an Ether Functionality for Linker Attachment 
Due to the lack of affinity, selectivity, and chemical stability of the first approach, the geminal diethyl 
moiety (R3-exit vector, Figure 2.13.B and C, Section 2.2.1.) was investigated for the development of 
recognition elements 2.35 and 2.36 fluorescent analogs.  
Scheme 2.6. Synthesis strategy for linker introduction through an ether linkage at the germinal diethyl 
portion of recognition elements 2.35 and 2.36. 
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To allow for a straightforward introduction of different linkers, a modifiable ligation handle was 
required at this position. Several probe templates were docked by DR. WOLFGANG GUBA at Hoffmann 
La-Roche into the binding pocket of the hCB1R crystal structure in complex with antagonist AM6538 
(for ligand structure see SI-4, Supplementary figure S-1, Section 5.2.1.),[181] which was the only 
cannabinoid receptor crystal structure reported by the beginning of this project. According to the in 
silico analysis, preferred linker attachment groups would not participate in hydrogen bonding. Thus, 
proton donating groups should be avoided at the linker portion. In addition, the configuration of the 
chiral center generated at the α-carbon of this probe template was deemed not influential for in vitro 
potencies. In order to address these criteria, derivatives containing an ether linkage were initially 
pursued (Scheme 2.6.).  
Key building blocks for this synthetic pathway were alcohols 2.75 and 2.76. The synthesis of these 
compounds was achieved through a hydroboration-oxidation stepwise reaction sequence of an alkene 
precursor. Similar as for the preparation of amino ester 2.6, alkene 2.78 was obtained using an adapted 
procedure from the literature[179] (Scheme 2.7.). The base required for α-carbon deprotonation had, 
however, to be exchanged from potassium bis(trimethylsilyl)amide to lithium diisopropyl amide 
(LDA) for a better outcome (up to 98% yield). Using this protocol, alkene 2.78 was obtained in 4 
synthetic steps from aminobutyric acid 2.65 without the need for chromatographic purification.  
Scheme 2.7. Synthesis of amino ester intermediate 2.78. 
The acid precursors 2.37 and 2.42 were conjugated to amino ester 2.78 using amide coupling 
conditions (Table 2.3.). Due to the low reactivity of both carboxylic acids and the tertiary amine, the 
coupling reagent used for this conversion had to be optimized. Using diisopropylethylamine (DIPEA) 
as a base in dichloromethane at room temperature, the uronium coupling reagents, i.e., 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluoro-phosphate (HBTU), 
and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) (Table 2.3., 
entries 1 to 3) as well as benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
(PyBop, Table 2.3., entry 4), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl, Table 2.3., entry 
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5), and DMTMM (Table 2.3., entry 6) were tested for their efficiency in generating amides 2.79 and 
2.80.  
The best outcomes were obtained when BOP-Cl was employed for the coupling of picolinic acid 2.42 
with amine 2.78 (Table 2.3., entry 5) and DMTMM for the amide formation between pyridine 
carboxylic acid 2.37 and amine 2.78 (Table 2.3., entry 6). Importantly, these conditions were further 
exploited for subsequent amide coupling reactions involving the carboxylic acids 2.37 and 2.42. 
Applying a hydroboration-oxidation reaction sequence,[182] treatment of allyl amides 2.79 and 2.80 with 
9-borabicyclo[3.3.1]nonane (9-BBN) afforded the desired alcohols 2.75 and 2.76 in good yields 
(Scheme 2.8.). 
Table 2.3. Coupling agents tested for the synthesis of amides 2.79 and 2.80. 
Entry Coupling Agent Result (Pyrazine 2.79) Result (Pyridine 2.80) 
1 HATU No conversion No conversion 
2 HBTU No conversion No conversion 
3 TBTU 32% No conversion 
4 PyBOP 41% 24% 
5 BOP-Cl No conversion 54% 
6 DMTMM 72% 12% 
Reaction conditions: carboxylic acid 2.37 or 2.42 (1.0 equiv.), amino ester 2.78 (1.0 equiv.), coupling agent (1.1 equiv.), 
DIPEA (5.0 equiv.), DCM (2 mL), room temperature, 24 h. For ligand structures see scheme 2.6. 
 
Scheme 2.8. Hydroboration-oxidation stepwise reaction of pyrazine 2.79 and pyridine 2.80.  
The following etherification step to generate probe precursor 2.74 (Scheme 2.6.) was particularly 
challenging. Both pyrazine and pyridine alcohols 2.75 and 2.76 (1.0 equiv.) were submitted to aliphatic 
ether formation conditions with tosyl- and triflate-activated PEG alcohols containing either N-Boc 
protected amine or a terminal azide for dye conjugation (1.5 equiv.). (See Supplementary table S-1, 
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Section 5.2.2. for more detailed information on the tested conditions.) For these attempts, different 
bases such as sodium hydride (7 to 12 equiv.), potassium tert-butoxide (7 equiv.) and lithium bases 
(LDA, LiHMDS, and nBuLi, 1.2 equiv.) were screened under varied temperatures ranging from –
78 °C to room temperature for lithium bases and up to 70 °C heating for inorganic bases and in 
distinct solvents systems, such as tetrahydrofuran and dimethylformamide. However, none of  these 
test settings led to N-Boc protected 2.74. In particular, no conversion of starting material was 
observed when reactions were carried out at lower temperatures, and starting material degradation 
occurred with temperature increase. Moreover, the reaction duration (8 to 48 h) and the addition of 
more equivalents of base did not lead to an improved outcome. Therefore, an alternative approach 




2.2.5. Small SAR of Unlabeled Ligands: Exploring Alternative Functionalities for Linker 
Attachment at the R3-Position 
The challenges encountered at the aliphatic ether formation step highlighted the poor suitability of 
this strategy for linker placement at the germinal diethyl portion of ligands 2.35 and 2.36 (Scheme 2.6., 
Section 2.2.4.). Therefore, a more general and reliable ligation handle was required for approaching 
this probe series. A prospective structure activity relationship (SAR) study was conducted to explore 
the tolerance of putative new conjugation sites at the pharmacophore. This analysis was also suitable 
for probing the relevance of the second ethyl substitution at the α-carbon as well as the preferred 
enantiomeric configuration of the scaffold. To this end, unlabeled derivatives of 2.35 and 2.36 coupled 
to natural and non-proteinogenic, i.e., unnaturally encoded, amino esters were synthesized.  
 
2.2.5.1. Design and Synthesis of SAR Ligands 
Natural amino acids, including cysteine, methionine, and tyrosine were selected for SAR investigations 
since their side chains provided potential thiol and phenol handles for linker conjugation. The 
respective thio- and aryl ether conjugates are accessible through a variety of mild reaction conditions, 
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which was crucial to avoid recognition element degradation upon linker installation. Both ether groups 
also had the advantage of not being hydrogen bond donors. Therefore, to suppress proton donating 
effects of the respective side chains, all amino acids were used as methyl ether conjugates (Scheme 
2.9.). In addition, (S)- and (R)-enantiomers of methionine were evaluated for the influence of the 
ligand’s chirality to CB2R binding. Amino ester derivatives of the selected natural amino acids were 
generated and conjugated to carboxylic acids pyrazine 2.37 and pyridine 2.42 using the previously 
established amide coupling conditions to afford the CB2R unlabeled ligands 2.81 to 2.88 (Scheme 2.9.). 
Scheme 2.9. Synthesis of SAR ligands 2.81 to 2.88 based on natural amino acids. Amino ethyl ester derivatives 
of: (S)-cysteine (2.89, R = SCH3), (S)-methionine (R = CH2SCH3), (R)-methionine (R = CH2SCH3), and (S)-tyrosine 
(2.90, R = phenyl-4-OCH3) were applied. For ligand structures see scheme 2.6., Section 2.2.4. 
Non-proteinogenic amino esters bearing 3-methoxypropane and methyl propyl sulfide side chains 
were synthesized for comparing the influence of a thioether with an ether linkage to the binding 
affinity towards the CB2R (see 2.96, 2.97 and 2.103, Schemes 2.10. and 2.11.). 
Scheme 2.10. Synthesis of non-proteinogenic amino ester building blocks utilized for the preparation of 
SAR ligands 2.94 to 2.99.  
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Furthermore, derivatives which encompass an ethyl substitution at the quaternary carbon were 
additionally prepared to evaluate the relevance of this moiety to the binding affinity (see 2.98, 2.99, 
2.102 and 2.104, Schemes 2.10. and 2.11.). For the synthesis of these ligands, diphenylmethylene 
protected glycine 2.62 and benzylidene protected 2.77 served as starting points (Scheme 2.10.). 
Introduction of the unnatural side chains was achieved using LDA as a base and either bromo-3-
methoxypropane or allyl bromide as alkylating reagents. Subsequent acidic deprotection of the amine 
group led to the corresponding amino esters, which were coupled to acid building blocks 2.37 and 
2.42 to yield the remaining SAR compounds 2.94 to 2.99 (Scheme 2.10.). 
 Scheme 2.11. Synthesis of non-proteinogenic amino ester building blocks utilized for the preparation of 
SAR ligands 2.101 to 2.104.  
Methyl sulfide amino esters were obtained in 3 steps from the allyl ligands 2.79, 2.80, and 2.95 (Scheme 
2.11.). First, treatment of allyl derivatives with 9-BBN, followed by a base afforded primary alcohols 
2.75, 2.76 and 2.101 in moderate to good yields. Standard Mitsunobu conditions with thioacetic acid 
were applied to convert the alcohol functionality into a carbonylthio substituent, which could be 
cleaved in situ to the respective thiol upon basic treatment. Addition of iodomethane to the reaction 
mixture enabled the formation of the SAR ligands 2.102 to 2.104. Several attempts were made for the 
synthesis of pyrazine monosubstituted 2.100 as congener of pyridine 2.101, however, the alcohol 
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product was not formed at the hydroboration-oxidation step – instead, a complex mixture of 
unidentified side products was obtained. Of note, the use of other thiocarboxylic acids for the 
Mitsunobu protocol, such as thiobenzoic acic, led to the formation of highly lipophilic byproducts 
which required tedious purification and resulted in lower isolated yields than of intermediates 2.102 
to 2.104. 
 
2.2.5.2. In vitro Pharmacology of SAR Ligands 
Compounds 2.79 to 2.88, 2.94 to 2.99, and 2.101 to 2.104 were subsequently evaluated in radioligand 
binding assays using membrane preparations of CHO cells overexpressing either human CB2R or 
CB1R which were performed by ELISABETH ZIRWES at Hoffmann La-Roche. The physicochemical 
parameters, i.e., PSA, AlogP, logD, aqueous solubility, and PAMPA of selected ligands were 
determined at Hoffmann La-Roche (Scheme 2.12 and Table 2.4.). 
These studies indicated significant differences between the recognition element cores and provided 
valuable information about the tolerability of substitutions at the amino ester portion (Scheme 2.12 
and Table 2.4.). Despite their structural similarity, pyridine 2.36 SAR analogs exhibited surprisingly 
higher affinity for CB2R compared to their corresponding pyrazine 2.35 derived congeners. The 
influence of the ethyl substitution motive at the α-carbon position on ligand binding was confirmed 
as seen by the considerable loss in binding affinities of, e.g., methoxide ligand pairs α- monosubstituted 
2.97 vs. α,α-disubstituted 2.99 (cf. hCB2R Ki of 17 nM vs. 1.5 nM, Table 2.4., entries 13 and 14) and 
methyl sulfide ligand pairs α- monosubstituted 2.103 vs. α,α-disubstituted 2.104 (cf. hCB2R Ki of 1’263 
nM vs. 1.3 nM, Table 2.4., entries 16 and 17). Initial investigations bearing enantiomeric pure (S)- and 
(R)-methionine derivatives anticipated a preference of the hCB2R towards (S)-configured derivatives 
up to fivefold (e.g., (S)-2.86 vs. (R)-2.87 cf. hCB2R Ki of 12 nM vs. 65 nM, Table 2.4., entries 8 and 9). 
Introduction of allyl and anisyl side chains at the pyridine core were well tolerated by the receptor, e.g., 
allyl-2.80 and anisyl-2.88 (cf. hCB2R Ki of 0.8 nM and 34 nM, Table 2.4., entries 2 and 10), indicating 
the feasibility for linker conjugation through thiol-ene click-reaction, metathesis, or Mitsunobu 
reactions. α,α-Disubstituted thioether 2.104 demonstrated equal potency to hCB2R and selectivity over 
hCB1R as the ether analog 2.99 (cf. 2.104: hCB2R Ki of 1.3 nM, hKi ratio CB1R/CB2R: 7 vs. 2.99: 1.5 
nM, hKi ratio CB1R/CB2R: 4, Table 2.4., entries 17 and 14).  
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Scheme 2.12. SAR ligands based on both natural and non-proteinogenic amino acids for evaluation of the 
new putative linker conjugation sites within recognition elements 2.35 and 2.36. Compounds with binding 
affinities towards the human CB2R lower than 10 nM are highlighted in green. Radioligand binding assays performed 
by ELISABETH ZIRWES at Hoffmann La-Roche. 
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Table 2.4. SAR studies around the recognition elements pyrazine 2.35 and pyridine 2.36 as well as 
evaluation of selected physicochemical properties: Exploration of linker elongation options at the α-




Ki hCB1R  
[nM] 
















1 2.79 16 2‘690 169 438.5 75 3.5 n.d. <0.6 
2.21 
2 / 69 / 28 
2 2.80 0.8 2.9 3 424.5 53 3.5 n.d. 3.1 n.d. 
3 2.81 1‘284 >10‘000 >8 430.5 76 2.3 3.6 n.d. n.d. 
4 2.82 991 2‘958 3 444.5 77 2.4 3.6 n.d. n.d. 
5 2.83 2’188 >10’000 >5 444.5 77 2.4 3.6 n.d. 
5.84 
5 / 77 / 18 
6 2.84 40 941 24 490.5 86 3.6 n.d. <0.1 n.d. 
7 2.85 3.2 19 6 416.5 54 4.1 n.d. <0.1 n.d. 
8 2.86 12 70 6 430.5 55 4.2 n.d. <0.1 
1.12 
2 / 67 / 31 
9 2.87 65 153 2 430.5 55 4.2 n.d. n.d.  
0 
0 / 57 / 43 
10 2.88 34 600 18 476.5 64 5.4 n.d. 1.6 n.d. 
11 2.96 3‘439 >10‘000 >3 442.5 87 2.2 3.4 n.d. 
4.27 
9 / 39 / 52 
12 2.98 97 2‘939 30 470.5 85 3.1 3.3 4.1 
0.58 
1 / 55 / 44 
13 2.97 17 99 6 428.5 65 4.0 3.3 0.6 
0.66 
1 / 75 / 24 
14 2.99 1.5 5.6 4 456.6 63 4.9 n.d. <0.1 n.d. 
15 2.102 815 5’879 7 486.6 76 3.8 n.d. n.d. 
4.16 
4 / 74 / 22 
16 2.103 1‘263 4‘688 4 444.6 56 4.8 n.d. 1.4 
0 
0 / 61 / 40 
17 2.104 1.3 8.5 7 472.6 54 5.6 n.d. 2.9 n.d. 
n.d. – not determined. [a] Surface sum of all polar atoms in the molecule; [b] Calculated partition coefficient values 
(AlogP) based on the contribution of each atom to the logP;[173] [c] Distribution coefficient values in a water and 1-
octanol mixture; [d] Solubility of the compound when diluted into aqueous environment from DMSO stock solution; 
[e] Parallel artificial membrane permeability assay (PAMPA) used to determine membrane permeation coefficient 
values (Peff);[175] [f] Percentage of compound found in acceptor, membrane and donor. Reference ligands data 
described in the Pharmacological Assessment, Section 5.2.10. Radioligand binding assays performed by ELISABETH 
ZIRWES at Hoffmann La-Roche. Kinetic solubility and PAMPAassays executed at Hoffmann La-Roche. 
To assess the suitability of these compounds as recognition element precursors for probe development, 
the characterization of their physicochemical properties was carried out (Table 2.4.). Special emphasis 
was put on lipophilicity and membrane permeation since these parameters are relevant for achieving 
sufficient exposures at the CB2R while counterbalancing the highly lipophilic and/or charged nature 
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of several fluorophores, such as Alexa- and Rhodamine-based dyes. The linker-dye construct has a 
significant impact on the molecular weight (MW) of the structure, thus pharmacophores with lower 
masses (MW < 500 g/mol) were preferred. The ability to cross biological membranes is directly 
correlated with parameters such as the calculated polar surface area (PSA).[174] Particularly, a PSA value 
less than or equal to 140 Å2 is an indicator of compound permeation through cellular membranes.[183] 
The SAR ligands correspond well to these criteria. While the molecular weight does not exceed 491 
g/mol (cf. tyrosine derivative 2.84, Table 2.4., entry 6), all molecules display PSA algorithms below 
140 Å2 (Table 2.4.). The passive membrane permeability of the SAR ligands was evaluated using the 
parallel artificial membrane permeability assay (PAMPA) model which was conducted at Hoffmann 
La-Roche. This method determines the permeation coefficient (Peff) of substances from a donor 
compartment, through a lipid-infused artificial membrane into an acceptor compartment, proving the 
concentration of the compound in all tested compartments – donor, membrane, and acceptor.[175] A 
permeation coefficient Peff above 0.5x10
-6 cm/s indicates passive membrane permeation, i.e., well 
partition of the molecule into the membrane to successfully reach the acceptor compartment. Here, 
methoxide pyrazine 2.96 exhibited the highest permeation coefficient and reached acceptor fractions 
of 9 % (Table 2.4., entry 11). 
The lipophilicity contributes to the solubility, membrane permeability, and potency of ligands, having 
a strong impact on their selectivity profile.[184] It is experimentally measured as partition coefficients 
(logP) or as distribution coefficients (logD) of the ligand between water and an immiscible organic 
solvent, e.g., 1-octanol.[185] Whereas logP is related solely with the non-ionizable portion of substrate 
in solution, logD encompasses both ionized and non-ionized forms of the compound in the solvent 
phases and is measured at physiological pH. The lipophilicity of a compound should be adjusted to 
enable both good aqueous solubility and membrane permeability (2 < logP < 3).[186] All tested analogs 
displayed logD values in the range of 3.3 to 3.6 (Table 2.4.) This result demonstrated the feasibility of 
these ligands to accommodate polar PEG-based linkers while maintaining favorable logD values. In 
practice, calculated logP values, such as AlogP,[173] often replace measured lipophilicity when analyzing 
a set of novel ligands. Overall, pyrazine-based derivatives displayed best predicted lipophilicity as the 
pyridine series. Their AlogP spams from 2.3 for pyrazine cysteinate 2.81 up to 5.6 for pyridine methyl 
sulfide 2.104 (Table 2.4., entries 3 and 17). The kinetic solubility assay provides the concentration of 
compound required for its precipitation in aqueous buffer and was conducted at Hoffmann La-
Roche.[187] To resemble the conditions in in vitro binding assays, this measurement is performed by 
adding increased amounts of a solution of the compound in dimethyl sulfoxide into an aqueous buffer 
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until precipitation occurs. The SAR analogs with the best kinetic solubility concentrations are the allyl 
pyridine 2.80, methoxide pyrazine 2.98, and methyl sulfide pyridine 2.104 with values of 3.1, 4.1, and 
2.9 µg/mL, respectively (Table 2.4., entries 2, 12, and 17). 
A careful evaluation of the in vitro pharmacology generated from SAR compounds (Scheme 2.12. and 
Table 2.4.), in combination with the molecular docking observations of linker composition, guided 
template selection for subsequent probe development. This analysis indicated that (i) modifications at 
the α-carbon of the amino ester moiety of the recognition element construct were well tolerated by 
the hCB2R, demonstrating that this position could provide a good exit vector for linker placement 
towards the extracellular portion of the receptor, (ii) the pyridine scaffold provided better binding 
affinity profile as the pyrazine ligand series, thus it was selected for further investigations, (iii) the ethyl 
group substitution at the α-carbon of the amino ester moiety was crucial for the SAR ligands to attain 
single digit nanomolar affinity at hCB2R (cf. 972-fold increase in hCB2R affinity for the α,α-
disubstituted pyridine 2.104 over its monosubstituted congener 2.103, Table 2.4., entries 16 and 17), 
(iv) a slight preference (fivefold) of the hCB2R for (S)-configured ligands was observed as seen by the 
(S)- and (R)-methionine congeners 2.86 and 2.87, yet both compounds displayed affinities at the 
nanomolar range for the hCB2R, (v) the methyl sulfide construct 2.104 demonstrated equivalent 
binding and physicochemical properties as the methoxide analog 2.99.  
Taking these observations into account, linker elongation with a thioether while preserving the diethyl 
substitution motive at the α-carbon position (ligand 2.104) was preferred as the best template for 




2.2.6. Third Approach Towards CB2R-Selective Fluorescent Ligands: Probing the R3-Position 
with a Thioether Functionality for Linker Attachment 
The preparation of racemic pyridine-based fluorescent ligands with a thioether handle for linker 
installation was developed upon the synthetic route of unlabeled congener 2.104 (Scheme 2.13.). Using 
this route, a thio-Mitsunobu reaction was employed to convert pyridine alcohol 2.76 into acethylthio 
intermediate 2.115. This key intermediate could be cleaved under basic conditions to the 
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corresponding thiol and alkylated in situ with the desired linker chains to give recognition element-
PEG-ylated linker constructs 2.110 to 2.113. Treatment of amine probe precursors with NBD chloride 
could be performed to access racemic NBD-labeled congeners 2.105 to 2.108. 
Scheme 2.13. Synthesis strategy for pyridine probe series 2.105 to 2.108: Linker introduction through a 
thioether linkage at the germinal diethyl portion of the amino ester residue. 
Initially, this route was tested applying iodinated azido-PEG2 linker 2.117 as a replacement for 
iodomethane, required for the preparation of SAR ligand 2.104 (see Scheme 2.11., Section 2.2.5.). 
Linker 2.117 was obtained in 2 steps from azido-PEG2 2.116 with an overall low 18% yield and was 
subsequently subjected to identical conditions as for the synthesis of methyl sulfide 2.104 (Scheme 
2.14.). Interestingly, azido-probe precursor 2.118 could be isolated in 25% yield from alcohol 2.76, 
which is comparable to those previously obtained with iodomethane as an alkylating reagent. These 
results demonstrated the feasibility of this synthesis route for liker conjugation.  
Scheme 2.14. Synthesis of probe precursor 2.118 using the protocol previously utilized for SAR ligand 2.104. 
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A systematic investigation of the optimal linker length was next carried out based on racemic 
intermediate 2.115. To this end, a modified procedure for linker installation was adopted to enable a 
straightforward synthesis of NDB-labeled 2.105 to 2.109 (Scheme 2.15.). Alternatively to the 
iodination step used to prepare compound 2.118 bearing an azido-linker, compound 2.115 was directly 
treated with tosyl-PEG linkers 2.124 to 2.127 or tosyl-alkyl linker 2.128 to provide N-Boc protected 
2.129 to 2.133. For this conversion, catalytic amounts of potassium iodide (0.3 equiv.) were added in 
a Finkelstein type reaction conditions. Consecutive deprotection of the Boc group using trifluoroacetic 
acid and NBD conjugation allowed for assembling this probe series.  
Scheme 2.15. Synthesis of pyridine-based racemic probe series labeled with NBD (2.105 to 2.109), Alexa 488 
(2.134), and Raman dye (2.135).  
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Applying this procedure, NBD-labeled compounds containing different linker lengths ranging from 
one to four ethylene glycol units (2.105 to 2.108)and alkyl chain (2.109) were synthesized. Moreover, 
to validate the robustness of linker placement at the R3-position of the probe template and the chosen 
length, the bulkier and charged reporters Alexa 488 dye (2.134) and Raman dye (2.135) were coupled 
to racemic precursor 2.115 using HATU (Scheme 2.15.). 
 
2.2.6.1. In vitro Pharmacology of Racemic Pyridine-based Probes 
To verify the feasibility of this design approach with regard to CB2R affinity, the synthesized unlabeled 
intermediates and fluorescent ligands were submitted to in vitro profiling. These assays were performed 
by ELISABETH ZIRWES and ANJA OSTERWALD at Hoffmann La-Roche using membrane preparations 
of CHO cells overexpressing both human and mouse CB2R or human CB1R. The in vitro results were 
used to guide synthesis efforts and select the most suitable linker length for generating high-quality 
probes targeting the CB2R (Table 2.5.). 
Racemic azido-derivative 2.118 displayed remarkable 60 nM affinity for the human CB2R and eightfold 
selectivity over the hCB1R (Table 2.5., entry 1). In addition, unlabeled 2.118 maintained low nanomolar 
affinity also towards mouse CB2R (c.f. mCB2R Ki of 52 nM). In functional cAMP assays this 
intermediate was a potent agonist of the CB2R while retaining the high selectivity over hCB1R (c.f. 
hCB2R EC50 of 1.9 nM and mCB2R EC50 of 5.4 nM, hEC50 ratio CB1R/CB2R > 10’000 nM). The 
performance of analog 2.118 in binding assays confirmed that linker elongation at the R3-position of 
the pyridine scaffold was well tolerated by the CB2R. 
Subsequent evaluation of the linker length influence on binding affinity, selectivity, and potency 
revealed NBD construct with two ethylene glycol linker units 2.106 as the most favorable with regard 
to CB2R affinity (Table 2.5., entry 13). In particular, this NBD-derivative displayed potent agonistic 
effect at the human CB2R exhibiting 4.7 nM functional affinity in the cAMP assay towards hCB2R and 
128-fold functional selectivity over the hCB1R at the (Table 2.5., entry 13). Despite the high PSA 
values of racemic NBD-congeners PEG3-2.107, PEG4-2.108, and alkyl-2.109 (>140 Å, Table 2.5., 
entries 14, 15, and 16),[174] these compounds were presumably able to permeate biological membranes 


































%Donor[g] hCB2R hCB1R mCB2R hCB2R hCB1R mCB2R 
1 2.118 
 






615.8 116 6.1 n.d. <0.1 n.d. 
2 2.129 
 






645.8 94 6.2 n.d. <0.3 n.d. 
3 2.130 
 






689.9 102 6.1 n.d. <0.1 
0 
0 / 79 / 21 
4 2.131 
 






733.9 111 6.0 n.d. <0.2 n.d. 
5 2.132 
 






778.0 120 5.9 n.d. <0.2 n.d. 
6 2.133 
 






657.9 86 7.9 n.d. <0.1 n.d. 
7 2.110 
 







545.7 84 4.6 2.7 98 
0.29 
1 / 48 / 51 
8 2.111 
 







589.8 93 4.5 2.6 210 
0 
0 / 64 / 36 
9 2.112 
 







633.8 101 4.4 2.7 168 
0.28 
1 / 41 / 58 
10 2.113 
 
2.6 164 n.d. 63 n.d. n.d. n.d. 677.9 110 4.3 n.d. >723 n.d. 
11 2.114 
 
2.7 204 n.d. 75 n.d. n.d. n.d. 557.8 76 6.3 n.d. 0.3 n.d. 
12 2.105 
 







708.8 151 6.4 n.d. 2 n.d. 
13 2.106 
 







752.9 160 6.3 2.8 9 n.d. 
14 2.107 
 







796.9 169 6.1 n.d. 14 
0.65 
2 / 38 / 61 
15 2.108 
 







841.0 177 6.0 n.d. 6.1 
0.70 
2 / 45 / 53 
16 2.109 
 







720.9 143 8.1 n.d. 14 
0.50 
2 / 12 / 87 
17 2.134 
 






1’106.2 251 5.3 n.d. n.d. 
0 
0 / 99 / 1 
18 2.135 
 







861.1 99 n.d. n.d. n.d. 
0 
0 / 9 / 91 
A – Alexa, n.d. – not determined. [a] Functional potency (cAMP assay), percentage efficacy (%eff.) given in 
parenthesis; [b] Surface sum of all polar atoms in the molecule; [c] Calculated partition coefficient values (AlogP) based 
on the contribution of each atom to the logP;[173] [d] Distribution coefficient values in a water and 1-octanol mixture; 
[e] Kinetic Solubility (Kin. sol.) of the compound when diluted into aqueous environment from DMSO stock solution; 
[f] Parallel artificial membrane permeability assay (PAMPA) used to determine membrane permeation coefficient 
values (Peff);[175] [g] Percentage of compound found in acceptor (Acc.), membrane (Memb.), and donor. Reference 
ligands data described in the Pharmacological Assessment, Section 5.2.10. Radioligand binding assays performed by 
ELISABETH ZIRWES and cAMP functional assays performed by ANJA OSTERWALD at Hoffmann La-Roche. Kinetic 
solubility and PAMPA assays were conducted at Hoffmann La-Roche. 
To analyze the PEG2 linker length robustness towards different reporter units, bulkier and charged 
fluorophores Alexa 488 (2.134) and Raman dye (2.135) were investigated (Table 2.5., entries 17 and 
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18). As for NBD-labeled 2.106, analogs 2.134 and 2.135 also exhibited agonist activity at hCB2R with 
low nanomolar binding to the target GPCR in both affinity and functional cAMP assays (cf. 2.134: 
hCB2R Ki of 3.6 nM and EC50 of 12 nM and 2.139: hCB2R Ki of 40 nM and EC50 of 0.6 nM). 
Consequently, further synthetic efforts towards enantiomerically pure probe scaffolds were conducted 




2.2.7. Synthesis of Enantiomeric Pure Fluorescent CB2R-Probes 
The linker attachment at one arm of the geminal diethyl moiety generated a quaternary chiral center 
at the α-carbon of the amino ester residue. To understand the influence of the absolute configuration 
on compound affinity and activity, enantiomer pairs of N-Boc protected probe precursor 2.130 and 
NBD-labeled 2.106 were investigated.  
 
2.2.7.1. Determination of the Absolute Configuration 
Suitable chiral resolution strategies for achieving an enantiomeric pure probe series were investigated 
in collaboration with KENNETH ATZ, BENJAMIN BERNNECKE, and ANDRE ALKER. Chiral separation of 
the racemic mixtures 2.130 and 2.106 through high-pressure liquid chromatography (HPLC) and 
supercritical fluid chromatography (SFC) – testing various combinations of chiral columns and solvent 
systems – was largely unsuccessful. Due to the high polarity of the PEG component and the flexibility 
of both scaffolds, enantiomeric separation of (±)-2.130 and (±)-2.106 was deemed unfeasible. In 
addition, these features would likely interfere with the determination of the absolute configuration of 
the corresponding enantiomer pairs via crystallography. Therefore, allyl amino ester building block 
2.78 was chosen for further optical resolution efforts and determination of the absolute configuration 
of advanced intermediates. The rationale behind this decision was the facile preparation of (±)-2.78 
in gram scale which would not interfere with the overall yield of the synthetic route. Furthermore, 
envisioning future applications of this probe design, modifications at the stage of amino ester 2.78 
would allow for a modular synthesis approach to enantiomeric pure derivatives – where the 
recognition element, amino ester-PEG2 linker, and fluorophore could be independently prepared. 
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Optical resolution of the racemic mixture 2.78 turned out to be extremely challenging. Using 
diastereomeric salt formation methods,[188] various chiral salts were screened, including camphor 
sulfonic acid, mandelic acid, lactic acid, dibenzoyl tartaric acid as well as tartaric acid, using different 
solvent and temperature systems (see Supplementary table S-2, Section 5.2.2. for more detailed 
information on the tested conditions). Salt pair (2S, 3S)- and (2R, 3R)-dibenzoyl tartaric acid in 
isopropanol gave the best separation results, however they were not satisfactory, leading to maximal 
30% enantiomeric excess (ee) after several recrystallization rounds.  
Enzyme-mediated kinetic resolution[189] attempts using four different commercially available enzymes, 
i.e., esterase from porcine liver (PLE), Alcalase® 2.4 L, Lipase Novozyme® 435, and Acylase I from 
porcine kidney, did not lead to conclusive results as, in all of the cases, amino ester 2.78 could not be 
extracted from the reaction mixture. Furthermore, kinetic resolution via amide coupling was tackled. 
This methodology relied on the principle that certain chiral amino acids, such as tosyl-(S)-proline[190] 
and (R)-O-acetylmandelic acid,[191] tend to form preferentially amides with one enantiomer of the 
racemic amine. Such a reactivity would lead to the isolation of the unreacted amine partner from the 
reaction mixture using either common column chromatography or precipitation techniques.  
Figure 2.14. Chiral HPLC and SFC separation attempts for racemic amino ester 2.78 and different analogs. 
Enantiomeric separation of amino ester 2.78, benzylidene protected-2.136, and Cbz protected-2.137 was not 
accomplished due to high polarity and lack of UV-signal of these derivatives. Separation of the components of 
racemates 2.80 and 2.138 was possible using both techniques as shown by the chiral HPLC chromatograms below 
their structure. The chiral separation experiments were conducted by KENNETH ATZ at Hoffmann La-Roche, 
conditions are described in the Experimental Procedures, Section 5.1. 
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Nevertheless, the amide coupling of these chiral compounds with amine 2.78 resulted in a racemic 
salt with no enantioselectivity. 
Both chiral HPLC and SFC were also applied for the enantiomeric separation of (±)-2.78 and selected 
derivatives, including pyridine 2.80, as well as benzylidene (2.136), Cbz (2.137) and Fmoc (2.138) 
protected analogs (Figure 2.14.). Using these methodologies, pyridine 2.80 and Fmoc-protected 2.138 
could be separated into their enantiomeric pure constituents which were subjected to crystallization 
experiments. The use of chiral salts, such as dibenzoyl tartaric acid, did not induced crystal formation 
of enantiomer pairs 2.80 and 2.138. To circumvent this issue, the amine group of (-)-2.138 was 
modified for introducing different groups which could lead to the formation of a crystalline product, 
e.g., tosyl-(S)-proline, tosyl, and (R)-O-acetylmandelic acid. This attempt led to the assignment of 
compound (-)-2.138 as the (R)-enantiomer as shown by the X-ray structure of its tosyl-(S)-proline 
congener 2.139 (Figure 2.15.). 
Figure 2.15. X-ray structure of tosyl-(S)-proline (R)-2.139 derivative used to assign the absolute 
configuration of this probe series. The synthesis of compound 2.139 was performed by BENJAMIN BRENNECKE 




2.2.7.2. Synthesis and in vitro Binding Evaluation of Enantiomeric Pure CB2R-Ligands 
Using Fmoc as a protective group for building block 2.78 was also well-suited to the modular concept 
pursued for the synthesis of this probe series. Based on this building block, a synthesis route for 
enantiomeric pure congeners was developed (Scheme 2.16.). In collaboration with BENJAMIN 
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BRENNECKE, this route was exploited for generating both (S)- and (R)-configured fluorescent analogs 
labeled with both NBD (2.106) and Alexa 488 (2.134). In brief, hydroboration-oxidation stepwise 
reaction sequence of enantiomeric pure Fmoc-protected 2.138, followed by thio-Mitsunobu reaction, 
enabled the concomitant introduction of the desired PEG2 linker chain and its amine deprotection 
under basic conditions, providing amino ester-linker construct 2.140. Subsequent amide coupling of 
2.140 with picolinic acid 2.42 using HATU and consecutive removal of the Boc protecting group led 
to the final assembly step of the respective fluorescent probes (R) and (S)-NBD (2.106) and Alexa 488 
(2.134).  
Scheme 2.16. Synthesis approach to enantiomeric pure CB2R-selective fluorescently labeled probes (S)-
2.106 and (S)-2.134. This synthesis route was also applied for (R)-configured 2.106 and 2.134, leading to similar 
yields. Intermediate 2.111 was prepared using identical conditions as for the racemic probe series described in Scheme 
2.11., Section 2.2.5. and Scheme 2.15., Section 2.2.6. For fluorophore structures see Figure 2.13., Section 2.2.1. The 
synthesis of (S) and (R)-configured intermediate 2.111 and (R)-2.134 was performed by BENJAMIN BRENNECKE. 
Enantiomer pairs of probe precursor 2.111, NBD-labeled 2.106, and Alexa 488-labeled 2.134 were 
subjected to in vitro binding and functional characterization at human and mouse CB2R and human 
CB1R (Table 2.6.). These assays were carried out by ELISABETH ZIRWES and ANJA OSTERWALD at 
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Hoffmann La-Roche. A comparison of the enantiomer pair of precursor 2.111 binding data indicated 
that there was sufficient space around the quaternary carbon junction within the binding cavity for 
accommodating both stereoisomers (cf. (S)-2.111 hCB2R Ki of 2.7 nM vs. (R)-111 hCB2R Ki of 4.6 nM, 
Table 2.6., entries 2 and 3). A similar observation was made for fully labeled Alexa 488 probe pair 
2.134 (cf. (S)-2.134 hCB2R Ki of 44 nM vs. (R)-2.134 hCB2R Ki of 62 nM, Table 2.6., entries 7 to 9), 
where only 1.4-fold enantio-discrimination with regard to hCB2R binding affinity favoring the (S)-
enantiomer was observed. The discrepancies between the biological data obtained from racemic Alexa 
488-2.134 and its enantiomeric pure congeners might derive from batch-to-batch intrinsic differences 
from in vitro assays as well as the purity and stability of purchased Alexa 488 carboxylic acid. 
Remarkably, for NBD-labeled probe pair 2.106 the enantio-discrimination favoring the (S)-
enantiomer was more evident (18-fold, cf. (S)-2.106 hCB2R Ki of 9.1 nM vs. (R)-2.106 hCB2R Ki of 
159 nM, Table 2.6., entries 4–6). Likewise, binding of both NBD- (S)-2.106 and Alexa 488- (S)-2.134 
labeled (S)-enantiomers to mouse CB2R was also more pronounced with a 19- and 4-fold difference, 
respectively (cf. (S)-2.106: mCB2R Ki of 33 nM vs. (R)-2.106 mCB2R Ki of 622 nM; and (S)-2.134: 
hCB2R Ki of 28 nM vs. (R)-2.134 hCB2R Ki of 104 nM, Table 2.6., entries 4–9). 
Table 2.6. Key characteristics of recognition element pyridine 2.36, labeling precursor 2.111 and fluorescent 
probes 2.106 and 2.134. 
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n.a. – not applicable, n.d. – not determined. [a] mCB1R data generated using mouse brain membranes; [b] Functional 
potency (EC50), percentage efficacy (%eff.) given in parenthesis. Reference ligands data described in the 
Pharmacological Assessment, Section 5.2.10. Radioligand binding assays performed by ELISABETH ZIRWES and 
cAMP functional assays performed by ANJA OSTERWALD at Hoffmann La-Roche. 
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2.2.7.3. Development of a CB2R-Fluorescent Probe Toolbox 
The promising binding data obtained for the (S)-configured fluorescent ligands NBD-2.106 and Alexa 
488-2.134 (Table 2.6., Section 2.2.7.) motivated the synthesis of additional probes exploiting (S)-amine 
2.111 as a template (Figure 2.16.). The strategy applied previously for the preparation of Alexa 488-
labeled 2.134 (Scheme 2.16., Section 2.2.7.) was utilized by BENJAMIN BRENNECKE, DR. YELENA 
MOSTINSKI, MARIE WEISE, and LEONARD MACH for introducing diverse fluorescent labels tailored 
toward subsequent biological investigations, such as AttoThio12 (2.141), Silicon-Rhodamine (SiR, 
2.142), cyanine 5.5 (Cy5.5, 2.143), and biotin (2.144) (Figure 2.16.). 
Figure 2.16. Structure of the conjugated fluorophores for the generation of the probes AttoThio12-2.141, 
SiR-2.142, Cy5.5-2.143, and biotinylated-2.144 from probe precursor (S)-2.111. These probes were synthesized 
by BENJAMIN BRENNECKE (SiR-2.142 and Cy5.5-2.143), DR. YELENA MOSTINSKI (AttoThio12-2.141 and SiR-2.142), 
MARIE WEISE (Biotin-2.144), and LEONARD MACH ((S)-2.111 re-synthesis). 
The fluorescently labeled derivatives (S)-2.141 to (S)-2.144 were subjected to in depth molecular 
pharmacology profiling which were conducted by ELISABETH ZIRWES and ANJA OSTERWALD at 
Hoffmann La-Roche using membrane preparations of CHO cells overexpressing either human and 
mouse CB2R or human CB1R (Table 2.7.). In all cases the high potency, selectivity, and agonistic 
function of the probe were preserved despite linker introduction and demonstrated to be largely 
independent of nature, size, and functionality of the attached fluorophore. These CB2R-selective 
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fluorescent ligands were also capable of preserving interspecies affinity and selectivity for both mouse 
and human CB2R. For example, AttoThio12 analog 2.141 (hCB2R Ki of 3.2 nM and mCB2R Ki of 4.6 
nM vs. hCB1R Ki of 63 nM and mCB1R Ki of 1’721 nM, Table 2.7., entry 3) exhibited single digit 
nanomolar binding affinities on human and mouse CB2R, while retaining very good selectivity over 
the CB1R (hKi ratio CB1R/CB2R: 20 and mKi ratio CB1R/CB2R: 374, Table 2.7., entry 3). NBD-labeled 
(S)-2.106 displayed the highest binding selectivity versus hCB1R (hKi ratio CB1R/CB2R: 68, Table 2.7., 
entry 1) which translated into functional selectivity in forskolin-stimulated cAMP release assays 
alongside with low nanomolar potency and full agonistic effects at CB2R. In particular, NBD derivative 
(S)-2.106 outperformed with regard to functional selectivity versus hCB1R (hEC50 ratio CB1R/CB2R 
for (S)-2.106: >4’545, Table 2.7., entry 1). 
Table 2.7. Key characteristics of (S)-configured fluorescent probes 2.106, 2.134, and 2.141 to 2.144. 

















hCB2R hCB1R mCB2R mCB1R hCB2R hCB1R mCB2R 
1 (S)-2.106 NBD 9.1 617 33 691 68 6.3 >10’000 
21 
(95) 
>4’545 474/550[c] 6.3 
2 (S)-2.134 Alexa488 44 321 28 >10’000 7 5.3 
86 
(109) 
n.d. 64 494/526[c] 5.3 
3 (S)-2.141 AttoThio12 3.2 63 4.6 1’721 20 9.0 n.d. n.d. n.d. 582/610[c] 9.0 
4 (S)-2.142 SiR 62 114 117 1’892 2 10.6 >10’000 
66 
(93) 
>149 652/674[d] 10.6 





5 690/730[e] 13.7 
6 (S)-2.144 Biotin 3.0 62 3.2 n.d. 21 n.d. >10’000 
7.8 
(85) 
5’587 n.a. n.d. 
n.d. – not determined. [a] mCB1R data generated using mouse brain membranes; [b] Functional potency (EC50), 
percentage efficacy (%eff.) given in parenthesis; [c] Fluorescence excitation and emission maxima measured in 
aqueous solution (DPBS, Dulbecco’s phosphate buffered saline); [d] Values derived from literature;[192] [e] 
Fluorescence excitation and emission maxima measured in DMSO; [f] Calculated partition coefficient values (AlogP) 
based on the contribution of each atom to the logP.[173] Reference ligands data described in the Pharmacological 
Assessment, Section 5.2.10. Radioligand binding assays performed by ELISABETH ZIRWES, cAMP functional assays 
performed by ANJA OSTERWALD, and absorption-emission spectra generated by SYLWIA HUBER at Hoffmann La-
Roche. 
Probe optimization and dye selection were supported by evaluation of the absorption and emission 
spectra of the CB2R ligands in buffer media, as well as in different organic solvents (Table 2.7., see 
Pharmacological Assessment, Section 5.2.10. for further details). This characterization provided 
important information for developing suitable test settings at the subsequent biological studies 
(Section 2.2.8.). These measurements were performed by SYLWIA HUBER at Hoffmann La-Roche and 
excluded the possibility of these compounds to form aggregates under the applied test settings.  
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Depending on the attached fluorescent label a broad lipophilicity range of AlogP values[173] from 6.3 
for NBD-labeled agonist 2.106 up to 13.7 for Cy5.5 analog 2.143 was covered, influencing the overall 
physicochemical properties and cellular permeability of the ligands. This was further confirmed by 
measuring effective permeation coefficients of pyridine 2.36 linker dye adducts in the PAMPA 
assay.[175] Here all NBD-labeled probes were able to passively permeate through membranes (2.107: 
Peff 0.7 cm/s*10
-6, 2.108: Peff 0.7 cm/s*10
-6, and 2.109: Peff 0.5 cm/s*10
-6; Table 2.5., entries 14 to 16, 
Section 2.2.6.), thereby suggesting that more lipophilic SiR- and Cy5.5-bearing structures 2.142 and 
2.143, respectively, are likely to be cell permeable as well.[192] Conversely, negatively charged Alexa-
labeled 2.134 (AlogP = 5.3, Table 2.7., entry 2) was not capable of passive membrane permeation 
according to the PAMPA assay ((S)-2.134: Peff 0.0 cm/s*10
-6, see Experimental Procedures, Sections 
5.2.9. and 5.2.10. for additional information). This feature enables investigation of extracellular 
membranes, but also intracellular compartments, by simple tuning the probe’s physicochemical 
properties through fluorophore selection. Importantly, essentially similar CB2R affinity and selectivity 
were retained independent of the selected conjugated signal agent. 
To identify potential off-targets of these labeled ligands, Alexa 488-labeled 2.134 was screened against 
the Cerep panel[193] which constitutes of a customized panel of 50 representative receptors and 
enzymes (Supplementary table S-3, data generated by Eurofins Cerep, Section 5.2.2.). In this assay, 
ligand 2.134 exhibited a very clean selectivity profile showing only a weak interaction with Adenosine 




2.2.8. Applications of Fluorescent Probes labeled with NBD, Alexa 488, and SiR for Detection 
and Visualization of the CB2R 
The applicability of this set of highly potent, selective and well-characterized CB2R fluorescent probes 
was further explored through broad comparative validation studies in an array of more complex 
chemical biology investigations. To this end, cross-validation experiments were elaborated in 
collaboration with three different laboratories, which are specialists in CB2R pharmacology. At first, 
these derivatives were subjected to flow cytometry studies using endogenously CB2R-expressing cell 
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lines, work which was performed by DR. CLAUDIA KORN, under the supervision of DR.CHRISTOPH 
ULMER and DR.UWE GRETHER at HOFFMANN-LA ROCHE in Basel. The group of DR. DMITRY 
VEPRINTSEV in Nottingham, in particular DR. DAVID SYKES, was interested in developing kinetic 
binding studies at hCB2R applying time-resolved fluorescence resonance energy transfer (TR-FRET) 
with these fluoroprobes. Furthermore, SiR-labeled 2.142 was exploited for confocal time-lapse 
imaging in CB2R-overexpressing cells by DR. SERGIO ODDI and DR. MAURO MACARRONE at the 
University of Teramo.  
In this section, proof-of-concept studies to verify the applicability and robustness of the fluorescent 
probe toolbox developed in this thesis across different cellular and molecular biology techniques, 
imaging modalities, and cell lines are presented. Moreover, interesting new findings regarding CB2R 
activation and expression which were unraveled by these ligands are discussed. A summary of the 
most relevant data generated in these collaborative efforts is given in the three following sections – 
flow cytometry, TR-FRET, and confocal time-resolved microscopy.  
 
2.2.8.1. Flow Cytometry Enabled Visualization and Detection of CB2R in Living Cells 
The specificity of these fluorescent analogs for human and mouse CB2R was evaluated by DR. 
CLAUDIA KORN at Hoffmann La-Roche using the flow cytometry technique in a fluorescence-
activated cell sorting (FACS) instrument (Figure 2.17.). For this experiment, CHO cells overexpressing 
either hCB2R, mCB2R or hCB1R as well as wild-type (WT)-CHO cells were incubated with different 
concentrations of Alexa 488-labeled (S)-2.134 (Figure 2.17.A). In comparison to its binding at the 
control WT cells or overexpressing hCB1R cells, fluorescent probe 2.134 was highly specific for CHO 
cells overexpressing both hCB2R and mCB2R. Moreover, Alexa 488-labeled 2.134 displayed excellent 
sensitivity profile down to low concentrations of 5 nM. In particular, significant concentration-
dependent increase in mean fluorescence intensity was measured for concentrations up to 10 µM for 
both human and mouse CB2R.  
Competition binding studies of fluorescently labeled (S)-2.134 were performed to further confirm 
ligand specificity and exclude unspecific binding (Figure 2.17.B). The known unlabeled CB2R ligands, 
agonist JWH133 (2.145)[194] and inverse agonist RO6851228 (2.146)[195] (for structures see 
Supplementary figure S-1, Section 5.2.1.) were selected as blockers for this analysis. After pre-
incubation of WT-CHO or hCB2R-CHO cells with ligands 2.145 and 2.146, Alexa 488-2.134 could 
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efficiently displace CB2R-agonist 2.145 at a broad concentration range. Moreover, the inverse agonist 
2.146 was also displaced by 0.37 µM Alexa 488-2.134. The FACS assay illustrated the high degree of 
target specificity of fluoroprobe 2.134 in a cellular setting.  
Figure 2.17. Alexa 488 probe (S)-2.134 enabled visualization and detection of human and mouse CB2Rs in 
flow Cytometry analysis. A) FACS analysis of the mean fluorescent intensity (MFI) of WT, hCB2R, mCB2R and 
hCB1R overexpressing CHO cells incubated with different concentration of 2.134. FACS plots show representative 
histograms of cells incubated with 0.37 µM ligand, and B) FACS analysis of the mean fluorescence intensity (MFI) 
of WT and hCB2R -CHO cells pretreated with JWH133 (2.145) or RO6851228 (2.146) (10 µM) and stained with 
different concentrations of 2.134. For blocker structures see Supplementary figure S-1, Section 5.2.1.). Experiments 
conducted by DR. CLAUDIA KORN at Hoffmann La-Roche. 
 
2.2.8.2. Generation of Equilibrium and Kinetic Binding Parameters at hCB2R Using a 
Fluorescent-based TR-FRET Assay 
Understanding ligand-binding kinetics has become an important aspect of drug discovery, as the 
kinetic parameters residence time (RT) and association rate constant (kon) are crucial for in vivo 
efficacy.[196] Particularly, as a considerable number of clinically approved drugs targeting GPCRs 
display non-equilibrium binding modes.[197] Currently, CB2R kinetic binding data is predominantly 
generated by radioligand binding assays which are based on tritiated CB2R ligands, precluding it from 
standard high throughput screening.[198] Alternatively, these data can be accessed exploiting Time-
resolved fluorescence resonance energy transfer (TR-FRET) technology, thereby circumventing the 
need for radiometric facilities and handling radioactive material.[199]  
A TR-FRET assay for measuring equilibrium binding constants has been reported applying SNAP-
CB2R HEK-293T cells covalently linked to terbium (TR-FRET donor).
[200] However, the 
determination of tracer and unlabeled ligand binding kinetics remains largely uncharted. Therefore, 
the CB2R-specific probes were explored by the group of DR. DMITRY VEPRINTSEV at The University 
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of Nottingham as tracers for TR-FRET applications. The binding affinities of CB2R specific unlabeled 
ligands, inverse agonist/antagonist SR144528 (2.20)[194, 201] and agonist HU308 (2.28),[194, 202] and were 
determined using NBD-2.106 and Alexa 488-2.134 congeners (Figure 2.18.). 
Figure 2.18. TR-FRET competition association binding kinetics at hCB2R using NBD-2.106 and Alexa 488-
2.134 as tracers. A) NBD-2.106 and B) Alexa 488-2.134 competition association binding curves in the absence 
(black curves) or presence of HU308 (2.28, red curves, upper panels) and SR144528 (2.20, blue curves, lower panels) at 
a fixed concentration of ligand and tracer. Each dot represents a new time point in the measured association of a 
tracer. For ligand structures see Supplementary figure S-1, Section 5.2.1. Experiments performed by DR. DAVID SYKES 
at the University of Nottingham. 
Table 2.8. Kinetic and equilibrium affinity binding parameters for CB2R-selective ligands SR144528 (2.20) 
and HU308 (2.28) determined using fluorescent tracers NBD-2.106 and Alexa 488-2.134.  
Ligand Structure 
TR-FRET kinetic and 
equilibrium parameters 
NBD (±)-2.106 Alexa 488 (S)-2.134 






kon (M-1min-1) 2.2 x108 6.9 x107 
koff (min-1) 0.30 0.17 
RT (min) 3.3 5.9 
Kinetic Kd (nM) 1.5[b] 2.6[c] 





(radioligand assay)  
kon (M-1min-1) 2.9 x107 7.7 x106 
koff (min-1) 0.35 0.20 
RT (min) 2.9 5.0 
Kinetic Kd (nM) 16[b] 28[c] 
Ki (nM) 12 61 
[a] Literature data determined through radioligand binding assay provided koff values for 2.20: 0.12 min-1 and for 2.28: 
0.25 min-1.[198] All values are represented by mean of [b] n = 3, [c] n = 5 experiments. Experiments performed by Dr. 
DAVID SYKES at the University of Nottingham. 
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The association and dissociation rates obtained for ligands SR144528 (2.20) and HU308 (2.28) were 
applied to calculated the equilibrium and kinetic parameters Kd, kon, and koff (Table 2.8.). Both NBD-
2.106 and Alexa 488-2.134 compounds were capable of generating CB2R equilibrium and kinetic 
binding constants. For the two CB2R modulators, the TR-FRET data with kinetic parameters and 
equilibrium affinity values were in excellent agreement with those previously obtained from 
radioligand binding assays.[194, 201-202] These results illustrated the potential for implementing this TR-
FRET methodology for important applications, including the study of CB2R ligand residence time and 
the development of high-throughput screening assays. 
 
2.2.8.3. Visualization of the CB2R with SiR-Probe 2.142: Tracing Internalization Events by Live 
Cell Confocal Imaging 
One primary advantage of cell permeable agonist probes is their ability to accumulate inside cells upon 
internalization and to track receptor recycling events. For imaging diagnosis, such a behavior provides 
amplified signal read-out, improved image contrast, and enhanced detection sensitivity.[55] In addition, 
fluorescent compounds with such properties have applicability for tracing receptor internalization and 
trafficking dynamics. As discussed in Section 2.2.8.3., SiR-labeled 2.142 was likely a cell permeable 
probe based on its physicochemical profile (Table 2.7., Section 2.2.7.3.). Therefore, this derivative was 
selected to specifically visualize hCB2R in living cells by confocal time-lapse imaging (Figure 2.19.). 
This investigation was conducted by DR. SERGIO ODDI at the University of Teramo.  
In accordance with the results obtained for the NBD-labeled analogues in the PAMPA assay (Table 
2.5., Section 2.2.6.), SiR-2.142 was confirmed as a membrane-permeable ligand, being able to 
successively enter hCB2R-overexpressing cells and to reach internal membranes (Figure 2.19.A and 
2.19.B). Treatment of hCB2R-overexpressing CHO cells with ligand 2.142 resulted in a time- and 
concentration dependent labeling of hCB2R at cell membranes, without the need for an intermediate 
washing step. In contrast to the long pre-incubation times (>30 min) often required by literature 
reported CB2R fluorescent probes for live cell imaging experiments,
[152, 154, 155b, 159, 163] which contribute 
to unspecific staining, ligand 2.142 displayed an instantaneous labeling effect.  
During the time-course of staining, the formation of small endosome-like vesicles (Figure 2.19.B, white 
triangles) within the cytosol was observed. These structures may indicate the presence of an agonist-
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stimulated internalization process of the CB2R, which occurs concomitantly to passive diffusion of 
the probe.  
Figure 2.19. Confocal Fluorescence Microscopy in live CHO cells using SiR probe-2.142 allowed for tracing 
CB2R internalization events. A) Time-lapse confocal microscopy frames for hCB2R (upper panels) and hCB1R (lower 
panels). CHO cells co-stained with 2.142 (red) and Hoechst 33342 (cyan, nucleus counter stain) at 1, 4, 6, 8 and 10 
min; Plasma and internal membranes are highlighted with white and yellow dashes, respectively. B, C) Airyscan high-
resolution imaging of hCB1R- and hCB2R-overexpressing CHO cells incubated either for 10 min with 0.4 µM 2.142 
(red) and counterstained with Hoechst 33342 (cyan), where B) hCB2R-CHO cells and C) control hCB1R-CHO cells. 
Experiments performed by DR. SERGIO ODDI at the University of Teramo. 
Since SiR analog-2.142 was practically non-fluorescent in the test settings, the bright labeling of cellular 
membranes was achieved even in the continued presence of the probe in the culture medium,[192, 203] 
thus permitting experimental imaging studies over prolonged time (Figure 2.19.A, lower panels, and 
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2.19.C). Of note, compound 2.142 did not produce membrane labeling in control hCB1R-
overexpressing CHO cells, under the tested conditions (Figure 2.19.A, lower panels, and 2.19.C). Thus, 





2.3. Conclusion and Outlook 
As a part of these thesis, a set of highly potent fluorescent probes targeting the CB2R were designed, 
synthesized, and cross-validated in different experimental settings conducted in three collaborating 
laboratories.  
Figure 2.20. Linker attachment sites investigated for the development of a CB2R-selective fluorescent 
agonist from recognition elements 2.35 and 2.36. For pyrazine 2.35, R1 corresponds to 3,3-difluoroazetidine and 
X to a nitrogen atom. For pyridine 2.36, R1 corresponds to cyclopropyl ring and X to a carbon atom. 
Assisted by molecular modeling studies, preclinical CB2R agonist drugs 2.35 and 2.36 were investigated 
as probe templates, which possessed two possible linker attachment sites: one at position 6 of the 
heteroaryl ring (R2) and the other at the geminal diethyl group (R3) (Figure 2.20). Since linker 
elongation at R2-position of pyrazine 2.35 resulted in hCB2R-innactive compounds, the synthesis of 
fluorescent ligands which were elongated at R3-position of the pharmacophores 2.35 and 2.36 was 
pursued. The tolerance of new conjugation sites for linker introduction within pyrazine 2.35 and 
pyridine 2.36 was explored through a small SAR analysis. These studies indicated that linker elongation 
of the pyridine 2.36 scaffold with a thioether at the diethyl substitution motive at the α-carbon position, 
was the most successful strategy for retaining high CB2R affinity. Based on this scaffold, racemic 
probes were synthesized with a thioether handle for conjugation with different linker lengths ranging 
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from one to four ethylene glycol units, and an alkyl linker. Evaluation of these constructs revealed 
NBD analog (±)-2.106 with PEG2 linker units as the most favorable template to advance optimization 
efforts. 
Scheme 2.17. General modular approach for the synthesis of enantiomeric pure probe template (S)-2.111, 
which allowed for the generation of the CB2R-selective fluorescent probes 2.106 and 2.134.  
The influence of the absolute configuration of probe template 2.111 on the affinity and activity of this 
compound series was investigated (Scheme 2.17.). The Fmoc-protective group enabled, not only chiral 
separation of amino ester (±)-2.138 using HPLC, but also the elucidation of its absolute configuration 
using X-ray. From this building block, a modular synthesis approach was developed for the 
preparation of enantiomer pairs of precursor 2.111 labeled with NBD (2.106) and Alexa 488 (2.134) 
dyes (Scheme 2.17.). Improved pharmacological profile was obtained with (S)-configured derivatives, 
thus amine (S)-2.111 was further explored by BENJAMIN BRENNECKE, DR. YELENA MOSTINSKY, 
LEONARD MACH, and MARIE WEISE for the attachment of a variety of fluorophores with different 
physicochemical and photophysical properties tailored for diverse applications. Despite large 
structural modifications with regard to linker elongation and dye attachment, the high potency, 
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selectivity and agonistic properties of recognition element 2.36 were mostly preserved in all 
synthesized probes. These tools show unprecedented highly consistent interspecies affinity and 
efficacy for both human and mouse CB2R in the low nanomolar range.  
The fluorescently labeled ligands were extensively validated using complementary in vitro experiments 
which demonstrated the versatility and robustness of probe platform (S)-2.111 to generate a toolbox 
of fluorescently-labeled CB2R-agonists. In flow cytometry experiments performed by DR. CLAUDIA 
KORN, Alexa 488-derivative 2.134 allowed to specific detect CB2R in overexpressing cells and 
demonstrated target specificity by competition against CB2R reference ligands. The analogs NBD-
2.106 and Alexa 488-2.134 were applied by DR. DAVID SYKES in a fluorescence-based TR-FRET assay 
for the generation of CB2R kinetic and equilibrium binding data, which were in excellent agreement 
with previous values obtained using radiometric ligand-binding assays. Finally, DR. SERGIO ODDI 
exploited SiR-2.142 to reliably image and monitor CB2R distribution in real-time live cell imaging by 
confocal microscopy on overexpressing hCB2R-CHO cells. Thereby, for the first time visualization of 
CB2R trafficking and internalization in living cells was achieved.  
Future applications involving the Raman-2.135 and biotin-2.144 probes, which were not to date 
explored, hold potential in interesting fields of research, such as in Raman spectroscopy and pulldown 
assays to identify relevant receptor-ligand interactions at the binding pocket. In particular, compound 
2.135 could be utilized for generating the first Raman imaging of CB2R. Moreover, the recent 
elucidation of the human CB2R crystal structure in both antagonist- (ligand: AM10257, PDB 5ZTY)
[204] 
and agonist-bound (ligand: AM12033, PDB 6KPF; see Figure 3.1., Section 2.1.1.)[81] states enable a 
deeper understanding of receptor-ligand interactions which could aid to new structure-based design 
strategies of probes with improved pharmacology. 
Altogether, the probe platform described in this chapter have the potential to provide tools that would 
enable to: (i) overcome the large interspecies differences encountered between rodent and human 
CB2R, (ii) have high specificity and low nanomolar affinity for CB2R with full agonist efficacy, and (iii) 
perform complementary biologically and pharmacologically experiments used to detect CB2R and 
study its function. Ultimate, these compounds have diverse applications as surrogate markers, e.g., for 
target engagement studies of the CB2R, identification of mechanisms of action, and deepen the 









3.1.1. Pancreatic Cancer – Current Status and Challenges 
Pancreatic cancer is the fourth most killing cancer worldwide and has the lowest survival rate among 
human cancers with an overall 5-year survival rate of approximately 8%.[205] Despite the various tumors 
types identified in the pancreas, the vast majority of pancreatic tumors (up to 90%) are represented by 
a specific subtype named pancreatic ductal adenocarcinoma (PDAC).[206] The only curative treatment 
option for this cancer type to date is complete tumor surgical resection in combination with 
chemotherapy.[207]  
Figure 3.1. Progression model for pancreatic cancer. PanINs represent progressive stages of neoplastic growth, 
each step in the progression from normal epithelium to low-grade PanIN on to highgrade PanIN is distinguished by 
histological features. Modified after J. YU et al.[208] and R. H. HRUBAN et al.[209]  
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Pancreatic cancer originates from precursor lesions, being pancreatic intraneoplasia (PanIN) the most 
common.[210] In particular, PanIN develops into invasive carcinoma through a multistep carcinogenic 
process, from clinically benign PanIN-1 to carcinoma in situ PanIN-3 (Figure 3.1.). The pancreas is 
located behind the stomach and surrounded by other organs, including the spleen, liver, and small 
intestine, which makes pancreatic tumors rarely palpable. In addition, most symptoms of PDAC do 
not appear until the tumor has grown large enough to interfere with its own or other organ functions 
(invasive carcinoma, Figure 3.1.). The situation is further aggravated by the lack of appropriate 
diagnostic tools, which leads to definitive disease confirmation at locally advanced and unresectable 
cancer stages.[211] The median size of PDAC at the time of diagnosis is circa 3 cm – these statistics 
have not changed in the past three decades in spite of advances in imaging technologies, and in clinical 
procedures.[212] Resection of tumors while they are small, well-defined, and localized results in higher 
chances of complete tumor clearance. Therefore, the early detection of PDAC, before cancer 
metastasizes, is critical to improving survival rates.[213]  
Due to its deep anatomical location, non-invasive imaging of the pancreas is extremely challenging. 
Imaging methodologies to diagnose PDAC are primarily based on endoscopy (invasive), computed 
tomography, MRI and ultrasonography, and have very low success rates at tracing early-stage 
tumors.[214] Detection and surgical removal of PanIN-3 is related to an increase in patient survival,[215] 
albeit distinguishing between tumorous and healthy tissue using current imaging techniques is often 
not possible, and may lead to incomplete tumor resection or even removal of healthy tissue.[216] In 
current practice, tumor identification is mainly subjective and relies heavily on the physician’s 
experience, leading to a significant variability in surgical outcomes.[217] Moreover, both the benign 
pancreatitis and malignant PDAC have abundant stroma, which is difficult to distinguish using 
conventional non-targeted-based imaging techniques. 
At present, carbohydrate antigen 19-9 (CA 19-9) is the only FDA approved biomarker for pancreatic 
cancer prognosis and following disease evolution, and is tested through radioimmunoassay.[218] 
Nevertheless, CA 19-9 is frequently associated with false positives as it lacks to differentiate between 
nonmalignant pancreatic diseases and cancer, as well as it fails to detect early-stage malignancies.[219] 
To improve conventional imaging outcomes, molecular imaging has the potential to precisely detect 
and characterize PanINs, as well as to provide real-time surgical guidance. It is known that patients 
life-time doubles after microscopically radical tumor resection (of at least 1 mm),[220] yet the only 
fluorophores so far approved by the FDA for peripheral tumor resection are non-specific, such as 
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methylene blue (3.1), fluorescein (3.2), and indocyanine green (ICG, 3.3) (Figure 3.2.).[221] Since none 
of these agents provide any kind of directed, specific targeting of tumor cells, critical structures, 
including ureters and nerves, cannot be preserved during surgery. Hence, molecular imaging tools that 
allow not only early detection, but also intraoperative visualization of PDAC are urgently needed. 
Figure 3.2. Structures of the non-selective fluorophores approved for clinical applications. A) Methylene blue 




3.1.2. Plectin-1 as a Biomarker for Pancreatic Cancer 
Cancer biomarkers are often used in oncology to differentiate between benign and malignant cells and 
characterize tumor types, holding the promise for the early detection of cancers. In particular, the ideal 
PDAC biomarker should be expressed in measurable concentrations at the early onset of the disease 
with high sensitivity and specificity.[222] Genetic alterations, such as mutations in the KRAS oncogene 
or p53, DPC4, and BRCA2 tumor suppressor genes generate an imbalance in key signaling 
pathways.[223] This process leads to the overexpression of specific biomarkers, which can be explored 
as targets for tumor-specific molecular agents. In stark contrast to the lack of effective contrast agents 
available, the cellular composition of PDAC provides a plethora of relevant targets for molecular 
imaging. Those targets include mesothelin,[224] plectin-1,[225] urokinase plasminogen activator,[226] 
insulin-like growth factor I receptor,[227] mucin 1,[228] vascular endothelial growth factor receptor 2 
(VEGFR2),[229] and zinc transporter 4.[230] Among these, plectin-1 is a scaffolding cytoskeletal protein 
that undergoes aberrant mislocalization to the cell surface of PanIN-3 lesions and PDAC.[225, 231] The 
absent expression of plectin-1 in the healthy pancreas, liver and peritoneum,[232] makes it an 
exceptionally specific and sensitive target for the early detection of PDAC. 
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The generation of an appropriate recognition element with optimized affinity, selectivity and 
physicochemical properties follows identification of the biomarker. For imaging probe development, 
the ideal recognition element encompasses connectivity handles for the attachment of linker and 
reporter unit entities. Besides small molecules, as utilized in the previous section of this thesis, 
peptides, aptamers and antibodies can also serve as a targeting moiety.[55] Particularly, peptides offer 
the advantage of non-immunogenicity and are amenable to chemical modification. In addition, peptide 
libraries allow for systematic hit identification and optimization in a faster process than for small 
molecules. Such libraries can be synthesized chemically – which enables introduction of non-natural 
amino acids and scaffold alterations – or biologically via phage, yeast or bacteria.[233] Phage display, the 
major methodology to screen for peptides, exploits Escherichia coli to express peptide libraries which 
were encoded in a specific plasmid.[234] Through a phage-display study, KELLY and collaborators[225] 
have identified a plectin-targeting peptide NH2-KTLLPTP-COOH (PTP, 3.4, Figure 3.3.A) which 
distinguished malignant pancreatic disease from chronic pancreatitis and healthy pancreas in vivo. In 
this study, the non-targeting and not selective peptide sequence NH2-SNLHPSD-COOH was also 
characterized (3.5, Figure 3.3.B). Successful preclinical trials applying the PET tracer In111-labelled 
tetrameric-3.4 in PDAC mouse model[232] advanced this tracer for phase 0/ early phase I clinical trials, 
terminated in 2016.[235] 
Figure 3.3. Structures of plectin-1 targeting peptides identified by KELLY et al.[225] A) Plectin-1 targeting 






3.1.3.  Molecular Imaging Probes for Pancreatic Cancer Imaging 
Cancer-targeted probes developed for diverse imaging modalities have been applied in both preclinical 
and clinical settings. For PDAC treatment, these tools have the potential to bridge the gap between 
diagnostic and intra-operative imaging and to monitor treatment response. Different classes of 
recognition elements were explored for the design of imaging tools for PDAC, including small 
molecules, peptides, aptamers, antibodies, and engineered protein fragments.[236] Most of these tools 
aim the specific binding to upregulated targets during the progress of the disease.  
As discussed in Section 1.2., sufficient functional and structural information for a thorough diagnosis 
will likely derive from the synergistic combination of techniques, rather than using a single modality.[69] 
Targeted fluorescent probes are efficient tools for precise and real-time intra-operative guidance, 
whereas PET tracers allow for disease detection with high tissue penetration, and the very good soft-
tissue contrast of MRI enables diagnosis confirmation and following surgery outcomes. In recent years, 
this concept has become very attractive for the design of integrated diagnostic and intra-operative 
tools. This section provides recent advances of molecular imaging strategies for PDAC, with an 
emphasis on clinical tests, dual-imaging and intra-operative applications. 
The use of disease-specific ligands can significantly improve PET diagnosis, when compared to the 
unspecific [18F]FDG (3.6, Figure 3.4.). This was confirmed in humans using the 18F-labeled cystine 
knot peptide 3.7 containing a 36 amino acid sequence peptide structured with a tertiary fold targeting 
integrin αvβ6[237] (Figure 3.4.). In preclinical settings, PET tracers targeting not only integrin classes, 
such as αvβ3[238] and αvβ6,[239] but also the tumor growth and metastasis promoters plectin-1,[232] tissue 
factor transmembrane glycoprotein,[240] activated leukocyte cell adhesion molecule,[241] and transferrin 
receptor[242] are currently being explored. Moreover, a dual PET and NIR tracer based on the 
monoclonal antibody mAB 5B1 which specifically binds to the clinically accepted CA 19-9 biomarker 
has been developed, showing promising results in identifying metastases foci in mice.[243] Nevertheless, 
several limitations, such as lack of specificity in detecting PDAC over other pancreatic abnormalities, 
short-half life, and high accumulation in the kidneys and liver still hamper the advance of these tracers 
into the human situation. 
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Figure 3.4. Structures of PDAC-selective molecular imaging probes.[237, 244] The reporter unit is highlighted in 
red.  
Targeted microbubbles were applied to study the tumor vasculature of PDAC using contrast-
enhanced ultrasound. These contrast agents were synthesized to specifically recognize and validate 
angiogenesis targets in mouse models, including VEGFR2, integrin, endoglin, and thymocyte antigen 
1 (Thy1).[245] In particular, first-in-human clinical evaluation of VEGFR2-targeted microbubbles for 
the detection of breast and ovarian cancer have demonstrated the feasibility of this emerging 
technique.[13b, 246] MRI imaging nanoparticles based on quantum dots coated with single-chain anti-
EGFR antibody to target the endothelial growth factor receptor (EGFR) have shown good specificity 
for PDAC both in vivo and ex vivo preclinical studies.[247] In addition, dual MRI and NIR molecular 
imaging agents targeting mucin-1 and plectin-1 were reported. These compounds contain a 
superparamagnetic iron oxide nanoparticle core labeled with Cy5.5[225, 248] or Cy7[249] fluorophores to 
allow for the visualization of PDAC in mouse. In general, the major drawback of nano-based imaging 
systems to image the pancreas is the eventual unsuccessful delivery to the site of interest due to PDAC 
dense stroma and hypoxic microenvironment.[250] 
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Currently, two PDAC-specific optical imaging (OI) agents are under clinical phase 1 evaluation for 
intraoperative guidance. These compounds share design similarities being both SGM-101[251] and 
cetuximab-IRDye800[252] NIR dye-antibody conjugates. In particular, cetuximab-IRDye800 probe 
targets EGFR and is additionally being tested in photoacoustic (PA) imaging settings. These trials have 
shown successful PDAC imaging but accompanied with interfering auto-fluorescence of the 
surrounding background, including tissues and blood. Importantly, these structures were capable of 
penetrating PDAC tumors, in converse to the hypothesis that the tumor density would restrict targeted 
imaging and therapy. Furthermore, the integrin αvβ6 has also been investigated for the synthesis of 
fluorescent imaging probes. Amide coupling of the 36-mer peptide cystine knot with a NIR dye 
(Atto740) led to the formation Atto740-3.7, which detected PDAC in mice both by fluorescent and 
photoacoustic techniques.[253] Another integrin αvβ6-targeting theranostic and OI agent was 
synthesized using streptavidin-biotin as a core for the attachment of multiple NH2-HYK-COOH 
peptide sequences, composed of 22 amino acids, and a NIFR dye (IRDye700DX).[254] First preclinical 
investigations in mice demonstrated the feasibility of this compound for PDAC treatment upon light 
irradiation and tumor surgical removal. More recently, WANG and collaborators[244] synthesized a dual 
MRI and NIFR derivative targeting both plectin-1 and integrin β4 (Cy7-3.8) and demonstrated its 
potential applications in PDAC diagnosis using MRI, followed by UV-guided tumor resection (Figure 
3.4.). 
All of these studies are currently in early clinical development and as such, their impact and 
contribution to revert PDAC prognosis are yet to be determined. Essential for a successful contrast 
agent is the high sensitivity and selectivity for cancerous over healthy tissue. In particular, dual-imaging 
probes that combine fluorophores with MRI signal agents, such as gadolinium(III) chelates, enable 
the use of a single molecule to non-invasively diagnose PDAC and guide surgical efforts. Dual 
fluorescent imaging tools are also very promising since different modalities, such as OI, photoacoustic 
imaging, and Raman spectroscopy utilize NIR dyes as a source of readout to provide complementary 
image information on depth, sensitivity, and resolution. These probes have also therapeutic 
applications, being used as theranostics to reduce or completely suppress cancer growth by light 
irradiation of the tumor region, after compound administration. 
At present, the most advanced imaging agents encompass high molecular weight recognition elements, 
e.g., antibodies, nanobodies, long peptide sequences of over 20 amino acids, and often require a 
nanocarrier for improving administration and distribution of the compound in vivo. The recent work 
 
89 
of WANG and co-workers[244] has demonstrated that small molecule ligands are also successful in 
reaching out the tumor tissue and providing high-quality images for both cancer detection and 
resection (Cy7-3.8, Figure 3.4.), therefore paving the way for the development of small molecule 
PDAC-specific fluorescent ligands. However, the synthesis of multivalent and dual-imaging small 




3.1.4. Exploring the DOTA Scaffold for Multivalent Probe Design 
Major advances in the medical diagnosis field have been achieved through the use of molecular cages 
that have the ability to complex, e.g., radionuclides and paramagnetic metals, for the development of 
imaging probes.[256] Molecular cages allow the reporter unit to provide a decent in vivo readout, while 
avoiding the inherent toxicity of such metals. In particular, macrocyclic polyamines, also known as 
complexones, belong to the most frequently employed cages for the design of imaging tools[257] (Figure 
3.5.).  
Figure 3.5. Structures of most common macrocyclic polyamines used in the medical field.  
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Among these, the cyclen (3.10)-based 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, 
3.13) and its derivatives, such as 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane 
(DOTAM, 3.16) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid) 
(DOTP, 3.17), have found increasing applications in the clinics (Figure 3.5.).[258] The presence of four 
nitrogen atoms, together with four carbonyl functionalities, generate an eightfold valency which can 
tightly bind to metal ions with high chemical stability and water solubility. Due to these attributes, 
cyclen-based gadolinium(III) chelates have become the gold standard of contrast agents for MRI.[34] 
However, these tools are not disease-specific and depend on the contrast of different tissue densities 
for a clear diagnosis. This methodology requires a large amount of contrast agent administration, 
which generally poses a risk of toxicity. [34] In recent years, this problem is being circumvented by the 
synthesis of targeted cyclen complexes by conjugating a recognition element prior to metal 
chelation.[258-259] Such a probe can be used in vivo for a multitude of imaging modalities, including MRI, 
PET, SPECT, luminescence imaging, and dual-imaging purposes, as exemplified by the dual NIR and 
OI analog reported for PDAC imaging[244] (Cy7-3.8, Figure 3.4., Section 3.1.3.).  
As discussed in Section 1.3., multivalency, i.e., the combination of multiple recognition elements 
through covalent linkage to a template, is a useful strategy to enhance target avidity and in vivo retention 
times at the site of interest (see Figure 1.4.A, Section 1.3.). These features are particularly relevant for 
a contrast agent to reach out to the pancreas, and eventually provide high-quality images. The cyclen 
core (3.10) encodes remarkable topological information as it allows for functionalization with up to 
four acetic acid arms. This approach leads to a multivalent architecture, which can be either 
symmetrical, possessing fourfold decoration[260] (Figure 3.6.), or unsymmetrical, with tailored multiple 
components[261] (Figure 3.7.).  
A series of symmetrical DOTA agents targeting the cancer biomarker integrin αvβ3 were synthesized 
containing one and/or up to three cyclic-RGDfk peptide (cRGD) targeting moieties.[260a] The 
attachment of cRGD peptides at the DOTA core was achieved via subsequent amide coupling 
reactions. However, this strategy was not successful in providing a fourfold cRGD functionalized 
DOTA analog, leading to very low isolated amounts of product which were no sufficient for in vitro 
evaluation. To overcome the associated synthetic issues, the preparation of a fully cRGD 
functionalized derivative was tackled exploring the DOTP scaffold (3.18, Figure 3.6., see Figure 3.5. 
for DOTP-3.17 structure).[262] The multivalent compounds were evaluated in competition binding 125I-
echistatin assays, demonstrating that their potency improved proportionally with the addition of 
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cRGD recognition elements.[260a] In particular, the tetra-decorated 3.18 displayed remarkable 0.1 nM 
potency towards integrin αvβ3, a 3800- and 130-fold increase in potency when compared to mono- 
and tri-substituted DOTA derivatives, respectively.[262] 
Figure 3.6. Symmetrically derivatized cyclen 3.18, containing four cRGD peptides connected by PEG 
linkers to a DOTP center.[262]  
Alternative to the amide formation strategy, the synthesis of DOTP-based derivatives containing four 
symmetrical substitutions has been recently described using both Copper (CuAAC)[263] and strain-
promoted (SPAAC)[264] azide-alkyne cycloaddition.[260b] These synthetic strategies were applied for the 
preparation of prostate cancer-specific theranostic conjugates which showed promising results in vivo, 
leading to low nanomolar affinities and good tumor uptake.[260b] 
The synthesis of more challenging heteromultifunctional DOTA compounds has been described by 
different research groups.[261, 265] The assembly of such constructs was predominantly accomplished 
using amide coupling reactions to introduce the linker, recognition element, and either a fluorescent 
dye – for an imaging probe – or a drug – for a drug-carrier. For example, HU and co-workers 
developed a multifunctionalized DOTAM template applied to image and treat osteoarthritis (3.19, 
Figure 3.7.).[261] The template 3.19 combined three peptide sequences targeting type II collagen (N-
acetylated-WYRGRL-COOH) as ligands and a free amine which was exploited for conjugating either 
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the NIR dye Cy5.5 or Pepstatin A, a cathepsin D inhibitor against cartilage degradation. In ex vivo 
experiments, compound Pepstatin A-3.19 demonstrated good inhibitory profile which was maintained 
up to 48 h.[261a] 
Figure 3.7. Unsymmetrically derivatized cyclen 3.19, containing three collagen II-targeting peptide 
sequences and either the NIR dye Cy5.5 or the drug Pepstatin A.[261a] 
This versatility in functionalization makes cyclen a general template for the modular synthesis of 
molecular imaging tools. Despite the numerous possible applications in medicine, the preparation of 
fully decorated DOTA compounds in heterogeneous fashion is challenging and often tedious.[266] In 
consequence, the assembly of hetero-multifunctional DOTA applying biorthogonal reactions remains 
largely uncharted. Current synthetic procedures are based on “protection-deprotection” steps, difficult 
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chromatographic purifications and low isolated yields, hampering further clinical development of 




3.1.5. Motivation for the Synthesis of Multivalent Cyclen-based Fluorescent Ligands and 
Specific Aims 
To overcome the aforementioned issues regarding the synthesis of hetero-multifunctional DOTA 
derivatives, the project described in this chapter aimed to develop a clickable imaging probe precursor 
using the DOTAM (3.16) as core. For the preparation of such a template, a three to one design was 
planned to allow for the incorporation of two distinct entities into the DOTAM scaffold – the 
recognition element and a reporter unit (Figure 3.8.). 
Figure 3.8. DOTAM-based clickable probe template and reporter unit attachment linkages considered for 
the preparation of multivalent fluorescent ligands. While terminal maleimides would enable introduction of 
three ligands to the DOTAM template, the reporter unit, i.e., fluorophore could be attached using either amide or 
triazole linkages.  
Maleimide groups were chosen as multivalent handles for the attachment of the recognition element 
moieties due to its broad applicability for Michael-type addition coupling with cysteines and reactive 
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thiols.[267] These functionalities should be easily introduced at the targeting ligand structure. The fourth 
arm of the DOTAM core would allow for the orthogonal labeling of the signal agent through either 
amide or triazole linkages (Figure 3.8). As such, synthesis strategies based on amide coupling or 
CuAAC were investigated for probe assembling. Fluorescent dyes were selected as reporter unit for 
the in vitro validation of the DOTAM-based template using confocal microscopy techniques. To 
enhance compound solubility and add flexibility to the attached arms the linker would be composed 
by polyethylene glycol (PEG) chains containing two ethylene glycol units. Linker length optimization 
could be necessary depending on the target of choice and experimental test settings.  
Ultimately, this new clickable precursor was utilized for the one-pot synthesis of heterogeneously 
tetrafunctionalized DOTA ligands applying subsequent biorthogonal conjugations in a modular and 





3.2.1. Design of a Tetrasubstituted Cyclen-based Fluorescent Probe 
The synthesis of a multivalent imaging agent to visualize early stages of PDAC was envisioned to 
explore the applicability and robustness of the clickable cyclen-based template. To this end, plectin-1 
targeting PTP-ligand (3.4, Figure 3.3.A, Section 3.1.2.) was selected as recognition element. The non-
targeting and, thus, not selective control peptide sequence (3.5, Figure 3.3.B, Section 3.1.2.) and a 
protected cysteine (3.20, R1, Figure 3.9.) were exploited for the synthesis of negative labeled controls. 
To both PTP-3.4 and control-3.5 peptide sequences an additional cysteine amino acid (Cys) was 
included in their C-terminus to enable their conjugation to the terminal maleimide groups at the probe 
template (R1, Figure 3.9.).  
The cell permeable cyanine (Cy) Cy3 and Cy5.5 dyes were chosen as fluorescent reporter units due to 
their complementary photophysical properties and broad applicability in both in vitro and in vivo assays 
(Figure 3.9.). These fluorophores can be modifiable to bear various functionalities, including 
carboxylic acid, alkyne, and azide, which were investigated for their attachment to the probe template. 
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Therefore, the synthesis of cyclen building blocks encompassing three maleimides and either a 
terminal amine (Figure 3.9.A), azide (Figure 3.9.B), or alkyne groups (Figure 3.9.C) was planned. 
Figure 3.9. Modular design of a cyclen-based precursor for the synthesis of multivalent fluorescent probes. 
Fluorophore labeling to probe template can be performed with A) amide coupling of the DOTAM-PEG2-amine to 
the carboxylic acid group of the dye, B) CuAAC reaction of the DOTAM-PEG2-azide to terminal alkyl functionality 
of the dye, or C) CuAAC reaction of the DOTAM-alkyne to the dye-PEG2-azide construct.  
Depending on the N-substitution of the maleimide group, such constructs might undergo retro-
Michael addition with other cysteine-containing cellular components.[268] To prevent this possible side-
reaction, the succinimidyl thioether ring should be hydrolyzed before any biological application 
(Figure 3.10.A). This additional step could not only increase the stability and aqueous solubility of the 
fluorescent ligand, but also enhance the flexibility of its targeting arms.  
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The relevance of multivalence to image PDAC would be verified with mono-derivatized controls 
(Figure 3.10.B). These compounds would be synthesized encompassing a 1:1 recognition element and 
fluorophore ratio.  
Figure 3.10. Stabilization of thiol-maleimide adducts for biological systems and monovalent probe design. 
Thiosuccinimide hydrolysis can be either achieved through mild ultrasonication or alkaline treatment.[268a] For R1 




3.2.2. Preparation of Fourfold N-Functionalized Cyclen Building Blocks and Linker Synthesis 
There are various synthesis routes which can be exploited to provide a bifunctional cyclen (3.10) 
scaffold.[261a, 266b, 269] In general, these routes exploit orthogonal protective groups, such as Fmoc, Boc 
and Cbz groups, to enable differentiation of one secondary amine of the cyclen ring over the remaining 
three. These groups are stable under common organic reaction conditions, yet are capable of 
sequential and selective removal. Thus, this strategy enables the use of amide coupling, reductive 
amination, and N-alkylation for the installation of the desired components for imaging probe 
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assembling. In this project, tert-butyl and benzyl were selected as protective groups for the conjugation 
of α-halogenated carboxylic acids into the cyclen core using two different synthetic strategies.  
The first route started with a triple N-alkylation reaction on the cyclen scaffold (3.10) using tert-butyl 
bromoacetate to afford DO3A intermediate 3.15 in excellent 90% yield (Scheme 3.1.A). Subsequent 
N-alkylation applying either benzyl bromoacetate or propargyl bromide provided key building blocks 
3.21 and 3.22. Alternatively, the N-monoalkylation of cyclen 3.10 using tert-butyl bromoacetate 
provided intermediate 3.23 in moderate yield after reversed-phase medium pressure liquid 
chromatography (MPLC) chromatography (Scheme 3.1.B). Treatment with benzyl bromoacetate 
under basic conditions afforded tetra-substituted cyclen 3.24 in 90% yield. These building blocks (3.21, 
3.22 and 3.24) were further explored for the introduction of linker functionalities via amide coupling. 
Scheme 3.1. Synthesis of fourfold N-functionalized cyclen. Synthesis route A) through DO3A intermediate 3.15 
formation and B) through N-monoalkylated intermediate 3.22 formation. 
The different linkers required for DOTA functionalization were synthesized either from the 
commercially available N-Boc protected PEG2-amine 3.25 or azido-PEG2-amine 3.31 (Scheme 3.2.). 
Standard Fmoc protection using Fmoc chloride and sodium bicarbonate in dioxane afforded Fmoc-
linker 3.26 in a moderate 43% yield (Scheme 3.2.A). The preparation of Cy5.5-labeled PEG2 linker 
(3.27) was achieved through amide coupling using HATU (Scheme 3.2.B). Maleimide-functionalized 
linker 3.28 was obtained from the reaction with activated maleimide N-methyl carbamate[270] under 
aqueous basic conditions in a very good 88% yield (Scheme 3.2.C). After these reactions, subsequent 
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deprotection of the Boc group with trifluoroacetic acid provided the amine functionality in 
quantitative yields. 
Scheme 3.2. Synthesis of PEG2 linker building blocks from N-Boc protected PEG2 amine (3.25) and azido-
PEG2 (3.31) linkers. A) Fmoc-protection of 3.25, B) Cy5.5-labeling of 3.25, C) Introduction of the maleimide 
functionality at 3.25, followed by Cy3 or Cy5.5 conjugation, and D) Cy3 or Cy5.5-labeling of 3.31. For fluorophore 
structures see Figure 3.9., Section 3.2.1. 
These linkers were employed for both the synthesis of novel DOTAM probe precursors, as described 
in the following sections, or further conjugated with the Cy3 and Cy5.5 fluorophores to investigate 
the fluorescent labeling strategies planned (Scheme 3.2.C and 3.2.D., for design approaches see Figure 
3.9., Section 3.2.1.). Using standard amide coupling conditions, the maleimide-linker derivative 3.28 
was conjugated to the carboxylic acid functionality of both cyanine 3 and cyanine 5.5 dyes in moderate 
to good yields (Scheme 3.2.C). The same conditions were also applied to azido-PEG2 3.25 to afford 




3.2.3. Synthesis of Fluorescently Labeled Monovalent Control Probes 
Before the development of the more complex N-functionalized cyclen tetrapodal templates, syntheses 
of monovalent congeners were carried out (Figure 3.10.B, Section 3.2.1.). These probes served as 
fluorescent controls for the biological validation of the DOTAM-based constructs (Figure 3.9., 
Section 3.2.1.). They can be applied in the assay design for optimization of the test settings as well as 
during the assay to compare the cellular uptake and imaging quality of mono- vs. tri-targeting peptides. 
Since these tools are devoid of the cyclen core, the influence of this macrocycle on the overall 
physicochemical properties of the probes can be additionally evaluated.  
For the preparation of these control tools, a Michael-type addition reaction of ligand cysteinates to 
the maleimide moiety of cyanine-labeled PEG2 linkers (3.29 and 3.30, see Scheme 3.2.C, Section 3.2.2.) 
was planned. To avoid the unwanted hydrolysis of the maleimide group to maleic acid amide which 
prevents thiol conjugation under biological conditions[271] (Figure 3.10.A, Section 3.2.1.), this reaction 
step was evaluated in a set of different solvent systems (Table 3.1.). These investigations were 
conducted using cysteinate PTP-3.4 and Cy5.5-labeled 3.30 as model reagents.  
Table 3.1. Solvent systems tested for the Michael-type addition reaction between Cy5.5-labeled maleimide-
PEG2 3.30 and cyteinate PTP-3.4. 
Entry Solvent Time Result 
1 ACN n.a. No conversion; suspension of 3.30 observed 
2 ACN:DMF (1:1, v:v) 6 d 3.35 
3 PBS buffer pH = 7.4 8 h maleic acid amide formation 
4 Sodium acetate-acetic acid buffer pH = 5 18 h 3.35 
5 Triethylammonium acetate buffer pH = 5 18 h 3.35 
n.a. – not applicable. Reaction conditions: Cy5.5-labeled PEG2 3.30 (1.0 equiv.), Cys-PTP-3.4 (1.5 equiv.), solvent 
(3 mL), room temperature. 
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Organic solvents, including dimethylformamide and acetonitrile were initially tested (Table 3.1., entries 
1 and 2). Although product 3.35 formation was observed in a mixture of dimethylformamide and 
acetonitrile (1:1, v/v), this reaction was extremely slow, requiring up to six days for complete 
conversion to the desired thiosuccinimide 3.35 (Table 3.1., entry 2). Since the formation of maleic acid 
amide occurs faster at higher pH (> 7.4), two acetate-based buffer systems at pH = 5 and phosphate 
buffered saline (PBS) buffer at pH = 7.4 were additionally screened (Table 3.1., entries 3 to 5). Under 
physiological conditions (pH = 7.4), hydrolysis of maleimide 3.30 to its maleic acid amide congener 
occurred before the thiol-maleimide bond formation to product 3.35 could take place (Table 3.1., 
entry 3). However, at pH = 5, applying both acetate buffers, the reaction resulted in complete 
conversion to the desired product 3.35, without maleic amide formation (Table 3.1., entries 4 and 5).  
Scheme 3.3. Synthesis of monovalent controls 3.40 to 3.45. Either acetic acid-sodium acetate or 
triethylammonium acetate buffer systems at pH = 5 were applied for the thiol-maleimide Michael addition; 
Ammonium carbonate buffer at pH = 8.9 was applied for the hydrolysis of succinimide rings.  
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Using these conditions (volatile triethylammonium acetate buffer at pH = 5, Table 3.1., entry 5), the 
cisteinate ligands PTP (3.4), control peptide (3.5), and protected cysteine (3.20) were converted to the 
thiosuccinimide cyanine labeled intermediates 3.34 to 3.39 (Scheme 3.3.). As discussed in Section 
3.2.1., thiosuccinimide hydrolysis leads to stable succinamic acid thioether bioconjugates which cannot 
undergo retro-Michael addition[268] (Figure 3.10.A, Section 3.2.1.). Therefore, the labeled succinimide 
derivatives 3.34 to 3.39 were subsequently hydrolyzed upon alkaline treatment with volatile 
ammonium carbonate buffer (pH = 8.9) to the stable derivatives 3.40 to 3.45 (Scheme 3.3.).  
For the non-peptidic 3.44 and 3.45, the methyl ester portion of their structures was further hydrolyzed 
to carboxylic acid under the reaction conditions (Scheme 3.3.). However, this additional conversion 
was not expected to interfere in the biological performance of compounds 3.44 and 3.45 as non-
targeting controls. The use of volatile buffers was crucial to regulate the reactions’ pH, while 
simplifying their work up to a single lyophilization step. This methodology avoided the need for 




3.2.4. First Approach Towards Cyclen-based Multivalent Ligands: Probing the R2-
Substitution with an Amine for Fluorophore Attachment 
The preparation of functionalized DOTAM derivatives using fully protected cyclen intermediates 3.22 
and 3.24 is well-known and has been described by several authors.[261a, 266, 269] Using these strategies, 
multiple entities can be conjugated to the probe scaffold through amide coupling reactions, usually 
with HATU as coupling reagent. Taking advantage of these established conditions, the first approach 
towards a DOTAM-based multivalent ligand template explored an amide bond formation for 
fluorophore introduction (Figure 3.9.A, Section 3.2.1.). With the DOTAM scaffolds 3.22 and 3.24 
and the set of PEG2 amine linkers 3.25 to 3.28 in hand, many possible amide coupling strategies could 
lead to the desired probe template.  
According to previously described conditions by HU and collaborators,[261a] heterovalent decorated 
DOTAM could be obtained through the Fmoc protected intermediate 3.47 (Scheme 3.4.). Using this 
methodology, benzyl deprotection of cyclen 3.21 followed by HATU-mediated coupling with N-Fmoc 
protected PEG2 3.26 afforded amide derivative 3.46. Subsequent acidic treatment of Fmoc 
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intermediate 3.46 allowed for deprotection of the tert-butyl moieties to afford free carboxylic acid 
functionalities, which were activated with HATU for coupling with maleimide PEG2 linker 3.28 
(Scheme 3.4.). Notably, this is the first report of cyclen functionalization with maleimide groups.  
Scheme 3.4. Synthesis of the fourfold functionalized fmoc protected DOTAM 3.47. 
The following Fmoc deprotection of 3.47 with diethylamine or piperidine (Table 3.2., entries 1 and 2) 
led to multiple side-products, including Michael addition of the secondary amine of these bases to the 
methylene portions of 3.47, without generating perceptible amounts of the desired macrocyclic free 
amine 3.48. Moreover, the reactivity of the maleimide group also hampers the addition of ethanethiol, 
usually employed as a scavenger to trap the released dibenzofulvene.[272] Consequently, a number of 
alternatives to a conventional Fmoc deprotection were examined. Conditions exploring tertiary amines, 
such as diisopropylamine (Table 3.2., entry 3) and 1,8-diazabicyclo[5.4. 0]undec-7-ene (DBU, Table 
3.2., entries 4 and 5) did provide the desired amine from 3.48, but the slow conversion to product led 
to the undesired hydrolysis of the maleimide to maleic amide over time.  
As such, the use of tetra-N-butylammonium fluoride (TBAF) in the presence of isopropanol, instead 
of the thiol as fulvene scavenger was next investigated (Table 3.2., entry 6).[273] This method (2 equiv. 
TBAF, 10 equiv. iPrOH, DMF, 0 °C, 15 min) proved to be well suited to deprotect Fmoc in this 
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context under mild conditions. Nevertheless, the isolation of intermediate free amine 3.48 was highly 
challenging. Column chromatography using either normal- or reversed-phase was not successful in 
separating TBAF and dibenzofulvene from the reaction mixture. A desalting column, followed by 
washes with water led to complete removal of the fulvene byproduct, but only partially TBAF. Finally, 
several extraction rounds with chloroform was the best method to obtain pure 3.48 in 60% yield. 
 
Table 3.2. Conditions tested for the Fmoc-deprotection of intermediate 3.47. 
Entry Base Solvent Time (min) Result 
1 10% Diethylamine DMF 30 Complex mixture[b] 
2 5% Piperidine DMF 30 Complex mixture[b] 
3 5% DIPEA ACN 60 3.48 + maleic acid amide side-product[c] 
4 3% DBU ACN 15 3.48 + maleic acid amide side-product[c] 
5 3% DBU DMF 15 3.48 + maleic acid amide side-product 
6 TBAF, iPrOH[a] DMF 15 3.48, 60% yield 
All test reactions were conducted at 0 °C. [a] TBAF (2 equiv.) and  iPrOH (10 equiv.); [b] Both Michael addition 
reaction of secondary amine moieties of these bases to Fmoc-3.47 and hydrolysis of these side-products to maleic 
acid amide congeners observed via liquid chromatography–mass spectrometry (LC-MS); [c] Observed via LC-MS. 
The subsequent amide coupling step for the installation of cyanine fluorophores to free amine 3.48 
was, however, not accomplished (Table 3.3.). Activation of the carboxylic acid functionality from Cy3 
and Cy5.5 dyes with several coupling reagents, including HATU, N,N,N',N'-tetramethyl-O-(N-
succinimidyl)uronium hexafluorophosphate (HSTU), 1,1'-carbonyldiimidazole (CDI), DMTMM, and 
propanephosphonic acid anhydride (T3P) in the presence of DIPEA, followed by the subsequent 
treatment with free amine 3.48 led to no observable conversion to the desired labeled product (Table 
3.3., entries 1 to 5). Up to 1 hour activation time of the acid portion before the addition of amine 3.48 
did not improve the reaction outcomes.  
In a similar manner, a pre-activation step using either N-hydroxysuccinimide (NHS), perfluorophenol 
(PFP), or fluoro-dipyrrolidinocarbenium hexafluorophosphate (BTFFH) to produce the congeners 
 
104 
NHS-ester, PFP-ester, or acid fluoride BTFFH-ester of the cyanine dyes was not sufficient to induce 
amide bond formation (Table 3.3., entries 6 to 8). To preclude the possible sterically hindrance from 
the pre-organized PEG chains, these reactions were executed in alternative solvent systems, such as 
acetonitrile, ethyl acetate, dichloromethane, and water using HATU (Table 3.3., entries 9 to 12). Yet, 
in all cases, starting materials could be recovered from the reaction mixture.  
 
Table 3.3. Amide coupling conditions for conjugating a cyanine dye at the free amine functionality of 3.48. 
Entry Coupling Agent Carboxylic acid Solvent Result 
1 HATU Cy3 or Cy5.5 DMF No conversion 
2 HSTU Cy3 or Cy5.5 DMF No conversion 
3 CDI Cy3 or Cy5.5 DMF No conversion 
4 DMTMM Cy3 or Cy5.5 DMF No conversion 
5 T3P Cy3 or Cy5.5 DMF No conversion 
6 n.a. NHS-Cy5.5 DMF No conversion 
7 n.a. PFP-Cy5.5 DMF No conversion 
8 n.a. BTFFH-Cy5.5 DMF No conversion 
9 HATU Cy3 or Cy5.5 ACN No conversion 
10 HATU Cy3 or Cy5.5 EtOAc No conversion 
11 HATU Cy3 or Cy5.5 DCM No conversion 
12 HATU Cy3 or Cy5.5 Water No conversion 
n.a. – not applicable. Reaction conditions: amine 3.48 (1.0 equiv.), cyanine carboxylic acid (Cy3-COOH or Cy5.5-
COOH, 1.0 equiv.), coupling agent (1.1 equiv.), DIPEA (5.0 equiv.), solvent (1 mL). Anhydrous solvents were used 
for all tested conditions, except for HSTU (entry 2). 
To evaluate the reactivity of this coupling, an inversion of amide and carboxylic acid functionalities 
from the DOTAM scaffold and linker was investigated (Scheme 3.5.). Since the hydrogenation 
reaction conditions required for the removal of the benzyl group of 3.21 are not orthogonal to the 




Scheme 3.5. Synthesis of carboxylic acid 3.52 from DOTA-building block 3.24. 
 
Table 3.4. Amide coupling conditions attempted for installing the fourth PEG2 linker unit at carboxylic 
acid intermediate 3.52. 
Entry PEG2 amine Coupling Agent Base Solvent Result 
1 Cy5.5-3.27 HATU DIPEA ACN No conversion 
2 Cy5.5-3.27 BOP-Cl DIPEA ACN No conversion 
3 Cy5.5-3.27 T3P Triethylamine ACN No conversion 
4 N-Boc-3.25 HATU DIPEA DMF No conversion 
5 N-Fmoc-3.26 HATU DIPEA DMF No conversion 
Reaction conditions: carboxylic acid 3.52 (1.0 equiv.), PEG2-amine 3.25, 3.26, or 3.27 (1.0 equiv.), coupling agent 
(1.1 equiv.), base (8.0 equiv.), solvent (1 mL). Anhydrous solvents were applied for all tested conditions. 
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Applying similar conditions as for the preparation of intermediate 3.47 (Scheme 3.4.), carboxylic acid 
3.52 was obtained in moderate 51% yield as confirmed by 1H-NMR and HR-MS analysis. However, 
the subsequent labeling procedure employing either HATU, BOP-Cl, or T3P for conjugation of 
intermediate 3.52 to Cy5.5-PEG2 linker 3.27 was unsuccessful (Table 3.4., entries 1 to 3). The 
installation of the smaller N-Boc (3.25) and N-Fmoc protected linkers (3.26) to acid 3.52 using HATU 
led to similar results (Table 3.4., entries 4 to 5). These attempts demonstrated the lack of feasibility of 
coupling the fluorophore-linker construct to cyclen template 3.52 by amide formation. 
Scheme 3.6. Attempted synthesis of Cy5.5 labeling of building block 3.21 prior to the installation of 
maleimide-PEG2 linker 3.28. Compounds 3.56 and 3.57 were obtained as a complex mixture which could not be 
separated under the tested HPLC conditions.  
To overcome this problem, introduction of the cyanine fluorophore at earlier steps in the synthesis 
route, prior to maleimide-linker 3.28 conjugation to the probe template, was pursued (Scheme 3.6.). 
To this end, the conditions established for the preparation of Fmoc-protected 3.47 and carboxylic 
acid 3.52 were explored for the generation of Cy5.5-labeled 3.55. Removal of the tert-butyl protective 
groups of 3.55 using trifluoroacetic acid exposed the carboxylic acids which were further treated with 
HATU (3.3 equiv.) and maleimide PEG linker 3.28 (3.3 equiv.). This amide coupling reaction, however, 
resulted only in the di- (3.56) and tri- (3.57) functionalized cyclen. Despite the addition of excess 
equivalents of coupling reagent and amine linker, conversion to the desired tri-substituted template 
 
107 
was not observed. Moreover, isolation of 3.56 and 3.57 was not achieved via HPLC due to the similar 
retention times of both intermediates in the screened conditions. 
Probe assembling via subsequent amide coupling reactions was deemed unfeasible for the synthesis 
of the envisioned tetrasubstituted heterogeneous DOTA conjugates (Figure 3.9., Section 3.2.1.). 





3.2.5. Second Approach Towards Cyclen-based Multivalent Ligands: Probing the R2-
Substitution with an Azide for Fluorophore Attachment 
Since amide bond formation was not a reliable method for fluorophore labeling of the DOTAM 
template, a triazole connectivity was next investigated.  
Scheme 3.7. Synthesis of the CuAAC parteners azido-DOTAM 3.58 and alkyne-dye 3.59. 
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The installation of an azide handle at the cyclen core would enable CuAAC reaction with a cyanine 
dye containing an alkyne functionality (Figure 3.9.B, Section 3.2.1.). Key building blocks for this 
synthesis pathway are the azido-DOTAM precursor 3.58 and Cy5.5 analog 3.59 (Scheme 3.7.). Starting 
from derivative 3.21, azide-PEG2 linker 3.31 was installed in 4 steps using the synthetic conditions 
previously employed for the preparation of other analogs, e.g., Fmoc-protected 3.47 (see Scheme 3.4., 
Section 3.2.4.). The CuAAC reaction partner 3.59 was obtained in moderate yield from the HATU 
coupling of Cy5.5 carboxylic acid and propargyl amine.  
There are several studies which describe the use of CuAAC to form stable conjugates within 
macrocyclic polyamines.[260b, 265a, 274] In the search for suitable conditions for the copper-catalyzed 
cycloaddition between azide 3.58 and alkyne 3.59, the most common CuAAC literature procedures 
applied for triazole formation at DOTA and DOTA-like structures were evaluated (Table 3.5.). 
Despite the use of diverse copper catalysts both in catalytic and stoichiometric amounts, none of the 
conditions tested led to the formation of triazole 3.60.  
CuAAC is known to perform best at neutral and alkaline solvents (6 > pH > 8), in particular at pH 
closer to 8.[275] At higher pH values, the cycloaddition proceeds at a faster rate, but hydrolysis of the 
maleimide to maleic amide is of greater concern. Therefore, the influence of the solvent and pH for 
conversion were also analyzed (Table 3.5., entries 1 to 4, 7 to 9, and 11 to 13), yet with no favorable 
result. In addition, tris(benzyltriazolylmethyl)amine (TBTA) was included to stabilize the Cu(I) 
oxidation state in solution while increasing the reaction rates[276] (Table 3.5., entries 4 to 6). However, 
in this case, no conversion to product 3.60 was observed.  
Besides copper sulfate, different copper sources were investigated in order to promote the CUAAC 
reaction between azide 3.58 and alkyne 3.59. As such, conditions exploiting Cu(II), Cu(I) and metallic 
copper catalysts were attempted, including copper iodide (Table 3.5, entries 7 to 10), tetrakis-
(acetonitrile)copper(I) hexafluorophosphate ([Cu(CH3CN)4]PF6, Table 3.5, entries 11 to 14), copper 
powder (Table 3.5, entries 16 and 17), copper wire (Table 3.5, entry 18), and copper on carbon (Table 
3.5, entry 19). None of these copper sources, however, led to successful outcomes. Moreover, all test 
reactions were maintained at room temperature since heating to 50 °C resulted in the degradation of 
DOTAM starting material 3.58. The lack of stability of this reagent upon exposure to mild 
temperatures might be triggered by the copper ions since otherwise, these molecules showed to 
tolerate up to 75 °C heating overnight. 
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Table 3.5. CuAAC reaction conditions attempted for the formation of triazole 3.60.  
Entry Copper Source Reducing Agent Solvent Result[a] 
1 CuSO4 Sodium ascorbate Acetate buffer pH = 5 No conversion 
2 CuSO4 Sodium ascorbate PBS buffer pH = 7 No conversion 
3 CuSO4 Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
4 CuSO4 Sodium ascorbate PBS buffer pH = 7:ACN (3:1), TBTA  No conversion 
5 CuSO4 Sodium ascorbate DMF, TBTA No conversion 
6 CuSO4 Sodium ascorbate DMSO:tert-BuOH, TBTA  No conversion 
7 CuI Sodium ascorbate Acetate buffer pH = 5 No conversion 
8 CuI Sodium ascorbate PBS buffer pH = 7 No conversion 
9 CuI Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
10 CuI Sodium ascorbate DMF No conversion 
11 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate Acetate buffer pH = 5 No conversion 
12 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate PBS buffer pH = 7 No conversion 
13 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
14 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate DMF No conversion 
15 CuCl2 Ascorbic acid Water No conversion 
16 CuSO4/Cu
 
powder[b] None iPrOH:water (3:1) No conversion 
17 Cu powder[b] None iPrOH:water (3:1) No conversion 
18 Cu wire[b] None iPrOH:water (3:1) No conversion 
19 3% Cu0 on carbon[b] None iPrOH:water (3:1) No conversion 
Reaction conditions: DOTAM-azide 3.58 (1.2 equiv.), Cyanine alkyne 3.59 (1 equiv.), copper catalyst (0.1 to 5 equiv. 
screened), reducing agent (4-to 10-fold equiv. excess in relation to copper catalyst). All test reactions were conducted 
at room temperature and stirred overnight. [a] No condition led to product formation, and starting material could be 
recovered in all test settings, [b] 50 to 100 equiv. screened. 
The unreacted maleimide groups of 3.58 were deemed to deactivate the copper catalyst under the 
tested conditions (Table 3.5.), thus, a second stepwise sequence with thiol-maleimide conjugation, 
followed by CuAAC was analyzed (Scheme 3.8.). In spite of the large excess of cysteinate-3.4 (up to 
6 equivalents), full conversion to the desired tripeptide was not achieved. The intramolecular [3+2] 
dipolar cycloaddition between azide and maleimide groups[277] could be a reason for the failure in 
obtaining both Cy5.5-3.60 and difunctionalized 3.61 products (Scheme 3.8.). An evidence of this side-
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reaction could be observed by 1H and 13C-NMR analysis, where polymerization of intermediate 3.58 
was detected over time.  
Scheme 3.8. Attempted synthesis of tripeptide conjugation at DOTAM-3.58 scaffold and presumed 
intramolecular side-reaction at the dipeptide 3.61 scaffold. 
Due to the untoward outcomes related with azide probe precursor 3.58, fluorophore labeling attempts 
exploring the CuAAC strategy required a new clickable functionality to replace the azide group, while 
retaining the orthogonality to maleimides. To this end, a terminal alkyne was selected as a suitable 




3.2.6. Third Approach Towards Cyclen-based Multivalent Ligands: Probing the R2-
Substitution with an Alkyne for Fluorophore Attachment 
To verify the feasibility of the click approach for fluorescent dye conjugation, while preventing possible 
intramolecular side-reactions (see Scheme 3.8., Section 3.2.5.), the reactive functionalities of cyanine 
dye and DOTAM coupling partners were exchanged (Figure 3.9.C, Section 3.2.1.). In contrast to the 
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previous attempt (Figure 3.9.B, Section 3.2.1.), this synthesis route was based on cyanine labeled azides 
3.32 or 3.33 and DOTAM-alkyne 3.62 as key building blocks.  
The fourfold bifunctionalized DOTAM 3.62 was prepared in four steps from the unsubstituted cyclen 
3.10 (Scheme 3.9.). The preparation of DOTAM 3.62 was more straightforward than of azide 
congener 3.58 (3.62: 50% yield from 3.22, Scheme 3.9. vs. 3.58: 13% yield from 3.21, Scheme 3.7., 
Section 3.2.5.). Subsequent treatment of alkyne 3.62 with recognition element Cys- 3.4, or non-
targeting controls Cys-3.5 and protected cysteine 3.20 (for structures see Scheme 3.3., Section 3.2.3.) 
at pH = 5 generated the multivalent alkyne derivatives 3.63 to 3.65 (Scheme 3.9.). The use of 4.5 
equivalents of cysteinate (3.4, 3.5, or 3.20) and at least 18 hours of stirring at room temperature was 
crucial for obtaining a clean conversion of 3.62 into the desired tri-substituted products, without 
residual mono- and di-valent intermediates. As discussed in Section 3.2.3., the volatile 
triethylammonium carbonate buffer pH = 5 was exploited for Michael addition procedures because 
of its facile removal from the reaction mixtures by a simple lyophilization process. 
Scheme 3.9. Synthesis of multivalent DOTAM-alkyne intermediates 3.63 to 3.65. 
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Table 3.6. CuAAC reaction conditions tested for the formation of triazole 3.71.  
Entry Copper Source Reducing Agent Solvent Result 
1 CuSO4 Sodium ascorbate Acetate buffer pH = 5 No conversion 
2 CuSO4 Sodium ascorbate PBS buffer pH = 7 No conversion 
3 CuSO4 Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
4 CuSO4 Sodium ascorbate PBS buffer pH = 7:ACN (3:1), TBTA No conversion 
5 CuSO4 Sodium ascorbate DMF, TBAT as additive No conversion 
6 CuSO4 Sodium ascorbate DMSO:tert-BuOH, TBTA No conversion 
7 CuI Sodium ascorbate Acetate buffer pH = 5 No conversion 
8 CuI Sodium ascorbate PBS buffer pH = 7 No conversion 
9 CuI Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
10 CuI Sodium ascorbate DMF No conversion 
11 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate Acetate buffer pH = 5 No conversion 
12 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate PBS buffer pH = 7 No conversion 
13 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate PBS buffer pH = 7:ACN (3:1) No conversion 
14 [Cu(CH₃CN)₄]PF₆ Sodium ascorbate DMF No conversion 
15 CuCl2 Ascorbic acid Water No conversion 
16 CuSO4/Cu
 
powder None iPrOH:water (3:1) 3.71, quantitative[a] 
17 Cu powder None iPrOH:water (3:1) 3.71, trace amounts[a] 
18 Cu wire None iPrOH:water (3:1) 3.71, trace amounts[a] 
19 3% Cu0 on carbon None iPrOH:water (3:1) 3.71, trace amounts[a] 
Reaction conditions: DOTAM-alkyne 3.65 (1 equiv.), cyanine azide 3.33 (1.2 equiv.), copper catalyst (0.1 to 5 equiv.), 
reducing agent (4-to 10-fold equiv. excess in relation to copper catalyst). All test reactions were conducted at room 
temperature and stirred overnight. [a] Conversion determined by LC-MS. 
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At pH = 5 the thiosuccinimide rings remained stable in the course of the reaction and lyophilization 
work up. As such, these intermediates were pure enough to be applied as crudes to the following 
copper-mediated cycloaddition attempts. The non-peptidic and smaller DOTAM-alkyne 3.65 was 
explored as a model compound for initial CuAAC attempts. Applying the fluorescent azide linker 3.33 
as reaction partners for triazole formation, a set of copper catalysts and solvent systems were 
investigated (Table 3.6.). Interestingly, the outcome of these test reactions was highly dependent on 
the copper source and reducing agent of choice. Conditions applying copper(II) salts in combination 
with sodium ascorbate or ascorbic acid (4 equiv. fold-excess) are the most widely used method to 
generate the copper(I) catalyst in situ.[278] However, this approach was unsuitable for the conjugation 
of DOTA-alkyne 3.65 with azide Cy5.5-3.33 (Table 3.6., entries 1 to 15), leading to the recovery of 
starting materials.  
Alternatively, the generation of the copper(I) active species in solution can be achieved by a 
comproportionation reaction of a copper(II) source, e.g., copper sulfate, and copper(0).[279] A system 
that requires higher reaction times and catalyst loadings for completion than the more common 
copper(II)/sodium ascorbate conditions. Notably, the expected cyclization occurred under metallic 
copper catalysis (Table 3.6., entry 16). In particular, combination of 0.1 M aqueous solution of CuSO4 
(3.5 equiv.) with an excess of copper powder (50 equiv.) in isopropanol and water provided 
quantitative conversion of model compound 3.65 to Cy5.5-labeled multivalent analog 3.71. The 
inclusion of copper sulfate showed to be essential for the outcome of this step as copper(0) sources 
alone, including copper powder, wire, and copper on palladium (Table 3.6., entries 17 to 19) resulted 
in only trace amounts of triazole product.  
The combination of copper powder and copper sulfate was further exploited for preparing the cyanine 
labeled derivatives 3.66 to 3.70 (Scheme 3.10.). Under the tested conditions, the control peptide-
targeting intermediates 3.68 and 3.69 were not formed, with the only outcome being degradation of 
starting material 3.64 upon copper sulfate treatment (ca. 5 hours). The presence of histidine at the 
control peptide sequence (3.5, see Figure 3.3., Section 3.1.2.), which has strong metal chelating 
properties, may provoke copper deactivation.[280] To understand this failed attempt, the cycloaddition 
between tri-histidine conjugate 3.64 with both azide linkers was analyzed using matrix-assisted laser 
desorption/ionization (MALDI).[281] The mass analysis of the crude mixture over time suggested that 
alkyne 3.64 indeed deactivated the copper catalyst by taking up to 4 copper ions in its scaffold before 
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degradation. Hence, further synthetic efforts were carried out on PTP (3.66 and 3.67) and cysteine 
(3.70 and 3.71) triazole conjugates. 
Scheme 3.10. CuAAC reaction for the generation of fluorescent copper complexes 3.66 to 3.71. Intermediates 
3.66, 3.67, 3.70, and 3.71 were used as crudes for the subsequent reaction steps. 
Possibly due to the activation mechanism of metallic copper, together with the inherent copper 
complexation by the cyclen core and peptides, a catalytic CuAAC reaction was not accomplished. In 
line with this, the corresponding thiosuccinimidyl triazoles 3.66, 3.67, 3.70, and 3.71 were furnished 
as copper-complexes (Scheme 3.10.). Each triazole (3.66, 3.67, 3.70, and 3.71) was bound to one 
copper ion as indicated by both MALDI and liquid chromatography–mass spectrometry (LC-MS) 
analysis.  
Copper chelates may lead to not only in cellular toxicity, but also preclude complexation of more 
relevant imaging metals by the cyclen core, e.g., gadolinium(III) and gallium(III). Similarly as for 
CuAAC attempts, the smaller cysteine conjugates 3.70 and 3.71 were applied as a model for screening 
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of copper demetalation methodologies. Classical precipitation conditions using sodium sulfite (10 to 
50 equiv. screened) failed in providing copper free congeners of 3.70 and 3.71. Under physiological 
conditions reduction of copper(II) to copper(I) may result in the decomplexation of this metal.[282] 
Thus, a reductive medium was generated by treating target compounds with an excess in equivalent 
amounts of sodium ascorbate (120 equiv.) in PBS buffer pH = 7.4. However, unwanted retro-Michael 
addition occurred before copper demetalation. The tendency of DOTA to undergo transmetalation 
was next explored using gadolinium, iron, zinc, calcium, and sodium ions as its chloride salt form.[283] 
For these experiments, the chloride salts of the tested metals were given in large excess (1200 equiv.) 
to the copper chelates 3.70 and 3.71 at controlled pH, from acidic 2.5 to physiological 7.4 up to basic 
12. However, these conditions were not suitable for copper removal at a preparative scale. Only iron 
chloride at physiological pH provided at very low rates a metal exchange.  
Figure 3.11. Chelating agents screened for copper demetalation of N-acetyl cysteine thiosuccinimides 3.70 
and 3.71. A) Structures of the chelating agents utilized in for copper demetalation attempts and B) Structure of the 
penicillamine (3.77) complex with copper as published by J. A. THICH et al.[284] (CCDC deposit number: 1133444).  
Protonation of the macrocyclic core at a highly acidic media (pH = 2-3) is a known method to induce 
demetalation of cyclen derivatives.[285] The subsequent treatment of such acidic solution with a strong 
copper scavenger could capture metal ions from solution and avoid their re-complexation. To 
investigate this hypothesis, the chelating ligands ethylenediaminetetraacetic acid (EDTA, 3.72),[286] 
Salen (3.73),[287] 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA, 3.12)[260b] , and penicillamine 
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(3.77),[288] as well as the polymer-bound metal scavengers dimercaptotriazine (DMT, 3.74),[289] thiourea 
QuadraPure TU (3.75),[290] and iminodiacetic acid Chelex resin (3.76) [274g] were screened for their 
copper chelating capacity (Figure 3.11.A).  




Equiv. amounts of CA Temperature pH Result 
1 EDTA, 3.72 302 r.t. 12 No conversion 
2 Salen ligand, 3.73 302 r.t. 2.5 No conversion 
3 NOTA, 3.12 302 50 °C 2.5 60% conversion[c], 25-30% isolated yields 
4 DMT on Silica, 3.74[b] 60 r.t. 2.5 70% conversion[c], 0% isolated yield 
5 QuadraPure TU, 3.75[b] 60 r.t. 2.5 No conversion, degradation of 3.71 
6 Chelex resin, 3.76[b] 24 mg resin/mg reactant r.t. 2.5 No conversion 
7 Penicillamine, 3.77 604 r.t. 2.5 Full conversion to 3.82[c], 28% isolated yield[d] 
Test reactions performed in 5 mg scale. Excess equivalent amounts of chelating agent were added to the reaction 
mixture after the adjustment of the solution pH with either TFA or sodium hydroxide. Reaction control performed 
via LC-MS analysis. All test reactions were stopped after 18 h stirring. [a] for structures see Figure 3.11.A, [b] equivalent 
amounts calculated as specified by the supplier; [c] Determined by LC-MS; [d] From HPLC chromatography. 
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The following copper removal attempts using chelating agents 3.12 and 3.72 to 3.77 were conducted 
using the trivalent DOTAM-cysteine labelled with Cy5.5 (3.71) as model reagent (Table 3.7.). At first, 
test derivative 3.71 was stirred at room temperature in a trifluoroacetic acid aqueous solution at pH = 
2.2 until their copper free congeners could be mainly detected by LC-MS analysis (30 min). After this 
time, the selected chelating agents were added to these solutions in excess equivalent amounts and 
evaluated according to their copper complexation performance. 
Experiments involving EDTA (3.72) were conducted exceptionally at basic pH = 12, where its copper 
coordination capacity reaches a maximum[291] (Table 3.7., entry 1). However, classical chelating metal 
ligands, such as EDTA (3.72) and Salen (3.73), were not suitable for this experiment, leading to no 
conversion to the desired copper free derivatives (Table 3.7., entries 1 and 2). Despite the cyclic amine 
NOTA (3.12) displayed promising copper scavenging properties with 60% conversion upon heating 
to 50 °C (Table 3.7., entry 3), these conditions might be unfavourable and too harsh for the more 
complex tri-peptides 3.66 and 3.67. Therefore, the use of silica and polymer bound chelating agents 
(3.74 to 3.76) was next evaluated (Table 3.7., entries 4 to 6). These reagents have the advantage of 
facile removal of reaction mixtures via filtration, however in all cases model compound 3.71 associated 
likewise to the resin. Attempts on isolating the copper free analogs from the resins were either 
ineffective or resulted in their degradation. 
Penicillamine (3.77) is a common drug used to treat heavy metal poisonings, in particular Wilson’s 
disease, i.e., copper accumulation.[292] Due to the stable copper complexes formed, this ligand was 
additionally selected for this experiment (Table 3.7., entry 7). The coordination of copper by 
penicillamine 3.77 is shown in Figure 3.11.B (3.78) and requires two molecules of 3.77 to coordinate 
one metal ion.[284] Therefore, the double of equivalents was applied for the screening of this compound 
in comparison to other molecular cages which coordinate copper in a 1:1 model, i.e., Salen (3.72), 
EDTA (3.73), and NOTA (3.12). Remarkably, complete removal of the copper ions was achieved in 
aqueous trifluoroacetic acid solution, followed by addition of 3.77. The large excess of chelating agent 
3.77 was stringently necessary for improved outcomes, yet it could be recovered by filtration before 
the subsequent purification step. The HPLC column of the crude filtrate led to the desired product 
(copper free-3.71) in moderate 28% yield, over 4 reaction steps (Table 3.7., entry 7). A strategy which 
was then applied for the synthesis of the more biologically relevant cyanine labeled tri-peptides 3.79 
and 3.80 (Scheme 3.11).  
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Scheme 3.11. Copper demetalation of using peniciallmine 3.77 to afford DOTAM-based multivalent probes 
3.79 to 3.82.  
To detect remaining copper at the final derivatives 3.79 to 3.82 and, thereby, determine the efficacy 
of the applied copper removal strategy, the inductively coupled plasma mass spectrometry (ICP-MS) 
technique was used (Table 3.8.). The ICP-MS represents a highly sensitive analytical method to 
determine traces of metal in organic samples, including copper.[293] These measurements were 
performed in collaboration with SEBASTIAN FASSBENDER and ANDREAS SCHULTZ at the Bundesanstalt 
für Materialforschung und –prüfung (BAM). The copper levels of compounds 3.79 to 3.82 were in 
the ppm range of detection and were applied to calculate the efficacy of this reaction step (Table 3.8). 
In comparison to blank control samples, the detected copper levels demonstrated the high reliability 
of the tested conditions (penicillamine at pH = 2.2) to remove copper from cyclen derivatives 3.79 to 





Table 3.8. Determination of copper concentration levels in final probes 3.79 to 3.82, determined by ICP-
MS, and calculated efficacy of copper removal. 
Entry Probe Copper levels (mol %) Copper removal efficacy (%) 
1 3.79 0.02 99.98 
2 3.80 0.10 99.90 
3 3.81 0.07 99.93 
4 3.82 0.02 99.98 
Analysis performed in 1 mg/mL sample. ICP-MS analysis performed at the BAM with the assistance of SEBASTIAN 
FASSBENDER and ANDREAS SCHULTZ. 
With the copper free congeners 3.79 to 3.82 in hand, final hydrolysis of the thiosuccinimide rings was 
performed (Scheme 3.12.). Applying the same conditions as for monovalent controls 3.40 to 3.45 
afforded complete conversion to the fluoroprobes 3.83 to 3.86.  
Scheme 3.12. Hydrolysis of the thiosuccinimide rings to provide the DOTAM-based multivalent probes 
3.83 to 3.86.  
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Considering the concept of orthogonal click reactions, each step should occur in any order to furnish 
the same product.[294] Nevertheless, such orthogonal behavior could not be demonstrated in this study, 
e.g., DOTAM azide-3.58 and Cy5.5 alkyne-3.59 (Section 3.2.5.) vs. DOTAM alkyne-3.62 and Cy5.5 
azide-3.33. Furthermore, any modification at the successful stepwise sequence towards final probes 
3.83 to 3.86 – i.e., from template 3.62: thiol-maleimide Michael addition, CuAAC, and thiosuccinimide 
hydrolysis – was unattainable and largely ineffective. By starting the synthesis pathway with the best 
CuAAC conditions (CuSO4, Cu powder, iPrOH, water, r.t., 18 h, Scheme 3.11.) at unlabeled cyclen-
based template 3.62, no triazole formation could be observed. Likewise, employing the alkaline 
hydrolysis step before fluorophore conjugation resulted in no appreciable conversion. Altogether, 
these observations emphasize the assumption that maleimide groups might display a coordinative 
effect at copper ions under the tested protocol. Hence, the probe assembling should strictly follow 




3.2.7. Applications of Multivalent Fluorescent Ligands labeled with Cy3 and Cy5.5 for 
Pancreatic Cancer Detection by Plectin-1 Visualization 
With this set of fluorescent ligands, confocal imaging studies were elaborated in collaboration with 
DR. SILKE RADETZKI at the screening unit facility of the FMP to validate the specificity of PTP-
targeted fluorescent ligands towards PDAC. To this end, the human pancreatic cancer cell lines Panc-
1 and MiaPaCa-2 were investigated for initial imaging assays due to their known expression of the 
plectin-1 protein-target.[249, 295]  
These cancer cell lines were incubated with different concentrations of the multivalent cyclen-based 
probes Cy3-3.83 and Cy5.5-3.84 (Figures 3.12. and 3.13.). For these experiments, the non-targeting 
cyclen-based controls Cy3-3.85 and Cy5.5-3.86 were utilized as unspecific negative controls. In 
comparison to the non-targeting control Cy3-3.85, PTP-targeted derivative 3.83 exhibited 2.7-fold 
mean increase in fluorescence at the two PDAC cells (Figure 3.12.A and B). This selectivity profile 
was observed for both cell lines in a concentration-dependent manner. In particular, a significant 
increase in mean fluorescence intensity was measured at 10 µM targeted compound 3.83 (Figure 
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3.12.C and D, left panels). Importantly, at the same concentration control cysteinate 3.85 did not 
produce bright cellular labeling as its targeted congener 3.83 (Figure 3.12.C and D, right panels). A 
similar trend was observed for multivalent Cy5.5 analog 3.84, where the mean fluorescence intensity 
rose with increasing concentrations of fluoroprobe (Figure 3.13.A and B). In both cell lines, PDAC-
targeted Cy5.5-3.84 displayed a mean 1.8-fold increase in fluorescence than its non-targeting analog 
Cy5.5-3.86, further illustrating the selectivity of the probe scaffold towards PDAC (Figure 3.13.C and 
D). 
Figure 3.12. Multivalent Cy3-labeled probe 3.83 enabled PDAC visualization in confocal fluorescence 
microscopy analysis. A, B) Analysis of the mean fluorescence intensity (MFI) of Panc-1 and MiaPaCa-2 cells, 
respectively,  incubated with different concentrations of either multivalent PTP 3.83 or non-targeting control 3.85, 
where A) Panc-1 cells and B) MiaPaCa-2 cells. C, D) Confocal microscopy images of Panc-1 and MiaPaCa-2 cells, 
respectively, incubated for 4 h with either 10 µM PTP-targeted 3.83 (green, left panel) or 10 µM non-targeting control 
Cys-3.85 (green, right panel) and counterstained with Hoechst 33342 (cyan, nucleus counter stain), where C) Panc-1 
cells and D) MiaPaCa-2 cells. Experiments performed by DR. SILKE RADETZKI. 
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Since PDAC cells are reported to express plectin-1 at both cellular membrane and cytosol,[232] staining 
of this protein-target would ideally require a membrane permeable probe. As illustrated in Figures 
3.11. and 3.12. (C and D, left panel), both fluorescent ligands Cy3-3.83 and Cy5.5-3.84 were confirmed 
to enter the tested Panc-1 and MiaPaCa-2 cell lines, reaching the cytosol. Under the applied test 
settings, however, the Cy3-labeled ligands generated an overall more intense and brighter fluorescence 
staining than the Cy5.5 analogs (cf., e.g., MFI of 3.83 at 20 µM = 15’133, Figure 3.12.B vs. MFI of 
3.84 at 20 µM = 4’406, Figure 3.13.B). Therefore, subsequent in vitro investigations to evaluate the 
influence of multivalency for binding were carried out using Cy3-analog 3.83. 
Figure 3.13. Multivalent Cy5.5-labeled probe 3.84 enabled PDAC visualization in confocal fluorescence 
microscopy analysis. A, B) Analysis of the mean fluorescence intensity (MFI) of Panc-1 and MiaPaCa-2 cells, 
respectively, incubated with different concentrations of either multivalent 3.84 or control 3.86, where A) Panc-1 cells 
and B) MiaPaCa-2 cells. C, D) Confocal microscopy images of Panc-1 and MiaPaCa-2 cells, respectively, incubated 
for 4 h with either 10 µM PTP-targeted 3.84 (red, left panel) or 10 µM non-targeting control Cys-3.86 (red, right panel) 
and counterstained with Hoechst 33342 (cyan, nucleus counter stain), where C) Panc-1 cells and D) MiaPaCa-2 cells. 
Experiments performed by DR. SILKE RADETZKI. 
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Figure 3.14. Confocal fluorescence microscopy images of PDAC cell lines incubated with Cy3-labeled PTP 
probe 3.83 in comparison to non-targeting multivalent and monovalent controls. A to H) Confocal 
microscopy images of Panc-1 cells (A to D) and MiaPaCa-2 cells (E to H) incubated for 4 h with 20 µM either 
multivalent PTP-targeted 3.83 (green, A and E), multivalent non-targeting control Cys-3.85 (green, B and F), 
monovalent PTP-targeted control 3.40 (green, C and G), or monovalent non-targeting control Cys-3.44 (green, D 
and H) and counterstained with Hoechst 33342 (cyan, nucleus counter stain). I) Analysis of the mean fluorescence 
intensity (MFI) of Panc-1 and MiaPaCa-2 cells treated with 20 µM either multivalent 3.83 or controls 3.85, 3.40, and 
3.44. Experiments performed by DR. SILKE RADETZKI. 
The overall PDAC-targeting affinity of trisubstituted PTP DOTAM-3.83 was compared to the non-
targeting tricysteinate-3.85 as well as to its monovalent analogs PTP-3.40 and Cys-3.44 (Figure 3.14.). 
For this experiment, Panc-1 and MiaPaCa-2 cells were incubated with 20 µM fluorescent ligand for 4 
h, then washed with PBS buffer to remove the nonbinding fraction of the respective fluorescent 
 
124 
compound. The following confocal fluorescence microscopy analysis indicated that both PTP-
targeted ligands 3.83 (three targeting PTP peptides) and 3.40 (one targeting PTP peptide) were capable 
of penetrating the cell membrane and producing stable labeling of the cytosol (Figure 3.14A, C, E, 
and G). Quantification of probe accumulation by integration of fluorescence intensities in the cells 
revealed an increased content of targeted ligands over their non-targeting controls (Figure 3.14.I). The 
monovalent derivative 3.40 (one targeting PTP peptide) displayed 1.6 and 1.8-fold mean increase on 
Panc-1 and MiaPaCa-2 cells, respectively over the non-targeting analog 3.44. Whereas, at the same 
concentration, multivalent targeting anaolg 3.83 (three targeting PTP peptides) showed a mean 2.5-
fold increase over the non-targeting trisubstituted control 3.85, a 1.8-fold over the monocysteinate-
3.44, and a twofold increase over 3.40 (one targeting PTP peptide). These findings were observed in 
the two tested cell lines, demonstrating the superior specificity of multivalent 3.83 to PDAC cells 
compared to its controls.  
In the course of the staining process, the fluroprobes and controls demonstrated to be chemically 
stable and did not exhibited the tendency to form aggregates in physiological buffer conditions. To 
further confirm these observations, the stability of the flurescent analogs in physiological conditions 
as well as their absorption emission spectra has to be evaluated in subsequent studies. To further 
confirm plectin-1 specific binding, blocking studies exploiting monoclonal anti-plectin-1 antibodies 
labeled with complementary fluorescent readouts to compounds 3.83 and 3.84 (Alexa 647-label for 
Cy3-3.83 blocking assay and fluorescein-label for Cy5.5-3.84 blocking assay) are planned.  
After confirmation of the selectivity of probes 3.83 and 3.84 towards PDAC, several biological test 
settings were conceived to validate their applicability and robustness using different cell lines and 
tissue samples, both derived from healthy and PDAC models, as well as complementary optical 
imaging modalities. These studies will be additionally conducted in two laboratories which are 
interested in pancreatic cancer detection. The fluorescent ligand set will be subjected to in depth 
pharmacological characterization carried out in the group of HAIYU HU in Beijing, in particular 
QINGHUA WANG, and the group of HANA ALGÜL in Munich. These investigations will provide the 
staining efficacy of PTP-targeted 3.83 and 3.84 towards plectin-1 in primary cells and tumorous tissue 
as well as their photophysical properties, which will guide further imaging efforts. Moreover, staining 
of PDAC in tissue samples derived from both preclinical PDAC murine model and clinical patients 




3.3. Conclusion and Outlook 
The synthesis of multivalent small-molecule based contrast agents is highly challenging and often 
involves difficult chromatographic purifications and low isolated yields. In stark contrast to the current 
situation, a clickable probe template may enable the preparation of a number of imaging tools in a 
parallel fashion rather than by sequential synthesis. Such a parallel approach can significantly reduce 
the number of precursors and intermediates required for the synthesis of different imaging agents 
based on the same vector. Inspired by these concepts, the third chapter of this thesis described a 
multivalent platform for probe assembling via subsequent click reactions which was applied for the 
preparation of imaging agents for PDAC detection.  
The selection of the macrocyclic amine cyclen as core for probe design was twofold. First, due to the 
broad applicability of cyclen-derived molecular cages, such as DOTA, among imaging modalities, 
including MRI, PET, SPECT, and dual-imaging. Second, the high versatility of this scaffold which 
allow for numerous strategies for linker installation at one, two, three, or all of its nitrogen atoms. In 
particular, the fourfold N-functionalization of cyclen was explored to introduce a 3 to 1 decoration 
pattern, allowing to differentiate one nitrogen exit vector over the remaining three. Suitable ligation 
handles were evaluated according to their orthogonality for conjugation of the recognition element 
and reporter unit.  
Maleimide was selected for the coupling with three thiol containing targeting moieties, investigations 
for the N-derivatization of the fourth arm was carried out. This position was tested for fluorescent 
dye attachment with three different functionalities: amine, azide, and alkyne. Using this approach, 
probe assembling was attempted via consecutives Michael-type addition reaction, followed by either 
amide coupling or CuAAC. Installation of PEG2-maleimide linkers led to the respective 
bifunctionalized cyclen precursors encompassing either free amine (3.48), terminal azide (3.58), or 
terminal alkyne (3.62) groups. These building blocks were subjected to a number of stepwise sequence 
pathways and optimization rounds. Nevertheless, alkyne 3.62 was the only template to afford tri-
substituted derivatives labeled with two cyanine dyes, Cy3 and Cy5.5.  
From precursor 3.62, these compounds have a stringent synthesis route which can be performed in 
one-pot: thiol-maleimide conjugation, followed by CuAAC (Scheme 3.13.). Removal of the copper ions 
from the reaction mixture was successful upon treatment with penicillamine. The final hydrolysis of  
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Scheme 3.13. General strategy for the synthesis of PTP-targeted congeners Cy3-3.83 and Cy5.5-3.84 from 
clickable probe platform 3.62. 
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succinimide groups afforded PTP-targeted Cy3-3.83 and Cy5.5-3.84 as well as cysteinate controls Cy3-
3.85 and Cy5.5-3.86. These reaction conditions were also applied for the synthesis of monovalent 
controls composed by one single targeting peptide or control moiety connected to both fluorophores. 
With this set of ligands, biological studies were performed applying the targeted clickable platform 3.62 
and follow up investigations are planned. The non-peptidic mono- (3.44 and 3.45) and cyclen-based 
controls (3.85 and 3.86) served as unspecific negative controls in the course of the evaluation process. 
Confocal microscopy imaging in two PDAC cell lines have illustrated the high specificity of the PTP-
targeted analogs 3.83 and 3.84 in comparison to their respective controls. Importantly, the cyclen 
scaffolds demonstrated to be stable under the applied test settings and the tendency of forming 
aggregates in physiological buffer was not observed during the time course of staining.  
Subsequent distribution of this toolset to collaboration partners at the HU group in Beijing and the 
ALGÜL group in Munich will provide in depth characterization of photophysical properties of the 
probes, provide their in vitro staining efficacy towards the plectin-1 protein, and PDAC imaging in 
tissue samples. This analysis is fundamental not only for a full profiling, but also for identifying 
possible limitations of the probe scaffold – such as unspecific binding or the need for labeling with 
other fluorescent dyes which provide complementary information to the already synthesized Cy3 and 
Cy5.5. 
Future applications of PTP-targeted analogs 3.83 and 3.84 involve theranostics, photodynamic 
therapy and dual-imaging modalities. For example, replacement of the cyanine dye moiety with a 
photosensitizer, such as porphyrin or IRDye800 may help to circumvent the inherent unspecific 
accumulation of these fluorophores in vivo. Targeted therapies could benefit of alkyne template 3.62 
for the attachment of anti-cancer drugs. Furthermore, the cyclen core allows for dual-OI and MRI or 
PET tracers to be explored by the complexation with, e.g., gadolinium(III) or 68Ga. Upon conjugation 
with more relevant NIR dyes, including IRDye800 and ICG, dual-imaging ligands are valuable tools 
for the diagnosis and intra-operative visualization of PDAC. With the modular approach developed 
in this thesis, the probe platform 3.62 becomes readily accessible for the tailored synthesis of 








Targeted fluorescent ligands have found diverse applications in the biomedical field, contributing to 
the visualization of protein-targets and the characterization of pathologies in living systems. 
Challenges in the assembly of an efficient probe are unique to the specific imaging experiments 
foreseen and may arise from several structural aspects necessary for installation of the reporter group. 
Those include the selection of a suitable design strategy and optimization of each component of the 
probe, i.e., ligand, linker, and reporter unit. This thesis investigated distinct probe design concepts to 
develop two novel fluorescently labeled platforms with high specificity for relevant pharmacological 
targets, the CB2R (Chapter 2.) and plectin-1 protein (Chapter 3.). 
Figure 4.1. The linear design strategy was selected for generating a CB2R-selective fluorescent probe 
platform in Chapter 2. 
The important, but still not fully elucidated, role of the CB2R in several inflammatory disorders as well 
as the lack of appropriate imaging tools to access its pharmacology demanded the need to develop 
versatile fluorescent ligands. A linear design strategy was employed to generate such imaging probes 
in the first part of this thesis (Figure 4.1.). Careful selection of a pharmacophore agonist as well as 
extensive evaluation of suitable linker placement and length allowed me to obtain a free amine 
precursor applied for labeling procedures. The synthesized fluorescent ligands displayed excellent 
affinity and selectivity values towards human and mouse CB2R, while retaining the agonistic effects of 
the selected recognition element. Moreover, their in vitro profiles were highly independent of the 
attached fluorophore structure and properties, highlighting the robustness of the developed probe 
template. These derivatives were cross-valeted in a broad range of optical imaging techniques, as 
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illustrated by the FACS, TR-FRET, and confocal microscopy investigations conducted in three 
different laboratories. Currently, the probe set is being applied to study CB2R expression and function 
in native systems.  
Figure 4.2. A cyclen-based multivalent probe template exploiting both the multivalent and the dual-
imaging design strategies was developed for PDAC imaging in Chapter 3. The metal chelating properties of 
the DOTA core enables dual-imaging possibilities with both MRI and PET imaging modalities. 
The second part of this thesis explored the cyclen core as a template for the synthesis of multivalent 
contrast agents, i.e., contain multiple targeting moieties (Figure 4.2.). The multivalent and the dual-
imaging design strategies were combined to develop a fully clickable probe platform. This key precursor 
enabled the one-pot assembly of heterogeneously tetrafunctionalized cyclen-based fluorescent ligands 
in aqueous buffers. Furthermore, a new methodology to efficiently remove copper ions from the 
cyclen scaffold after CuAAC reaction (up to 99% efficiency) was identified. Such a synthetic route 
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could address major bottlenecks encountered for the unsymmetrically derivatization of cyclen, 
including long reaction sequences based on subsequent amide coupling procedures, followed by 
complex chromatographic purifications, which overall have led to low yields. Upon installation of 
three plectin-1 targeting peptides and a cyanine fluorophore (Cy3 or Cy5.5), these probes were utilized 
to precisely image plectin-1 in pancreatic cancer cell lines using confocal microscopy. These 
experiments demonstrated the superior selectivity and binding avidity of the tri-substituted ligands 
towards plectin-1 when compared to monovalent and unspecific controls.  
The work performed in this thesis was successfully employed for interrogating several aspects of 
medicinal chemistry research and illustrated how well-characterized fluorescent probes support early 
stages of the drug development process. In particular, both CB2R and plectin-1 imaging platforms 
provided means to confidently detect the investigated protein targets in vitro and to visualize their 
downstream cellular events. In the CB2R case study, the synthesized labeled derivatives also enabled 
assessment of ligand-binding kinetics with the possibility of implementing optical-based HTS assays 
and aided in preclinical and translational test settings.  
While attending to certain limitations in the probe development field, these toolset of fluorescent 
derivatives will enable to investigate specific unsolved questions regarding their protein-targets, 
highlighting remaining challenges. For the CB2R, exploring Raman spectroscopy to assess how the 
CB2R-selective labeled agonists bind to the target will be crucial for generating novel compound 
classes with improved binding to CB2R. In addition, the CB2R-targeted fluoroprobes hold promising 
applications in more advanced drug development stages, such as determining dose selection of in 
humans. The plectin-1 targeted probes still require follow up studies in healthy control cells and PDAC 
tissues. Afterwards, these cyclen-based derivatives have potential applications as dual-imaging tools 
when in complex form with gadolinium(III) or 68Gallium. Such tools have important clinical 
applications to both evaluate the response of patients to PDAC treatment and guide intra-operative 
cancer resection. Moreover, the straightforward conditions established to assemble multivalent ligands 
from a novel cyclen-based template may guide and will facilitate the synthesis of analogs in diverse 
research fields. 
Altogether, the design strategies exploited for the synthesis of both probe platforms presented in this 
thesis as well as the validation approaches used to characterize their pharmacology may serve as a 





5. Experimental Procedures 
 
5.1. General Synthetic Information 
Reactions with air or moisture-sensitive substances were, if not otherwise indicated, carried out under 
an inert atmosphere of argon or nitrogen with the help of the Schlenk technique. All other chemicals 
were purchased from commercial suppliers and used as received unless otherwise specified. Peptide 
sequences were purchased from Peptides and elephants. Control peptide (NH2-SNLHPSDC-COOH) 
was used as received from the supplier. Plectin-1 targeting peptide (PTP) was purchased in its 
protected crude form (Boc-NH-K(Boc)T(tert-Bu)LLPT(tert-Bu)PC(Trt)-COOH); PTP deprotection 
was performed following a conventional acidic deprotection protocol and purified by reversed-phase 
HPLC as specified in the corresponding subsection. 
Reaction progress was monitored by thin layer chromatography on aluminum backed silica gel plates 
(silica gel 60 F 254 from E. Merck), visualizing with UV light (λ = 254 nm). For reactants with high 
molecular weight (> 2’000 g/mol), MALDI was additionally used to monitor reaction progress. 
MALDI measurements were performed on a Bruker Microflex MALDI-TOF LT/SH using 2,5-
dihydroxyacetophenone (2,5-DHAP) matrix and dried droplet sample preparation. 2,5-DHAP matrix 
was prepared according to supplier specifications. 
Chromatographic separations were carried out using Biotage Isolera One apparatus with RediSep®Rf 
columns from Teledyne Isco. High performance liquid chromatography (HPLC) separations were 
carried out using Waters LC150-System with a Macherey-Nagel VP 250/21 Nucleodur 100-7 C18Ec 
column, eluted with a gradient system of 10:90 to 90:10 acetonitrile:water with 0.1% TFA as acidic 
modifier at a 30 mL/min flow. Chiral separation was performed on Waters equipment using a 250 x 
50 mm Reprosil Chiral NR column, eluted under isocratic mode with 90:10 heptane:(ethyl acetate with 
0.01 mol ammonium acetate) at a 35ml/min flow. 
The analytical data was obtained with the help of the following equipment. 
1H and 13C NMR spectra were recorded at either Bruker AV 300 (295K, 300 MHz, 75 MHz) or Bruker 
AV 600 (300K, 600 MHz, 151 MHz) spectrometers in CDCl3 or DMSO-d6 as solvents. Spin 
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multiplicities were described as singlet (s), duplet (d), triplet (t), quartet (q), and mulitplet (m). Coupling 
constants (J) were recorded in Hz. All 13C NMR-spectra were recorded with 1H-broad-band 
decoupling. All chemical shifts for experiments performed in CDCl3 are reported in ppm (δ) relative 
to tetramethylsilane (δ = 0.00 ppm) and were calibrated with respect to their deuterated solvents (δ = 
1H: 7.26 ppm, 13C: 77.16 ppm). For experiments performed in DMSO-d6 the deuterated DMSO-d6 
solvent signal was used as the reference with 2.50 ppm (δ = 1H: 2.50 ppm, 13C: 39.52 ppm). NMR data 
were analyzed with MestReNova software. 
Mass and UV spectra were obtained with two different spectrometers using the same column. LC-MS 
(method 1): Agilent Technologies 6220 Accurate Mass TOF LC/MS linked to Agilent Technologies 
HPLC 1200 Series instrument using a Thermo Accuore RP-MS 2.6 µm, 30 x 2.1 mm column at 25 °C 
(Eluent A = water with 0.1% TFA; Eluent B = acetonitrile with 0.1% TFA), at a flow of 0.8 mL/min 
with the following gradient: 0.0 min to 0.2 min, 95% A; 1.1 min, 1% A; 2.5 min, stop time; 1.3 min, 
post time; UV-detection: 220 nm, 254 nm, 300 nm. LC-MS (method 2): Agilent Technologies 6120 
Quadrupole LC/MS instrument linked to Agilent Technologies HPLC 1290 Infinity using a Thermo 
Accuore RP-MS 2.6 µm, 30 × 2.1 mm column at 25 °C (Eluent A = water with 0.1% TFA; Eluent B 
= acetonitrile with 0.1% TFA), at a flow of 0.8 mL/min with the following gradient: 0.0 min to 0.2 
min, 95% A; 1.1 min, 1% A; 2.5 min, stop time; 1.3 min, post time; UV-detection: 220 nm, 254 nm, 
300 nm. Alternatively, LC−high-resolution MS spectra were recorded with an Agilent LC system 
consisting of an Agilent 1290 high-pressure system, a CTC PAL autosampler, and an Agilent 6520 
QTOF. The separation was achieved on a Zorbax Eclipse Plus C18 1.7 µm, 2.1 mm × 50 mm column 
at 55 °C (Eluent A = water with 0.01% formic acid; Eluent B = acetonitrile with 0.01% formic acid) 
at a flow of 1 mL/min with the following gradient: 0.0 min, 5% B; 0.3 min, 5% B; 4.5 min, 99% B; 5 
min, 99% B. 
ICP-MS analysis was performed on a Thermo Element 2 (double-focusing sector-field ICP-MS) 
instrument equipped with nickel cones. A glass concentric nebulizer (200 µL/min) operated in self-
aspirating mode and a glass cyclonic spray chamber (20 mL) were used for sample introduction. The 
analysis was conducted using 16 L/min cool gas flow, 1.05 L/min auxiliary gas flow, 1.171 to 1.190 
L/min sample gas flow, and a plasma power of 1250 W. Copper isotopes 63Cu and 65Cu were detected 
at low (R = 300) and medium (R = 4’000) resolution using an integration time of 10 ms. For each 
sample, three runs (with three passes each) per resolution were performed. Between each new sample, 
the sample tube was washed with 1% (v/v) nitric acid for 60 s, followed by a sample take-up time of 
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90 s. For these experiments, the nitric acid (Geyer Chemsolute p.a., 65.0%) was distilled by sub-boiling 
(twice) at the BAM. The copper ICP multi-element standard solution IV containing 1000 mg/L 
copper in 6.5% suprapure nitric acid (Merc) was used for calibration. 
Compound names are derived from Chemdraw and are not necessarily identical with the IUPAC 
nomenclature. 
 
5.2. To “Tracing the Cannabinoid Type 2 Receptor with a Fluorescent Probe Toolbox” 
5.2.1. Supplementary Figure 
Supplementary figure S-1. Structures of reference ligands. SR144528 (2.20), CB2R agonist, reference ligand for 
TR-FRET assay. HU-308, CB2R agonist, reference ligand for TR-FRET assay (2.28). JWH133 (2.145), CB2R agonist, 
reference ligand for FACS, binding and cAMP assays. RO6851228 (2.146), CB2R agonist, reference ligand for FACS 
assay. GW842166X (SI-1), CB2R agonist, used for blocking experiments of NMP6-probe 2.26.[152] AM12033, (SI-
2) non-selective agonist, used for crystallization of the CB2R.[81] WIN55212-2 (SI-3), non-selective, reference ligand 
for binding and cAMP assays. AM6538 (SI-4), CB2R antagonist, used for crystallization of the CB2R.[181] Rimonabant 
(SI-5), CB1R agonist, reference ligand for binding and cAMP assays. CP55,940 (SI-6), non-selective agonist, 
reference ligand for binding and cAMP assays. 
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5.2.2. Supplementary Tables 









1 NaH 7.0 THF 0 to 66 °C 5 h SM degradation SM degradation 
2 NaH 7.0 DMF 0 to 50 °C 5 h SM degradation SM degradation 
3 NaH 12.0 THF 0 °C to r.t. 24 h No conversion No conversion 
4 KOtBU 7.0 THF 0 to 66 °C. 5 h SM degradation SM degradation 
5 KOtBU 7.0 DMF 0 to 50 °C. 5 h SM degradation SM degradation 
6 NaH, Bu4BnBr 7.0 DMF 0 °C to r.t. 3 d No conversion No conversion 
7 KOtBu, Bu4BnBr 7.0 DMF 0 °C to r.t. 3 d No conversion No conversion 
8 LDA 1.2 THF –78 °C to r.t. 3 d No conversion No conversion 
9 LiHMDS 1.2 THF –78 °C to r.t. 3 d No conversion No conversion 
10 nBuLi 1.2 THF –78 °C to r.t. 3 d No conversion No conversion 
T – temperature, R = tosyl or triflate leaving groups. Reaction conditions: 2.75 or 2.76 (1.0 equiv.), N-Boc PEG2 




Supplementary table S-2. Reaction conditions tested for the crystallization of amino ester (±)-2.78 using 
diastereomeric salt formation strategies. 
Entry Chiral salt 
Equiv. of  
chiral salt 
Solvent Volume (µL) Result 
1 
(R)-Tartaric acid 0.5 
methanol 70 No crystal formation 
2 isopropanol 200 No crystal formation 
3 ethyl acetate 100 No crystal formation 
4 chloroform 110 No crystal formation 
5 tetrahydrofuran 90 No crystal formation 
6 
(S)-Tartaric acid 0.5 
methanol 70 No crystal formation 
7 isopropanol 200 No crystal formation 
8 ethyl acetate 100 No crystal formation 
9 chloroform 110 No crystal formation 





methanol 70 No crystal formation 
12 isopropanol 200 No crystal formation 
13 ethyl acetate 350 No crystal formation 
14 chloroform 290 No crystal formation 





methanol 70 No crystal formation 
17 isopropanol 200 No crystal formation 
18 ethyl acetate 350 No crystal formation 
19 chloroform 290 No crystal formation 
20 tetrahydrofuran 130 No crystal formation 
21 
(S)-Mandelic acid 1.0 
methanol 70 No crystal formation 
22 isopropanol 200 No crystal formation 
23 ethyl acetate 160 No crystal formation 
24 chloroform 270 No crystal formation 
25 tetrahydrofuran 90 No crystal formation 
26 
(R)-Mandelic acid 1.0 
methanol 70 No crystal formation 
27 isopropanol 200 No crystal formation 
28 ethyl acetate 160 No crystal formation 
29 chloroform 270 No crystal formation 
30 tetrahydrofuran 90 No crystal formation 
31 
(S)-Latic acid 1.0 
methanol 70 No crystal formation 
32 isopropanol 200 No crystal formation 
33 ethyl acetate 100 No crystal formation 
34 chloroform 110 No crystal formation 





methanol 70 No crystal formation 
37 isopropanol 200 53% yield, 31% ee 
38 ethyl acetate 100 No crystal formation 
39 chloroform 110 15% yield, ee not calculated 





methanol 70 No crystal formation 
42 isopropanol 200 28% yield, 30% ee 
43 ethyl acetate 100 No crystal formation 
44 chloroform 110 No crystal formation 
45 tetrahydrofuran 110 No crystal formation 
Reaction conditions: Amino ester (±)-2.78 (20 mg, 0.17 mmol) and the corresponding chiral salt were dissolved in 
the minimum amount of solvent necessary for their complete dilution (described for each example at the volume 
column). The solution was shaken at 50 °C for 2 h with 700 rpm, cooled to room temperature and stored at 4 °C 
for 18 h. Tubes containing crystals were centrifuged at 4 °C for 25 min (120 rcf), and the crystals were washed with 
ice cold solvent. This procedure was repeated twice.  
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Supplementary table S-3. In vitro pharmacology data of Alexa 488-2.134 for a representative set of common 
off-targets. 
Assay name Readout Value (% inhibition) 
MAO-A (h) Enzymatic activity 1 
5-HT transporter (h) (antagonist radioligand) Specific binding -8 
5-HT1A (h) (agonist radioligand) Specific binding 1 
5-HT2A (h) (agonist radioligand) Specific binding 5 
5-HT2B (h) (agonist radioligand) Specific binding 2 
5-HT3 (h) (antagonist radioligand) Specific binding 6 
A1 (h) (agonist radioligand) Specific binding 2 
A3 (h) (agonist radioligand) Specific binding 77 
Abl kinase (h) Enzymatic activity 13 
ACE (h) Enzymatic activity -22 
acetylcholinesterase (h) Enzymatic activity -5 
alpha 1A (h) (antagonist radioligand) Specific binding 0 
alpha 2A (h) (antagonist radioligand) Specific binding 5 
AR(h) (agonist radioligand) Specific binding 1 
AT1 (h) (antagonist radioligand) Specific binding 0 
beta 1 (h) (agonist radioligand) Specific binding 9 
beta 2 (h) (antagonist radioligand) Specific binding 7 
BZD (central) (agonist radioligand) Specific binding -1 
Ca2+ channel (L, diltiazem site) (benzothiazepines) 
(antagonist radioligand) 
Specific binding 6 
CB1 (h) (agonist radioligand) Specific binding 41 
CCK1 (CCKA) (h) (agonist radioligand) Specific binding 23 
CDK2 (h) (cycA) Enzymatic activity 5 
Cl- channel (GABA-gated) (antagonist radioligand) Specific binding 30 
COX2(h) Enzymatic activity -5 
D1 (h) (antagonist radioligand) Specific binding 10 
D2S (h) (agonist radioligand) Specific binding -11 
Estrogen ER alpha (h) (agonist radioligand) Specific binding 0 
FP (h) (agonist radioligand) Specific binding 14 
glycine (strychnine-insensitive) (antagonist radioligand) Specific binding 8 
GR (h) (agonist radioligand) Specific binding 33 
GSK3alpha (h) Enzymatic activity -13 
GSK3beta (h) Enzymatic activity -10 
H1 (h) (antagonist radioligand) Specific binding 2 
H2 (h) (antagonist radioligand) Specific binding 15 
H3 (h) (agonist radioligand) Specific binding -1 
HIV-1 protease Enzymatic activity 47 
ZAP70 kinase (h) Specific binding 35 
M1 (h) (antagonist radioligand) Specific binding -5 
M2 (h) (antagonist radioligand) Specific binding 8 
MMP-9 (h) Enzymatic activity 21 
mu (MOP) (h) (agonist radioligand) Specific binding 0 
N muscle-type (h) (antagonist radioligand) Specific binding 14 
N neuronal alpha 4beta 2 (h) (agonist radioligand) Specific binding -7 
norepinephrine transporter (h) (antagonist radioligand) Specific binding 9 
PCP (antagonist radioligand) Specific binding 4 
PDE3B (h) Enzymatic activity 15 
PDE4D2 (h) Enzymatic activity 32 
PPARgamma (h) (agonist radioligand) Specific binding 29 
xanthine oxidase/ superoxide O2- scavenging Enzymatic activity -6 
ZAP70 kinase (h) Enzymatic activity 39 
Representative off target testing.[193] Data shown is the mean percentage of inhibition for binding assays and the 
mean percentage of inhibition for enzyme and cell-based assays at a test concentration of 10 µM (n=2). Data were 
generated at Eurofins Cerep (France).  
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5.2.3. Synthesis of Pyrazine Carboxylic Acid 2.37 
5-(3,3-Difluoro-azetidin-1-yl)-pyrazine-2-carboxylic acid methyl ester (2.39) 
5-Chloro-pyrazine-2-carboxyic acid methyl ester 2.38 (100 mg, 0.58 mmol) was dissolved in 1,4-
dioxane (1 mL). To this solution was added 3,3-difuoroazetidine hydrochloride (91 mg, 0.70 mmol), 
and triethylamine (0.2 mL, 1.51 mmol). The mixture was stirred 22 h at 45 °C, and then cooled to 
room temperature. Brine (1 mL) was added to the stirring mixture, and the mixture was extracted with 
ethyl acetate (3x). The organic phases were combined and washed successively with 10% sodium 
bicarbonate solution (5 mL) and brine (5 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude was purified by column chromatography (Silica gel, 4 g, cHex:EtOAc, 30 
to 50% EtOAc) to yield a 59 mg (44%) of 2.39 as a white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 8.83 (s, 1H), 7.87 (s, 1H), 4.54 (t, J = 11.7 Hz, 4H), 3.96 (s, 3H). 
The analytical data are in accordance with those reported in the literature.[170] 
 
6-Bromo-5-(3,3-difluoro-azetidin-1-yl)-pyrazine-2-carboxylic acid methyl ester (2.40) 
To a solution of 2.39 (59 mg, 0.25 mmol) in chloroform (1 mL) was added N-bromosuccinimide (89 
mg, 0.52 mmol). The reaction mixture was stirred at 60 °C for 20 h. After cooling to room temperature, 
water (2 mL) was added to quench, and the organic phase was separated and washed successively with 
water (3 mL) and brine (3 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. 
The crude material was purified by column chromatography (Silica gel, 4 g, cHex:EtOAc, 50% 
EtOAc) to give the desired product 2.40 (57.9 mg, 75%) as a light yellow solid. 
1H NMR (600 MHz, DMSO-d6) δ ppm 8.71 (s, 1H), 4.79 (t, J = 12.5 Hz, 4H), 3.85 (s, 3H). 




6-Bromo-5-(3,3-difluoro-azetidin-1-yl)-pyrazine-2-carboxylic acid (2.41) 
To a solution of 2.40 (4.6 g, 14.9 mmol) in tetrahydrofuran (18 mL) and water (9 mL) was added 
lithium hydroxide (467 mg, 19.5 mmol) at room temperature, and stirred at this temperature for 20 h. 
Afterwards, the solvent was concentrated under reduced pressure, and the aqueous phase acidified 
with hydrochloric acid aq. sol. (1 M, pH 2-3). The solid was separated, triturated with toluene (3 mL) 
and dried in vacuo to give the title compound 2.41 (3.1 g, 71%) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ ppm 8.69 (s, 1H), 4.76 (t, J = 12.5 Hz, 4H). 
The analytical data are in accordance with those reported in the literature.[170] 
 
6-Cyclopropylmethoxy-5-(3,3-Difluoro-azetidin-1-yl)-pyrazine-2-carboxylic acid (2.37) 
To a solution of cyclopropanemethanol (0.55 mL, 6.79 mmol) in anhydrous dimethyl sulfoxide (9 mL) 
was added potassium hydroxide (0.66 g, 11.8 mmol) at room temperature. To the mixture was added 
a solution of 2.41 (1.0 g, 3.40 mmol) in dimethyl sulfoxide (1 mL). The reaction mixture was stirred at 
room temperature for 3 h. Afterwards, water (3 mL) was added, and the aqueous mixture was acidified 
with hydrochloric acid aq. sol. (1 M, pH 3-4). The solid was filtered, triturated with toluene (3 mL) 
and dried in vacuo to give compound 2.37 (873 mg, 90%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 12.72 (s, 1H), 8.30 (s, 1H), 4.64 (t, J = 12.4 Hz, 4H), 4.15 (d, J = 
7.2 Hz, 2H), 1.31 – 1.22 (m, 1H), 0.60 – 0.53 (m, 2H), 0.41 – 0.34 (m, 2H). 




5.2.4. Synthesis of Picolinic Acid 2.42 
5-Bromo-6-methylpicolinonitrile (SI-7) 
To a stirring solution of 3-bromo-6-fluoro-2-methyl-pyridine 2.43 (30 g, 158 mmol) in dimethyl 
sulfoxide (40 mL) sodium cyanide (31 g, 633 mmol) was added at room temperature. The reaction 
mixture was heated to 100 °C and stirred for 2 h. After cooling to room temperature, the reaction was 
quenched with the addition of water (40 mL) and the mixture extracted with diethyl ether (3x). The 
combined organic phases were dried over MgSO4, and concentrated under reduced pressure to obtain 
a crude oil. Purification by column chromatography (Silica gel, 80 g, cHex:EtOAc, 25% EtOAc) gave 
the title compound SI-7 as a colorless oil (5.3 g, 17%).  
1H NMR (300 MHz, CDCl3) δ ppm 7.95 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 2.71 (s, 3H).  
The analytical data are in accordance with those reported in the literature.[171] 
 
5-Cyclopropyl-6-methylpicolinonitrile (2.44) 
Compound SI-7 (371 mg, 1.88 mmol), cycopropyboronic acid (258 mg, 3.01 mmol), 
tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 138 mg, 150 µmol), Xantphos (113 mg, 196 
µmol) and cesium carbonate (735 mg, 2.26 mmol) were suspended in 1,4-dioxane (10 mL) and purged 
with argon. The mixture was stirred at 110 °C for 12 h, cooled to room temperature, filtered, and 
concentrated under reduced pressure. Purification by column chromatography (Silica gel, 25 g, 
cHex:EtOAc, 5 to 20% EtOAc) afforded the title compound 2.44 in 64% yield (1.9 g) as a light orange 
solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.45 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 2.68 (s, 3H), 
2.00 – 1.88 (m, 1H), 1.15 – 1.05 (m, 2H), 0.77 – 0.64 (m, 2H). 




6-Cyano-3-cyclopropyl-2-methylpyridine 1-oxide (2.45) 
To a solution of compound 2.44 (1.9 g, 11.9 mmol) in dichloromethane (20 mL) 3-chloroperbenzoic 
acid (4.8 g, 27.6 mmol) was added. The reaction mixture was stirred for 12 h at 60 °C. Afterwards, the 
mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. 
Subsequent purification by column chromatography (Silica gel, 40 g, cHex:EtOAc, 35% EtOAc) 
afforded N-oxide 2.45 (1.6 g, 77%) as a yellow solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.44 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 2.65 (s, 3H), 
2.03 – 1.88 (m, 1H), 1.21 – 1.08 (m, 2H), 0.79 – 0.71 (m, 2H). 
The analytical data are in accordance with those reported in the literature.[171] 
 
5-Cyclopropyl-6-(hydroxymethyl)picolinonitrile (SI-8) 
To a stirring solution of N-oxide 2.45 (1.6 g, 9.18 mmol) in dichloromethane (20 mL) 2,2,2-
trifluoroacetic anhydride (6.5 mL, 45.9 mmol) was added. The reaction mixture was stirred at room 
temperature for 8 h, poured onto water (40 mL) and extracted with dichloromethane (3x). The 
combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. 
The crude residue was purified by column chromatography (Silica gel, 25 g, cHex:EtOAc, 15% 
EtOAc) to give the title compound SI-8 in 95% yield (1.5 g) as a yellow oil.  
1H NMR (300 MHz, CDCl3) δ ppm 7.56 (dd, J = 8.0, 0.9 Hz, 1H), 7.37 (dd, J = 7.9, 0.8 Hz, 1H), 4.93 
(s, 2H), 4.12 (bs, 1H), 1.80 (tt, J = 8.4, 5.3 Hz, 1H), 1.19 – 1.09 (m, 2H), 0.78 – 0.70 (m, 2H). 





Intermediate SI-8 (1.5 g, 8.61 mmol) was dissolved in tetrahydrofuran (20 mL). Tetrabromomethane 
(5.7 g, 17.2 mmol) and triphenylphosphine (2.2 g, 17.2 mmol) were added. The reaction mixture was 
stirred for 12 h at room temperature and concentrated under reduced pressure. n-Heptane (30 mL) 
and EtOAc (20 mL) were added to the crude residue and the suspension was stirred for 15 min at 
room temperature. The resulting precipitate composed by triphenylphosphine was filtered off. The 
filtrate was poured onto water (30 mL) and extracted with ethyl acetate (3x). The combined organic 
layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The crude material 
was purified by column chromatography (Silica gel, 25 g, cHex:EtOAc, 10% EtOAc) to give the title 
compound 2.46 in 55% yield (1.1 g) as a light orange solid. 
1H NMR (300 MHz, CDCl3) δ ppm 7.89 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 4.88 (s, 2H), 
2.25 – 2.14 (m, 1H), 1.20 – 1.09 (m, 2H), 0.93 – 0.82 (m, 2H). 
The analytical data are in accordance with those reported in the literature.[171] 
 
5-Cyclopropyl-6-(4-fluorobenzyl)picolinonitrile (SI-9) 
Compound 2.46 (650 mg, 2.74 mmol) was dissolved in 1,4-dioxane (20 mL). To the stirring solution 
cesium carbonate (1.3 g, 4.11 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(Pd(dppf)Cl2, 380 mg, 466 µmol) and 4-fluorophenylboronic acid (671 mg, 4.80 mmol) were added 
and the mixture was purged with argon. The reaction mixture was heated to 110 °C for 12 h. After 
cooling to room temperature, the crude mixture was filtered, poured onto water (10 mL) and extracted 
with ethyl acetate (3x). The combined organic layers were dried over MgSO4, and concentrate under 
reduced pressure. The crude material was purified by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 5% EtOAc) to give the title compound SI-9 in 47% yield (465 mg) as a colorless oil. 
 
142 
1H NMR (300 MHz, CDCl3) δ ppm 7.50 (d, J = 7.9 Hz, 1H), 7.33 (dd, J = 8.0, 0.7 Hz, 1H), 7.21 – 
7.13 (m, 2H), 7.01 – 6.91 (m, 2H), 4.34 (s, 2H), 1.94 – 1.83 (m, 1H), 1.07 – 0.98 (m, 2H), 0.71 – 0.61 
(m, 2H). 
The analytical data are in accordance with those reported in the literature.[171] 
 
5-Cyclopropyl-6-(4-fluorobenzyl)picolinic acid (2.42) 
Intermediate SI-9 (300 mg, 1.19 mmol) was dissolved in water (10 mL) and methanol (3 mL). Sodium 
hydroxide (190 mg, 4.76 mmol) was added, and the reaction mixture was heated to 80 °C upon stirring 
for 24 h. After this time, the reaction mixture was poured onto hydrochloric acid aq. sol. (0.5 M, 25 
mL) and extracted with ethyl acetate (3x). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude material was diluted in a mixture of acetonitrile and 
water (1:1) and purified by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 10 
to 90% ACN) to give the title compound 2.42 (257 mg, 80%) as a white solid after lyophilization. 
1H NMR (600 MHz, DMSO-d6) δ ppm 7.82 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.29 – 7.22 
(m, 2H), 7.12 – 7.06 (m, 2H), 4.34 (s, 2H), 2.01 (ddt, J = 10.7, 7.4, 3.7 Hz, 1H), 1.00 – 0.90 (m, 2H), 
0.70 – 0.62 (m, 2H). 




5.2.5. Synthesis of Amino Ester Building Blocks  
Ethyl 2-(benzylideneamino)butanoate (2.77) 
Thionyl chloride (3.5 mL, 47.9 mmol) was added dropwise to a solution of amino butyric acid 2.65 
(3.8 g, 36.9 mmol) in ethanol (40 mL), over a period of 5 min at 0 °C. The reaction mixture was stirred 
at 0 °C for 1 additional hour. Afterwards, the resulting solution was refluxed (78 °C) for 4 h. The 
reaction mixture was cooled to room temperature and concentrated under reduced pressure to yield 
ethyl 2-aminobutanoate as a colorless oil (4.8 g, quant.), used without further purification for the next 
step. 
Ethyl 2-aminobutanoate (4.8 g, 36.9 mmol) and dried magnesium sulfate (4.4 g, 36.9 mmol) were 
stirred in anhydrous dichloromethane (30 mL) at room temperature for 20 min. After which time, 
benzaldehyde (3.8 mL, 36.9 mmol) and triethylamine (9.5 mL, 68.2 mmol) were added sequentially 
and dropwise. The resulting mixture was stirred for 30 h at the same temperature then filtered and 
concentrated. The residue was dissolved in diethyl ether (8 mL) and water (8 mL) and the separated 
aqueous layer was extracted with ether. The combined ether solutions were washed with brine (8 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure to give the desired imine 2.77 as 
a clear oil (7.5 g, 93%). 
1H NMR (600 MHz, CDCl3) δ ppm 8.28 (s, 1H), 7.80 – 7.76 (m, 2H), 7.44 – 7.39 (m, 3H), 4.25 – 4.17 
(m, 2H), 3.87 (dd, J = 8.2, 5.5 Hz, 1H), 2.09 – 2.00 (m, 1H), 1.94 – 1.88 (m, 1H), 1.27 (t, J = 7.1 Hz, 
3H), 0.92 (t, J = 7.4 Hz, 3H). 




Ethyl 2-amino-2-ethylbutanoate hydrochloride (2.61) 
Potassium bis(trimethylsilyl)amide (820 mg, 4.11 mmol) in tetrahydrofuran (12 mL) was added 
dropwise to a solution of 2.77 (600 mg, 2.74 mmol) in tetrahydrofuran (4 mL) and cooled to –50 °C. 
After 1 h, iodoethane (0.3 mL, 3.56 mmol) was added at the same temperature. The cooling bath was 
removed, and the mixture was stirred at room temperature for additional 20 h. Afterwards, the reaction 
mixture was concentrated under reduced pressure, to remove most of the solvent. The residue was 
then partitioned between dichloromethane (10 mL) and water (10 mL). The organic layer was 
separated, and the aqueous phase was extracted with dichloromethane (4x). The combined organic 
extracts were washed with brine (5 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to yield ethyl 2-(benzylideneamino)-2-ethylbutanoate 2.66 (643 mg, 95%) as a dark yellow oil, 
used without further purification for the subsequent deprotection. 
To a solution of 2.66 (643 mg, 2.60 mmol) in diethyl ether (12 mL) hydrochloric acid aq. sol. (1 M, 
10.3 mL) was added dropwise at 0 °C. After the addition, the reaction mixture was allowed to warm 
to room temperature and stirred for additional 15 h. The ether layer was then separated, and the water 
phase was extracted with dichloromethane (2x). The organic extracts were extracted with hydrochloric 
acid aq. sol. (1 M, 2x). The aqueous layers were combined to give 2.61 (328 mg, 64%) as light yellow 
solid after lyophilization.  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.51 (s, 3H), 4.19 (q, J = 6.9 Hz, 2H), 1.80 (q, J = 7.3 Hz, 4H), 
1.19 (t, J = 6.9 Hz, 3H), 0.84 (t, J = 7.4 Hz, 6H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 171.0, 64.1, 62.6, 28.9, 14.4, 8.1.  




General procedure for the synthesis of racemic α,α-disubstituted α-amino esters 
To a solution of lithium diisopropylamine (LDA, 1.5 equiv.) in tetrahydrofuran (4 mL) at –78 °C was 
added 2.77 (1.0 equiv.) in tetrahydrofuran (4 mL), followed by the dropwise addition of allyl bromide 
or 1-bromo-3-methoxypropane (1.5 equiv.). The mixture was stirred at room temperature for 24 h, 
and then concentrated under reduced pressure. The residue was then partitioned between ethyl acetate 
(15 mL) and water (15 mL). The organic layer was separated, and the aqueous phase was extracted 
with ethyl acetate (4x). The combined organic extracts were washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude residue was dissolved in diethyl ether (15 
mL) and treated with hydrochloric acid aq. sol. (1 M, 3.5 equiv.) at 0 °C. The reaction mixture was 
allowed to warm to room temperature, and stirred for additional 15 h. The ether layer was separated, 
and the water phase washed with dichloromethane (2x). The combined dichloromethane phases were 
extracted with hydrochloric acid aq. sol. (0.2 M, 2x). The aqueous layers were combined and 
lyophilized to yield the corresponding amino ester hydrochloric salt, without the need of further 
purification steps. 
Ethyl 2-amino-2-ethylpent-4-enoate (2.78)  
Following the general procedure above, 2.78 was obtained in 96% yield as a light yellow oil, over 2 
steps (1.1 g) starting from allyl bromide (0.73 mL, 8.41 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 5.74 – 5.60 (m, 1H), 5.21 – 5.05 (m, 2H), 4.15 (q, J = 7.1 Hz, 
2H), 2.53 (dd, J = 13.5, 6.4 Hz, 1H), 2.21 (dd, J = 13.5, 8.4 Hz, 1H), 1.84 – 1.66 (m, 3H), 1.60 – 1.48 
(m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.5 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ ppm 176.8, 132.9, 119.5, 119.4, 61.0, 44.0, 32.9, 14.4, 8.3.  




Ethyl 2-amino-2-ethyl-5-methoxypentanoate (2.93)  
Following the general procedure above, 2.93 was obtained in 92% yield as a colorless oil, over 2 steps 
(158 mg) starting from 1-bromo-3-methoxypropane (0.15 mL, 1.40 mmol).  
1H NMR (600 MHz, CDCl3) δ ppm 8.86 (bs, 2H), 4.30 – 4.26 (m, 2H), 3.44 – 3.29 (m, 2H), 3.29 (s, 
3H), 2.15 – 1.95 (m, 5H), 1.65 – 1.58 (m, 1H), 1.32 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.5 Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ ppm 170.2, 72.0, 64.9, 62.6, 58.5, 33.3, 30.0, 24.1, 14.3, 8.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C10H21NO3: 204.1595, found 204.1588. 
 
General ethyl esterification procedure for natural amino acids 
Thionyl chloride (2.0 equiv.) was added dropwise to a solution of amino acid (1.0 equiv.) in ethanol (2 
mL) at 0 °C. The reaction mixture was stirred at 0 °C for additional 1 h. Afterwards, the resulting 
solution was refluxed (78 °C) for 4 h. The reaction mixture was cooled to room temperature, while 
stirring for 20 h. The reaction mixture was concentrated under reduced pressure. The obtained 
hydrochloric salts were used without further purification for the next step. 
Ethyl S-methyl-L-cysteinate (2.89)  
Following the general procedure above, 2.89 was obtained in quantitative yield (68 mg) as a white solid 
starting from S-Methyl-L-Cysteine (50 mg, 0.37 mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 8.90 (bs, 2H), 4.51 – 4.20 (m, 3H), 3.26 (s, 2H), 2.22 (s, 3H), 1.33 
(s, 3H). 




Ethyl L-2-amino-3-(4-methoxyphenyl)propanoate (2.90)  
Following the general procedure above, 2.90 was obtained in quantitative yield (94 mg) as a white solid 
starting from O-Methyl-L-Tyrosine (72 mg, 0.37 mmol). 
1H NMR (300 MHz, DMSO-d6) δ ppm 8.76 (bs, 2H), 7.16 (d, J = 8.3 Hz, 2H), 6.88 (d, J = 8.4 Hz, 
2H), 4.16 – 4.05 (m, 3H), 3.73 (s, 3H), 3.24 – 2.96 (m, 2H), 1.11 (t, J = 7.1, 3H). 
The analytical data are in accordance with those reported in the literature.[298] 
 
General procedure for the synthesis of racemic α-monosubstituted α-amino esters 
To a solution of lithium diisopropylamine (1.05 equiv.) in anhydrous tetrahydrofuran (3 mL) cooled 
to –78 °C was added N-(diphenylmethylene)glycine ethyl ester 2.62 (1.0 equiv.). The reaction mixture 
was stirred for 1 h at this temperature. Afterwards, allyl bromide or 1-bromo-3-methoxypropane (1.05 
equiv.) was slowly added. The mixture was stirred at –78 °C for additional 1 h, and at room 
temperature for additional 22 h. The reaction was concentrated under reduced pressure, and the 
remained residue partitioned between ethyl acetate (12 mL) and water (12 mL). The organic layer was 
separated, and the aqueous phase was extracted with ethyl acetate (4x). The combined organic extracts 
were washed with brine (5 mL), dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude diphenylmethylene ester analog was dissolved in diethyl ether (3 mL) and treated with 
hydrochloric acid aq. sol. (1 M, 3.5 equiv.) at 0 °C. The reaction mixture was allowed to warm to room 
temperature, and stirred for additional 15 h. The ether layer was separated, and the water phase was 
extracted with dichloromethane (2x). The dichloromethane extracts were extracted with hydrochloric 
acid aq. sol. (0.2 M, 2x). The aqueous layers were combined and lyophilized to yield the corresponding 




Ethyl 2-aminopent-4-enoate (2.91) 
Following the general procedure above, 2.91 was obtained in 91% yield as a light yellow oil, over 2 
steps (277 mg) starting from allyl bromide (0.17 mL, 1.96 mmol).  
1H NMR (600 MHz, CDCl3) δ ppm 8.68 (bs, 2H), 5.88 – 5.81 (m, 1H), 5.29 (d, J = 16.8 Hz, 1H), 5.22 
(d, J = 9.7 Hz, 1H), 4.31 – 4.15 (m, 3H), 2.86 – 2.79 (m, 2H), 1.27 (t, J = 6.6 Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ ppm 168.7, 130.3, 121.3, 62.6, 52.9, 34.5, 14.1.  
HR-MS (ESI) m/z [M+H]+ calcd. for C7H13NO2: 144.1019, found 144.1020. 
 
Ethyl 2-amino-5-methoxypentanoate (2.92)  
Following the general procedure above, 2.92 was obtained in 82% yield as a colorless oil, over 2 steps 
(106 mg) starting from 1-bromo-3-methoxypropane (0.09 mL, 0.79 mmol).  
1H NMR (600 MHz, CDCl3) δ ppm 8.65 (bs, 2H), 4.22 (d, J = 54.0 Hz, 3H), 3.44 (bs, 2H), 3.33 (s, 
3H), 2.17 (bs, 2H), 1.80 (bs, 2H), 1.30 (s, 3H).  
13C NMR (151 MHz, CDCl3) δ ppm 169.4, 71.9, 62.8, 58.8, 53.2, 27.8, 25.4, 14.3.  




Synthesis of chiral amino ester building blocks 
Ethyl 2-(((benzyloxy)carbonyl)amino)-2-ethylpent-4-enoate (2.137) 
Ethyl 2-amino-2-ethylpent-4-enoate hydrochloride 2.78 (100 mg, 0.48 mmol) and benzyl 
chloroformate (0.5 mL, 3.38 mmol) were stirred in water (1.5 mL) at 0 °C. Subsequently sodium 
bicarbonate (0.41 g, 4.89 mmol) dissolved in water (3.5 mL) was dropwise added to the reaction 
mixture. The reaction was stirred for additional 30 min at 0 °C and then 36 h at room temperature. 
After this time, ethyl acetate (15 mL) was added to quench the reaction. The aqueous layer was 
extracted with ethyl acetate (3x). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by column chromatography 
(Silica gel, 25 g, cHex:EtOAc, 10 to 50% EtOAc) to give (±)-2.137 (116 mg, 79%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz) δ ppm 7.31 – 7.27 (m, 2H), 7.25 – 7.16 (m, 2H), 5.77 – 5.66 (m, 1H), 
5.61 – 5.42 (m, 1H), 5.10 – 4.89 (m, 4H), 4.13 (q, J = 7.1 Hz, 2H), 3.00 (dd, J = 14.1, 7.3 Hz, 1H), 2.42 
(ddt, J = 14.0, 7.4, 1.1 Hz, 1H), 2.26 (dq, J = 14.7, 7.5 Hz, 1H), 1.81 – 1.65 (m, 1H), 1.19 (t, J = 7.1 
Hz, 3H), 0.69 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ ppm 173.2, 154.2, 136.8, 132.5, 128.6, 128.1, 128.0, 118.9, 66.3, 64.5, 
61.9, 39.7, 28.4, 14.4, 8.4.  
HR-MS (ESI) m/z [M+H]+ calcd. for C17H25NO4 [M+H]




Ethyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-ethylpent-4-enoate (2.138) 
Ethyl 2-amino-2-ethylpent-4-enoate hydrochloride 2.78 (700 mg, 4.09 mmol) was dissolved in sodium 
carbonate aq. sol. (1 M, 20 mL) and cooled to 0 °C. 9H-Fluoren-9-ylmethyl chloroformate (Fmoc-Cl, 
1.1 g, 4.09 mmol) in 1,4-dioxane (20 mL) was added at 0 °C. The reaction mixture was stirred for 3 h 
at room temperature, poured onto water (30 mL) and extracted with ethyl acetate (3x 50 mL). The 
combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The crude 
material was purified by column chromatography (Silica gel, 80 g, cHex:EtOAc, 10 to 50% EtOAc) 
to give (±)-2.138 (1.1 g, 70%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ ppm 7.77 (dt, J = 7.5, 0.9 Hz, 2 H), 7.61 (d, J = 7.4 Hz, 2 H), 7.41 (td, 
J = 7.5, 1.4 Hz, 2 H), 7.32 (td, J = 7.5, 1.2 Hz, 2 H), 5.85 (s, 1 H), 5.52 – 5.70 (m, 1 H), 5.12 – 5.01 (m, 
2 H), 4.47 – 4.17 (m, 5 H), 3.12 (dd, J = 14.0, 7.2 Hz, 1 H), 2.52 (dd, J = 14.0, 7.5 Hz, 1 H), 2.37 (dq, 
J = 14.6, 7.4 Hz, 1 H), 1.82 (dq, J = 14.6, 7.3 Hz, 1 H), 1.31 (t, J = 7.1 Hz, 3 H), 0.79 (t, J = 7.4 Hz, 3 
H). 
13C NMR (75 MHz, CDCl3) δ ppm 173.4, 154.1, 144.1, 144.0, 141.4, 132.5, 127.8, 127.8, 127.2, 125.2, 
125.2, 120.1, 119.0, 77.2, 66.3, 64.5, 62.0, 47.4, 39.7, 28.4, 14.4, 8.4.  
HR-MS (ESI) m/z [M+H]+ calcd. for C24H27NO4: 394.1941, found 394.2016.  
 
The chiral separation of 2.138 was performed by KENNETH ATZ at Hoffmann La-Roche, Basel.  
The racemic mixture was separated into the two enatiomers by reversed-phase chiral HPLC 
(Nucleosil-Si, 40 g, nHep:EtOAc, 0 to 100% EtOAc). 
[α]20d = –3.16° for (S)-2.138 and [α]
20




Ethyl (S)-2-ethyl-2-((R)-1-tosylpyrrolidine-2-carboxamido)pent-4-enoate (2.139)  
This synthesis procedure was performed by BENJAMIN BRENNECKE at FMP, Berlin. 
 
To a stirring solution of (R)-2.138 (199 mg, 0.51 mmol) in dichloromethane (10 mL) at room 
temperature piperidine (250 µL, 2.53 mmol) was added. After 4 h stirring, the reaction mixture was 
concentrated under reduced pressure to give the corresponding free amine as colorless oil, which was 
used crude for the next reaction. 
N-Toluenesulfonyl-(S)-proline (53 mg, 0.20 mmol) was dissolved in acetonitrile (5 mL). N,N-
diisopropylethylamine (70 µL, 0.40 mmol) and HATU (76 mg, 0.20 mmol) were subsequently added, 
and the solution was stirred for 10 min at room temperature. The crude amine (ethyl (R)-2-amino-2-
ethylpent-4-enoate, 34 mg, 0.20 mmol) was then added and the reaction was stirred at room 
temperature for 12 h. The solvents were evaporated under reduced pressure and the crude material 
was purified by column chromatography (Silica gel, 4 g, cHex:EtOAc 20 to 30% EtOAc) to provide 
42 mg of 2.139 (50%) as colorless oil.  
1H NMR (300 MHz, CDCl3) δ ppm 7.79 – 7.69 (m, 2 H), 7.65 (s, 1 H), 7.38 – 7.27 (m, 2 H), 5.83 – 
5.64 (m, 1 H), 5.13 – 5.08 (m, 1 H), 5.08 – 5.02 (m, 1 H), 4.22 (qd, J = 7.1, 1.6 Hz, 2 H), 4.07 – 4.02 
(m, 1 H), 3.59 – 3.49 (m, 1 H), 3.23 – 3.13 (m, 1 H), 3.15 – 3.05 (m, 1 H), 2.50 (dd, J = 13.9, 8.2 Hz, 
1 H), 2.43 (s, 3 H), 2.42 – 2.31 (m, 1 H), 2.13 – 2.05 (m, 1 H), 1.91 (dt, J = 14.1, 7.3 Hz, 1 H), 1.86 – 
1.54 (m, 3 H, 3-H), 1.28 (t, J = 7.1 Hz, 3 H), 0.76 (t, J = 7.4 Hz, 3 H).  
13C NMR (75 MHz, CDCl3) δ ppm 172.9, 170.3, 144.3, 133.3, 132.6, 130.0, 128.0, 118.9, 64.8, 62.9, 
61.8, 49.8, 39.5, 30.4, 27.7, 24.6, 21.7, 14.4, 8.4.  




Ethyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-ethyl-5-hydroxypentanoate (SI-10) 
(S)-2.138 (484 mg, 1.23 mmol) was dissolved in tetrahydrofuran (20 mL) and 9-
Borabicyclo[3.3.1]nonane (9-BBN, 0.5 M in THF, 6 mL, 3 mmol) was added. The reaction was stirred 
for 20 h at room temperature, then sodium hydroxide aq. sol. (2 M, 5.5 mL, 11.1 mmol) and hydrogen 
peroxide aq. sol. (35%, 4.3 mL, 44.3 mmol) were added and the reaction was stirred for further 45 
min. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2x). The combined 
organic layers were washed with brine (1x), dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification of the crude by column chromatography (Silica gel, 40 g, cHex:EtOAc, 
10 to 50% EtOAc) yielded SI-10 (379 mg, 75% yield) as colorless oil.  
1H NMR (600 MHz, DMSO-d6) δ ppm 7.89 (d, J = 7.6 Hz, 2 H), 7.71 (br d, J=7.4 Hz, 2 H), 7.45 – 
7.37 (m, 3 H), 7.35 – 7.29 (m, 2 H), 4.26 (br d, J = 7.2 Hz, 2 H), 4.23 – 4.17 (m, 1 H), 4.05 (q, J = 7.0 
Hz, 2 H), 3.34 (br t, J = 6.0 Hz, 5 H), 1.77 – 1.70 (m, 1 H), 1.88 – 1.66 (m, 3 H), 1.29 – 1.21 (m, 1 H), 
1.30 – 1.20 (m, 1 H), 1.12 (t, J = 7.1 Hz, 3 H), 0.71 (br t, J = 7.4 Hz, 3 H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 173.0, 154.4, 143.8, 140.7, 127.6, 127.0, 125.2, 120.1, 65.2, 
60.8, 60.2, 46.7, 29.4, 26.5, 26.0, 14.8, 7.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C24H29NO5: 412.2046, found 412.2119. 
 
The procedure above was applied for the synthesis of (R)-SI-10, which was performed by BENJAMIN 






Triphenylphosphine (546 mg, 2.08 mmol) was dissolved in tetrahydrofuran (6 mL), the solution was 
cooled to 0° C and diisopropyl azodicarboxylate (409 µL, 2.08 mmol) was added dropwise. After 10 
min the Mitsunobu betaine formed as a precipitate and (S)-SI-10 (428 mg, 1.04 mmol) and thioacetic 
acid (149 µL, 2.08 mmol) dissolved in tetrahydrofuran (6 mL) were added. The mixture was stirred 
for 45 min at 0 °C, then the cooling was removed and the reaction was stirred for 1 additional hour. 
The solvent was evaporated under reduced pressure and the residue was purified by column 
chromatography (Silica gel, 40 g, cHex:EtOAc, 0 to 20% EtOAc) to obtain the title product (S)-SI-11 
(380 mg, 78% yield) as colorless oil.  
1H NMR (600 MHz, CDCl3) δ ppm 7.77 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.42 – 7.38 (m, 
2H), 7.34 – 7.30 (m, 2H), 5.83 (s, 1H), 4.43 – 4.34 (m, 2H), 4.24 (dq, J = 19.1, 6.3 Hz, 3H), 2.85 – 2.76 
(m, 2H), 2.42 – 2.31 (m, 2H), 2.28 (s, 3H), 1.79 – 1.73 (m, 1H), 1.33 – 1.25 (m, 5H), 0.74 (t, J = 7.4 
Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ ppm 195.7, 173.7, 168.8, 154.0, 144.1, 141.5, 127.8, 127.2, 125.2, 120.1, 
72.5, 66.3, 64.5, 62.1, 47.5, 34.6, 30.7, 29.0, 28.7, 27.1, 25.1, 24.6, 21.7, 14.4, 8.4.  
HR-MS (ESI) m/z [M+H]+ calcd. for C26H31NO5S: 470.1923, found 470.1996. 
  
The procedure above was applied for the synthesis of (R)-SI-11, which was performed by BENJAMIN 






The synthesis of both enantiomers of 2.140 was performed by BENJAMIN BRENNECKE at FMP, Berlin. 
 
(S)-SI-11 (100 mg, 0.21 mmol) and PEG2 linker 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 
4-methylbenzenesulfonate 2.125 (155 mg, 0.38 mmol) were dissolved in absolute ethanol (8 mL) and 
the solution was deoxygenated by a stream of argon. After, the reaction mixture was cooled to –25 °C 
and potassium iodide (11 mg, 64 µmol) and sodium ethanolate (44 mg, 0.64 mmol) were added. The 
solution was slowly allowed to warm up to room temperature and stirred for 2 h at the same 
temperature. Water (8 mL) was added and the aqueous phase was extracted with ethyl acetate (3x). 
The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude material was purified by column chromatography (Silica gel, 10 g, DCM:MeOH, 
3 to 5% MeOH, KMnO4 stain) to yield the title product (S)-2.140 (41 mg, 44%) as colorless oil.  
1H NMR (600 MHz, DMSO-d6) δ ppm 6.74 (m, 1 H), 4.09 (q, J = 7.1, 2 H), 3.55 – 3.45 (m, 6 H), 
3.37 (t, J = 6.1 Hz, 2 H), 3.07 – 3.03 (m, 2 H), 2.62 – 2.61 (m, 2 H), 2.49 – 2.44 (m, 2 H), 1.71 – 1.41 
(m, 5 H), 1.37 (s, 9 H), 1.35 - 1.22 (m, 1 H), 1.18 (t, J = 7.1 Hz, 3 H), 0.77 (t, J = 7.5 Hz, 3 H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 175.8, 155.6, 77.6, 70.2, 69.5, 69.1, 60.7, 60.2, 39.8, 38.2, 32.3, 
31.7, 30.4, 28.2, 23.8, 14.2, 8.1.  
HR-MS (ESI) m/z [M+H]+ calcd. for C20H41N2O6S: 437.2680, found: 437.2690. 
[α]20d = –1.08°(c = 1.0, MeOH). 
 
The same procedure was applied for the synthesis of (R)-2.140, [α]20d = +1.90°(c = 1.0, MeOH). 
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5.2.6. Synthesis of Pyrazine-based NBD-Labeled Probes 
Ethyl 2-(6-bromo-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxamido)-2-ethylbutanoate 
(2.60) 
To a solution of 6-Bromo-5-(3,3-difluoro-azetidin-1-yl)-pyrazine-2-carboxylic acid 2.41 (300 mg, 1.02 
mmol) in dichloromethane (10 mL) at room temperature were added N,N-diisopropylethylamine 
(0.82 mL, 4.76 mmol) and DMTMM (207.5 mg, 0.75 mmol). The mixture was stirred for 1 h at room 
temperature before ethyl 2-amino-2-ethylbutanoate hydrochloride 2.61 (133.1 mg, 0.68 mmol) in 
dichloromethane (2 mL) was added. The mixture was stirred at room temperature for 40 h. Afterwards, 
the reaction was diluted with dichloromethane (8 mL) and washed with hydrochloric acid aq. sol. (0.2 
M, 3x) and brine (1x). The organic layer was dried over MgSO4, and concentrated under reduced 
pressure. Purification by column chromatography (Silica gel, 25 g, cHex:EtOAc, 25% EtOAc) 
afforded 272 mg (61%) of compound 2.60 as a white solid. 
1H NMR (300 MHz, CDCl3) δ ppm 8.78 (s, 1H), 8.29 (s, 1H), 4.70 (t, J = 12.0 Hz, 4H), 4.29 (q, J = 
7.1 Hz, 2H), 2.55 (dq, J = 14.8, 7.5 Hz, 2H), 1.90 (dq, J = 14.5, 7.4 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H), 
0.77 (t, J = 7.4 Hz, 6H). 
The analytical data are in accordance with those reported in the literature.[170] 
 
2-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethan-1-ol (SI-12) 
To a solution of ethanolamine (36 µL, 0.60 mmol) and cesium carbonate (353 mg, 1.00 mmol) in 
dimethylformamide (5 mL) at room temperature 7-chloro-4-nitrobenzofurazan (NBD-Cl, 100 mg, 
0.50 mmol) was added. The reaction mixture was stirred at room temperature for 20 h, and 
concentrated under reduced pressure. The residue was diluted in a mixture of acetonitrile and water 
(1:1) and purified by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% 
ACN). The fractions containing the product were combined and lyophilized to afford 60 mg (54%) 
of compound SI-12 as an orange solid.  
 
156 
1H NMR (300 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 6.45 (d, J = 9.0 Hz, 
1H), 4.95 (t, J = 5.0 Hz, 1H), 3.69 (q, J = 5.5 Hz, 2H), 3.55 (bs, 2H).  




To a solution of SI-12 (31 mg, 0.14 mmol) in dimethyl sulfoxide (1 mL) was added potassium 
hydroxide (8 mg, 0.14 mmol) at room temperature. After 30 min, a solution of 2.60 (50 mg, 0.12 
mmol) in dimethyl sulfoxide (1 mL) was added to the mixture. The reaction was stirred at room 
temperature for additional 20 h, and quenched with water (3 mL). The reaction mixture was 
concentrated under reduced pressure, taken up in a mixture of acetonitrile and water (1:1) and purified 
by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). The 
fractions containing product were combined and lyophilized to yield compound 2.47 as an orange 
solid in 29% yield (20 mg).  
1H NMR (300 MHz, DMSO-d6) δ ppm 9.58 (t, J = 5.8 Hz, 1H), 8.53 (d, J = 8.8 Hz, 1H), 8.24 (s, 1H), 
8.13 (s, 1H), 6.57 (d, J = 8.9 Hz, 1H), 4.73 – 4.54 (m, 6H), 4.19 (q, J = 7.1 Hz, 2H), 4.00 (bs, 2H), 2.32 
(dq, J = 14.6, 7.2 Hz, 2H), 1.80 (dq, J = 14.5, 7.3 Hz, 2H), 1.21 (t, J = 7.0 Hz, 3H), 0.65 (t, J = 7.4 Hz, 
6H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.7, 158.6, 158.1, 147.7, 147.4, 145.0, 137.9, 133.5, 
130.5, 117.2, 99.6, 76.6, 64.6, 62.8, 61.4, 42.3, 27.4, 14.1, 8.2.  




General procedure for PEG linker attachment on pyrazine probe precursor 2.60  
To a solution of N-Boc PEG1-5 or hydroxyhexyl linker (1.2 equiv.) in dimethyl sulfoxide (2.5 mL) 
was added potassium hydroxide (2.0 equiv.) at room temperature. After 30 min, a solution of 2.60 (1.0 
equiv.) in dimethyl sulfoxide (1 mL) was added to the mixture. The reaction was stirred at room 
temperature for additional 20 h, after which time water (3 mL) was added. The reaction mixture was 
concentrated under reduced pressure and purified by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 20 to 50% EtOAc). 
Ethyl 2-(6-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)-5-(3,3-difluoroazetidin-1-yl)-
pyrazine-2-carboxamido)-2-ethylbutanoate (2.67)  
Following the general procedure above, 2.67 was obtained in 30% yield (39 mg) as a light yellow solid 
starting from linker tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate (58 mg, 0.28 mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 8.22 (s, 1H), 6.78 (bs, 1H), 4.62 (t, J = 12.5 Hz, 
4H), 4.46 (dd, J = 5.8, 3.4 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.89 – 3.74 (m, 2H), 3.48 (t, J = 5.9 Hz, 
2H), 3.09 (q, J = 5.8 Hz, 2H), 2.34 (dq, J = 14.8, 7.4 Hz, 2H), 1.83 (dq, J = 14.4, 7.3 Hz, 2H), 1.35 (s, 
9H), 1.22 (t, J = 7.1 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H). 
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.8, 156.6, 148.8, 147.5, 133.3, 130.7, 117.1, 77.6, 69.1, 
67.9, 65.5, 64.6, 62.8, 61.5, 28.2, 27.4, 26.4, 14.1, 8.2.  





yl)oxy)-pyrazine-2-carboxamido)-2-ethylbutanoate (2.68)  
Following the general procedure above, 2.68 was obtained in 26% yield (36 mg) as a light yellow solid 
starting from linker tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate (70 mg, 0.28 mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 8.22 (s, 1H), 6.73 (bs, 1H), 4.62 (t, J = 12.5 Hz, 
4H), 4.52 – 4.41 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.89 – 3.78 (m, 2H), 3.60 (dd, J = 6.1, 3.4 Hz, 2H), 
3.52 (dd, J = 6.0, 3.4 Hz, 2H), 3.39 – 3.37 (m, 2H), 3.05 (q, J = 6.0 Hz, 2H), 2.34 (dq, J = 14.9, 7.5 Hz, 
2H), 1.83 (dq, J = 14.4, 7.2 Hz, 2H), 1.34 (s, 9H), 1.22 (t, J = 7.1 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.8, 155.6, 147.5, 133.3, 130.7, 77.6, 76.6, 69.7, 69.5, 
69.2, 65.3, 64.6, 62.9, 61.5, 28.2, 27.4, 14.1, 8.2.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C27H43F2N5O8: 626.2972, found 626.2985. 
 
Ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-((2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadec-
an-16-yl)oxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.69)  
Following the general procedure above, 2.69 was obtained in 22% yield (49 mg) as a light yellow solid 
starting from linker tert-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl) carbamate (121 mg, 0.41 
mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 8.22 (s, 1H), 6.74 (bs, 1H), 4.62 (t, J = 12.6 Hz, 
4H), 4.51 – 4.45 (m, 2H), 4.22 (q, J = 7.0 Hz, 2H), 3.86 – 3.78 (m, 2H), 3.64 – 3.44 (m, 9H), 3.36 (d, J 
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= 6.1 Hz, 2H), 3.04 (q, J = 6.0 Hz, 2H), 2.34 (dq, J = 14.9, 7.5 Hz, 2H), 1.83 (dq, J = 14.4, 7.1 Hz, 
2H), 1.35 (s, 9H), 1.22 (t, J = 7.1 Hz, 4H), 0.70 (t, J = 7.3 Hz, 7H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.8, 155.6, 147.5, 133.3, 130.7, 77.6, 76.5, 69.8, 69.7, 
69.4, 69.2, 68.1, 65.3, 64.6, 61.4, 28.2, 27.4, 14.1, 8.2.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C29H47F2N5O9: 670.3234, found 670.3252. 
 
Ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-((2,2-dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-aza-
docosan-22-yl)oxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.71)  
Following the general procedure above, 2.71 was obtained in 15% yield (51 mg) as a light yellow solid 
starting from linker tert-butyl (17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl) carbamate (210 mg, 0.55 
mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 8.22 (s, 1H), 6.74 (bs, 1H), 4.62 (t, J = 12.5 Hz, 
4H), 4.48 (dd, J = 5.8, 3.6 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.83 (dd, J = 5.7, 3.6 Hz, 2H), 3.64 – 3.43 
(m, 17H), 3.40 – 3.30 (m, 3H), 3.04 (q, J = 6.0 Hz, 2H), 2.34 (dq, J = 14.9, 7.5 Hz, 2H), 1.83 (dq, J = 
14.4, 7.3 Hz, 2H), 1.36 (s, 9H), 1.22 (t, J = 7.1 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.8, 155.6, 147.8, 147.5, 133.3, 130.7, 78.0, 69.8, 69.8, 
69.8, 69.5, 69.1, 68.1, 65.3, 64.6, 62.8, 61.4, 28.2, 27.4, 14.1, 8.2.  





2-car-boxamido)-2-ethylbutanoate (2.72)  
Following the general procedure above, 2.72 was obtained in 11% yield (14 mg) as light yellow solid 
starting from linker tert-butyl (6-hydroxyhexyl)carbamate (100 mg, 0.23 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 8.43 (s, 1H), 8.40 (s, 1H), 4.58 (t, J = 12.1 Hz, 4H), 4.41 (t, J = 
6.3 Hz, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.13 (q, J = 6.5 Hz, 2H), 2.62 (dq, J = 14.8, 7.4 Hz, 2H), 1.93 – 
1.80 (m, 4H), 1.66 (bs, 1H), 1.56 – 1.38 (m, 16H), 1.32 (t, J = 7.1 Hz, 3H), 0.76 (t, J = 7.4 Hz, 6H).  
13C NMR (75 MHz, CDCl3) δ ppm 174.3, 162.8, 156.1, 147.8, 147.1, 147.0, 134.1, 131.7, 120.1, 116.5, 
112.9, 79.2, 66.7, 66.4, 63.7, 63.4, 63.0, 61.8, 40.6, 30.2, 28.8, 28.6, 28.5, 26.6, 26.1, 14.4, 8.8.  
HR-MS (ESI) m/z [M+H]+ calcd. for C27H43F2N5O6: 594.3074, found 594.3091. 
 
General Boc-deprotection and NBD-labeling procedure 
Trifluoroacetic acid (0.25 mL) was added dropwise to a stirring solution of the corresponding N-Boc-
protected compound 2.67 to 2.72 (1.0 equiv.) in dichloromethane (2.25 mL) at 0 °C. The reaction 
mixture was stirred at room temperature for 2 h. Afterwards, the mixture was concentrated under 
reduced pressure, and the residue re-suspended in ethyl acetate (5 mL). The solvent was removed 
under reduced pressure. This process was repeated 3 times to remove trifluoroacetic acid traces. The 
removal of the tert-butyloxycarbonyl group was quantitative as observed by TLC (50% EtOAc in 
cHex). Free amine intermediates 2.54 to 2.59 were obtained as the corresponding trifluoroacetic acid 
salts, without the need of further purification steps. 
To a solution of amine intermediates 2.54 to 2.59 (1.0 equiv.) and cesium carbonate (5.0 equiv.) in 
dimethylformamide (2 mL) at room temperature 7-chloro-4-nitrobenzofurazan (NBD-Cl, 1.0 equiv.) 
was added. The reaction was stirred at room temperature for 24 h. The reaction mixture was 
concentrated under reduced pressure, and the obtained residue was diluted in a mixture of acetonitrile 
and water (1:1) and purified by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 
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ethoxy)ethoxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.48)  
Following the general procedure above, 2.48 was obtained in 17% yield (2 mg) as a dark yellow solid 
starting from 2.67 (27 mg, 0.05 mmol).  
1H NMR (600 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.41 (d, J = 8.9 Hz, 1H), 8.17 (d, J = 2.3 Hz, 
2H), 6.46 (d, J = 9.0 Hz, 1H), 4.55 – 4.41 (m, 6H), 4.21 (q, J = 7.1 Hz, 2H), 3.90 – 3.85 (m, 2H), 3.82 
(t, J = 5.2 Hz, 2H), 2.34 (dq, J = 14.8, 7.4 Hz, 2H), 1.83 (dq, J = 14.5, 7.3 Hz, 2H), 1.22 (t, J = 7.1 Hz, 
3H), 0.70 (t, J = 7.4 Hz, 6H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 173.1, 161.7, 147.4, 147.3, 137.6, 133.2, 130.5, 116.9, 99.4, 
65.3, 64.6, 62.6, 61.4, 43.5, 27.4, 14.0, 8.2.  





ino)ethoxy)ethoxy)ethoxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.49)  
Following the general procedure above, 2.49 was obtained in 26% yield (4 mg) as a dark yellow solid 
starting from 2.68 (29 mg, 0.05 mmol).  
1H NMR (600 MHz, DMSO-d6) δ ppm 9.41 (s, 1H), 8.54 – 8.42 (m, 1H), 8.25 – 8.16 (m, 2H), 6.46 
(d, J = 8.9 Hz, 1H), 4.57 (t, J = 12.4 Hz, 4H), 4.46 – 4.41 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.84 – 
3.79 (m, 2H), 3.73 (t, J = 5.4 Hz, 2H), 3.68 – 3.59 (m, 6H), 2.34 (dt, J = 14.9, 7.4 Hz, 2H), 1.84 (dq, J 
= 14.5, 7.3 Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H), 0.71 (t, J = 7.4 Hz, 6H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 173.1, 161.7, 147.6, 147.3, 137.8, 133.2, 130.7, 117.1, 99.4, 
69.9, 69.6, 68.1, 67.9, 64.6, 62.7, 61.4, 43.3, 27.4, 14.1, 8.2.  
HR-MS (ESI) m/z [M+H]+ calcd. for C28H36F2N8O9: 668.2675, found 668.2688. 
 
Ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-(2-(2-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)am-
ino)ethoxy)ethoxy)ethoxy)ethoxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.50)  
Following the general procedure above, 2.50 was obtained in 2% yield (1 mg) as a dark yellow solid 
starting from 2.69 (39 mg, 0.06 mmol).  
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1H NMR (600 MHz, DMSO-d6) δ ppm 9.41 (s, 1H), 8.54 – 8.45 (m, 1H), 8.20 (d, J = 14.6 Hz, 1H), 
6.46 (d, J = 9.0 Hz, 1H), 4.58 (t, J = 12.4 Hz, 4H), 4.47 – 4.42 (m, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.81 
– 3.76 (m, 2H), 3.70 (t, J = 5.3 Hz, 2H), 3.64 (s, 2H), 3.57 – 3.53 (m, 4H), 3.53 – 3.48 (m, 5H), 2.33 
(dt, J = 14.9, 7.4 Hz, 2H), 1.83 (dq, J = 14.5, 7.3 Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H), 0.69 (t, J = 7.4 Hz, 
6H). 
13C NMR (151 MHz, DMSO-d6) δ ppm 173.1, 161.8, 147.7, 147.4, 137.8, 133.2, 130.7, 118.9, 117.1, 
115.3, 99.5, 69.8, 69.8, 69.7, 69.7, 68.1, 65.3, 64.6, 62.8, 61.4, 27.4, 14.1, 8.2.  
HR-MS (ESI) m/z [M+H]+ calcd. for C30H40F2N8O10: 711.2908, found 711.2919. 
 
Ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-((14-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)-3, 
6,9,12-tetraoxatetradecyl)oxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.51)  
Following the “General procedure for PEG linker attachment on pyrazine probe precursor 2.60” 
described on page 160, ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-((2,2-dimethyl-4-oxo-3,8,11,14,17-
pentaoxa-5-azanon-adecan-19-yl)oxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.70) was obtained 
in 5% yield (17 mg) as a light yellow solid starting from linker tert-butyl (14-hydroxy-3,6,9,12-
tetraoxatetradecyl)carbamate (186 mg, 0.55 mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 8.22 (s, 1H), 6.74 (bs, 1H), 4.62 (t, J = 12.6 Hz, 
4H), 4.52 – 4.44 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.82 (dd, J = 5.8, 3.6 Hz, 2H), 3.64 – 3.43 (m, 12H), 
3.36 (d, J = 6.2 Hz, 2H), 3.04 (q, J = 6.1 Hz, 2H), 2.34 (dq, J = 15.3, 8.0, 7.5 Hz, 2H), 1.83 (dq, J = 
14.5, 7.2 Hz, 2H), 1.36 (s, 9H), 1.22 (t, J = 7.0 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H).  




Boc-protected 2.70 (12 mg, 0.02 mmol) was applied as starting material following the general 
procedure described above to give NBD-labeled 2.51 20% yield (3 mg) as a dark yellow solid.  
1H NMR (600 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.21 (d, J = 15.3 Hz, 
2H), 6.47 (d, J = 9.0 Hz, 1H), 4.60 (t, J = 12.4 Hz, 4H), 4.48 – 4.44 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 
3.82 – 3.79 (m, 2H), 3.71 (t, J = 5.3 Hz, 2H), 3.65 (s, 2H), 3.58 (dd, J = 5.9, 3.5 Hz, 2H), 3.55 (dd, J = 
5.9, 3.4 Hz, 2H), 3.52 – 3.48 (m, 5H), 2.34 (dq, J = 14.8, 7.5 Hz, 2H), 1.84 (dq, J = 14.5, 7.4 Hz, 2H), 
1.22 (t, J = 7.1 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 173.1, 161.8, 147.7, 147.4, 137.8, 133.2, 130.7, 117.1, 99.5, 
69.8, 68.8, 69.7, 69.7, 68.1, 68.0, 65.3, 64.6, 62.8, 61.4, 43.4, 27.4, 14.1, 8.2.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C32H44F2N8O11: 777.2990, found 777.3020. 
 
Ethyl 2-(5-(3,3-difluoroazetidin-1-yl)-6-((17-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)-3, 
6,9,12,15-pentaoxaheptadecyl)oxy)pyrazine-2-carboxamido)-2-ethylbutanoate (2.52)  
Following the general procedure above, 2.52 was obtained in 42% yield (20 mg) as a dark yellow solid 
starting from 2.71 (46 mg, 0.06 mmol).  
1H NMR (600 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.22 (d, J = 15.0 Hz, 
1H), 6.48 (d, J = 8.9 Hz, 1H), 4.61 (t, J = 12.4 Hz, 4H), 4.49 – 4.45 (m, 2H), 4.22 (q, J = 7.1 Hz, 2H), 
3.86 – 3.80 (m, 2H), 3.74 – 3.41 (m, 20H), 2.34 (dq, J = 14.9, 7.5 Hz, 2H), 1.84 (dq, J = 14.5, 7.3 Hz, 
2H), 1.22 (t, J = 7.1 Hz, 3H), 0.70 (t, J = 7.4 Hz, 6H). 
13C NMR (151 MHz, DMSO-d6) δ ppm 173.1, 161.8, 158.4, 158.2, 147.7, 147.4, 137.8, 133.2, 130.7, 
118.9, 117.1, 99.5, 69.8, 69.8, 69.8, 69.7, 68.1, 68.0, 65.3, 64.6, 62.8, 61.4, 43.4, 27.4, 14.1, 8.2.  





yl)oxy)-pyrazine-2-carboxamido)-2-ethylbutanoate (2.53)  
Following the general procedure above, 2.53 was obtained in 35% yield (4 mg) as a dark yellow solid 
starting from 2.72 (10 mg, 0.02 mmol).  
1H NMR (300 MHz, DMSO-d6) δ ppm 9.54 (t, J = 5.8 Hz, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.22 (d, J = 
5.6 Hz, 1H), 6.41 (d, J = 9.0 Hz, 1H), 4.60 (t, J = 12.5 Hz, 4H), 4.37 (t, J = 6.4 Hz, 2H), 4.20 (q, J = 
7.1 Hz, 2H), 3.48 (q, J = 7.0 Hz, 2H), 2.36 (dq, J = 14.7, 7.4 Hz, 2H), 1.81 (dq, J = 14.1, 7.2 Hz, 4H), 
1.75 – 1.70 (m, 2H), 1.51 – 1.44 (m, 4H), 1.21 (t, J = 7.1 Hz, 3H), 0.68 (t, J = 7.4 Hz, 6H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 173.1, 161.8, 147.6, 145.2, 144.4, 144.1, 137.9, 132.9, 130.7, 
121.5, 99.0, 66.2, 64.7, 62.8, 61.4, 43.3, 27.9, 27.5, 26.1, 25.3, 14.0, 8.2.  




5.2.7. Synthesis of SAR Compounds 
General peptide coupling procedure 
To 1.0 equiv. of 6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxylic acid (2.37) 
or 5-cyclopropyl-6-(4-fluorobenzyl)picolinic acid (2.42) in dichloromethane (2 mL) at room 
temperature were added N,N-diisopropylethylamine (5.0 equiv.) and 4-(4,6-Dimethoxy-1,3,5-triazin-
2-yl)-4-methylmorpholinium chloride (DMTMM) or Bis(2-oxo-3-oxazolidinyl)phosphinic chloride 
(BOP-Cl) (1.1 equiv.). The mixture was stirred at room temperature for 1 h before the desired amino 
ester (1.0 equiv.) in dichloromethane (1 mL) was added. The mixture was stirred at room temperature 
for 24 h, diluted with dichloromethane (5 mL) and washed with hydrochloric acid aq. sol. (0.2 M, 3x) 
and brine (1x). The organic layer was dried over MgSO4 and concentrated under reduced pressure. 
Purification was performed either by reversed-phase preparative HPLC or MPLC methodologies as 
described for each example. For reversed-phase preparative HPLC purifications, the crude residues 
were dissolved in acetonitrile and water (1:1) mixture. Fractions containing the product were 
combined and either lyophilized (HPLC) or concentrated under reduced pressure (MPLC) to yield the 
desired non-labeled compound. 
 
Ethyl 2-(6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxamido)-2-
ethylpent-4-enoate (2.79)  
Following the general procedure above, 2.79 was obtained in 72% yield (166 mg) as a light yellow oil 
starting from pyrazine carboxylic acid 2.37 (150 mg, 0.53 mmol) and ethyl 2-aminopent-4-enoate 2.78 
(91 mg, 0.53 mmol). Purification was performed by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 30% EtOAc).  
1H NMR (300 MHz, CDCl3) δ ppm 8.42 (s, 1H), 8.31 (s, 1H), 5.68 – 5.54 (m, 1H), 5.08 – 4.98 (m, 
2H), 4.61 (t, J = 12.1 Hz, 4H), 4.25 (t, J = 7.3 Hz, 4H), 3.34 (dd, J = 13.9, 7.0 Hz, 1H), 2.67 – 2.54 (m, 
2H), 1.97 – 1.85 (m, 1H), 1.36 – 1.22 (m, 4H), 0.77 (t, J = 7.4 Hz, 3H), 0.69 – 0.62 (m, 2H), 0.43 – 
0.37 (m, 2H).  
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13C NMR (75 MHz, CDCl3) δ ppm 173.6, 162.0, 147.8, 147.2, 134.2, 132.8, 131.4, 118.7, 116.5, 71.4, 
65.4, 63.4 (t, 3JCF = 27.7 Hz), 61.8, 39.7, 28.4, 14.5, 9.9, 8.6, 3.6.  
HR-MS (ESI) m/z [M+H]+ calcd. for C21H28F2N4O4 : 439.2112, found 439.2184. 
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethylpent-4-enoate (2.80)  
Following the general procedure above, 2.80 was obtained in 56% yield (239 mg) as a light yellow oil 
starting from picolinic acid 2.42 (300 mg, 1.01 mmol) and ethyl 2-aminopent-4-enoate 2.78 (173 mg, 
1.01 mmol). Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 
10% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.95 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 
7.31 – 7.20 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 5.72 – 5.58 (m, 1H), 5.16 – 4.96 (m, 2H), 4.43 – 4.22 (m, 
4H), 3.30 (dd, J = 14.0, 6.9 Hz, 1H), 2.69 – 2.49 (m, 2H), 2.00 – 1.88 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H), 
1.05 – 0.96 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H), 0.83 – 0.65 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ ppm 173.3, 1643.6, 163.2, 160.0, 158.5, 146.9, 139.9, 134.8, 134.8, 134.8, 
132.8, 130.6, 130.5, 119.8, 118.6, 115.3, 115.1, 65.0, 61.8, 40.8, 39.4, 28.3, 14.4, 12.8, 8.5, 7.9.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C25H29FN2O3: 447.2055, found 447.2083. 
 
Ethyl N-(6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carbonyl)-(S)-
methyl-(L)-cysteinate (2.81)  
Following the general procedure above, 2.81 was obtained in 50% yield (39 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (51 mg, 0.18 mmol) and ethyl (S)-methyl-(L)-cysteinate 
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2.89 (30 mg, 0.18 mmol). Purification was performed by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 30% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.41 (s, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.95 (s, 1H), 4.95 (dt, J = 
7.9, 5.1 Hz, 1H), 4.65 (t, J = 12.0 Hz, 4H), 4.36 – 4.14 (m, 4H), 3.17 – 2.97 (m, 2H), 2.12 (s, 3H), 1.31 
(t, J = 7.1 Hz, 3H), 0.76 – 0.60 (m, 2H), 0.46 – 0.32 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 170.9, 164.2, 148.0, 147.1, 147.1, 147.0, 134.6, 129.9, 119.8, 116.2, 
71.9, 63.6 (t, 3JCF = 27.8 Hz), 62.1, 51.9, 36.3, 16.4, 14.2, 9.8, 3.6, 3.6.  
HR-MS (ESI) m/z [M+H]+ calcd. for C18H24F2N4O4S: 431.1559, found 431.1568.  




Following the general procedure above, 2.82 was obtained in 53% yield (80 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (97 mg, 0.34 mmol) and ethyl (L)-methioninate (60 mg, 
0.34 mmol). Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 
30% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 10.63 (s, 1H), 8.40 (s, 1H), 8.13 (d, J = 8.1 Hz, 1H), 4.86 (td, J = 
7.4, 5.0 Hz, 1H), 4.69 (t, J = 12.0 Hz, 4H), 4.32 – 4.15 (m, 4H), 2.57 (t, J = 6.9 Hz, 2H), 2.36 – 2.12 
(m, 2H), 2.10 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H), 0.75 – 0.62 (m, 2H), 0.39 (dt, J = 6.3, 4.7 Hz, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.8, 164.4, 159.3, 158.8, 148.0, 146.8, 146.7, 146.7, 134.1, 129.7, 
116.1, 133.2, 112.5, 72.1, 63.8 (t, 3JCF = 27.8 Hz), 62.0, 51.9, 31.7, 30.1, 15.6, 14.2, 9.7, 3.6, 3.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C19H26F2N4O4S: 445.1716, found 445.1736.  






Following the general procedure above, 2.83 was obtained in 85% yield (27 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (21 mg, 0.07 mmol) and ethyl (D)-methioninate (13 mg, 
0.07 mmol). Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 
30% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.43 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 4.85 (td, J = 7.5, 5.0 Hz, 
1H), 4.64 (t, J = 12.1 Hz, 4H), 4.30 – 4.16 (m, 4H), 2.64 – 2.52 (m, 2H), 2.33 – 2.22 (m, 1H), 2.17 – 
2.06 (m, 1H), 2.10 (s, 3H), 1.33 – 1.26 (m, 4H), 0.751 – 0.64 (m, 2H), 0.41 – 0.36 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 172.0, 164.2, 147.9, 147.2, 134.9, 130.3, 120.0, 116.4, 112.8, 71.7, 
63.5 (t, 3JCF = 27.8 Hz), 61.9, 51.7, 32.1, 30.2, 15.7, 14.3, 9.8, 3.6, 3.6.  
HR-MS (ESI) m/z [M+H]+ calcd. for C19H26F2N4O4S: 445.1716, found 445.1689.  
[α]20d = –0.09° (c = 1.0, CHCl3). 
 
Ethyl (L)-2-(6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxamido)-
3-(4-me-thoxyphenyl)propanoate (2.84)  
Following the general procedure above, 2.84 was obtained in 48% yield (47 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (57 mg, 0.20 mmol) and ethyl (L)-2-amino-3-(4-
methoxyphenyl)propanoate 2.90 (45 mg, 0.20 mmol). Purification was performed by column 
chromatography (Silica gel, 4 g, cHex:EtOAc, 30% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 9.44 (s, 1 H), 8.39 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.05 (d, J = 
8.5 Hz, 2H), 6.79 (d, J = 8.5 Hz, 2H), 4.96 (dt, J = 8.2, 5.6 Hz, 1H), 4.67 (t, J = 12.0 Hz, 4H), 4.21 (q, 
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J = 7.1 Hz, 2H), 4.06 (qd, J = 11.2, 7.3 Hz, 2H), 3.77 (s, 3H), 3.27 – 3.06 (m, 2H), 1.27 (t, J = 7.1 Hz, 
3H), 1.22 – 1.14 (m, 1H), 0.72 – 0.60 (m, 2H), 0.40 – 0.29 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.5, 164.1, 158.9, 147.9, 146.9, 146.8, 134.1, 130.5, 129.7, 127.6, 
116.1, 114.1, 112.5, 72.0, 63.8 (t, 3JCF = 27.8 Hz), 61.9, 55.3, 53.2, 37.1, 14.3, 9.7, 3.6, 3.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C24H28F2N4O5: 491.2101, found 491.2107.  
[α]20d = +0.49° (c = 1.0, CHCl3). 
 
Ethyl N-(5-cyclopropyl-6-(4-fluorobenzyl)picolinoyl)-(S)-methyl-(L)-cysteinate (2.85)  
Following the general procedure above, 2.85 was obtained in 36% yield (27 mg) as a colorless oil 
starting from picolinic acid 2.42 (49 mg, 0.18 mmol) and ethyl (S)-methyl-(L)-cysteinate 2.89 (30 mg, 
0.18 mmol). Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 
10% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.70 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 
8.0 Hz, 1H), 7.22 (dd, J = 8.4, 5.4 Hz, 2H), 6.97 (t, J = 8.6 Hz, 2H), 4.97 (dt, J = 8.3, 5.4 Hz, 1H), 4.36 
(s, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.05 (dd, J = 5.3, 2.6 Hz, 2H), 2.11 (s, 3H), 1.96 – 1.86 (m, 1H), 1.31 
(t, J = 7.1 Hz, 3H), 1.09 – 0.91 (m, 2H), 0.67 (t, J = 5.2 Hz, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 170.7, 164.2, 163.0, 159.8, 158.5, 145.7, 140.3, 134.5, 134.4, 130.4, 
130.3, 120.2, 115.2, 114.9, 61.7, 51.9, 40.6, 36.5, 16.2, 14.1, 12.6, 7.8.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C22H25FN2O3S: 439.14621, found 439.1478.  




Ethyl (5-cyclopropyl-6-(4-fluorobenzyl)picolinoyl)-(L)-methioninate (2.86)  
Following the general procedure above, 2.86 was obtained in 48% yield (70 mg) as a colorless oil 
starting from picolinic acid 2.42 (92 mg, 0.34 mmol) and ethyl (L)-methioninate (60 mg, 0.34 mmol). 
Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 10% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.56 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 
8.0 Hz, 1H), 7.21 (dd, J = 8.4, 5.4 Hz, 2H), 6.98 (t, J = 8.7 Hz, 2H), 4.86 (td, J = 7.9, 5.0 Hz, 1H), 4.36 
(s, 2H), 4.24 (q, J = 7.1 Hz, 2H), 2.55 (t, J = 7.6 Hz, 2H), 2.35 – 2.20 (m, 1H), 2.09 (s, 4H), 1.95 – 1.86 
(m, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.08 – 0.89 (m, 2H), 0.78 – 0.56 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.8, 164.5, 163.2, 159.9, 158.5, 145.8, 140.6, 134.6, 134.5, 130.5, 
130.4, 120.4, 115.4, 115.1, 61.7, 51.6, 40.7, 32.2, 30.1, 15.5, 14.2, 12.7, 8.0, 8.0.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C23H27FN2O3S: 453.1619, found 453.1619.  
[α]20d = +0.04° (c = 1.0, CHCl3). 
 
Ethyl (5-cyclopropyl-6-(4-fluorobenzyl)picolinoyl)-(D)-methioninate (2.87)  
Following the general procedure above, 2.87 was obtained in 41% yield (12 mg) as a colorless oil 
starting from picolinic acid 2.42 (20 mg, 0.07 mmol) and ethyl (D)-methioninate (13 mg, 0.07 mmol). 
Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 10% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.52 (d, J = 8.5 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 
8.0 Hz, 1H), 7.25 – 7.15 (m, 2H), 7.03 – 6.93 (m, 2H), 4.86 (td, J = 7.9, 5.0 Hz, 1H), 4.36 (s, 2H), 4.24 
(q, J = 7.1 Hz, 2H), 2.54 (t, J = 8.0 Hz, 2H), 2.32 – 2.20 (m, 1H), 2.14 – 2.02 (m, 1H), 2.09 (s, 4H), 
1.94 – 1.85 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.03 – 0.97 (m, 2H), 0.69 – 0.64 (m, 2H).  
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13C NMR (75 MHz, CDCl3) δ ppm 171.9, 164.5, 163.2, 160.0, 158.5, 145.9, 140.6, 134.7, 130.6, 130.5, 
120.5, 115.4, 115.2, 61.7, 51.7, 40.8, 32.3, 30.2, 15.6, 14.3, 12.8, 8.0, 8.0.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C23H27FN2O3S: 445.1619, found 453.1594.  
[α]20d = –0.06° (c = 1.0, CHCl3). 
 
Ethyl (L)-2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-3-(4-methoxyphenyl) propan-
oate (2.88)  
Following the general procedure above, 2.88 was obtained in 38% yield (37 mg) as a colorless oil 
starting from picolinic acid 2.42 (54 mg, 0.20 mmol) and ethyl (L)-2-amino-3-(4-
methoxyphenyl)propanoate 2.90 (45 mg, 0.20 mmol). Purification was performed by column 
chromatography (Silica gel, 4 g, cHex:EtOAc, 10% EtOAc). 
1H NMR (300 MHz, CDCl3) δ ppm 8.58 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 
7.9 Hz, 1H), 7.20 – 7.12 (m, 2H), 7.11 – 7.04 (m, 2H), 7.01 – 6.91 (m, 2H), 6.88 – 6.71 (m, 2H), 4.97 
(dt, J = 8.3, 6.0 Hz, 1H), 4.33 (d, J = 5.0 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 3.33 – 3.03 
(m, 2H), 2.02 – 1.81 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.10 – 0.95 (m, 2H), 0.68 (d, J = 3.8 Hz, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.3, 164.7, 163.2, 160.0, 158.8, 158.6, 145.4, 140.9, 134.8, 134.4, 
130.5, 130.4, 127.9, 120.6, 115.4, 115.1, 114.0, 61.7, 55.3, 53.7, 40.7, 37.3, 14.3, 12.8, 8.1, 8.1.  
HR-MS (ESI) m/z [M+H]+ calcd. for C28H29FN2O4: 477.2184, found 477.2188.  





4-eno-ateenoate (2.94)  
Following the general procedure above, 2.94 was obtained in 55% yield (157 mg) as a light yellow oil 
starting from pyrazine carboxylic acid 2.37 (200 mg, 0.70 mmol) and ethyl 2-aminopent-4-enoate 2.91 
(126 mg, 0.70 mmol). Purification was performed by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 30% EtOAc).  
1H NMR (300 MHz, CDCl3) δ ppm 8.43 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 5.82 – 5.68 (m, 1H), 5.18 
– 5.11 (m, 2H), 4.82 – 4.75 (m, 1H), 4.61 (t, J = 12.1 Hz, 4H), 4.28 – 4.15 (m, 4H), 2.71 – 2.58 (m, 
2H), 1.29 (t, J = 7.1 Hz, 4H), 0.69 – 0.63 (m, 2H), 0.39 – 0.34 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.9, 163.7, 147.8, 147.2, 134.9, 132.6, 130.6, 119.2, 116.5, 71.5, 
63.4 (t, 3JCF = 27.8 Hz), 61.6, 51.4, 36.9, 14.4, 9.9, 3.6, 3.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C19H24F2N4O4: 411.1838, found 411.1832.  
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)pent-4-enoate (2.95)  
Following the general procedure above, 2.95 was obtained in 28% yield (83 mg) as a light yellow oil 
starting from picolinic acid 2.42 (200 mg, 0.74 mmol) and ethyl 2-aminopent-4-enoate 2.91 (133 mg, 
0.74 mmol). Purification was performed by column chromatography (Silica gel, 4 g, cHex:EtOAc, 
10% EtOAc).  
1H NMR (300 MHz, CDCl3) δ ppm 8.46 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 
8.0 Hz, 1H), 7.24 – 7.15 (m, 2H), 7.03 – 6.91 (m, 2H), 5.78 – 5.67 (m, 1H), 5.16 – 5.09 (m, 2H), 4.84 
– 4.78 (m, 1H), 4.34 (d, J = 3.1 Hz, 2H), 4.30 – 4.17 (m, 2H), 2.75 – 2.54 (m, 2H), 1.95 – 1.86 (m, 1H), 
1.29 (t, J = 7.1 Hz, 3H), 1.03 – 0.96 (m, 2H), 0.69 – 0.63 (m, 2H). 
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13C NMR (75 MHz, CDCl3) δ ppm 171.5, 164.3, 163.2, 160.0, 158.5, 146.0, 140.4, 134.7, 132.6, 130.6, 
130.5, 120.4, 119.2, 115.4, 115.1, 61.5, 51.8, 40.8, 36.9, 14.4, 12.8, 8.0, 7.9.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C23H25FN2O3: 419.1741, found 419.1736. 
 
Ethyl 2-(6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxamido)-5-
methoxy-pentanoate (2.96)  
Following the general procedure above, 2.96 was obtained in 39% yield (48 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (80 mg, 0.28 mmol) and ethyl 2-amino-5-
methoxypentanoate 2.92 (50 mg, 0.28 mmol). Purification was performed by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN).  
1H NMR (600 MHz, CDCl3) δ ppm 8.43 (s, 1H), 7.77 (d, J = 8.3 Hz, 1H), 4.77 – 4.74 (m, 1H), 4.61 
(t, J = 12.0 Hz, 4H), 4.24 – 4.14 (m, 4H), 3.39 (t, J = 6.3 Hz, 2H), 3.29 (s, 3H), 2.05 – 2.00 (m, 1H), 
1.92 – 1.80 (m, 1H), 1.73 – 1.56 (m, 2H), 1.31 – 1.23 (m, 4H), 0.71 – 0.61 (m, 2H), 0.38 (t, J = 5.1 Hz, 
2H).  
13C NMR (151 MHz, CDCl3) δ ppm 172.5, 163.9, 147.8, 147.3, 147.2, 147.2, 134.9, 130.6, 118.3, 116.5, 
114.7, 72.0, 71.6, 63.4 (t, 3JCF = 27.8 Hz), 61.6, 58.6, 51.9, 29.7, 25.6, 14.3, 9.8, 3.5, 3.5.  
HR-MS (ESI) m/z [M+H]+ calcd. for C20H28F2N4O5: 443.2101, found 443.2105. 
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-5-methoxypentanoate (2.97)  
Following the general procedure above, 2.97 was obtained in 23% yield (27 mg) as a colorless oil 
starting from picolinic acid 2.42 (76 mg, 0.28 mmol) and ethyl 2-amino-5-methoxypentanoate 2.92 
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(50 mg, 0.28 mmol). Purification was performed by reversed-phase preparative HPLC (C-18, 
Water:ACN with 0.1% TFA, 30 to 90% ACN).  
1H NMR (300 MHz, CDCl3) δ ppm 8.44 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 
7.9 Hz, 1H), 7.23 – 7.14 (m, 2H), 7.03 – 6.93 (m, 2H), 4.78 – 4.71 (m, 1H), 4.35 (s, 2H), 4.22 (q, J = 
7.1 Hz, 2H), 3.39 (t, J = 6.2 Hz, 2H), 3.31 (s, 3H), 2.09 – 1.97 (m, 1H), 1.94 – 1.79 (m, 2H), 1.69 – 
1.59 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H), 1.02 – 0.96 (m, 2H), 0.69 – 0.63 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 172.3, 164.5, 162.5, 160.8, 158.5, 146.1, 140.4, 134.6, 130.5, 120.5, 
115.4, 115.2, 72.1, 61.5, 58.7, 52.2, 40.8, 29.6, 25.7, 14.4, 12.8, 8.0, 8.0.  
HR-MS (ESI) m/z [M+H]+ calcd. for C24H29FN2O4: 429.2184, found 429.2190. 
 
Ethyl 2-(6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carboxamido)-2-
ethyl-5-methoxypentanoate (2.98)  
Following the general procedure above, 2.98 was obtained in 60% yield (121 mg) as a colorless oil 
starting from pyrazine carboxylic acid 2.37 (123 mg, 0.43 mmol) and ethyl 2-amino-2-ethyl-5-
methoxypentanoate 2.93 (88 mg, 0.43 mmol). Purification was performed by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). 
1H NMR (300 MHz, CDCl3) δ ppm 8.40 (s, 1H), 4.61 (t, J = 12.1 Hz, 4H), 4.34 – 4.19 (m, 4H), 3.37 
– 3.26 (m, 2H), 2.68 – 2.54 (m, 2H), 1.98 – 1.81 (m, 2H), 1.58 – 1.48 (m, 1H), 1.37 – 1.25 (m, 5H), 
0.75 (t, J = 7.4 Hz, 3H), 0.67 – 0.63 (m, 2H), 0.43 – 0.38 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 174.1, 162.9, 147.8, 147.2, 134.2, 131.6, 116.6, 72.6, 71.4, 63.4 (t, 
3JCF = 27.8 Hz), 61.9, 58.6, 32.1, 28.7, 24.9, 14.4, 10.0, 8.7, 3.6.  





Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-methoxypentanoate (2.99) 
Following the general procedure above, 2.99 was obtained in 25% yield (50 mg) as a colorless oil 
starting from picolinic acid 2.42 (117 mg, 0.43 mmol) and ethyl 2-amino-2-ethyl-5-methoxypentanoate 
2.93 (88 mg, 0.43 mmol). Purification was performed by reversed-phase preparative HPLC (C-18, 
Water:ACN with 0.1% TFA, 30 to 90% ACN).  
1H NMR (600 MHz, CDCl3) δ ppm 9.00 (s, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 
7.27 – 7.24 (m, 2H), 6.96 (t, J = 8.7 Hz, 2H), 4.36 (s, 2H), 4.32 – 4.25 (m, 2H), 3.35 – 3.27 (m, 2H), 
3.26 (d, J = 1.1 Hz, 3H), 2.60 – 2.50 (m, 2H), 2.00 – 1.86 (m, 3H), 1.59 – 1.48 (m, 1H), 1.41 – 1.34 (m, 
1H), 1.32 (t, J = 7.1 Hz, 3H), 1.02 – 0.96 (m, 2H), 0.77 (t, J = 7.4 Hz, 3H), 0.67 – 0.64 (m, 2H).  
13C NMR (151 MHz, CDCl3) δ ppm 173.8, 163.4, 162.4, 160.8, 158.5, 147.0, 139.9, 134.8, 134.8, 130.6, 
130.5, 119.8, 115.3, 115.2, 72.6, 65.1, 61.8, 58.5, 40.8, 31.9, 28.6, 24.7, 14.4, 12.8, 8.6, 7.9.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C26H33FN2O4: 479.2317, found 479.2318. 
 
Synthesis of the aliphatic ether series: PEG elongation through a thioether linkage 
General Hydroboration-oxidation procedure 
To a solution of the corresponding alkene (1.0 equiv.) in tetrahydrofuran (2 mL) at room temperature 
and nitrogen atmosphere were added 9-Borabicyclo[3.3.1]nonane (9-BBN, 0.5 M in THF, 1.5 equiv.). 
The mixture was stirred at room temperature for 36 h, after which time the excess of 9-BBN was 
quenched with ethanol (3.5 equiv.). The mixture was stirred at room temperature for 30 min, followed 
by the concurrent dropwise addition of sodium hydroxide aq. sol. (2 M, 4 mL/mmol) and hydrogen 
peroxide aq. sol. (30%, 4 mL/mmol) at 0 °C. After complete addition, stirring was continued at the 
same temperature for additional 1 h. The solution was extracted with diethyl ether (3x), dried over 
Mg2SO4, filtered, and concentrated under reduced pressure. Subsequent purification by column 







Following the general procedure above, 2.75 was obtained in 64% yield (79 mg) as a colorless oil 
starting from alkene 2.79 (117 mg, 0.27 mmol).  
1H NMR (600 MHz, CDCl3) δ ppm 8.43 – 8.37 (m, 2H), 4.61 (td, J = 12.1, 3.3 Hz, 4H), 4.35 – 4.22 
(m, 5H), 3.62 – 3.53 (m, 1H), 2.76 – 2.55 (m, 2H), 2.22 – 1.91 (m, 2H), 1.86 (dp, J = 14.5, 7.4 Hz, 1H), 
1.76 – 1.67 (m, 1H), 1.56 – 1.45 (m, 1H), 1.35 – 1.25 (m, 4H), 0.75 (t, J = 7.4 Hz, 3H), 0.68 – 0.63 (m, 
2H), 0.43 – 0.39 (m, 2H).  
13C NMR (151 MHz, CDCl3) δ ppm 173.7, 163.1, 147.8, 147.3, 134.3, 131.2, 116.5, 71.5, 67.9, 65.4, 
65.1, 63.6, 63.4, 63.2 62.2, 31.3, 28.8, 23.7, 14.3, 9.9, 8.6, 3.6, 3.6.  
HR-MS (ESI) m/z [M+H]+ calcd. for C21H30F2N4O5: 457.2218, found 457.2295. 
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-hydroxypentanoate (2.76)  
Following the general procedure above, 2.76 was obtained in 99% yield (246 mg) as a colorless oil 
starting from alkene 2.80 (239 mg, 0.56 mmol). 
1H NMR (600 MHz, CDCl3) δ ppm 9.02 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.27 – 7.24 (m, 3H), 6.99 
– 6.94 (m, 2H), 4.41 (s, 2H), 4.36 (s, 2H), 4.33 – 4.27 (m, 2H), 3.62 – 3.55 (m, 1H), 2.65 – 2.60 (m, 
1H), 2.56 – 2.52 (m, 1H), 2.05 – 1.95 (m, 1H), 1.95 – 1.85 (m, 2H), 1.55 – 1.49 (m, 1H), 1.43 – 1.35 
(m, 1H), 1.33 (td, J = 7.1, 1.8 Hz, 3H), 1.02 – 0.98 (m, 2H), 0.77 (td, J = 7.4, 2.6 Hz, 3H), 0.67 – 0.65 
(m, 2H).  
13C NMR (151 MHz, CDCl3) δ ppm 173.8, 163.6, 160.9, 158.6, 146.9, 140.0, 134.8, 130.5, 130.5, 119.9, 
115.3, 115.2, 65.1, 62.8, 61.9, 40.8, 31.5, 28.9, 27.8, 14.4, 14.4, 12.9, 8.6, 7.9.  
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HR-MS (ESI) m/z [M+H]+ calcd. for C25H31FN2O4: 443.2301, found 443.2337. 
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-5-hydroxypentanoate (2.101)  
Following the general procedure above, 2.101 was obtained in 34% yield (29 mg) as a colorless oil 
starting from alkene 2.95 (83 mg, 0.21 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 8.52 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 
8.0 Hz, 1H), 7.24 – 7.14 (m, 2H), 7.04 – 6.90 (m, 2H), 4.79 (td, J = 7.9, 5.2 Hz, 1H), 4.35 (s, 2H), 4.23 
(q, J = 7.1 Hz, 2H), 3.69 (t, J = 6.2 Hz, 2H), 2.12 – 1.98 (m, 2H), 1.95 – 1.82 (m, 3H), 1.70 – 1.57 (m, 
2H), 1.29 (t, J = 7.1 Hz, 3H), 1.04 – 0.95 (m, 2H), 0.71 – 0.61 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 172.3, 164.6, 163.2, 160.0, 158.5, 145.9, 140.5, 134.7, 130.6, 130.5, 
120.5, 115.4, 115.1, 62.3, 61.6, 52.0, 40.8, 29.7, 28.4, 14.3, 12.8, 8.0, 8.0.  
HR-MS (ESI) m/z [M+H]+ calcd. for C23H27FN2O4: 415.2028, found 415.2018. 
 
General thio-Mitsunobu procedure 
Diisopropyl azodicarboxylate (DIAD, 2.0 equiv.) in anhydrous tetrahydrofuran (0.2 mL) was added 
dropwise to a stirred solution of triphenylphoshine (2.0 equiv.) in anhydrous tetrahydrofuran (1 mL) 
at 0 °C under nitrogen atmosphere. The mixture was stirred at this temperature for 30 min, until 
formation of a white precipitate of Mitsunobu betaine, and a solution of thioacetic acid (2.0 equiv.) 
and the corresponding alcohol (2.0 equiv.) in anhydrous tetrahydrofuran (1 mL) was added slowly. 
The reaction was stirred at 0 °C for 1 h and then allowed to reach room temperature, and stirred for 
additional 1 h. The reaction mixture was concentrated under reduced pressure, and the residue taken 
up into a mixture of diethyl ether and cyclohexane (1:1) and triturated at 0 °C. The resulting white 
solid was filtered off and washed with diethyl ether and cyclohexane (1:1) mixture. The filtrate was 
evaporated under reduced pressure, and the residue purified by column chromatography (Silica gel, 4 





Following the general procedure above, SI-13 was obtained in 32% yield (13 mg) as a light yellow oil 
starting from compound 2.75 (36 mg, 0.08 mmol). 
1H NMR (600 MHz, CDCl3) δ ppm 8.42 (s, 1H), 8.40 (s, 1H), 4.63 (t, J = 12.0 Hz, 4H), 4.32 – 4.24 
(m, 4H), 2.87 – 2.77 (m, 2H), 2.71 – 2.56 (m, 2H), 2.28 (s, 3H), 1.96 – 1.82 (m, 2H), 1.61 – 1.50 (m, 
1H), 1.36 – 1.24 (m, 5H), 0.75 (t, J = 7.4 Hz, 3H), 0.70 – 0.63 (m, 2H), 0.43 – 0.40 (m, 2H).  
13C NMR (151 MHz, CDCl3) δ ppm 195.9, 173.9, 163.2, 147.8, 147.1, 134.1, 131.1, 116.5, 71.6, 65.5, 
63.5, 62.1, 34.6, 30.7, 29.0, 28.7, 24.8, 14.4, 10.0, 8.6, 3.6.  
HR-MS (ESI) m/z [M+Na]+ calcd. for C23H32F2N4O5S: 537.1954, found 537.1966.  
 
Ethyl 5-(acetylthio)-2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)pentanoate (SI-14)  
Following the general procedure above, SI-14 synthesized starting from compound 2.101 (29 mg, 0.07 
mmol). After filtration work-up, intermediate SI-14 was obtained, along with diisopropyl 
azodicarboxylate by-products, and used crude for further reaction steps.  






Following the general procedure above, 2.115 was obtained in 55% yield (24 mg) as a light yellow oil 
starting from compound 2.76 (39 mg, 0.09 mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 8.99 (s, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.30 – 7.19 (m, 3H), 7.02 – 6.91 (m, 2H), 4.39 – 4.23 (m, 4H), 2.88 – 2.76 (m, 2H), 2.69 – 2.45 (m, 
2H), 2.28 (s, 3H), 2.01 – 1.81 (m, 3H), 1.64 – 1.49 (m, 1H), 1.43 – 1.23 (m, 5H), 1.04 – 0.95 (m, 2H), 
0.76 (t, J = 7.4 Hz, 3H), 0.70 – 0.62 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ ppm 195.8, 173.6, 163.5, 160.0, 158.5, 146.8, 140.0, 134.8, 134.8, 130.6, 
130.5, 119.8, 115.4, 115.1, 65.0, 61.9, 40.8, 34.4, 30.7, 29.1, 28.6, 24.7, 24.7, 14.4, 12.8, 8.5, 7.9, 7.9. 
HR-MS (ESI) m/z [M+Na]+ calcd. for C27H33FN2O4S: 523.2037, found 523.2058. 
 
General acetylthio cleavage procedure using iodomethane 
Thioether derivative (1.0 equiv.) and iodomethane (1.0 equiv.) were added to oxygen-free absolute 
ethanol (2 mL) under nitrogen atmosphere. The suspension was cooled to –20 °C, sodium ethoxide 
(2.2 equiv.) was added, and the mixture was allowed to warm up slowly to room temperature. The 
resulting pale yellow solution was stirred for 20 h. The reaction mixture was concentrated, and the 
resulting residue was dissolved in an acetonitrile and water (1:1) solution and purified by reversed-
phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). The fractions 





ethyl-5-(methylthio)pentanoate (2.102)  
Following the general procedure above, 2.102 was obtained in 38% yield (3 mg) as a light yellow oil 
starting from compound SI-13 (8 mg, 0.02 mmol). 
1H NMR (600 MHz, CDCl3) δ ppm 8.41 (s, 1H), 8.39 (s, 1H), 4.64 (t, J = 12.0 Hz, 4H), 4.31 – 4.25 
(m, 4H), 2.71 – 2.58 (m, 2H), 2.51 – 2.38 (m, 2H), 2.07 – 1.94 (m, 4H), 1.90 – 1.84 (m, 1H), 1.63 – 
1.56 (m, 1H), 1.36 – 1.24 (m, 5H), 0.75 (t, J = 7.4 Hz, 3H), 0.71 – 0.64 (m, 2H), 0.45 – 0.39 (m, 2H).  
13C NMR (151 MHz, CDCl3) δ ppm 174.0, 162.9, 147.8, 147.0, 133.9, 131.4, 116.5, 71.6, 65.5, 63.5, 
62.0, 34.7, 34.1, 28.8, 24.4, 15.6, 14.5, 10.0, 8.6, 3.6.  
HR-MS (ESI) m/z [M+H]+ calcd. for C22H32F2N4O4S: 487.2146, found 487.2231. 
 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-5-(methylthio)pentanoate (2.103)  
Following the general procedure above, 2.103 was obtained in 16% yield (4 mg) as a light yellow oil, 
over 2 steps starting from crude compound SI-14. 
1H NMR (600 MHz, DMSO-d6) δ ppm 8.58 (d, J = 8.1 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.52 (d, J 
= 8.0 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.11 (tt, J = 9.8, 3.0 Hz, 2H), 4.51 – 4.47 (m, 1H), 4.41 – 4.34 (m, 
2H), 4.19 – 4.09 (m, 2H), 2.53 – 2.51 (m, 1H), 2.48 – 2.44 (m, 1H), 2.10 – 2.03 (m, 1H), 2.00 – 1.84 
(m, 5H), 1.57 – 1.52 (m, 2H), 1.20 (t, J = 7.1 Hz, 3H), 1.03 – 0.95 (m, 2H), 0.70 – 0.68 (m, 2H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 171.6, 163.7, 161.6, 160.0, 158.1, 146.5, 140.4, 135.0, 134.1, 
130.7, 130.6, 120.0, 115.0, 114.8, 60.7, 52.0, 32.5, 30.0, 24.7, 14.4, 14.0, 12.1, 8.3, 8.2.  





Following the general procedure above, 2.104 was obtained in 46% yield (9 mg) as a light yellow oil 
starting from compound 2.115 (20 mg, 0.04 mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 9.06 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 
7.31 – 7.21 (m, 2H), 7.04 – 6.91 (m, 2H), 4.38 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 2.67 – 2.36 (m, 4H), 
2.09 – 1.83 (m, 6H), 1.67 – 1.52 (m, 1H), 1.42 – 1.31 (m, 4H), 1.03 – 0.97 (m, 2H), 0.77 (t, J = 7.4 Hz, 
3H), 0.71 – 0.64 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.8, 163.3, 160.0, 158.5, 146.7, 140.2, 135.0, 134.7, 130.6, 130.5, 
120.0, 115.4, 115.1, 65.2, 61.9, 40.7, 34.4, 34.1, 28.6, 24.2, 15.5, 14.5, 12.8, 8.6, 8.0.  
HR-MS (ESI) m/z [M+H]+ calcd. for C26H33FN2O3S: 473.2296, found 473.2283.  
 
5.2.8. Synthesis of Racemic NBD-Labeled Probes 
General procedure for linker tosylation 
N-Boc PEG2–5, azido PEG2, or N-Boc hydroxyhexyl (1.0 equiv.) was dissolved in dichloromethane 
(1.5 mL) and treated with p-toluenesulfonyl chloride (3.0 equiv.) and pyridine (5.0 equiv.) at 0 °C. The 
reaction was allowed to warm to room temperature, and then stirred at 40 °C for 12h. The mixture 
was diluted with dichloromethane, and washed with hydrochloric acid aq. sol. (0.2 M, 5 mL), water (5 
mL), and brine (5 mL), dried over MgSO4, and concentrated under reduced pressure. The crude 
product was purified by column chromatography (Silica gel, 4 g, cHex:EtOAc, 15 to 30% EtOAc), 




2-(2-(2-Azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (SI-15)  
Following the general procedure above, SI-15 was obtained in 83% yield (80 mg) as a colorless oil 
starting from 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol 2.116 (50 mg, 0.29 mmol). This example was 
synthesized with replacement of the base pyridine by triethylamine (5.0 equiv.) and addition of catalytic 
amounts of N,N-dimethylaminopyridine (DMAP, 0.1 equiv.). 
1H NMR (300 MHz, CDCl3) δ ppm 7.79 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.19 – 4.12 (m, 
2H), 3.72 – 3.59 (m, 8H), 3.22 – 3.05 (m, 1H), 3.35 (t, J = 5.1 Hz, 2H), 1.13 (t, J = 7.2 Hz, 2H). 
The analytical data are in accordance with those reported in the literature.[300] 
 
1-Azido-2-(2-(2-iodoethoxy)ethoxy)ethane (2.117)  
Tosylate SI-15 (80 mg, 0.24 mmol) and sodium iodide (109 mg, 0.72 mmol) were dissolved in 
dimethylformamide (2 mL). The mixture was stirred at 50 °C for 5 h under nitrogen atmosphere. The 
solvent was evaporated under reduced pressure, and the residue dissolved in ethyl acetate (5 mL). The 
organic solution was washed with water (3 mL), and the aqueous phase, extracted with ethyl acetate 
(3x). The combined organic extracts were washed with brine (5 mL), dried over MgSO4, and 
evaporated under reduced pressure. Purification by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 15% EtOAc) afforded linker 2.117 as colorless oil in 22% yield (15 mg). 
1H NMR (300 MHz, CDCl3) δ ppm 3.77 (t, J = 6.8 Hz, 2H), 3.73 – 3.65 (m, 6H), 3.40 (t, J = 5.1 Hz, 
2H), 3.27 (t, J = 6.8 Hz, 2H). 
The analytical data are in accordance with those reported in the literature.[301] 
 
2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (2.124)  
Following the general procedure above, 2.124 was obtained in quantitative yield (86 mg) as a colorless 
oil starting from linker tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate 2.119 (50 mg, 0.24 mmol). 
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1H NMR (300 MHz, CDCl3) δ ppm 7.81 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 4.80 (s, 1H), 
4.16 (dd, J = 5.7, 3.6 Hz, 2H), 3.63 (dd, J = 5.5, 3.8 Hz, 2H), 3.44 (t, J = 5.1 Hz, 2H), 3.24 (q, J = 5.2 
Hz, 2H), 2.45 (s, 3H), 1.45 (s, 9H). 
The analytical data are in accordance with those reported in the literature.[302] 
 
2,2-Dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate (2.125)  
Following the general procedure above, 2.125 was obtained in quantitative yield (114 mg) as a colorless 
oil starting from linker tert-butyl (2-(2-(2-hydroxyethoxy)ethoxy)ethyl)carbamate 2.120 (60 mg, 0.24 
mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 7.79 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.93 (bs, 1H), 
4.16 (t, J = 4.8 Hz, 2H), 3.68 (t, J = 4.8 Hz, 2H), 3.60 – 3.45 (m, 6H), 3.34 – 3.22 (m, 2H), 2.44 (s, 3H), 
1.43 (s, 9H). 




Following the general procedure above, 2.126 was obtained in 66% yield (71 mg) as a colorless oil 
starting from linker tert-butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate 2.121 (70 mg, 
0.24 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 7.79 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 5.00 (bs, 1H), 
4.20 – 4.11 (m, 2H), 3.73 – 3.65 (m, 2H), 3.59 (s, 8H), 3.54 – 3.49 (m, 2H), 3.34 – 3.25 (m, 2H), 2.44 
(s, 3H), 1.43 (s, 9H). 






Following the general procedure above, 2.127 was obtained in 94% yield (111 mg) as a colorless oil 
starting from linker tert-butyl (14-hydroxy-3,6,9,12-tetraoxatetradecyl)carbamate 2.122 (81 mg, 0.24 
mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 7.78 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 5.01 (bs, 1H), 
4.18 – 4.09 (m, 2H), 3.70 – 3.64 (m, 2H), 3.64 – 3.55 (m, 12H), 3.54 – 3.48 (m, 2H), 3.28 (t, J = 5.0 
Hz, 2H), 2.43 (s, 3H), 1.42 (s, 9H). 
The analytical data are in accordance with those reported in the literature.[305] 
 
6-((Tert-butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate (2.128)  
Following the general procedure above, 2.128 was obtained in 42% yield (38 mg) as a colorless oil 
starting from linker tert-butyl (6-hydroxyhexyl)carbamate 2.123 (52 mg, 0.24 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 7.78 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 4.49 (s, 1H), 
4.00 (t, J = 6.4 Hz, 2H), 3.12 – 2.98 (m, 2H), 2.44 (s, 3H), 1.69 – 1.56 (m, 2H), 1.43 (s, 11H), 1.35 – 
1.21 (m, 4H). 




General procedure for linker attachment at pyridine (±)-2.115 scaffold 
Thioderivative (±)-2.115 (1.0 equiv.) and the corresponding tosyl linker 2.124 to 2.128 or iodinated 
linker 2.117 (1.8 equiv.) were added to absolute ethanol previously degassed (2 mL) under nitrogen 
atmosphere. The suspension was cooled to –20 °C, sodium ethoxide (3.0 equiv.) was added along with 
catalytic amounts of potassium iodide (0.3 equiv.), and the mixture was allowed to warm up slowly to 
room temperature. The resulting solution was stirred for 20 h. The reaction mixture was concentrated 
under reduced pressure. The resulting residue was dissolved in acetonitrile and water (1:1) and purified 
by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). 
Ethyl 5-((2-(2-(2-azidoethoxy)ethoxy)ethyl)thio)-2-(5-cyclopropyl-6-(4-fluorobenzyl)picolin-
amido)-2-ethylpentanoate ((±)-2.118) 
Following the general procedure above, (±)-2.118 was obtained in 46% yield (7 mg) as a pale yellow 
solid starting from linker 1-azido-2-(2-(2-iodoethoxy)ethoxy)ethane 2.117 (10 mg, 0.04 mmol). This 
example was synthesized without addition of potassium iodide.  
1H NMR (600 MHz, DMSO-d6) δ ppm 8.71 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 
1H), 7.36 – 7.30 (m, 2H), 7.14 – 7.06 (m, 2H), 4.36 (s, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.58 – 3.55 (m, 
2H), 3.52 – 3.42 (m, 6H), 3.38 – 3.34 (m, 2H), 2.54 (t, J = 6.8 Hz, 2H), 2.50 – 2.44 (m, 2H), 2.40 – 
2.26 (m, 2H), 2.10 – 2.06 (m, 1H), 1.92 – 1.88 (m, 1H), 1.87 – 1.80 (m, 1H), 1.41 – 1.35 (m, 1H), 1.30 
– 1.21 (m, 4H), 1.01 – 0.98 (m, 2H), 0.71 – 0.66 (m, 5H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 173.8, 162.3, 161.6, 160.0, 158.0, 145.8, 140.2, 135.0, 134.4, 
130.7, 119.3, 115.0, 114.9, 70.2, 69.6, 69.4, 69.2, 63.6, 61.34, 50.0, 33.4, 31.3, 30.4, 27.6, 23.9, 14.0, 12.1, 
8.1, 8.0.  





dioxa-11-thia-5-azahexadecan-16-oate ((±)-2.129)  
Following the general procedure above, (±)-2.129 was obtained in 50% yield (16 mg) as a pale yellow 
solid starting from linker 2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate 
2.124 (32 mg, 0.09 mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 9.02 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 
7.30 – 7.21 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 4.95 (bs, 1H), 4.46 – 4.19 (m, 4H), 3.56 – 3.43 (m, 4H), 
3.29 – 3.24 (m, 2H), 2.67 – 2.47 (m, 6H), 2.06 – 1.82 (m, 4H), 1.64 – 1.56 (m, 1H), 1.43 (s, 9H), 1.33 
(t, J = 7.1 Hz, 3H), 1.05 – 0.94 (m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.79 – 0.64 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.5, 163.2, 160.0, 158.5, 156.1, 146.8, 140.1, 134.8, 130.6, 
130.5, 119.8, 115.4, 115.1, 79.4, 70.7, 70.0, 65.1, 61.9, 40.8, 40.5, 34.5, 32.5, 31.6, 28.6, 28.6, 24.8, 14.5, 
12.8, 8.6, 7.9.  






Following the general procedure above, (±)-2.130 was obtained in 49% yield (13 mg) as a pale yellow 
solid starting from linker 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-
methylbenzenesulfonate 2.125 (29 mg, 0.07 mmol). 
1H NMR (300 MHz, CDCl3) δ ppm 9.01 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.30 – 7.20 (m, 2H), 7.03 – 6.92 (m, 2H), 5.02 (bs, 1H), 4.40 – 4.23 (m, 4H), 3.62 – 3.45 (m, 8H), 3.34 
– 3.30 (m, 2H), 2.68 – 2.44 (m, 6H), 2.05 – 1.82 (m, 3H), 1.64 – 1.55 (m, 1H), 1.43 (s, 9H), 1.35 – 1.18 
(m, 4H), 1.03 – 0.97 (m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.72 – 0.62 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.5, 163.2, 158.5, 156.1, 146.8, 140.0, 134.8, 130.6, 130.5, 
119.8, 115.4, 115.1, 79.3, 71.0, 70.4, 70.3, 65.1, 61.9, 40.9, 40.4, 34.5, 32.5, 31.5, 28.6, 24.9, 14.5, 12.9, 
8.6, 7.9.  







Following the general procedure above, (±)-2.131 was obtained in 52% yield (19 mg) as a pale yellow 
solid starting from linker 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-
methylbenzenesulfonate 2.126 (40 mg, 0.09 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 9.01 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.30 – 7.21 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 5.03 (bs, 1H), 4.43 – 4.21 (m, 4H), 3.66 – 3.68 (m, 12H), 
3.33 – 3.27 (m, 2H), 2.69 – 2.44 (m, 6H), 2.08 – 1.76 (m, 4H), 1.64 – 1.55 (m, 1H), 1.43 (s, 9H), 1.33 
(t, J = 7.1 Hz, 3H), 1.03 – 0.96 (m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.78 – 0.64 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.5, 163.2, 160.0, 158.5, 156.1, 146.8, 134.8, 130.6, 130.5, 
119.8, 115.4, 115.1, 79.3, 71.0, 70.7, 70.4, 70.4, 65.1, 61.9, 40.8, 34.5, 32.5, 31.5, 28.6, 24.9, 14.5, 12.8, 
8.6, 7.9.  






Following the general procedure above, (±)-2.132 was obtained in 56% yield (22 mg) as a pale yellow 
solid starting from linker 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-
methylbenzenesulfonate 2.127 (44 mg, 0.09 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 9.01 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38(d, J = 8.0 Hz, 1H), 
7.29 – 7.21 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 5.04 (bs, 1H), 4.39 – 4.24 (m, 4H), 3.68 – 3.47 (m, 16H), 
3.35 – 3.30 (m, 2H), 2.69 – 2.42 (m, 6H), 2.08 – 1.80 (m, 4H), 1.65 – 1.51 (m, 1H), 1.43 (s, 9H), 1.33 
(t, J = 7.1 Hz, 3H), 1.04 – 0.95 (m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.78 – 0.64 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.4, 160.0, 158.5, 156.1, 146.8, 140.1, 134.9, 130.6, 130.5, 
119.9, 115.4, 115.1, 79.3, 70.7, 70.7, 70.7, 70.4, 70.3, 65.1, 61.9, 40.8, 40.5, 34.5, 32.5, 31.5, 28.6, 24.8, 
14.5, 12.8, 8.6, 7.9.  






Following the general procedure above, (±)-2.133 was obtained in 51% yield (17 mg) as a pale yellow 
solid starting from linker 6-((tert-butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate 2.128 (33 mg, 
0.09 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 9.02 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.32 – 7.19 (m, 2H), 6.96 (t, J = 8.6 Hz, 2H), 4.53 (s, 1H), 4.38 – 4.24 (m, 4H), 3.11 – 3.04 (m, 2H), 
2.67 – 2.37 (m, 6H), 2.07 – 1.84 (m, 3H), 1.60 – 1.24 (m, 22H), 1.06 – 0.94 (m, 2H), 0.76 (t, J = 7.4 
Hz, 3H), 0.79 – 0.63 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 173.8, 163.5, 160.0, 158.3, 156.1, 146.8, 140.0, 134.8, 130.6, 130.5, 
119.8, 115.4, 115.1, 79.2, 65.1, 61.9, 40.8, 34.6, 32.1, 32.0, 30.1, 29.6, 28.6, 28.6, 26.5, 24.7, 14.4, 12.8, 
8.6, 7.9, 7.9.  




General Boc-deprotection and NBD-labeling procedure 
Trifluoroacetic acid (0.3 mL) was added dropwise to a stirring solution of the corresponding N-Boc-
protected compound (±)-2.129 to (±)-2.133 (1.0 equiv.) in dichloromethane (2.3 mL) at 0 °C. The 
reaction mixture was stirred at room temperature for 2 h. Afterwards, the mixture was concentrated 
under reduced pressure, and the residue re-suspended in ethyl acetate (5 mL). The solvent was 
removed under reduced pressure. This process was repeated 3 times to remove trifluoroacetic acid 
traces. The removal of the tert-butyloxycarbonyl group was quantitative as observed by TLC (50% 
EtOAc in cHex). The free amines (±)-2.110 to (±)-2.114 were obtained as the corresponding 
trifluoroacetic acid salts, without the need of further purification. 
To a solution of (±)-2.110 to (±)-2.114 (1.0 equiv.) and cesium carbonate (5.0 equiv.) in 
dimethylformamide (2 mL) at room temperature 7-chloro-4-nitrobenzofurazan (NBD-Cl, 1.0 equiv.) 
was added. The reaction was stirred at room temperature for 24 h. The reaction mixture was 
concentrated under reduced pressure, and the obtained residue was diluted in a mixture of acetonitrile 
and water (1:1) and purified by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 





Following the general procedure above, (±)-2.105 was obtained in 49% yield (5 mg) as a dark yellow 
solid starting from compound (±)-2.129 (10 mg, 0.02 mmol).  
1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.41 (s, 1H), 8.69 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 7.74 
(d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.11 – 7.06 (m, 2H), 6.44 (d, J = 9.0 
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Hz, 1H), 4.34 (s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.70 – 3.63 (m, 4H), 3.51 (t, J = 6.7 Hz, 2H), 2.54 (t, J 
= 6.7 Hz, 2H), 2.46 – 2.41 (m, 2H), 2.34 – 2.24 (m, 2H), 2.09 – 2.05 (m, 1H), 1.88 – 1.75 (m, 2H), 
1.38 – 1.32 (m, 2H), 1.20 (t, J = 7.1 Hz, 4H), 1.10 – 0.96 (m, 2H), 0.70 – 0.64 (m, 4H).  
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.2, 158.0, 146.1, 145.3, 
144.4, 144.1, 140.3, 137.8, 135.0, 134.4, 130.7, 120.9, 119.3, 114.9, 99.5, 70.2, 67.6, 63.6, 61.4, 43.3, 
33.4, 31.3, 30.5, 26.6, 23.9, 14.4, 12.1, 8.2, 8.1, 8.0.  




Following the general procedure above, (±)-2.106 was obtained in 26% yield (3 mg) as a dark yellow 
solid starting from compound (±)-2.130 (10 mg, 0.01 mmol).  
1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.43 (s, 1H), 8.70 (s, 1H), 8.49 (d, J = 9.0 Hz, 1H), 7.74 
(d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.11 – 7.06 (m, 2H), 6.54 (d, J = 9.0 
Hz, 1H), 4.34 (s, 2H), 4.31 (q, J = 7.1 Hz, 2H), 3.69 (t, J = 5.3 Hz, 2H), 3.49 – 3.51 (m, 3H), 3.43 – 
3.39 (m, 3H), 2.48 (t, J = 6.7 Hz, 2H), 2.40 – 2.45 (m, 2H), 2.35 – 2.26 (m, 3H), 2.10 – 2.04 (m, 2H), 
1.92 – 1.77 (m, 3H), 1.38 – 1.33 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 1.01 – 0.96 (m, 2H), 0.70 – 0.65 (m, 
4H).  
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.3, 144.4, 
144.1, 140.3, 137.8, 135.0, 134.4, 130.7, 130.6, 120.8, 119.3, 115.1, 114.9, 99.5, 70.2, 69.8, 69.4, 63.6, 
61.4, 43.4, 33.4, 31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.1, 8.0.  





Following the general procedure above, (±)-2.107 was obtained in 49% yield (3 mg) as a dark yellow 
solid starting from compound (±)-2.131 (10 mg, 0.01 mmol).  
1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.70 (s, 1H), 8.50 (d, J = 8.8 Hz, 1H), 7.75 
(d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.12 – 7.06 (m, 2H), 6.47 (d, J = 9.0 
Hz, 1H), 4.34 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.70 (t, J = 5.3 Hz, 2H), 3.70 – 3.62 (m, 2H), 3.55 – 
3.53 (m, 2H), 3.49 – 3.47 (m, 3H), 3.41 – 3.39 (m, 5H), 3.37 – 3.34 (m, 2H), 2.45 (td, J = 7.1, 3.0 Hz, 
2H), 2.37 – 2.26 (m, 2H), 2.10 – 2.05 (m, 2H), 1.92 – 1.87 (m, 1H), 1.84 – 1.79 (m, 1H), 1.41 – 1.33 
(m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 1.01 – 0.97 (m, 2H), 0.70 – 0.65 (m, 4H).  
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.3, 144.1, 
140.3, 137.8, 135.0, 134.4, 130.7, 130.6, 120.8, 119.3, 115.1, 114.9, 99.5, 70.1, 69.8, 69.7, 69.4, 68.0, 
63.6, 61.4, 43.4, 33.4, 31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.1, 8.0.  






Following the general procedure above, (±)-2.108 was obtained in 23% yield (3 mg) as a dark yellow 
solid starting from compound (±)-2.132 (14 mg, 0.02 mmol).  
1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.45 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 9.0 Hz, 1H), 7.75 
(d, J = 8.0 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.12 – 7.07 (m, 2H), 6.47 (d, J = 9.0 
Hz, 1H), 4.34 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.70 (t, J = 5.3 Hz, 1H), 3.56 – 3.54 (m, 2H), 3.50 – 
3.48 (m, 2H), 3.46 – 3.40 (m, 16H), 3.38 – 3.36 (m, 2H), 2.47 – 2.44 (m, 1H), 2.37 – 2.27 (m, 2H), 2.10 
– 2.06 (m, 1H), 1.93 – 1.97 (m, 1H), 1.85 – 1.79 (m, 1H), 1.41 – 1.33 (m, 1H), 122 (t, J = 7.1 Hz, 3H), 
1.03 – 0.95 (m, 2H), 0.72 – 0.64 (m, 4H).  
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.3, 144.4, 
144.1, 140.3, 137.8, 135.0, 134.4, 130.7, 130.6, 120.8, 119.3, 115.0, 114.9, 99.5, 70.2, 69.8, 69.7, 69.7, 
69.4, 68.0, 63.6, 61.4, 60.2, 43.4, 33.4, 31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.2, 8.0.  






Following the general procedure above, (±)-2.109 was obtained in 18% yield (2 mg) as a dark yellow 
solid starting from compound (±)-2.133 (11 mg, 0.02 mmol).  
1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.52 (t, J = 5.7 Hz, 1H), 8.72 (s, 1H), 8.50 (d, J = 8.9 Hz, 
1H), 7.75 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.35 – 7.31 (m, 2H), 7.11 – 7.06 (m, 2H), 6.38 
(d, J = 9.0 Hz, 1H), 4.34 (d, J = 3.5 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.42 (q, J = 6.8, 6.3 Hz, 2H), 
2.40 (t, J = 7.1 Hz, 2H), 2.37 – 2.27 (m, 4H), 2.10 – 2.06 (m, 1H), 1.93 – 1.78 (m, 3H), 1.59 – 1.64 (m, 
2H), 1.44 – 1.20 (m, 11H), 1.02 – 0.96 (m, 2H), 0.70 – 0.65 (m, 4H).  
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.2, 144.4, 
144.1, 140.3, 138.0, 135.0, 134.4, 130.7, 130.6, 120.5, 119.3, 115.0, 114.9, 99.1, 63.6, 61.4, 43.3, 33.4, 
30.8, 30.7, 28.9, 27.8, 27.7, 27.5, 25.9, 23.7, 14.1, 12.1, 8.2, 8.1.  







Alexa 488 carboxylic acid tris-triethylammonium salt (2.5 mg, 3.0 µmol) was dissolved in 
dimethylformamide (1 ml) and N,N-diisopropylethylamine (1 µl, 6.0 µmol) was added. HATU (1.2 
mg, 3.0 µmol) was added and the solution was stirred at room temperature for 10 min, then (±)-2.111 
(1.8 mg, 3.0 µmol) was added and stirring was continued for 5 h at room temperature. The mixture 
was concentrated under reduced pressure and then purified by reversed-phase preparative HPLC (C-
18, Water:ACN with 0.1% TFA, 05 to 75% ACN) to yield Alexa 488 conjugate (±)-2.134 (3.3 mg, 
36%) as a purple powder after lyophilization.  
Due to the low amount of compound, NMR spectra of probe 2.134 could not be recorded. 







Raman emitter 4-((4-(dimethylamino)phenyl)buta-1,3-diyn-1-yl)benzoic acid (1.1 mg, 3.8 µmol) was 
dissolved in dimethylformamide (400 µL) and N,N-diisopropylethylamine (1.8 µL, 10.2 µmol) was 
added. HATU (1.5 mg, 3.8 µmol) was added and the solution was stirred at room temperature for 10 
min, then (±)-2.111 (1.5 mg, 2.5 µmol) was added and stirring was continued for 1 h at room 
temperature. The mixture was was concentrated under reduced pressure and then purified by reversed-
phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 25 to 90% ACN) to yield Raman emitter 
conjugate (±)-2.135 (0.8 mg, 20%) as an orange powder after lyophilization.  
1H NMR (600 MHz, DMSO-d6) δ ppm δ 8.71 (s, 1H), 8.59 (t, J = 5.6 Hz, 1H), 7.86 (d, J = 8.4 Hz, 
2H), 7.76 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.9 Hz, 
2H), 7.33 (dd, J = 8.6, 5.6 Hz, 2H), 7.14 – 7.06 (m, 2H), 6.70 (d, J = 9.0 Hz, 2H), 4.35 (s, 2H), 4.21 (q, 
J = 7.1 Hz, 2H), 3.54 – 3.41 (m, 14H), 2.97 (s, 6H), 2.47 – 2.43 (m, 2H), 2.33 (ddd, J = 30.8, 13.8, 6.0 
Hz, 2H), 2.08 (ddd, J = 13.7, 8.4, 5.3 Hz, 1H), 1.94 – 1.78 (m, 2H), 1.41 – 1.32 (m, 1H), 1.31 – 1.18 
(m, 6H), 1.03 – 0.94 (m, 2H), 0.69 (dd, J = 4.5, 2.4 Hz, 2H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 172.8, 165.3, 162.3, 161.6, 160.0, 158.0, 150.9, 145.8, 140.3, 
135.0, 134.6, 134.4, 133.7, 132.0, 130.7, 130.6, 127.5, 123.8, 119.3, 114.9, 115.0, 111.8, 105.5, 85.2, 80.4, 
76.4, 71.8, 70.1, 69.5, 69.4, 68.8, 67.0, 63.6, 61.4, 40.1, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1, 33.4, 31.3, 
30.4, 27.6, 23.9, 14.1, 12.1, 8.2, 8.0.  




5.2.9. Synthesis of Pyridine-based Enantiomeric Pure Probes 
Ethyl (S)-18-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-18-ethyl-2,2-dimethyl-4-oxo-
3,8,11-tri-oxa-14-thia-5-azanonadecan-19-oate ((S)-2.130) 
Picolinic acid 2.42 (50 mg, 184 µmol) was dissolved in a mixture of dichloromethane and acetonitrile 
(1 mL, 1:1, v/v). N,N-diisopropylethylamine (48 µL, 276 µmol) and HATU (70 mg, 184 µmol) were 
added, and the reaction mixture was stirred at room temperature for 10 min. Afterwards, (S)-2.140 (89 
mg, 203 µmol) dissolved in a mixture of dichloromethane and acetonitrile (1 mL, 1:1, v/v) was added 
and the reaction was stirred at room temperature for 18 h. The solvents were evaporated under 
reduced pressure and the residue was purified by column chromatography (Silica gel, 4 g, 
cHex:EtOAc, 10 to 90% EtOAc) to yield (S)-2.130 (105 mg, 82%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ ppm 9.00 (s, 1 H), 7.89 (d, J = 7.9 Hz, 1 H), 7.39 (m, 1 H), 7.26 (m, 2 
H), 6.97 (m, 2 H), 5.00 (bs, 1 H), 4.37 (s, 2 H), 4.33 – 4.23 (m, 2 H), 3.64 – 3.47 (m, 8 H), 3.36 – 3.23 
(m, 2 H), 2.67 – 2.62 (m, 2 H), 2.62 – 2.44 (m, 4 H), 2.07 – 1.97 (m, 1 H), 1.95 – 1.83 (m, 2 H), 1.58 
(m, 1 H), 1.43 (s, 9 H), 1.33 (t, J = 7.1 Hz, 3 H), 1.32 (m, 1 H), 1.03 – 0.97 (m, 2 H), 0.76 (t, J = 7.4 
Hz, 3 H), 0.69 – 0.60 (m, 2 H).  
13C NMR (151 MHz, CDCl3) δ ppm 173.7, 163.5, 162.5, 160.9, 158.6, 146.9, 140.0, 134.8, 134.8, 130.6, 
130.5, 119.8, 115.4, 115.2, 79.3, 71.0, 70.4, 65.1, 61.9, 40.9, 40.5, 34.6, 32.5, 31.5, 28.6, 28.6, 24.9, 14.5, 
12.9, 8.6, 7.9, 7.9.  
HR-MS (ESI) m/z [M+H]+ calcd. for C36H53FN3O7S: 690.3583, found: 690.3586.  
[α]20d = +6.34° (c = 1.0, CHCl3). 
 
The same procedure was applied for the synthesis of (R)-2.130, which was performed by BENJAMIN 





Compound (S)-2.130 (27 mg, 39 µmol) was dissolved in dichloromethane (2 mL) and trifluoroacetic 
acid (2 mL) was added. The solution was stirred at room temperature for 30 min, then poured into 
potassium bicarbonate aq. sol. (2 M, 30 mL). The mixture was extracted with ethyl acetate (2x). The 
combined organic layers were washed with sodium hydroxide aq. sol. (1 M), dried over MgSO4 and 
filtered. Evaporation of the solvent under reduced pressure yielded the free amine (S)-2.111 (28 mg, 
97%) as a colorless oil, which was used crude for the subsequent dye conjugation. 
 
The same procedure was applied for the synthesis of (R)-2.111, which was performed by BENJAMIN 




Following the general NBD-labeling procedure described for racemic compound (±)-2.106, 2.8 mg of 
(S)-NBD conjugate 2.106 were obtained (73%) starting from amine (S)-2.111 (3 mg, 5.1 µmol) as a 
dark yellow solid. 
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Following the general NBD-labeling procedure described for racemic compound (±)-2.106, 4.5 mg of 




oxo-5,8-dioxa-11-thia-2-azahexadecan-16-oate (Alexa 488-2.134) 
Following the Alexa 488-labeling procedure described for racemic compound (±)-2.134, 3.7 mg of 
(S)-Alexa 488 conjugate 2.134 were obtained (37%) starting from amine (S)-2.111 (4.1 mg, 7.0 µmol) 
as a purple powder. 
NMR spectra of probe 2.134 could not be recorded due to the low amount of compound obtained.  
HR-MS (ESI) m/z [M+H]+ calcd. for C52H57FN5O15S3: 1106.2992, found: 1106.2986.  
PAMPA assay: Peff: 0 cm/s*10








The synthesis of this compound was performed by BENJAMIN BRENNECKE at FMP, Berlin. 
 
Silicon Rhodamine carboxylic acid (5 mg, 10.6 µmol) was dissolved in acetonitrile (2 mL) and N,N-
diisopropylethylamine (4 µL, 21.2 µmol) and HATU (4 mg, 10.6 µmol) were added successively. The 
solution was stirred for 5 min, then (S)-2.111 (7 mg, 11.7 µmol) was added and the reaction was stirred 
at room temperature for 24 h. The mixture was purified by reversed-phase preparative HPLC (C-18, 
Water:ACN with 0.1% TFA, 30 to 90% ACN) to yield 8 mg (73%) SiR-(S)-2.142 as blue powder after 
lyophilization.  
1H NMR (600 MHz, CDCl3) δ ppm 9.03 (s, 1 H), 8.02 (d, J = 8.0 Hz, 1 H), 7.94 (dd, J = 8.0, 1.4 Hz, 
1 H), 7.86 (d, J = 8.0 Hz, 1 H), 7.75 (d, J = 1.4 Hz, 1 H), 7.37 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 2.7 Hz, 
2 H), 7.26 – 7.23 (m, 2 H), 7.10 (bs, 1 H), 7.00 – 6.94 (m, 4 H), 6.90 (m, 2 H), 4.36 (s, 2 H), 4.28 (m, 
2 H), 3.65 – 3.51 (m, 10 H), 3.08 (s, 12 H), 2.56 (t, J = 6.7 Hz, 2 H), 2.62 – 2.55 (m, 1 H), 2.52 – 2.40 
(m, 3 H), 2.02 – 1.96 (m, 1 H), 1.95 – 1.83 (m, 2 H), 1.61 – 1.49 (m, 1 H), 1.32 (t, J = 7.1 Hz, 3 H), 
1.35 – 1.27 (m, 1 H), 1.01 (m, 2 H), 0.75 (t, J = 7.4 Hz, 3 H), 0.70 (s, 3 H), 0.66 (m, 2 H), 0.62 (s, 3 H).  
13C NMR (151 MHz, CDCl3) δ ppm 173.6, 169.1, 166.3, 163.7, 161.2, 161.0, 160.9, 158.7, 152.7, 147.5, 
146.6, 140.3, 140.0, 139.0, 136.5, 134.8, 134.7, 130.6, 130.6, 129.9, 129.0, 127.9, 127.0, 124.4, 121.0, 
119.8, 116.9, 115.4, 115.2, 69.6, 70.2, 70.3, 70.9, 65.1, 62.0, 42.8, 40.8, 40.3, 34.5, 32.5, 31.6, 28.7, 24.8, 
14.4, 12.9, 8.5, 8.0, 8.0, 1.2, 0.1.  
HR-MS (ESI) m/z [M+H]+ calcd. for C58H71FN5O8SSi: 1044.4771, found: 1044.4814.  
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5.2.10. Pharmacological Assessment of CB2R-Agonist Probes and Fluorescence Imaging 
Experiments  
5.2.10.1. X-Ray Crystal Structure of Proline Derivative 2.139 
The following experiment were performed by ANDRE ALKER at Hoffmann La-Roche, Basel. 
 
Ethyl (S)-2-ethyl-2-((R)-1-tosylpyrrolidine-2-carboxamido)pent-4-enoate (2.139) 
Crystals were grown by vapor diffusion using chloroform. A suitable single crystal was mounted in a 
loop. Data were collected at room temperature on a Synergy-S diffractometer (Rigaku) with Cu-K-
alpha-radiation (1.54184Å) and processed with the Crysalis-package. Structure solution and 
refinement was performed using the ShelXTL software (Bruker AXS, Karlsruhe).  
Formula: C21H31N2O5S  
Unit Cell Parameters: a 11.8304 (10) Å, b 12.8390 (10) Å, c 15.0869 (10) Å, P2(1)2(1)2(1) 
CCDC 1923120 contains the supplementary crystallographic data for this structure. These data can be 





5.2.10.2. Molecular Docking 
The docking studies were conducted by DR. WOLFGANG GUBA at Hoffmann La-Roche, Basel. 
 
The X-ray structure of active state CB2R in complex with agonist AM1203 (PDB 6KPF) was used as 
template to dock CB2R ligands.
[81] The docking experiments were performed with the software GOLD 
(Chemical Computing Group) with default settings.[307] The best 10 docking poses for each compound 
were energy-minimized within the binding pocket using MOE (Molecular Operating environment ver. 
2014.09, Chemical Computing Group, Montreal, Canada) and examined visually to select the most 
reasonable docking mode with respect to molecular interactions and internal conformational strain. 
Finally, the consistency of the selected poses was evaluated using the available structure-activity 
relationship information. 
 
5.2.10.3. Absorption-Emission Spectra of Fluorescent Probes  
The following experiments were conducted by SYLWIA HUBER at Hoffmann La-Roche, Basel. 
 
UV/Vis absorbance spectra of 50 µM probes 2.106, 2.134, 2.141, and 2.143 in various solvents (see 
below) were recorded in wavelength range of 250-750 nm to determine the wavelength with the 
maximal absorbance signal used later for excitation of the compound (1 cm path length, room 
temperature, scan step 1 nm; Thermo Evolution 600 UV/Vis spectrophotometer, Thermo Electron 
Scientific Instruments LLC, Madison, WI, USA). Due to the limited solubility of the probes in DPBS, 
the spectra in DPBS were measured in a cuvette with 10 cm path length at 5 µM in presence of 0.1 % 
(v/v) dimethyl sulfoxide. Technical excitation and emission fluorescence spectra (uncorrected for 
chromatic aberrations) of the fluorescent probes were measured at 10 µM compound concentration 
(20°C, integration time 1s scan step 2 nm, slits 2.4 mm and 2 mm in excitation and emission, 
respectively; ISS Inc. PC1 fluorometer, Champaign, IL, USA) in organic dimethyl sulfoxide, 
dichloromethane, acetonitrile, ethyl acetate and methanol, and aqueous solvent DPBS (Dulbecco’s 
phosphate buffered saline). Exceptionally, the spectra in DPBS were measured at 1.0 µM in the 
presence of 0.1 % (v/v) dimethyl sulfoxide and then scaled to expected fluorescence signal intensity at 
concentration of 10 µM by multiplication of the signal intensity by factor of 10. 
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As expected, the observed fluorescence intensity increased with decreasing dielectric constant of the 
solvents: aqueous solution (PBS, 25 = 79.0) < dimethyl sulfoxide (20 = 47) < acetonitrile (20 = 36.64) 
≤ methanol (25 = 32.6) < dichloromethane (20 = 9.08) ≤ ethyl acetate (25 = 6).
[308] Thus, the 
fluorescence intensity (quantum yield) of the fluorescence of probes 2.106, 2.134, 2.141, and 2.143 is 
expected to increase when in close proximity of the cell membrane ( = 3) or when bound to the 
hydrophobic binding site of CB2R. The relatively lower fluorescence intensity values observed for 
2.106 (NBD-labeled) and 2.141 (AttoThio12-labeled) in methanol and ethyl acetate, respectively, may 
indicate on specific solvent effects, but overall the expected trend of increasing of fluorescence signal 
intensity with reduction of solvent polarity is observed. Overall, the fluorescence features of these 
probes enable their applications in e.g. tissue imaging for CB2R-specific disorders. 
Supplementary table S-4. Fluorescence excitation and emission wavelengths for fluoroprobes 2.106, 2.134, 
2.141, and 2.143 with corresponding fluorescence intensities and Stokes’ shifts recorded in distinct solvents.  
Probe Fluorescence data DPBS DMSO ACN MeOH DCM EtOAc 
(±)-2.106 
(NBD) 
Excitation  [nm] 474 478 470 470 468 468 
Emission  [nm] 550 544 534 538 528 528 
Stokes shift [nm] 76 66 64 68 60 60 
Signal intensity *106 [a.u.] 1.2 22.2 24.5 11.5 24.5 26.4 
(S)-2.134 
(Alexa 488) 
Excitation  [nm] 494 512 498 494 498 498 
Emission  [nm] 526 540 526 526 526 526 
Stokes shift [nm] 32 28 28 32 28 28 
Signal intensity *106 [a.u.] 64.2 49.9 52.9 70.7 43.2 37.0 
(S)-2.141 
(AttoThio12) 
Excitation  [nm] 582 584 574 574 574 574 
Emission  [nm] 610 618 606 606 600 604 
Stokes shift [nm] 28 34 32 32 26 30 
Signal intensity *106 [a.u.] 11.4 12.2 17.5 13.7 20.0 9.6 
(S)-2.143 
(Cy5.5) 
Excitation  [nm] n.t. 690 690 690 690 690 
Emission  [nm] n.t. 730 707 710 722 714 
Stokes shift [nm] n.a. 40 17 20 32 24 





A)  UV-Vis spectra of (±)-2.106 (NBD) B) Fluorescence spectra of (±)-2.106 (NBD) 
C)  UV-Vis spectra of 2.134 (Alexa 488) D)  Fluorescence spectra of 2.134 (Alexa 488) 
E) UV-Vis spectra of 2.141 (AttoThio12) F) Fluorescence spectra of 2.141 (AttoThio12) 
G) UV-Vis spectra of 2.143 (Cy5.5) H) Fluorescence spectra of 2.143 (Cy5.5) 
Supplementary figure S-2. Solution spectra of compounds NBD-2.106 (A and B), Alexa 488-2.134 (C and 
D), AttoThio12-2.141 (E and F), and Cy5.5-2.143 (G and H). A), C), E) and G) UV-Vis spectra (50 µM probe 
for A, C and G; 10 µM probe for E). B), D), F) and H) technical excitation and emission fluorescence spectra not 
corrected for chromatic aberrations (10 µM probe) in indicated organic solvents and aqueous solution. Excitation 
and emission spectra are depicted with dashed or solid lines, respectively. 
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5.2.10.4. In vitro Pharmacology and ADME Profile 
The binding affinity (Ki) of all compounds reported in this thesis were determined by ELISABETH 
ZIRWES and the cAMP functional assays (EC50) of these compounds were performed by ANJA 
OSTERWALD, both at Hoffmann La-Roche, Basel. 
 
Radioligand binding assay and cAMP assay 
Radioligand binding assays and forskolin-stimulated cAMP assays were performed as described by 
Soethoudt et al.[194] CHO-DUKX_HOMSA_CNR2_Clone_90_CRE-Luc, CHO-
DUKX_HOMSA_CNR1 _Clone_20_CRE-Luc, and CHO-K1_MUSMU_CNR2_beta arrestin 
(DiscoverX #93-0472C2) cells were cultured and membranes for radioligand binding assays were 
prepared in analogy to Soethoudt et al.[194] Excluding the culturing step, mouse brain_140603 
membranes were prepared using the same protocol (protein concentration: 2290 µg/ml, KD: 8.291 
nM, Bmax: 9.67 pmol/ mg protein). Ki measurements were performed using 0.3 nM 3H-CP55´940 (SI-
6) radioligand for hCB1R, hCB2R and mCB2R and 1.5 nM 3H- SI-6 radioligand for mCB1R. Reference 
compounds for binding and cAMP assays were selected in accordance to literature.[194] The 
corresponding mean Ki and EC50 values, as well as standard error of the mean (SEM), are stated below. 
Data are means from one or two independent experiments performed in triplicate. 
hCB2R Ki: the mean Ki value of the positive control JWH133 (2.145) used for each run was 34.9 nM 
and standard error of the mean (SEM) for this standard compound was ±3.4 nM (n=128). 
hCB1R Ki: the mean Ki value of the positive control Rimonabant (SI-5) used for each run was 2.8 nM 
and standard error of the mean (SEM) for this standard compound was ±0.2 nM (n=105). 
mCB2R Ki: the mean Ki value of the positive control WIN55212-2 (SI-3) used for each run was 5.8 
nM and standard error of the mean (SEM) for this standard compound was ±1.3 nM (n=57). 
hCB2R, mCB2R, and hCB1R cAMP EC50: the mean EC50 value of the positive control CP55,940 (SI-
6) used for each run were 0.08 nM, 0.05 nM and 0.11 nM, respectively, and standard error of the mean 




The chemical structures of reference compounds JWH133 (2.145, CB2R selective agonist), 
Rimonabant (SI-5, CB1R selective agonist), WIN55212-2 (SI-3, non-selective agonist) and CP55,940 
(SI-6, non-selective agonist) are shown in Supplementary figure S-1, Section 5.2.1. 
Lipophilicity (logD), kinetic solubility and PAMPA assays were prepared and carried out as described 
in literature.[194]  
 
5.2.10.5. Fluorescence Assays: FACS, TR-FRET, and Confocal Imaging 
 
FACS Assay 
The following experiments were performed by DR. CLAUDIA KORN at Hoffmann La-Roche, Basel.  
 
General procedure for FACS in hCB2R-overexpressing CHO cells 
For the validation of CB2R-selective fluoroprobes via FACS analysis, 50’000 WT-CHO (wildtype), or 
CHO cells overexpressing hCB2R, mCB2R, or hCB1R were incubated with different concentrations of 
CB2R-agonist probes (0.005 µM – 10 µM) in PBS/0.5% BSA/2 mM EDTA for 30 min at 4 °C. For 
cold ligand replacement experiments, 50’000 WT-CHO cells or CHO cells overexpressing hCB2R 
were pre-incubated with 10 µM JWH133 (2.145) or RO6851228 (2.146) (see Supplementary figure S-1, 
Section 5.2.1. for chemical structures) in PBS/0.5% BSA/2 mM EDTA at room temperature. After 
30 min, different concentrations of probe Alexa 488-2.134 were added to the cell suspensions (5 nM 
– 370 nM) and cells were incubated for another 30 min at 4 °C. In both experiments, after probe 
incubation, cells were washed 3 times with PBS/0.5% BSA/2 mM EDTA and re-suspended in 
PBS/0.5% BSA/2 mM EDTA containing 1:1000 AquaZombie (Biolegend 423102). After exclusion 
of dead cells, mean fluorescent intensity of viable cells was determined. Data are presented in mean ± 





The following experiments were performed by DR. DAVID SYKES at The University of Nottingham, 
Nottingham.  
 
General procedure for TR-FRET assay 
Cell culture: Cells were maintained under classical cell culture conditions in a humidified environment 
at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum 
(FBS) containing blasticidin (5 µg/ml; Invitrogen) and Zeocin (20 µg/ml; Invitrogen). For inducible 
expression, SNAP-tagged hCB2R cDNAs, in pcDNA4/TO were introduced through transfection, 
using PEI into HEK293-TR cells (Invitrogen, which express Tet repressor protein to allow inducible 
expression). A mixed population stable line was selected by resistance to blasticidin (TR vector, 5 
µg/ml) and Zeocin; (receptor plasmid, 20 µg/ml). For receptor-inducible expression, cells were seeded 
into t175 cm2 flasks, grown to 70% confluence and DMEM containing 1 µg/ml tetracycline added. 
24h later cells were labelled with SNAP-Lumi4-Tb (CisBio) and membranes prepared as described in 
detail below. 
Terbium labeling of SNAP-tagged CB2R HEK293-TR cells: Cell culture medium was removed from 
the t175 cm2 flasks containing confluent adherent CB2R HEK293-TR cells. Cells were washed once 
in PBS (GIBCO Carlsbad, CA) and once in Tag-lite labeling medium (LABMED, CisBio) to remove 
the excess cell culture media, then ten milliliter of LABMED containing 100 nM of SNAP-Lumi4-Tb 
was added to the flask and incubated for 1 h at 37 °C under 5% CO2. Cells were washed once in PBS 
(GIBCO Carlsbad, CA) to remove the excess of SNAP-Lumi4-Tb then detached using 5 ml of 
GIBCO enzyme-free Hank’s-based cell dissociation buffer (GIBCO, Carlsbad, CA) and collected in 
a vial containing 5 ml of DMEM (Sigma-Aldrich) supplemented with 10% fetal calf serum. Cells were 
pelleted by centrifugation (5 min at 1500 rpm) and the pellets were frozen to −80 °C. To prepare 
membranes, homogenization steps were conducted at 4 °C (to avoid receptor degradation) as 
described by Herenbrink et al.[309] 
Fluorescent ligand-binding assays: All fluorescent ligand binding experiments were conducted in white 
384-well Optiplate plates, in assay binding buffer LABMED (Cisbio, Codolet, France) containing 
5mM HEPES, 0.5% BSA, 0.02% pluronic acid pH 7.4, and 100 µM GppNHp. GppNHp prevents G 
protein binding to GPCRs and was included to remove the G protein-coupled population of receptors 
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that can result in two distinct populations of binding sites in membrane preparations, since the 
Motulsky-Mahan model is only appropriate for ligands competing at a single site. In all cases, 
nonspecific binding was determined by the presence of 1 µM SR144528 (2.20). Data are presented in 
mean ± SEM from a representative of 3-8 experiments. 
Determination of fluorescent ligand binding kinetics and equilibrium affinity: To accurately determine 
association rate (kon) and dissociation rate (koff) values, the observed rate of association (kob) was 
calculated using at least five different concentrations fluorescent ligand. The appropriate 
concentration of fluorescent ligand binding was incubated with human CB2R HEK293-TR cell 
membranes (4 µg per well) in assay binding buffer (final assay volume, 40 µL). The degree of 
fluorescent ligand bound to the receptor was assessed at multiple time points by HTRF detection to 
allow construction of association kinetic curves. The resulting data were globally fitted to the 
association kinetic model (Eq. 1, see signal detection and data analysis section below) to derive a single 
best-fit estimate for kon and koff as described under data analysis. Fluorescent probe Kd values were 
determined through saturation analysis. The appropriate concentration of fluorescent ligand binding 
was incubated with hCB2R HEK293-TR cell membranes (4 µg per well) in assay binding buffer (final 
assay volume: 40 µL) performed at equilibrium, by simultaneously fitting total and nonspecific (NSB) 
binding data (Eq. 2, see signal detection and data analysis section below) allowing the determination of 
fluorescent ligand binding affinity. 
Determination of ligand binding kinetics: To determine the association and dissociation rates of CB2R 
specific ligands, we used a competition-association binding assay.[310] This approach involves the 
simultaneous addition of both fluorescent ligand and competitor to the receptor preparation so that 
at t = 0 all receptors are unoccupied. To achieve this aim HEK293 cell membranes containing hCB2R 
(4 µg per well) were added to wells containing 62.5 nM NBD-2.106 or 150 nM Alexa 488-2.134, 
concentrations which avoid ligand depletion in the assay volume, and a fixed concentration of 
modulators SR144528 (2.20) or HU308 (2.28), designed to produce approximately 50% inhibition of 
probe binding, in a total assay volume of 40 µL. The degree of fluorescent ligand bound to the receptor 
was assessed at multiple time points by HTRF detection. The kinetic parameters of fluorescent ligands 
NBD-2.106 and Alexa 488-2.134, plus those of unlabeled compounds, were determined using a start 
time of ~30 s and an interval time of 20 s. Non-specific binding was determined as the amount of 
HTRF signal detected in the presence of 2.20 (1µM) and was subtracted from each time point, 
meaning that the signal at t = 0 was always equal to zero. Each time point was conducted on the same 
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384-well plate incubated at room temperature with orbital mixing (1 sec of 100 RPM/cycle). Data 
were globally fitted using Eq. 3 (see below) to simultaneously calculate kon and koff of unlabelled 
compounds.  
Competition binding: To determine the affinity of CB2R-specific ligands, a simple competition kinetic 
binding assay was used. This approach involved the simultaneous addition of both fluorescent ligand 
and competitor to the CB2R preparation. 62.5 nM NBD-2.106 or 150 nM Alexa 488-2.134, 
concentrations which avoid ligand depletion in the assay volume, were added simultaneously with 
increasing concentrations of the unlabeled compound to CB2R cell membranes (4 µg per well) in 40 
µL of assay buffer in a 384-well plate incubated at room temperature with orbital mixing. The degree 
of fluorescent ligand bound to the receptor was assessed at equilibrium by HTRF detection. 
Nonspecific binding was determined as the amount of HTRF signal detected in the presence of 2.20 
(1 µM) and was subtracted from total binding, to calculate specific binding for construction of IC50 
curves. Data were fitted to Eq. 4 to calculate IC50 estimates which were converted to Ki values using 
the Cheng-Prusoff correction Eq. 5. 
Signal detection and data analysis: Signal detection was performed on a Pherastar FSX (BMG Labtech, 
Offenburg, Germany). The terbium donor was always excited with eight laser flashes at a wavelength 
of 337 nm. TR-FRET signals were collected at 520 (acceptor) and 620 nm when using the green 
acceptor fluorescent ligands (±)-NBD-2.106 and Alexa 488 (R)-2.134. 
HTRF ratios were obtained by dividing the acceptor signal by the donor signal and multiplying this 
value by 10’000. All experiments were analyzed by non-regression using Prism 8.0 (GraphPad 
Software, San Diego, USA). 
Fluorescent ligand association data were fitted as follows to a global fitting model using GraphPad 
Prism 8.0 to simultaneously calculate kon and koff using the following equation,  
kob = [L]*kon + koff                                                               (Eq. 1) 
Y = Ymax*(1-exp(-1*kob*X)) 
Where, kob equals the observed rate of ligand association and kon and koff are the association and 
dissociation-rate constants respectively of the fluorescent ligand. In this globally fitted model of tracer 
binding, tracer concentrations [L] are fixed, kon and koff are shared parameters whilst kob is allowed to 
vary. Here, Y is the level of receptor-bound tracer, Ymax is the level of tracer binding at equilibrium, X 




Saturation binding data were analyzed by non-linear regression according to a one-site equation by 
globally fitting total and nonspecific binding (NSB). Individual estimates for the fluorescent ligand 
dissociation constant (Kd) were calculated using the following equations where L is the fluorescent 
ligand concentration: 
Total Binding = Specific + NSB =  
Bmax. [L]
Kd + [L]
+ slope[L] + background 
NSB = Slope[L] + background 
Fitting the total and NSB data sets globally (simultaneously), sharing the value of slope, provides one 
best-fit value for both the Kd and the Bmax. 
Association and dissociation rates for unlabeled compounds were calculated using the following 
equations first described by Motulsky and Mahan:[310] 
KA = k1[L] + k2                                                                 (Eq. 3) 
KB = k3[I] + k4  
S = √((KA  −  KB)
2+4.K1K3.L.I.10
−18) 
KF = 0.5(kA + kB + S) 
KS = 0.5(kA + kB – S)  
𝑄 =  














Where: X = Time (min), Y = Specific binding (eg. HTRF units, HTRF ratio 520nm/620nm*10,000), 
k1 = kon tracer (M
-1min-1), k2 = koff tracer (min
-1), L = Concentration of tracer used (nM), I = 
Concentration unlabeled ligand (nM). Fixing the above parameters allows the following to be 
calculated: k3 = Association-rate constant of unlabeled ligand (M
-1min-1), k4 = Dissociation-rate 
constant of unlabeled ligand (min-1), Bmax = Maximal specific binding of the system at equilibrium 
binding (eg. HTRF units, HTRF ratio 520nm/620nm*10,000). 
Competition displacement binding data were fitted to sigmoidal (variable slope) curves using a “four-
parameter logistic equation”: 




IC50 values obtained from the inhibition curves were converted to Ki values using the method of 
Cheng and Prusoff:[311] 
Ki = IC50/(1+[fluorescent tracer concertation]/Kd)                                    (Eq. 5) 
 
Time-lapse confocal microscopy and Airyscan high-resolution imaging 
The following experiments were performed by DR. SERGIO ODDI at The University of Teramo, 
Teramo. 
 
General procedure for imaging acquisition 
To minimize receptor internalization and, thus, to maximize the signal on the plasma membrane, 
confocal imaging experiments were performed at 22 °C. For real-time labelling studies, cells were 
plated onto 8-well chamber slides (Ibidi, Milan, Italy), at a density of 20’000 cells/well and cultured 
for 24 h. For a nuclear staining, the medium was replaced by 1 µg/mL Hoechst 33342 in RPMI (Sigma-
Aldrich, Milan, Italy) and the cells were incubated for 10 min at 37 °C, then washed with PBS twice. 
A small volume of SiR-2.142, dissolved at 10 mM in DMSO, was mixed with the 20% (w/v) Pluronic 
F-127 stock solution in DMSO (Sigma-Aldrich) at a ratio of 1:1 immediately before use. Prior to 
imaging, the solution of 2.142 and Pluronic F-127 was diluted at 0.4 µM in HEPES-buffered RPMI 
and quickly added to the cells without any washing step. SiR-2.142 was excited using a 640 nm laser 
line and the corresponding fluorescence emission was detected using a 655 nm long-pass filter, 
whereas Hoechst 33342 was excited with a dedicated 405 nm UV diode, and the corresponding 
fluorescence emission was detected using a 490/40 nm band-pass filter. Images within each 
experiment were collected by using identical laser-power, offset, and gain setting that was adjusted to 
minimize the level of auto-fluorescence under 640 nm. Live imaging was performed at 22 ± 2 °C by 
recording one frame every 15 sec for 10 min. At the end of recording session, living cells were imaged 
using the Airyscan mode. Each image was taken at the equatorial plan of the cells, using the ZEN 
Blue 2.3 software (Zeiss). Super-resolution image processing was performed using the Airyscan 
processing toolbox within the ZEN software package. The data were exported as TIFF files and 
analyzed using the Fiji software (National Institutes of Health; https://imagej.net/Fiji). A Gaussian 
kernel filter was applied to the images using a standard deviation of 0.8 pixels. All intensity profiles 
were background subtracted and normalized to the frame taken at the end of registration. For 
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presentation purposes, images were exported in Artstudio Pro version 2.0.13 (Lucky Clan, Lodz, 




5.3. To “Development of a DOTA-based Clickable Platform for Pancreatic Cancer Imaging” 
 
5.3.1. Synthesis of DOTA Building Blocks 
Tri-tert-butyl 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (3.15) 
A suspension of cyclen 3.10 (1.0 g, 5.80 mmol) and sodium acetate (1.6 g, 19.0 mmol) in 
dimethylacetamide (12 mL) was stirred at –20 °C. To this suspension, a solution of tert-butyl 
bromoacetate (2.8 mL, 19.1 mmol) in dimethylacetamide (4 mL) was added dropwise over a period of 
30 min. The temperature was maintained at –20 °C during the addition. After which, the reaction 
mixture was allowed to warm slowly to room temperature. After 20 hours of vigorous stirring, the 
reaction mixture was poured into water (60 mL), which gave a clear solution. Subsequent portion wise 
addition of potassium bicarbonate (3.0 g, 30.0 mmol) stimulated the precipitation of compound 3.15 
to a white solid. The precipitate was collected by filtration and dissolved in chloroform (50 mL). The 
organic solution was washed with water (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure to about 15 mL. Addition of ethyl ether (50 mL) led to crystallization of compound 
3.15 to a white fluffy solid (2.7 g, 90%).  
1H NMR (300 MHz, CDCl3) δ ppm 3.37 (s, 4H), 3.29 (s, 2H), 3.10 (t, J = 4.7 Hz, 3H), 2.99 – 2.80 
(m, 10H), 1.66 (s, 4H), 1.46 (s, 27H).  






To a suspension of compound 3.15 (2.0 g, 3.88 mmol) in acetonitrile (20 mL), potassium carbonate 
(0.8 g, 5.82 mmol) and subsequently benzyl bromoacetate (0.7 mL, 4.66 mmol) were added. The 
reaction was vigorously stirred at room temperature for 15 h. The precipitated solids were removed 
by filtration, and the filtrate was concentrated under reduced pressure to give the crude product, which 
was purified by column chromatography (Silica gel, 15 g, DCM:MeOH, 0 to 10% MeOH) to afford 
tert-butyl analog 3.21 in 88% yield (2.3 g) as a light yellow oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.32 – 7.27 (m, 1H), 7.26 – 7.20 (m, 3H), 5.08 (dd, J = 16.0, 3.2 
Hz, 2H), 3.61 – 3.53 (m, 1H), 3.34 (s, 11H), 3.18 – 2.57 (m, 13H), 1.45 – 1.26 (m, 27H).  




Tri-carboxylic acid DOTAM alkyne (3.22) 
To a solution of 3.15 (1.6 g, 2.91 mmol) in acetonitrile (60 mL) was added potassium carbonate (1.0 
g, 7.35 mmol) and the suspension was stirred for 20 min. The solution was placed in an ice-bath and 
propargyl bromide (0.35 mL, 2.92 mmol) was added dropwise. The ice-bath was removed, and the 
reaction was allowed to reach room temperature and stirred over night at room temperature. Inorganic 
solids were removed by filtration, and the filtrate was concentrated under reduced pressure to give the 
crude product. Purification by column chromatography (Silica gel, 4 g, DCM:MeOH, 5 to 15% 
MeOH) was performed to yield t-butyl protected 3.22 as a colorless solid (1.5 g, 91%).  
1H NMR (300 MHz, CDCl3) δ ppm 3.92 (d, J = 41.7 Hz, 2H), 3.46 (d, J = 9.2 Hz, 2H), 3.39 – 3.25 
(m, 3H), 3.24 – 2.98 (m, 8H), 2.94 – 2.21 (m, 9H), 2.17 – 2.11 (m, 1H), 1.50 – 1.40 (m, 27H), 1.24 (s, 
2H).  
The analytical data are in accordance with those reported in the literature.[274d] 
 
Tert-butyl 2-(1,4,7,10-tetraazacyclododecan-1-yl)acetate (3.23) 
To a stirring solution of cyclen 3.10 (3.4 g, 20.0 mmol) in chloroform (40 mL) at 0 ºC tert-butyl 
bromoacetate (1.5 mL, 10.0 mmol) in chloroform (10 mL) was slowly added (1 h). Stirring was 
continued for additional 3 hours, and the reaction mixture was concentrated under reduced pressure. 
Subsequently, the crude residue was purified by reversed-phase column chromatography (C-18, 30 g, 
Water:MeOH with 0.1% triethylamine, 25 to 90% MeOH) to yield the title compound 3.23 in 51% 
yield (2.9 g) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ ppm 3.22 (s, 2H), 2.78 – 2.52 (m, 16H), 2.48 – 2.41 (m, 3H), 1.41 
(s, 9H). 





A suspension of compound 3.23 (100 mg, 0.35 mmol) and potassium carbonate (134 mg, 0.97 mmol) 
in acetonitrile (7 mL) was purged with nitrogen. To this suspension, a solution of benzyl bromoacetate 
(0.2 mL, 1.40 mmol) in acetonitrile (3 mL) was added dropwise at room temperature. The reaction 
mixture was stirred at room temperature for 8 h. Afterwards, the crude mixture was filtered and 
concentrated under reduced pressure. The crude material was diluted with dichloromethane (10 mL), 
washed with water (3x), and brine (3x), dried over MgSO4, and concentrated under reduced pressure. 
The crude material was purified by column chromatography (Silica gel, 4 g, DCM:MeOH, 0 to 4% 
MeOH) to afford the title compound 3.24 in 91% yield as a colorless oil (232 mg). 
1H NMR (300 MHz, CDCl3) δ ppm δ 7.38 – 7.27 (m, 15H), 5.23 – 5.02 (m, 6H), 3.88 – 1.69 (m, 25H), 
1.44 (s, 9H).  




5.3.2. Synthesis of Linker Building Blocks 
(9H-Fluoren-9-yl)methyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (3.26) 
9-Fluorenylmethyl chloroformate (228 mg, 0.88 mmol) was added to a solution of N-Boc-1,2-bis(2-
aminoethoxy)ethane 3.25 (200 mg, 0.80 mmol) dissolved in a mixture of 1,4-dioxane and sodium 
carbonate aq. sol. (15% w/w, 2.5 mL, 1:1, v:v), and the reaction mixture was stirred at room temperature. 
After 3 h, the reaction mixture was diluted with chloroform (5 mL), and washed with water (1x), 
hydrochloric acid aq. sol. (1M, 1x) and brine (1x). The organic layer was dried over MgSO4, filtered 
and evaporated under reduced pressure. The crude residue was purified by column chromatography 
(Silica gel, 15 g, DCM:MeOH, 3% MeOH) to afford N-Boc protected compound 3.26 in 74% yield 
(278 mg) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ ppm 7.75 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.4 Hz, 2H), 7.39 (td, J = 
7.5, 1.2 Hz, 2H), 7.30 (td, J = 7.5, 1.3 Hz, 2H), 5.45 (s, 1H), 5.15 – 4.98 (m, 1H), 4.41 (d, J = 7.0 Hz, 
2H), 4.22 (t, J = 7.0 Hz, 1H), 3.67 – 3.46 (m, 7H), 3.39 (q, J = 5.3 Hz, 2H), 3.30 (q, J = 5.2 Hz, 2H), 
1.43 (s, 9H). 
The analytical data are in accordance with those reported in the literature.[312] 
Subsequently, N-Boc protected 3.26 (278 mg, 0.58 mmol) was dissolved in dichloromethane (3 mL) 
and trifluoroacetic acid (3 mL) was slowly added to the solution. The reaction mixture was stirred at 
room temperature for 2 h to complete conversion to product. Afterwards, the solvent was removed 
under reduced pressure, and co-evaporated with toluene (3x) to yield free amine 3.26 as a white solid 
(quant.). The residue was directly used as a trifluoroacetic acid salt for the next reaction step, without 







Cyanine 5.5 carboxylic acid (20 mg, 0.03 mmol), HATU (13 mg, 0.03 mmol), and N,N-
diisopropylethylamine (18 uL, 0.10 mmol) were dissolved in dimethylformamide (2 mL) at room 
temperature under nitrogen atmosphere. After 10 min, N-Boc-1,2-bis(2-aminoethoxy)ethane 3.25 (8.5 
mg, 0.03 mmol) in dimethylformamide (1 mL) was added to the reaction mixture and stirred for 30 
min at room temperature. After completion, the reaction mixture was concentrated under reduced 
pressure, taken up in a mixture of acetonitrile and water (1:1) and purified by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 95% ACN). The fractions containing 
product were combined and lyophilized to yield tert-butyl protected 3.27 in 62% yield (17 mg) as a 
blue powder.  
1H NMR (600 MHz, DMSO-d6) δ ppm 8.45 (t, J = 13.1 Hz, 2H), 8.25 (dd, J = 8.5, 3.2 Hz, 2H), 8.12 
– 8.03 (m, 3H), 7.82 – 7.65 (m, 5H), 7.51 (t, J = 7.5 Hz, 2H), 6.73 (t, J = 5.7 Hz, 1H), 6.62 (t, J = 12.3 
Hz, 1H), 6.34 (dd, J = 24.0, 13.8 Hz, 2H), 4.22 (t, J = 7.4 Hz, 2H), 3.73 (s, 3H), 3.34 (td, J = 6.1, 3.7 
Hz, 7H), 3.15 (q, J = 5.9 Hz, 2H), 3.04 (q, J = 6.1 Hz, 2H), 2.07 (t, J = 7.3 Hz, 2H), 1.96 (d, J = 3.3 
Hz, 13H), 1.78 – 1.71 (m, 2H), 1.56 (p, J = 7.3 Hz, 2H), 1.39 (dt, J = 11.8, 6.9 Hz, 2H), 1.34 (s, 9H). 
13C NMR (151 MHz, DMSO-d6) δ ppm 174.3, 171.9, 157.5, 155.7, 155.6, 152.8, 140.4, 139.7, 133.1, 
131.3, 130.3, 130.2, 129.9, 127.7, 127.6, 127.5, 125.5, 124.7, 122.1, 122.1, 111.6, 103.1, 102.8, 87.1, 84.6, 
77.6, 69.5, 69.4, 69.1, 50.7, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1, 38.4, 35.0, 31.5, 28.2, 27.0, 26.8, 26.6, 
25.7, 24.9.  
HR-MS (ESI) m/z [M+2] calcd. for C51H66N4O5: 407.2511, found 407.2460. 
Subsequently, tert-butyl protected 3.27 (17 mg, 0.02 mmol) was dissolved in dichloromethane (0.2 mL) 
and trifluoroacetic acid (0.2 mL) was slowly added to the solution. The reaction mixture was stirred at 
room temperature for 2 h to complete conversion to product. Afterwards, the solvent was removed 
under reduced pressure, and co-evaporated with toluene (3x) to yield free amine 3.27 as a blue solid 
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(quant.). The residue was directly used as a trifluoroacetic acid salt for the next reaction step, without 
the need of further purification. 
 
1-(2-(2-(2-Aminoethoxy)ethoxy)ethyl)-1H-pyrrole-2,5-dione (3.28) 
N-Boc-1,2-bis(2-aminoethoxy)ethane 3.25 (500 mg, 2.01 mmol) was dissolved in sodium bicarbonate 
sat. sol. and cooled to 0 °C. The activated maleimide (methyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-
carboxylate, 344 mg, 2.21 mmol) was added. The reaction mixture was stirred at 0 °C for 1 h, and then 
at room temperature for 45 min. The mixture was extracted with chloroform (3x) and the combined 
organic phases were dried over MgSO4, filtered over celite, and concentrated under reduced pressure. 
The crude residue was purified by column chromatography (Silica gel, 15 g, DCM:MeOH, 4% MeOH) 
to afford N-Boc protected compound 3.28 as a colorless oil in 80% yield (527 mg).  
1H NMR (300 MHz, CDCl3) δ ppm 6.68 (s, 2H), 5.02 (s, 1H), 3.73 – 3.67 (m, 2H), 3.63 – 3.43 (m, 
8H), 3.25 (t, J = 5.2 Hz, 2H), 1.40 (s, 9H).  
The analytical data are in accordance with those reported in the literature.[313] 
Subsequently, tert-butyl protected 3.28 (500 mg, 1.52 mmol) was dissolved in dichloromethane (5 mL) 
and trifluoroacetic acid (5 mL) was slowly added to the solution. The reaction mixture was stirred at 
room temperature for 2 h to complete conversion to product. Afterwards, the solvent was removed 
under reduced pressure, and co-evaporated with toluene (3x) to yield free amine 3.28 as a light yellow 
oil (quant.). The residue was directly used as a trifluoroacetic acid salt for the next reaction step, 






Cyanine 5.5 carboxylic acid (20 mg, 0.03 mmol), HATU (13 mg, 0.03 mmol), and N,N-
diisopropylethylamine (18 uL, 0.10 mmol) were dissolved in dimethylformamide (2 mL) at room 
temperature under nitrogen atmosphere. After 10 min, propargyl amine (38 mg, 0.03 mmol) in 
dimethylformamide (1 mL) was added to the reaction mixture and stirred for 30 min at room 
temperature. After completion, the reaction mixture was concentrated under reduced pressure, taken 
up in a mixture of acetonitrile and water (1:1) and purified by reversed-phase preparative HPLC (C-
18, Water:ACN with 0.1% TFA, 30 to 90% ACN). The fractions containing product were combined 
and lyophilized to yield the title compound 3.59 in 93% yield (20 mg) as a blue powder.  
1H NMR (600 MHz, DMSO-d6) δ ppm 8.46 (t, J = 13.2 Hz, 2H), 8.31 – 8.19 (m, 3H), 8.12 – 8.05 (m, 
4H), 7.79 – 7.72 (m, 2H), 7.71 – 7.67 (m, 2H), 7.52 (t, J = 7.5 Hz, 2H), 6.64 (t, J = 12.2 Hz, 1H), 6.36 
(dd, J = 22.3, 14.1 Hz, 2H), 4.26 – 4.21 (m, 2H), 3.85 – 3.81 (m, 2H), 3.75 (s, 2H), 3.06 (s, 1H), 2.09 
(s, 3H), 1.97 (s, 12H), 1.76 (t, J = 7.9 Hz, 2H), 1.61 – 1.53 (m, 2H), 1.44 – 1.38 (m, 2H). 
13C NMR (151 MHz, DMSO-d6) δ ppm 174.3, 173.5, 171.6, 152.8, 140.4, 139.7, 133.1, 133.0, 131.3, 
131.2, 130.3, 130.2, 129.9, 127.7, 127.6, 127.5, 125.5, 124.7, 122.1, 122.1, 111.6, 103.1, 102.8, 81.3, 72.8, 
50.7, 43.4, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1, 34.8, 31.5, 30.7, 27.7, 26.9, 26.8, 26.6, 25.7, 24.7.  




General procedure for maleimide-PEG-dye constructs 
Cy3 or Cy5.5 carboxylic acid (1 equiv., 0.05 mmol), HATU (1 equiv.) and N,N-diisopropylethylamine 
(3 equiv.) were dissolved in ACN (4 mL). After 10 min, maleimide-PEG2 linker 3.28 (1 equiv.) 
dissolved in ACN (1 mL) was added to the reaction mixture and stirred at room temperature for 30 
min. Afterwards, the reaction mixture was directly purified by reversed-phase preparative HPLC (C-
18, Water:ACN with 0.1% TFA, 30 to 95% ACN). The fractions containing product were combined 




Following the general procedure described above, linker 3.29 was obtained in 74% yield (24 mg) 
starting from Cy3 carboxylic acid (23 mg, 0.05 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 8.38 (t, J = 13.4 Hz, 1H), 7.45 – 7.33 (m, 5H), 7.28 (s, 1H), 7.23 
(s, 1H), 7.18 – 7.06 (m, 2H), 6.90 (s, 1H), 6.71 (s, 1H), 6.65 – 6.46 (m, 2H), 4.06 (q, J = 7.8 Hz, 2H), 
3.75 – 3.38 (m, 13H), 2.49 (t, J = 6.8 Hz, 1H), 2.29 (t, J = 7.3 Hz, 1H), 1.91 – 1.78 m, 2H), 1.72 (s, 
15H), 1.64 – 1.44 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ ppm 175.2, 174.9, 174.6, 174.1,, 173.8, 170.9, 150.7, 142.8, 142.1, 140.7, 
140.5, 134.5, 129.1, 125.7, 125.6, 125.5, 122.4, 122.3, 122.2, 122.1, 118.5, 114.6, 111.2, 111.0, 110.9, 
104.5, 104.1, 103.8, 103.6, 70.3, 70.0, 69.9, 68.0, 49.2, 49.2, 49.2, 49.1, 44.6, 44.4, 39.2, 37.3, 36.1, 34.3, 
31.7, 31.5, 28.3, 28.2, 28.1, 27.2, 26.4, 26.0, 25.4.  







Following the general procedure described above, linker 3.30 was obtained in 55% yield (23 mg) 
starting from Cy5.5 carboxylic acid (30 mg, 0.07 mmol).  
1H NMR (600 MHz, DMSO-d6) δ ppm 8.46 (t, J = 13.1 Hz, 2H), 8.26 (dd, J = 8.8, 4.1 Hz, 2H), 8.13 
– 8.03 (m, 4H), 7.79 – 7.72 (m, 2H), 7.69 (t, J = 7.7 Hz, 2H), 7.52 (t, J = 7.5 Hz, 2H), 7.00 (s, 2H), 
6.63 (t, J = 12.3 Hz, 1H), 6.35 (dd, J = 25.4, 13.8 Hz, 2H), 4.23 (t, J = 7.5 Hz, 2H), 3.74 (s, 3H), 3.55 
– 3.53 (m, 2H), 3.51 – 3.48 (m, 2H), 3.47 – 3.44 (m, 2H), 3.41 – 3.39 (m, 2H), 3.31 (t, J = 6.0 Hz, 2H), 
3.16 – 3.12 (m, 2H), 2.07 (s, 3H), 1.97 (s, 12H), 1.79 – 1.72 (m, 2H), 1.60 – 1.54 (m, i2H), 1.42 – 1.36 
(m, 2H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 174.3, 173.5, 171.9, 170.8, 164.2, 157.8, 152.8, 143.7, 140.4, 
139.7, 134.5, 133.0, 133.0, 131.3, 131.2, 130.3, 130.2, 129.9, 127.7, 127.6, 127.5, 125.5, 124.7, 122.1, 
122.1, 118.0, 111.6, 103.1, 102.8, 69.4, 69.3, 69.1, 66.9, 50.7, 43.4, 40.0, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1, 
38.4, 36.7, 35.0, 31.5, 27.0, 26.8, 26.6, 25.7, 24.9.  




General procedure for PEG azide-dye construct 
Cy3 or Cy5.5 carboxylic acid (1 equiv., 0.07 mmol), HATU (1 equiv.) and N,N-diisopropylethylamine 
(3 equiv.) were dissolved in ACN (4 mL). After 10 min, azido-PEG2 linker 3.31 (1.2 equiv.) dissolved 
in ACN (1 mL) was added to the reaction mixture and stirred at room temperature for 30 min. 
Afterwards, the reaction mixture was purified by reversed-phase preparative HPLC (C-18, Water:ACN 
with 0.1% TFA, 30 to 90% ACN). The fractions containing product were combined and lyophilized 
to yield the desired product. 
1-(6-((2-(2-(2-Azidoethoxy)ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethyl-2-((E)-3-((E)-
1,3,3-trimethylindolin-2-ylidene)prop-1-en-1-yl)-3H-indol-1-ium (3.32) 
Following the general procedure described above, linker 3.32 was obtained in 63% yield (26 mg) 
starting from Cy3 carboxylic acid (30 mg, 0.07 mmol).  
1H NMR (300 MHz, CDCl3) δ ppm 8.39 (t, J = 13.5 Hz, 1H), 7.46 – 7.32 (m, 4H), 7.30 – 7.27 (m, 
1H), 7.25 – 7.23 (m, 1H), 7.13 (dd, J = 8.0, 4.0 Hz, 2H), 6.74 – 6.53 (m, 3H), 4.07 (t, J = 7.8 Hz, 2H), 
3.71 – 3.60 (m, 8H), 3.59 – 3.53 (m, 2H), 3.49 – 3.36 (m, 4H), 3.22 (s, 4H), 2.28 (t, J = 7.3 Hz, 2H), 
1.88 – 1.77 (m, 2H), 1.75 – 1.69 (m, 12H), 1.61 – 1.48 (m, 2H).  
13C NMR (75 MHz, CDCl3) δ ppm 174.6, 174.1, 173.8, 142.8, 142.7, 140.6, 140.5, 129.1, 128.9, 125.6, 
124.2, 122.2, 122.1, 111.2, 111.0, 104.2, 103.9, 101.2, 1000.0, 97.6, 83.4, 70.6, 70.4, 70.1, 69.9, 66.1, 
62.1, 50.8, 50.6, 49.3, 49.1, 44.6, 39.2, 36.3, 34.7, 31.5, 28.2, 28.2, 27.2, 26.5, 25.4.  







Following the general procedure described above, linker 3.33 was obtained in 79% yield (43 mg) 
starting from Cy5.5 carboxylic acid (42 mg, 0.07 mmol).  
1H NMR (600 MHz, DMSO-d6) δ ppm 8.46 (t, J = 13.1 Hz, 2H), 8.30 – 8.23 (m, 2H), 8.14 – 8.04 (m, 
4H), 7.83 – 7.65 (m, 5H), 7.52 (t, J = 7.5 Hz, 2H), 6.63 (t, J = 12.2 Hz, 1H), 6.35 (dd, J = 23.7, 13.8 
Hz, 2H), 4.23 (t, J = 7.5 Hz, 2H), 3.74 (s, 4H), 3.59 – 3.56 (m, 2H), 3.55 – 3.51 (m, 2H), 3.50 – 3.46 
(m, 2H), 3.40 – 3.33 (m, 4H), 3.17 (q, J = 5.9 Hz, 2H), 2.08 (t, J = 7.3 Hz, 2H), 2.03 – 1.92 (m, 11H), 
1.79 – 1.72 (m, 2H), 1.60 – 1.53 (m, 2H), 1.43 – 1.36 (m, 2H).  
13C NMR (151 MHz, DMSO-d6) δ ppm 174.3, 173.5, 171.9, 158.0, 157.7, 152.8, 140.4, 139.7, 133.0, 
133.0, 131.3, 131.2, 130.3, 130.2, 129.9, 127.7, 127.6, 127.5, 125.5, 124.7, 122.1, 122.1, 111.6, 103.1, 
102.8, 69.6, 69.5, 69.2, 50.7, 50.0, 43.4, 38.4, 35.0, 31.5, 31.5, 29.4, 27.0, 26.8, 26.6, 25.7, 24.9.  




5.3.3. Plectin-1 Targeting Peptide Deprotection Procedure 
L-lysyl-L-threonyl-L-leucyl-L-leucyl-L-prolyl-L-threonyl-L-prolyl-L-cysteine (Cys-3.4) 
The crude PTP sequence 3.4 (200 mg, 0.14 mmol) was dissolved in a fresh prepared deprotection 
cocktail (10 mL, composed by trifluoroacetic acid (94%), water (2.5%), dithiothreitol (DTT, 2.5%) 
and triisopropyl silane (TIPS, 1%), purged with nitrogen and stirred at room temperature for 20 h. 
After full conversion to product, the crude mixture concentrated under reduced pressure and co-
evaporated with toluene (2x). The crude powder was taken up in a mixture of acetonitrile and water 
(1:1) and purified by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 10 to 60% 
ACN, 220 nm). The fractions containing product were combined and lyophilized to yield the title 
compound 3.4 as a white powder (77 mg, 64%). 
HR-MS (ESI) m/z [M+H]+, [M+2H]+2 calcd. for C39H69N9O11S: [M+H]
+ 872.4910, found 872.5027; 
[M+2H]+2 436.7491, found 436.7552. 
 
5.3.4. Synthesis of Monovalent Control Probes 
General procedure 
A mixture of maleimide-linker-dye contruct 3.29 or 3.30 (1.0 equiv.) and ligand (1.3 equiv.) was stirred 
in volatile triethylammonium acetate buffer pH=5.0 (1 mL) and acetonitrile (0.3 mL) at room 
temperature for 20 h. The completion of the reaction was monitored by LC-MS, where quantitative 
conversion to product was seen. Subsequently, the reaction mixture was filtered and directly purified 
by reversed-phase preparative HPLC (C-18, Water:ACN with 0.1% TFA, 15 to 75% ACN, 220 nm 
detection). The fractions containing product were lyophilized to give compounds 3.34 to 3.39.  
Afterward, intermediates 3.34 to 3.39 (1 equiv.) were stirred at room temperature in a mixture of 
volatile ammonium carbonate buffer pH 8.9 and water (1:1, v/v, 1.5 mL). Hydrolysis of succinimide 
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rings was observed after 12 h of stirring at room temperature. After completion, the reaction mixture 





Following the general procedure described above, compound 3.40 was obtained in 25% yield (3.5 mg) 
as a pink powder starting from maleimide-PEG2-Cy3 3.29 (8.5 mg, 0.01 mmol) and Cys-PTP-3.4 
(KTLLPTPC, 4.3 mg, 0.006 mmol).  
3.34 (succinimide precursor): HR-MS (ESI) m/z [M+2] calcd. for C79H121N13O16S: 769.9382, found 
769.9348. 
3.40: HR-MS (ESI) m/z [M+2], [M+3H]+3 calcd. for C79H123N13O17S: [M+2] 778.9435, found 
778.9526; [M+3H]+3 520.3033, found 520.3062. 









Following the general procedure described above, compound 3.41 was obtained in 45% yield (3.0 mg) 
as a blue powder starting from maleimide-PEG2-Cy5.5 3.30 (6.7 mg, 0.008 mmol) and Cys-PTP-3.4 
(KTLLPTPC, 9.5 mg, 0.011 mmol).  
3.35 (succinimide precursor): HR-MS (ESI) m/z [M+3] calcd. for C89H127N13O16S: 555.6420, found 
555.6429.  
3.41: HR-MS (ESI) m/z [M+3H]+3, [M+2H]+2 calcd. for C89H128N13O17S: [M+3H]
+3 561.9830, found 
561.9851; [M+2H]+2 842.4709, 842.4733. 









Following the general procedure described above, compound 3.42 was obtained in 61% (6 mg) as a 
pink powder starting from maleimide-PEG2-Cy3 3.29 (4.3 mg, 0.006 mmol) and Cys-control peptide 
3.5 (SNLHPSDC, 8.5 mg, 0.01 mmol).  
3.36 (succinimide precursor): HR-MS (ESI) m/z [M+2] calcd. for C74H105N15O19S: 769.8710, found 
769.8692.  
3.42: HR-MS (ESI) m/z [M+3H]+3, [M+2] calcd. for C74H107N15O20S: [M+3H]
+3 520.2585, found 
520.2606; [M+2] 778.8763, found 778.8850.  









Following the general procedure described above, compound 3.43 was obtained in 63% (7.2 mg) as a 
blue powder starting from maleimide-PEG2-Cy5.5 3.30 (5.4 mg, 0.007 mmol) and Cys-control peptide 
3.5 (SNLHPSDC, 7.8 mg, 0.009 mmol).  
3.37 (succinimide precursor): HR-MS (ESI) m/z [M+3H]+3, [M+2] calcd. for C84H111N15O19S: [M+2] 
556.2707, found 556.2720; [M+2] 833.3960, found 833.4021. 
3.43: HR-MS (ESI) m/z [M+3H]+3, [M+2H]+2 calcd. for C84H112N15O20S: [M+3H]
+3 561.9382, found 
561.9388; [M+2H]+2 842.4037, found 842.4045. 








Following the general procedure described above, compound 3.44 was obtained in 67% (3.6 mg) as a 
pink powder starting from maleimide-PEG2-Cy3 3.29 (4.3 mg, 0.006 mmol) and methyl acetyl-L-
cysteinate 3.20 (1.7 mg, 0.01 mmol).  
3.38 (succinimide precursor): HR-MS (ESI) m/z [M]+ calcd. for C46H63N5O8S: 845.4392, found 845.4321.  
3.44: HR-MS (ESI) m/z [M]+, [M+2] calcd. for C45H63N5O9S: [M]
+ 849.4341, found 849.4419; [M+2] 
424.7168, found 424.7238.  







Following the general procedure described above, compound 3.45 was obtained in 85% (5.5 mg) as a 
blue powder starting from maleimide-PEG2-Cy5.5 3.30 (5.4 mg, 0.007 mmol) and methyl acetyl-L-
cysteinate 3.20 (1.6 mg, 0.009 mmol). 
3.39 (succinimide precursor): HR-MS (ESI) m/z [M]+ calcd. for C56H69N5O8S: 971.4861, found 971.4861. 
3.45: HR-MS (ESI) m/z [M]+, [M+2H]+2 calcd. for C55H68N5O9S: [M]
+ 974.4732, found 974.4832; 
[M+2H]+2 488.2442, found 488.2438. 





5.3.5. Synthesis of Tetravalent DOTAM Probe Precursors 
Tri-tert-butyl 2,2',2''-(10-(1-(9H-fluoren-9-yl)-3,14-dioxo-2,7,10-trioxa-4,13-diazapentadecan-
15-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (3.46) 
Benzyl-protected intermediate 3.21 (1.2 g, 1.80 mmol) was hydrogenolyzed over 10 % palladium on 
activated carbon (180 mg) in methanol (100 mL) for 12 h at room temperature. The catalyst was 
removed by filtration, and the filtrate was concentrated under reduced pressure. The crude material 
was subsequently used for amide coupling with Fmoc-protected linker 3.26.  
To a stirring solution of crude hydrogenolyzed material (572 mg, 1.0 mmol) in dimethylformamide (8 
mL) at room temperature HATU (380 mg, 1.0 mmol) and N,N-diisopropylethylamine (0.7 mL, 4.0 
mmol) were added. After 10 min, Fmoc-PEG2 linker 3.26 (407 mg, 1.0 mmol) dissolved in 
dimethylformamide (2 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the solution was diluted with ethyl acetate (50 
mL) and washed with water (2x). The organic layer was dried over MgSO4, filtered, and concentrated 
under reduced pressure. The crude oil was purified by column chromatography (Silica gel, 15 g, 
DCM:MeOH, 0 to 10% MeOH) to afford Fmoc-protected compound 3.46 as a colorless oil in 62% 
yield (574 mg).  
1H NMR (300 MHz, CDCl3) δ ppm 8.01 (s, 1H), 7.78 – 7.72 (m, 2H), 7.61 (d, J = 7.5 Hz, 2H), 7.43 
– 7.27 (m, 4H), 6.52 (s, 1H), 5.54 – 5.41 (m, 1H), 4.36 (d, J = 7.1 Hz, 2H), 4.21 (t, J = 7.2 Hz, 1H), 
3.64 – 3.49 (m, 8H), 3.42 – 3.35 (m, 3H), 2.95 (s, 4H), 2.88 (d, J = 0.7 Hz, 4H), 2.79 (s, 11H), 1.87 (s, 
4H), 1.44 (d, J = 3.2 Hz, 28H). 







Tert-butyl protected 3.46 (570 mg, 0.62 mmol) was dissolved in dichloromethane (8 mL) and 
trifluoroacetic acid (4 mL) was slowly added to the solution. The reaction mixture was stirred at room 
temperature for 16 h to complete conversion to product. Afterwards, the solvent was removed under 
reduced pressure, and co-evaporated with toluene (3x) to yield the free amine as a white solid (quant.). 
The residue was directly used for the next reaction step, without the need of further purification. 
To a stirring solution of crude tricarboxylic acid (164 mg, 0.22 mmol) in dimethylformamide (4 mL) 
at room temperature HATU (246 mg, 0.65 mmol) and N,N-diisopropylethylamine (0.3 mL, 1.73 
mmol) were added. After 10 min, maleimide-PEG2 linker 3.28 (148 mg, 0.65 mmol) dissolved in 
dimethylformamide (3 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the solution was concentrated under reduced 
pressure, taken up in a mixture of acetonitrile and water (1:1) and purified by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). The fractions containing 
product were lyophilized to afford Fmoc-protected 3.47 as a white powder in 46% yield (138 mg).  
1H NMR (300 MHz, DMSO-d6) δ ppm 8.34 (s, 3H), 7.89 (d, J = 7.5 Hz, 3H), 7.68 (d, J = 7.5 Hz, 
2H), 7.37 (dt, J = 27.3, 7.4 Hz, 5H), 7.02 (s, 5H), 4.53 – 3.86 (m, 14H), 3.72 – 2.70 (m, 62H).  
13C NMR (75 MHz, DMSO-d6) δ ppm 170.9, 143.9, 140.8, 134.6, 127.6, 127.1, 125.1, 120.2, 69.5, 69.3, 
69.1, 68.9, 67.0, 49.6, 36.8.  






To a stirring solution of Fmoc-protected 3.47 (221 mg, 0.16 mmol) in dimethylformamide (7 mL) at 
room temperature and under nitrogen atmosphere, isopropanol (121 µL, 1.58 mmol) in 
dimethylformamide (0.5 mL) was added, followed by tetrabutylammonium fluoride (TBAF, 320 µL, 
0.32 mmol) in dimethylformamide (0.5 mL). After 15 min stirring at room temperature, the reaction 
mixture was concentrated under reduced pressure and taken up in in acidic water (8.0 mL water with 
0.1%TFA). This aqueous solution was extracted with chloroform (10x), and the combined organic 
phase was extracted with water (1x). The combined aqueous phase was lyophilized to yield crude 
compound 3.48 as a red solid in 97% yield (180 mg, 0.16 mmol) without the need of further 
purification procedure.  





2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (3.52) 
Tri-benzyl protected intermediate 3.24 (215 mg, 0.29 mmol) was hydrogenolyzed over 10 % Palladium 
on Carbon (7.5 mg) in methanol (10 mL) for 12 h at room temperature. The catalyst was removed by 
filtration, and the filtrate was concentrated under reduced pressure. The crude tricarboxylic acid 3.51 
was subsequently used for amide coupling with maleimide-PEG2 linker 3.28. 
To a stirring solution of crude hydrogenolyzed 3.51 (100 mg, 0.22 mmol) in dimethylformamide (6 
mL) at room temperature HATU (256 mg, 0.67 mmol) and N,N-diisopropylethylamine (0.5 mL, 2.6 
mmol) were added. After 10 min, maleimide-PEG2 linker 3.28 (153 mg, 0.67 mmol) dissolved in 
dimethylformamide (2 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the crude material was concentrated under 
reduced pressure, diluted in a mixture of acetonitrile and water (1:1) and purified by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 5 to 75% ACN, 220 nm detection). The 
fractions containing product were lyophilized to give tert-butyl protected 3.52 as a pale yellow powder 
in 51% yield (120 mg).  
1H NMR (300 MHz, CDCl3) δ ppm 6.76 – 6.70 (m, 6H), 3.71 (t, J = 5.4 Hz, 7H), 3.64 – 3.59 (m, 7H), 
3.57 – 3.52 (m, 18H), 2.44 – 2.11 (m, 31H), 1.45 (s, 9H).  
HR-MS (ESI) m/z [M+H]+ calcd. for C50H78N10O17: 1091.5619, found 1091.5681. 
The obtained tert-butyl protected analog of compound 3.52 (120 mg, 0.11 mmol) was subsequently 
dissolved in dichloromethane (3 mL) and trifluoroacetic acid (3 mL) was slowly added to the solution. 
The reaction mixture was stirred at room temperature for 2 h to complete conversion to the free 
carboxylic acid 3.52. Afterwards, the solvent was removed under reduced pressure, and co-evaporated 
with toluene (3x) to yield 3.52 as a white solid (quant.). The residue was directly used for the next 






Benzyl-protected intermediate 3.21 (1.2 g, 1.8 mmol) was hydrogenolyzed over 10 % palladium on 
activated carbon (180 mg) in methanol (100 mL) for 12 h at room temperature. The catalyst was 
removed by filtration, and the filtrate was concentrated under reduced pressure.  
To a stirring solution of crude hydrogenolyzed material (20 mg, 0.03 mmol) in dimethylformamide (1 
mL) at room temperature HATU (11 mg, 0.03 mmol) and N,N-diisopropylethylamine (41 µL, 0.24 
mmol) were added. After 10 min, Cy5.5-PEG2 linker 3.27 (21 mg, 0.03 mmol) dissolved in 
dimethylformamide (0.5 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the reaction mixture was concentrated under 
reduced pressure, diluted in a mixture of acetonitrile and water (1:1) and purified by reversed-phase 
preparative HPLC (C-18, Water:ACN with 0.1% TFA, 30 to 90% ACN). The fractions containing 
product were lyophilized to afford compound tri-tert-butyl protected analog of 3.54 as a blue powder 
in 47% yield (20 mg).  
HR-MS (ESI) m/z [M+2], [M+3H]+3 calcd. for C74H108N8O10: [M+2] 634.4089, found 634.4097; 
[M+3H]+3 423.9469, found 423.9440. 
This compound (20 mg, 0.02 mmol) was subsequently dissolved in dichloromethane (1 mL) and 
trifluoroacetic acid (1 mL) was slowly added to the solution. The reaction mixture was stirred at room 
temperature for 2 h to complete conversion to tricarboxylic acid analog of title compound 3.54. 
Afterwards, the solvent was removed under reduced pressure, and co-evaporated with toluene (3x) to 
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yield compound 3.54 as a white solid (quant.). The residue was directly used for the next reaction step, 




Benzyl-protected intermediate 3.21 (1.2 g, 1.8 mmol) was hydrogenolyzed over 10 % Palladium on 
Carbon (180 mg) in MeOH (100 mL) for 12 h at room temperature. The catalyst was removed by 
filtration, and the filtrate was concentrated under reduced pressure.  
To a stirring solution of crude hydrogenolyzed material (300 mg, 0.52 mmol) in dimethylformamide 
(8 mL) at room temperature HATU (198 mg, 0.52 mmol) and N,N-diisopropylethylamine (0.4 mL, 
2.1 mmol) were added. After 10 min, azido-PEG2 linker 3.31 (100 mg, 0.57 mmol) dissolved in 
dimethylformamide (2 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the reaction mixture was diluted with ethyl 
acetate (50 mL) and stirred for additional 10 min. The crude solution was washed with water (2x), 
dried over MgSO4, filtered, and concentrated under reduced pressure. The crude material was purified 
by column chromatography (Silica gel, 4 g, DCM:MeOH, 0 to 10% MeOH) to afford compound 3.57 
in 33% yield (125 mg).  
1H NMR (300 MHz, CDCl3) δ ppm 8.00 (s, 1H), 3.71 – 3.48 (m, 8H), 3.43 – 3.32 (m, 4H), 3.01 – 2.70 
(m, 16H), 2.49 – 2.03 (s, 8H), 1.49 – 1.37 (m, 27H).  
13C NMR (75 MHz, CDCl3) δ ppm 172.7, 171.7, 162.7, 81.9, 81.9, 77.6, 77.2, 76.7, 70.5, 70.3, 70.1, 
69.5, 56.0, 55.8, 55.7, 50.8, 39.2, 38.7, 36.6, 31.5, 28.1, 28.0, 28.0.  






Tert-butyl protected 3.57 (125 mg, 0.17 mmol) was dissolved in dichloromethane (2 mL) and 
trifluoroacetic acid (4 mL) was slowly added to the solution. The reaction mixture was stirred at room 
temperature for 2 h to complete conversion to product. Afterwards, the solvent was removed under 
reduced pressure, and co-evaporated with toluene (3x) to yield the free tricarboxylic acid intermediate 
as a white solid (quant.). The residue was directly used for the next reaction step, without the need of 
further purification. 
To a stirring solution of crude tricarboxylic acid (120 mg, 0.22 mmol) in dimethylformamide (8 mL) 
at room temperature HATU (257 mg, 0.67 mmol) and N,N-diisopropylethylamine (0.19 mL, 1.10 
mmol) were added. After 10 min, maleimide-PEG2 linker 3.28 (153 mg, 0.67 mmol) dissolved in 
dimethylformamide (2 mL) was added to the stirring mixture. The reaction mixture was stirred for 
additional 30 min at room temperature. Subsequently, the solution was concentrated under reduced 
pressure, diluted in a mixture of acetonitrile and water (1:1) and purified by reversed-phase preparative 
HPLC (C-18 column, Water:ACN with 0.1% TFA, 30 to 90% ACN). The fractions containing product 
were lyophilized to afford the title compound 3.58 as a white powder in 44% yield (115 mg).  
Polymerization of intermediate 3.58 was observed during the 1H and 13C-NMR analysis. 
1H NMR (300 MHz, DMSO-d6) δ ppm 8.32 – 7.89 (m, 4H), 7.13 – 6.92 (m, 2H), 3.66 – 3.34 (m, 
52H), 3.26 – 3.17 (m, 8H), 2.97 – 2.69 (m, 16H). 
13C NMR (75 MHz, DMSO-d6) δ ppm 171.0, 163.4, 134.6, 118.9, 69.8, 69.7, 69.6, 69.3, 69.3, 69.1, 
69.0, 68.8, 67.0, 40.4, 40.1, 39.8, 39.5, 39.2, 39.0, 38.7, 38.1, 37.8, 36.8, 30.3. 





Alkyne-DOTA intermediate 3.22 (227 mg, 0.59 mmol), HATU (673 mg, 1.77 mmol) and N,N-
diisopropylethylamine (0.5 mL, 2.95 mmol) were stirred in anhydrous dimethylformamide (6 mL) 
under nitrogen at room temperature. After 10 min, maleimide-PEG2 linker 3.28 (690 mg, 1.77 mmol) 
dissolved in dimethylformamide (4 mL) was added to the reaction mixture and stirred further for 30 
min. After completion, the reaction mixture was concentrated under reduced pressure, diluted in a 
mixture of acetonitrile and water (1:1) and purified by reversed-phase preparative HPLC (C-18, 
Water:ACN with 0.1% TFA, 5 to 60% ACN, 220 nm detection) to afford probe template 3.62 as a 
colorless solid (358 mg, 60%) after lyophilization. 
1H NMR (300 MHz, CDCl3) δ ppm 8.11 (d, J = 32.9 Hz, 3H), 6.74 (s, 6H), 3.92 – 3.66 (m, 15H), 3.66 
– 3.47 (m, 26H), 3.47 – 3.20 (m, 19H), 2.50 (s, 1H).  
13C NMR (75 MHz, CDCl3) δ ppm 171.0, 134.4, 78.1, 70.1 69.3. 68.0, 68.0, 51.7, 51.1, 43.5, 39.5, 39.4, 
37.5, 37.4.  




5.3.6. Synthesis of DOTAM-based Probes 
General procedure 
A mixture of trimaleimide-PEG2 DOTAM alkyne 3.62 (1.0 equiv.) and terminal cysteine ligands 3.4, 
3.5, or 3.20 (4.5 equiv.) was stirred in volatile buffer triethylammonium acetate pH = 5.0 (2 mL) at 
room temperature for 20 h. The completion of the reaction was monitored by LC-MS, where 
quantitative conversion to product was seen. Afterward, the reaction mixture was lyophilized to give 
crudes 3.63 to 3.65, which were used without further chromatographic purification for the next 
reaction steps.  
To a solution of alkyne 3.63 or 3.65 (1.0 equiv.), azido-PEG2-dye construct 3.32 or 3.33 (1.2 equiv.), 
and copper powder (125 equiv.) in a mixture of isopropanol and water (6 mL, 2:1, v/v) copper sulfate 
aq. sol. (0.1M, 3.5 equiv.) was added. The reaction was stirred at room temperature for 2 h until the 
DOTA core of 3.63 or 3.65 was saturated with copper. After which time, additional copper sulfate aq. 
sol. (0.1M, 3.5 equiv.) was added to the reaction mixture and it was allowed to stir at the same 
temperature for additional 16 h. After full conversion to product, the reaction mixture was filtered, 
and the filtrate was lyophilized to give crude intermediates 3.66, 3.67, 3.70, or 3.71 as copper 
complexes. Of note, in all examples, product mass with one additional copper ion was observed in 
the LC-MS analysis, indicating copper complexation by the DOTAM core. 
Subsequent copper demetalation was performed. To a stirring solution of crude copper complex 3.66, 
3.67, 3.70, or 3.71 labeled with either Cy3 or Cy5.5 (1 equiv.) in trifluoroacetic acid aq. sol. (pH = 2.2, 
8 mL) at room temperature D-penicillamine 3.77 (260 equiv.) was added. The reaction mixture was 
stirred at room temperature for 18 h. The completion of the reaction was monitored by LC-MS, where 
product mass without copper was exclusively observed. Afterwards, the crude product was filtered 
and purified by reversed-phase preparative HPLC (C-18 Hydro Synergi, Water:ACN with 0.1% TFA, 
25 to 60% ACN). The fractions containing product were collected and lyophilized to give copper free 
compounds 3.79 to 3.82. 
Copper free intermediates 3.79 to 3.82 labeled with either Cy3 or Cy5.5 (1 equiv.) were stirred at room 
temperature in a mixture of volatile ammonium carbonate buffer pH 8.9 and water (6 mL, 1:1, v/v). 
Hydrolysis of succinimide rings was observed after 18 h of stirring. After completion, the reaction 
mixture was lyophilized to afford the desired products 3.83 to 3.86 in quantitative yield.  
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Tri-PTP-PEG2 DOTAM probe labeled with Cy3 (3.83) 
Following the general procedure described above, compound 3.83 was obtained in 15% yield as a pink 
powder starting from DOTAM-based platform 3.62 (5.0 mg, 4.93 µmol), Cys-PTP-3.4 (KTLLPTPC, 
19.3 mg, 22.2 µmol), and Cy3-labeled azide linker 3.32 (3.6 mg, 5.92 µmol).  
3.63 (alkyne precursor): HR-MS (ESI) m/z [M+2H]+2 calcd. for C164H277N37O48S3: 1816.4873, found 
1816.4922.  
3.79 (succinimide precursor): HR-MS (ESI) m/z [M+7H]+7, [M+6] calcd. for C200H327N43O51S3: 
[M+7H]+7607.3431, found 607.3413; [M+6] 708.2263, found 708.2238.  
3.83: HR-MS (ESI) m/z [M+7H]+7, [M+6], [M+5H]+5 calcd. for C200H333N43O54S3: [M+7H]
+7 
614.9186, found 614.9184; [M+6] 717.2316, found 717.2370; [M+5H]+5 860.8843, found 860.8849. 
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Supplementary figure S-9. HR-MS trace (+ ESI) of purified compound 3.83. 
 
Tri-PTP-PEG2 DOTAM probe labeled with Cy5.5 (3.84) 
Following the general procedure described above, compound 3.84 was obtained in 29% yield as a blue 
powder starting from DOTAM-based platform 3.62 (5.0 mg, 4.93 µmol), Cys-PTP-3.4 (KTLLPTPC, 
19.3 mg, 22.2 µmol), and Cy5.5-labeled azide linker 3.33 (4.4 mg, 5.92 µmol).  




3.80 (succinimide precursor): HR-MS (ESI) m/z [M+7], [M+6] calcd. for C210H333N43O51S3: [M+7] 
625.0578, found 625.0612; [M+6] 728.9002, found 728.9016. 
3.84: HR-MS (ESI) m/z [M+7H]+7, [M+6H]+6, [M+5H]+5 calcd. for C210H339N43O54S3: [M+7H]
+7 
632.9253, found 632.9255; [M+6]+6 738.2450, found 738.2436; [M+5H]+5 886.0937, found 886.0947. 
Supplementary figure S-10. HR-MS trace (+ ESI) of purified compound 3.84. 
 
Tri-cysteine-PEG2 DOTAM probe labeled with Cy3 (3.85) 
Following the general procedure described above, compound 3.85 was obtained in 38% yield as a pink 
powder starting from DOTAM-based platform 3.62 (10 mg, 9.85 µmol), methyl acetyl-L-cysteinate 
3.20 (7.9 mg, 44.3 µmol), and Cy3-labeled azide linker 3.32 (7.3 mg, 11.8 µmol).  
3.65 (alkyne precursor): HR-MS (ESI) m/z [M+2H]+2, [M+H]+ calcd. for C65H103N13O24S3: [M+2H]
+2 
773.8273, found 773.8365; [M+H]
+ 1546.6474, found 1546.6578. 
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3.81 (succinimide precursor): HR-MS (ESI) m/z [M+2], [M+3] calcd. for C101H153N19O27S3: [M+2] 
1080.5507, found: 1080.5182, [M+3] 720.7032, found: 720.6791.  
3.85: HR-MS (ESI) m/z [M+3], [M+2] calcd. for C98H153N19O30S3: [M+3] 724.3402, found 724.3520; 
[M+2] 1086.0091, 1086.0198. 
Supplementary figure S-11. HR-MS trace (+ ESI) of purified compound 3.85. 
 
Tri-cysteine-PEG2 DOTAM probe labeled with Cy5.5 (3.86) 
Following the general procedure described above, compound 3.86 was obtained in 38% yield as a blue 
powder starting from DOTAM-based platform 3.62 (10 mg, 9.85 µmol), methyl acetyl-L-cysteinate 
3.20 (7.9 mg, 44.3 µmol), and Cy3-labeled azide linker 3.33 (8.7 mg, 11.8 µmol).  
3.65 (alkyne precursor): HR-MS (ESI) m/z [M+2H]+2, [M+H]+ calcd. for C65H103N13O24S3: [M+2H]
+2 
773.8273, found 773.8365; [M+H]
+ 1546.6474, found 1546.6578. 
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3.82: HR-MS (ESI) m/z [M+3H]+3, [M+2] calcd. for C111H159N19O27S3: [M+3H]
+3 763.0344, found: 
763.0332, [M+2] 1143.0402, 1143.0399. 
3.86: HR-MS (ESI) m/z [M+3], [M+3Na]+3 calcd. for C108H159N19O30S3: [M+3] 766.3559, found 
766.3648; [M+3Na]+3 789.0113, 789.0124.  




5.3.7. Determination of the Copper Content of final DOTAM probes by ICP-MS Analysis  
The following experiments were performed by SEBASTIAN FASSBENDER and ANDREAS SCHULTZ at the 
Bundesanstalt für Materialforschung und –prüfung (BAM), Berlin. 
 
Sample preparation 
Stock solutions of the DOTA-fluoroprobe 3.79 to 3.82 were prepared by dissolving 1-2 mg of probe 
into 1 mL ultrapure water (MilliQ). An additional blank control with no sample was also prepared. 
The stock solutions and blank were acidified by adding 100 µL concentrated sub-boiled nitric acid. 
For the preparation of the measuring solutions, 50 µL of acidified stock solutions or blank were 
pipetted into a disposable pre-washed sample tube filled with around 45 mL of MilliQ. Additional 500 
µL concentrated sub-boiled nitric acid was added and the sample tube was filled up to 50 mL with 
MilliQ.  
A blank solution containing 500 µL concentrated sub-boiled nitric acid pipetted into a disposable pre-
washed sample tube, which was then filled up to 50 mL with MilliQ, was additionally prepared (SBW1).  
A standard spiked solution containing a concentration of 100 µg/L copper was prepared by 
performing twice a 1:100 dilution of Merc ICP multi-element standard solution IV (999 mg/L Cu in 
6.5% suprapur nitric acid) in 2% (v/v) nitric acid. Spiked calibration solutions of 1, 2, and 3 µg/L 
copper were prepared by pipetting 50 µL measuring sample solution and 500, 1000, 1500 µL standard 
spiked solution (100 µg/L Cu), respectively, and 500 µL concentrated sub-boiled nitric acid into 
disposable pre-washed sample tubes, which were then filled up to 50 mL with MilliQ. 
 
Data evaluation 
Instrumental limits of detection (LOD) and quantitation (LOQ) were determined as 3x/10x the 
standard deviation of 7 measurements of blank measuring solution SBW1 conducted during the whole 
sequence. 
No differences were found between measurement results obtained using low and medium resolution 
with the exception of the intensity of measuring solution 3.81. This was found to be below LOQ for 
medium resolution. The signal stability was better for 65Cu at low resolution. In conclusion, a 
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significant contribution of interferences on Copper detection in low resolution could be precluded 
and the results of 65Cu at low resolution were used for calculating the final results and uncertainties. 
The intensity of the blank measuring solution was found to be indistinguishable from the intensities 
of the blank stock solution. Therefore, no contribution of the sample preparation to copper 
concentrations in the measuring solutions containing probes was expected. Uncertainty estimation 
was done following the GUM guidelines[314] using the Kragten approach.[315] 
Supplementary table S-5. Copper concentrations in measuring probe samples determined by ICP-MS. 
Probe 
Cu concentration in solid 
sample (µg/g) 
Expanded uncertainty  
U (k=2, 95%) (µg/g) 
Relative uncertainty (%) 
3.79 228 15 6.5 
3.80 (batch 01) 1068 43 4.0 
3.80 (batch 02) 1392 35 2.5 
3.81 (batch 01) 741 17 2.3 
3.81 (batch 02) 762 70 9.2 





5.3.8. Confocal Fluorescence Microscopy using Multivalent DOTAM-based Probes and 
Controls 
The following experiments were performed by DR. SILKE RADETZKI at FMP, Berlin.  
 
General procedure for confocal imaging in human pancreatic cell lines 
The human pancreatic cancer lines Panc-1 and MiaPaCa-2, which have amplified plectin-1 expression, 
were grown according to stablished protocols,[249, 295] using Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco BRL, Gaithersburg, MD, USA) containing 4.5 g/L glucose, supplemented with 10% 
(v/v) fetal bovine serum (FBS, Gibco BRL), 100 U/mL penicillin-streptomycin (Gibco BRL). For 
Panc-1 cells, 2mM Glutamin was included in the culture medium. Cells were plated onto 384-well 
microplates (CellCarrier-384 ultra, PerkinElmer) at a density of 3’000 cells/well in 40µl medium/well 
and incubated for 20 h in a 5% carbon dioxide, humidified atmosphere at 37° C. Live cell nuclei 
staining was achieved with the addition of 1µM Hoechst 33342, followed by 1 h incubation at 37 °C. 
Cells were fixed with 4% paraformaldehyde in PBS buffer for 20 min, then washed three times with 
PBS buffer (70 µL/well). Cells were incubated with 50 µL/well probe (either PTP-labeled DOTA 
probes 3.83 and 3.84, monovalent controls 3.40 to 3.45, or non-targeting DOTA-labeled controls 
3.85 and 3.86) in PBS for 4 h at room temperature in the dark, then washed three times with PBS 
buffer (70 µL/well). Images were acquired using an Opera Phenix™ High Content Screening System 
microscope (PerkinElmer) with 40 times magnification. Confocal images were captured using Hoechst 
33342, Cy3, and Cy5.5 fluorescence channels by recording nine frames per well. Images were 
processed with the Harmony software (v4.9), designed for High Content Screening Systems 
(PerkinElmer) using the mean fluorescence intensity in cytoplasmic cell region as readout parameter. 
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*Polymerization of this intermediate over time was observed in the range of the NMR measurement.  
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